0001347178-20-000003.txt : 20200226 0001347178-20-000003.hdr.sgml : 20200226 20200226070216 ACCESSION NUMBER: 0001347178-20-000003 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 107 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200226 DATE AS OF CHANGE: 20200226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vanda Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001347178 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 030491827 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34186 FILM NUMBER: 20653273 BUSINESS ADDRESS: STREET 1: 2200 PENNSYLVANIA AVE NW STREET 2: SUITE 300E CITY: WASHINGTON STATE: DC ZIP: 20037 BUSINESS PHONE: 202-734-3400 MAIL ADDRESS: STREET 1: 2200 PENNSYLVANIA AVE NW STREET 2: SUITE 300E CITY: WASHINGTON STATE: DC ZIP: 20037 10-K 1 vnda1231201910k.htm 10-K Document
false--12-31FY201900013471780.0010.00115000000015000000052477593535496125247759353549612279000000.0010.00120000000200000000000P7YP11YP5YP5Y002034-052035-022035-07P10Y 0001347178 2019-01-01 2019-12-31 0001347178 2019-06-30 0001347178 2020-02-18 0001347178 2018-12-31 0001347178 2019-12-31 0001347178 2018-01-01 2018-12-31 0001347178 2017-01-01 2017-12-31 0001347178 us-gaap:CommonStockMember 2017-12-31 0001347178 us-gaap:RetainedEarningsMember 2018-12-31 0001347178 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001347178 us-gaap:CommonStockMember 2018-12-31 0001347178 us-gaap:CommonStockMember 2019-12-31 0001347178 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001347178 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001347178 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001347178 us-gaap:CommonStockMember 2016-12-31 0001347178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001347178 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001347178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001347178 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001347178 2016-12-31 0001347178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001347178 us-gaap:RetainedEarningsMember 2017-12-31 0001347178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001347178 us-gaap:RetainedEarningsMember 2016-12-31 0001347178 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001347178 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001347178 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001347178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001347178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001347178 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001347178 us-gaap:RetainedEarningsMember 2019-12-31 0001347178 2017-12-31 0001347178 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001347178 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001347178 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001347178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001347178 vnda:FanaptMember 2018-01-01 2018-12-31 0001347178 vnda:HetliozMember 2018-01-01 2018-12-31 0001347178 vnda:HetliozMember 2019-01-01 2019-12-31 0001347178 vnda:FanaptMember 2019-01-01 2019-12-31 0001347178 vnda:HetliozMember 2017-01-01 2017-12-31 0001347178 vnda:FanaptMember 2017-01-01 2017-12-31 0001347178 vnda:CustomerSixMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001347178 vnda:CustomerSixMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001347178 vnda:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001347178 vnda:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001347178 vnda:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001347178 vnda:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001347178 vnda:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerSixMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:CustomerFourMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:CustomerFiveMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerFourMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerFiveMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:SECSchedule1209AllowanceProductReturnsMember 2019-01-01 2019-12-31 0001347178 vnda:SECSchedule1209AllowanceProductReturnsMember 2018-12-31 0001347178 vnda:SECSchedule1209AllowanceProductReturnsMember 2019-12-31 0001347178 vnda:SECSchedule1209AllowanceProductReturnsMember 2017-12-31 0001347178 vnda:SECSchedule1209AllowanceProductReturnsMember 2016-12-31 0001347178 vnda:SECSchedule1209AllowanceProductReturnsMember 2018-01-01 2018-12-31 0001347178 vnda:SECSchedule1209AllowanceProductReturnsMember 2017-01-01 2017-12-31 0001347178 vnda:NoncurrentInventoryAndOtherMember 2018-12-31 0001347178 vnda:NoncurrentInventoryAndOtherMember 2019-12-31 0001347178 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2019-12-31 0001347178 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2018-12-31 0001347178 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001347178 2018-01-01 2018-02-08 0001347178 2018-02-09 2019-12-31 0001347178 us-gaap:USTreasuryAndGovernmentMember vnda:NoncurrentInvestmentsMember 2019-12-31 0001347178 us-gaap:AssetBackedSecuritiesMember vnda:NoncurrentInvestmentsMember 2019-12-31 0001347178 us-gaap:CorporateDebtSecuritiesMember vnda:NoncurrentInvestmentsMember 2019-12-31 0001347178 vnda:NoncurrentInvestmentsMember 2019-12-31 0001347178 us-gaap:AssetBackedSecuritiesMember vnda:CurrentInvestmentMember 2018-12-31 0001347178 us-gaap:USTreasuryAndGovernmentMember vnda:CurrentInvestmentMember 2018-12-31 0001347178 vnda:CurrentInvestmentMember 2018-12-31 0001347178 us-gaap:CorporateDebtSecuritiesMember vnda:CurrentInvestmentMember 2018-12-31 0001347178 us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001347178 us-gaap:FairValueInputsLevel1Member us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001347178 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0001347178 us-gaap:FairValueInputsLevel3Member 2018-12-31 0001347178 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0001347178 us-gaap:FairValueInputsLevel1Member 2018-12-31 0001347178 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001347178 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001347178 us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0001347178 us-gaap:FairValueInputsLevel3Member us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001347178 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001347178 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001347178 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001347178 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0001347178 us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001347178 us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0001347178 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001347178 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001347178 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001347178 us-gaap:FairValueInputsLevel1Member us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001347178 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001347178 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0001347178 us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001347178 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001347178 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001347178 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001347178 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0001347178 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0001347178 us-gaap:FairValueInputsLevel3Member us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001347178 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001347178 us-gaap:CashEquivalentsMember 2019-12-31 0001347178 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001347178 us-gaap:FurnitureAndFixturesMember 2018-12-31 0001347178 vnda:ComputerHardwareAndOtherEquipmentMember 2019-12-31 0001347178 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001347178 vnda:ComputerHardwareAndOtherEquipmentMember 2019-01-01 2019-12-31 0001347178 vnda:ComputerHardwareAndOtherEquipmentMember 2018-12-31 0001347178 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001347178 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2019-01-01 2019-12-31 0001347178 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2019-01-01 2019-12-31 0001347178 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2019-01-01 2019-12-31 0001347178 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2019-01-01 2019-12-31 0001347178 vnda:LondonLeaseMember 2019-12-31 0001347178 vnda:WashingtonDcLeaseMember 2019-12-31 0001347178 vnda:WashingtonDcLeaseMember vnda:SubleaseMember 2019-12-31 0001347178 vnda:HetliozMember 2018-12-31 0001347178 vnda:HetliozMember 2018-04-01 2018-04-30 0001347178 vnda:FanaptMember 2019-12-31 0001347178 vnda:HetliozMember 2014-01-01 2014-01-31 0001347178 vnda:HetliozMember 2019-12-31 0001347178 vnda:FanaptMember 2018-12-31 0001347178 srt:EuropeMember vnda:RegulatoryApprovalMilestoneMember vnda:TradipitantMember 2019-01-01 2019-12-31 0001347178 vnda:TradipitantMember 2018-07-01 2018-07-31 0001347178 vnda:CftrActivatorsAndInhibitorsMember 2019-01-01 2019-12-31 0001347178 country:US vnda:RegulatoryApprovalMilestoneMember vnda:TradipitantMember 2019-01-01 2019-12-31 0001347178 vnda:CftrActivatorsAndInhibitorsMember srt:MaximumMember vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember 2019-01-01 2019-12-31 0001347178 vnda:CftrActivatorsAndInhibitorsMember vnda:FutureRegulatoryApprovalAndSalesMilestonesMember 2019-01-01 2019-12-31 0001347178 vnda:CftrActivatorsAndInhibitorsMember vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember 2019-01-01 2019-12-31 0001347178 vnda:SalesMilestoneMember vnda:TradipitantMember 2019-01-01 2019-12-31 0001347178 vnda:HetliozMember 2004-02-01 2019-12-31 0001347178 vnda:PreNDAApprovalMilestonesMember vnda:TradipitantMember 2019-12-31 0001347178 vnda:CftrActivatorsAndInhibitorsMember vnda:RegulatoryApprovalMilestoneMember 2019-01-01 2019-12-31 0001347178 vnda:ScenarioFourMember 2016-11-16 2019-12-31 0001347178 vnda:CftrActivatorsAndInhibitorsMember vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember 2019-03-01 2019-03-31 0001347178 vnda:TradipitantMember 2019-01-01 2019-12-31 0001347178 vnda:CftrActivatorsAndInhibitorsMember vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember 2017-01-01 2017-12-31 0001347178 vnda:PublicOfferingMember 2018-03-01 2018-03-31 0001347178 vnda:PublicOfferingMember 2018-03-31 0001347178 us-gaap:OverAllotmentOptionMember 2018-03-01 2018-03-31 0001347178 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001347178 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001347178 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001347178 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-12-31 0001347178 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0001347178 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0001347178 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001347178 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-12-31 0001347178 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0001347178 vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember 2017-01-01 2017-12-31 0001347178 vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember 2019-01-01 2019-12-31 0001347178 vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember 2018-01-01 2018-12-31 0001347178 vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember 2018-12-31 0001347178 vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember 2016-01-01 2016-12-31 0001347178 vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember 2016-12-31 0001347178 vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember 2019-12-31 0001347178 vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember 2017-12-31 0001347178 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001347178 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001347178 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0001347178 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0001347178 us-gaap:RestrictedStockUnitsRSUMember 2016-12-31 0001347178 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0001347178 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001347178 vnda:ServiceOptionAwardsMember 2019-12-31 0001347178 vnda:StockOptionsAndRestrictedStockUnitsRSUsMember vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember 2019-01-01 2019-12-31 0001347178 vnda:ServiceOptionAwardsMember 2019-01-01 2019-12-31 0001347178 vnda:TwoThousandSixteenPlanMember 2019-12-31 0001347178 srt:MaximumMember us-gaap:OtherNoncurrentLiabilitiesMember 2018-12-31 0001347178 stpr:DC 2019-01-01 2019-12-31 0001347178 vnda:IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember 2019-01-01 2019-12-31 0001347178 vnda:EstimatedRealizabilityofDeferredTaxAssetMember 2019-01-01 2019-12-31 0001347178 vnda:OrphanDrugMember 2019-12-31 0001347178 us-gaap:DomesticCountryMember 2019-12-31 0001347178 vnda:IncomeBeforeIncomeTaxesCurrentYearMember 2019-01-01 2019-12-31 0001347178 2019-04-01 2019-06-30 0001347178 2018-10-01 2018-12-31 0001347178 2019-07-01 2019-09-30 0001347178 2018-07-01 2018-09-30 0001347178 2018-04-01 2018-06-30 0001347178 2018-01-01 2018-03-31 0001347178 2019-01-01 2019-03-31 0001347178 2019-10-01 2019-12-31 vnda:product utreg:sqft xbrli:shares iso4217:USD xbrli:shares vnda:Segment iso4217:USD xbrli:pure vnda:installment

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 10-K
 
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2019
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File No. 001-34186
 
VANDA PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
 
Delaware
03-0491827
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
2200 Pennsylvania Avenue NW, Suite 300 E
Washington DC 20037
(202) 734-3400
(Address and telephone number, including area code, of registrant’s principal executive offices)
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
VNDA
The Nasdaq Global Market
Securities registered pursuant to Section 12(g) of the Exchange Act: None
 
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☐    No  ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.    Yes  ☐    No  ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.    ☒
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
 
☒
  
Accelerated filer
 
☐
 
 
 
 
 
 
 
Non-accelerated filer
 
☐
  
Smaller reporting company
 
☐
 
 
 
 
 
 
 
 
 
 
  
Emerging growth company
 
☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).    Yes  ☐    No  ☒
As of June 30, 2019, the last business day of the registrant’s last completed second quarter, the aggregate market value of the Common Stock held by non-affiliates of the registrant was approximately $731.2 million based on the closing price of the registrant’s Common Stock, as reported by The Nasdaq Global Market, on such date. Shares of Common Stock held by each executive officer and director and stockholders known by the registrant to own 10% or more of the outstanding stock based on public filings and other information known to the registrant have been excluded since such persons may be deemed affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.
The number of shares of the registrant’s Common Stock, par value $0.001 per share, outstanding as of February 18, 2020 was 53,648,617.
The exhibit index as required by Item 601(a) of Regulation S-K is included in Item 15 of Part IV of this report.
DOCUMENTS INCORPORATED BY REFERENCE
Specified portions of the registrant’s proxy statement with respect to the registrant’s 2020 Annual Meeting of Stockholders, which is to be filed pursuant to Regulation 14A within 120 days after the end of the registrant’s fiscal year ended December 31, 2019, are incorporated by reference into Part III of this Form 10-K.
 


Vanda Pharmaceuticals Inc.
Form 10-K
Table of Contents
 
 
Page
 
Item 1
Item 1A
Item 1B
Item 2
Item 3
Item 4
Item 5
Item 6
Item 7
Item 7A
Item 8
Item 9
Item 9A
Item 9B
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15



PART I
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
 
This annual report on Form 10-K (Annual Report) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (Securities Act) and Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act). Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “project,” “target,” “goal,” “likely,” “will,” “would,” and “could,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The forward-looking statements in this Annual Report may include, among other things, statements about:
 
•
the ability of Vanda Pharmaceuticals Inc. (we, our, the Company or Vanda) to continue to commercialize HETLIOZ® (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in the United States (U.S.) and Europe;
•
our ability to increase market awareness of Non-24 and the market acceptance of HETLIOZ®;
•
our ability to continue to generate U.S. sales of Fanapt® (iloperidone) for the treatment of schizophrenia;
•
our dependence on third-party manufacturers to manufacture HETLIOZ® and Fanapt® in sufficient quantities and quality;
•
our level of success in commercializing HETLIOZ® and Fanapt® in new markets;
•
our ability to reach agreement with the U.S. Food and Drug Administration (FDA) regarding our regulatory approval strategy, preclinical animal testing requirements or proposed path to approval for tradipitant;
•
our ability to prepare, file, prosecute, defend and enforce any patent claims and other intellectual property rights;
•
our ability to maintain rights to develop and commercialize our products under our license agreements;
•
our ability to obtain approval from the FDA for HETLIOZ® for the treatment of jet lag disorder;
•
the ability to obtain and maintain regulatory approval of our products, and the labeling for any approved products;
•
our expectations regarding the timing and success of preclinical studies and clinical trials;
•
the ability of our products to be demonstrably safe and effective;
•
limitations on our ability to utilize some or all of our prior net operating losses and orphan drug and research and development credits;
•
the size and growth of the potential markets for our products and the ability to serve those markets;
•
our expectations regarding trends with respect to our revenues, costs, expenses, liabilities and cash, cash equivalents and marketable securities;
•
the scope, progress, expansion, and costs of developing and commercializing our products;
•
our ability to identify or obtain rights to new products;
•
our ability to attract and retain key scientific or management personnel;
•
the cost and effects of litigation;
•
our ability to obtain the capital necessary to fund our research and development or commercial activities;
•
regulatory developments in the U.S., Europe and other jurisdictions;
•
potential losses incurred from product liability claims made against us; and
•
the use of our existing cash, cash equivalents and marketable securities.
 
All written and verbal forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained throughout this report. We caution investors not to rely too heavily on the forward-looking statements we make or that are made on our behalf. We undertake no obligation, and specifically decline any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

1

We encourage you to read Management’s Discussion and Analysis of Financial Condition and Results of Operations and our consolidated financial statements contained in this Annual Report. We also encourage you to read Item 1A of Part I of this Annual Report, entitled Risk Factors, which contains a more complete discussion of the risks and uncertainties associated with our business. In addition to the risks described in this Annual Report, other unknown or unpredictable factors also could affect our results. Therefore, the information in this report should be read together with other reports and documents that we file with the Securities and Exchange Commission from time to time, including on Form 10-Q and Form 8-K, which may supplement, modify, supersede or update those risk factors. As a result of these factors, we cannot assure you that the forward-looking statements in this report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.

2

ITEM 1.
BUSINESS
Overview
Vanda Pharmaceuticals Inc. (we, our, the Company or Vanda) is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.
We strive to advance novel approaches to bring important, new medicines to market through responsible innovation. We are committed to the use of technologies that support sound science, including genetics and genomics, in drug discovery, clinical trials and the commercial positioning of our products.
Our commercial portfolio is currently comprised of two products, HETLIOZ® for the treatment of Non-24 and Fanapt® for the treatment of schizophrenia. HETLIOZ® is the first treatment for Non-24 approved by the FDA. In addition, we have a number of drugs in development, including:
 
•
HETLIOZ® (tasimelteon) for the treatment of jet lag disorder, Smith-Magenis Syndrome (SMS), pediatric Non-24 and delayed sleep phase disorder (DSPD);
•
Fanapt® (iloperidone) for the treatment of bipolar disorder and a long acting injectable (LAI) formulation program for the treatment of schizophrenia;
•
Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis and motion sickness;
•
VTR-297, a small molecule histone deacetylase (HDAC) inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications;
•
VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist, with potential use for the treatment of psychiatric disorders; and
•
Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors for the treatment of dry eye and ocular inflammation and for the treatment of secretory diarrhea disorders, including cholera.
We were incorporated in 2003 and are headquartered in Washington, D.C.
Our Strategy
Our goal is to further solidify our position as a leading global biopharmaceutical company focused on developing and commercializing innovative therapies addressing high unmet medical needs through the application of our drug development expertise and our pharmacogenetics and pharmacogenomics expertise. The key elements of our strategy to accomplish this goal are to:
 
•
Maximize the commercial success of HETLIOZ® and Fanapt®;
•
Enter into strategic partnerships to supplement our capabilities and to extend our commercial reach;
•
Pursue the clinical development and regulatory approval of our products, including tradipitant;
•
Apply our pharmacogenetics and pharmacogenomics expertise to differentiate our products;
•
Expand our product portfolio through the identification and acquisition of additional products; and
•
Utilize novel and innovative approaches in pursuit of each of these strategies.


3

Commercialized Products
Our commercial product portfolio consists of:
Product
  
Indication
  
2019 Net Sales (in millions)
  
Geography
hetlioz.gif
  
Non-24
  
$143.0
  
United States

Europe
 
 
 
 
 
 
 
fanapt.gif
  
Schizophrenia
  
$84.2
  
United States

Israel
 
 
 
 
 
 
 
HETLIOZ® 
In January 2014, HETLIOZ® was approved in the U.S. for the treatment of Non-24 Sleep-Wake Disorder otherwise known as Non-24. Non-24 is a serious, rare and chronic circadian rhythm sleep-wake disorder characterized by the inability to entrain (synchronize) the master body clock with the 24-hour day-night cycle. HETLIOZ® is the first FDA approved treatment for Non-24. HETLIOZ® is a melatonin agonist of the human MT1 and MT2 receptors, with greater specificity for MT2. These receptors are thought to be involved in the control of circadian rhythms. HETLIOZ® is believed to reset the master body clock in the suprachiasmatic nucleus, located in the hypothalamus, resulting in the entrainment and alignment of the body’s melatonin and cortisol rhythms to the 24-hour day-night cycle.
Most people have a master body clock that naturally runs longer than 24 hours and light is the primary environmental cue that resets it to 24 hours each day. Individuals with Non-24 have a master body clock that is not reset, and continually delays, resulting in prolonged periods of misalignment between their circadian rhythms and the 24-hour day-night cycle, including the timing of melatonin and cortisol secretion. As a result of this misalignment, Non-24 is associated with significant disruption of the sleep-wake cycle and impairments in social and occupational functioning, and marked subjective distress. Individuals with Non-24 cycle in and out of phase and suffer from disrupted nighttime sleep patterns and/or excessive daytime sleepiness.
HETLIOZ® was launched commercially in the U.S. in April 2014. In addition, in July 2015, the European Commission (EC) granted centralized marketing authorization with unified labeling for HETLIOZ® for the treatment of Non-24 in totally blind adults and included post-marketing commitments related to a pediatric investigation plan. This authorization is valid in the 27 countries that are members of the European Union (E.U.), as well as European Economic Area members Iceland, Liechtenstein and Norway. HETLIOZ® was launched commercially in Germany in August 2016. We have applied for renewal of this marketing authorization, which expires in the ordinary course in July 2020.
In January 2010, the FDA granted orphan drug designation status for HETLIOZ® in Non-24 in blind individuals. The FDA grants orphan drug designation to drugs that may provide significant therapeutic advantage over existing treatments and target conditions affecting 200,000 or fewer U.S. patients per year. Orphan drug designation provides potential financial and regulatory incentives, including study design assistance, tax credits, waiver of FDA user fees, and up to seven years of market exclusivity upon marketing approval. In February 2011, the European Medicines Agency (EMA) designated HETLIOZ® as an orphan medicinal product for the same indication.
Non-24 affects a majority of totally blind individuals, or approximately 80,000 people in the U.S. Blind individuals who develop Non-24 lack the light sensitivity necessary to synchronize the master body clock in the brain with the 24-hour day-night cycle. More rarely, Non-24 also can affect sighted individuals. As with the totally blind, Non-24 in sighted individuals appears to be a comorbidity with certain other conditions. For example, a comorbidity has been established between psychiatric mood disorders and Non-24. Hospitalized individuals with neurological and psychiatric disorders can become insensitive to social cues, which may predispose them to the development of Non-24. This recognition of comorbidity led Vanda to an initiative to engage with the psychiatric community. Patients diagnosed with traumatic brain injury, including concussions, frequently suffer from sleep disorders, some of which may be circadian rhythm sleep-wake disorders, including Non-24.

4

While there are no FDA or EC approved treatments for Non-24 other than HETLIOZ®, there are a number of drugs approved and prescribed for patients with sleep disorders. The most commonly prescribed drugs are hypnotics. See Competition below for a discussion of commonly prescribed drugs for patients with sleep disorders.
Fanapt® 
Fanapt® is a product for the treatment of schizophrenia. In May 2009, the FDA granted U.S. marketing approval of Fanapt® for the acute treatment of schizophrenia in adults. In October 2009, we entered into an amended and restated sublicense agreement with Novartis. We had originally entered into a sublicense agreement with Novartis in June 2004 pursuant to which we obtained certain worldwide exclusive licenses from Novartis relating to Fanapt®. Pursuant to the amended and restated sublicense agreement, Novartis had exclusive commercialization rights to all formulations of Fanapt® in the U.S. and Canada. In January 2010, Novartis launched Fanapt® in the U.S. On December 31, 2014, Novartis transferred all the U.S. and Canadian commercial rights to the Fanapt® franchise to us as part of a settlement agreement. Additionally, our distribution partners launched Fanapt® in Israel in 2014. In May 2016, the FDA approved a supplemental New Drug Application (sNDA) for Fanapt® for the maintenance treatment of schizophrenia in adults.
In July 2017, the EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion recommending against approval of Fanaptum® (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the E.U. The CHMP was of the opinion that the benefits of Fanaptum® did not outweigh its risks and recommended against marketing authorization. The negative opinion was upheld upon appeal in November 2017. (See Part I, Item 3, Legal Proceedings of this Annual Report for information relating to subsequent proceedings in this matter.)
Schizophrenia is a chronic, debilitating mental disorder characterized by hallucinations, delusions, racing thoughts and other psychotic symptoms (collectively referred to as “positive symptoms”), as well as moodiness, anhedonia (inability to feel pleasure), loss of interest, eating disturbances and withdrawal (collectively referred to as “negative symptoms”), and attention and memory deficits (collectively referred to as “cognitive symptoms”). Schizophrenia develops in late adolescence or early adulthood in approximately 1% of the world’s population. Most schizophrenia patients today are treated with drugs known as “atypical” antipsychotics, which were first approved in the U.S. in the late 1980s. These antipsychotics have been named “atypical” for their ability to treat a broader range of negative symptoms than the first-generation “typical” antipsychotics, which were introduced in the 1950s and are now generic. Atypical antipsychotics are generally regarded as having improved side effect profiles and efficacy relative to typical antipsychotics. See Competition below for a discussion of commonly prescribed atypical antipsychotics in addition to Fanapt®.

5

Research and Development
We have the following products in clinical development or under regulatory review:
researchanddevelopment.jpg
HETLIOZ® for Jet Lag Disorder
In March and May 2018, respectively, we announced the results of our JET8 and JET studies for the treatment of jet lag disorder. In the JET8 clinical study, HETLIOZ® demonstrated significant and clinically meaningful benefits in nighttime and daytime symptoms of jet lag disorder, including improvement in sleep time and benefits in measurements of next day alertness.
The JET study showed effectiveness in treating travelers who traveled either five or eight time zones from Washington, DC to London and San Francisco or Los Angeles to London, respectively. The results support the previously reported pivotal JET5 and JET8 Phase III studies, which demonstrated significant effects in circadian advances of five and eight hours, respectively.
Additionally, in September 2018, we announced results from a driving study, which demonstrated that tasimelteon did not impair measures of driving performance.
The FDA accepted the filing of our sNDA for HETLIOZ® for the treatment of jet lag disorder in December 2018. The FDA determined the action target date under the Prescription Drug User Fee Act Amendments of 2017 (PDUFA-VI) to be August 16, 2019. Vanda received a complete response letter (CRL) on August 16, 2019 from the FDA related to the sNDA for HETLIOZ® for the treatment of jet lag disorder, in which the FDA asserted that the measures demonstrating improved sleep were of unclear clinical significance. We met with the FDA to discuss the CRL in a Post Action meeting and are continuing to pursue approval of the sNDA.
Jet lag disorder is a common circadian disorder frequently observed in millions of travelers who cross multiple time zones. Jet lag disorder is characterized by nighttime sleep disruption, a decrease in daytime alertness and impairment to social and occupational functioning. Jet lag disorder symptoms are more severe during eastward travel. U.S. Department of Commerce, International Trade Administration reports state that more than 20 million U.S. residents make trips abroad each year to overseas destinations in Europe, the Middle East and Asia.

6

HETLIOZ® for SMS
We reported results from an SMS placebo controlled study in December 2018, which showed that HETLIOZ® improved sleep quality and increased sleep duration in patients with SMS. SMS is a rare genetic disorder caused by a deletion on chromosome 17. The U.S. National Institute of Health estimates that SMS affects approximately one in 15,000 to 25,000 births in the U.S. We met with the FDA in the fourth quarter of 2019 to discuss the HETLIOZ® SMS clinical study results. We submitted an sNDA, including data for a liquid formulation, and expect regulatory action by the FDA in 2020.
HETLIOZ® for Pediatric Non-24
We plan to develop HETLIOZ® for the treatment of pediatric Non-24. A pharmacokinetic study of the HETLIOZ® pediatric liquid formulation was completed in the first quarter of 2018.
HETLIOZ® for DSPD
A clinical program of HETLIOZ® in DSPD is ongoing. DSPD is a circadian rhythm disorder in which a person's sleep is delayed beyond the socially acceptable or conventional bedtime. This delay in falling asleep causes difficulty in waking up at the desired time and affects social and occupational functioning.
Fanapt® for Bipolar Disorder (oral tablets)
A Phase III study of Fanapt® in bipolar disorder is ongoing. Bipolar disorders are brain disorders that cause changes in a person’s mood, energy and ability to function. Bipolar disorder is a category that includes three different conditions - bipolar I, bipolar II and cyclothymic disorder.
People with bipolar disorders have extreme and intense emotional states that occur at distinct times, called mood episodes. These mood episodes are categorized as manic, hypomanic or depressive. People with bipolar disorders generally have periods of normal mood as well.
Fanapt® LAI
In October 2018, we enrolled our first patient in a pharmacokinetic study of the LAI formulation of Fanapt®.  This pharmacokinetic study is ongoing and will serve to inform the dosing for a later clinical study of Fanapt® LAI for the treatment of schizophrenia.
Tradipitant for Atopic Dermatitis
We announced results in September 2017 from a randomized Phase II clinical study of tradipitant as a monotherapy in the treatment of patients with atopic dermatitis. Tradipitant was shown to improve the intensity of the worst itch patients experienced, as well as atopic dermatitis disease severity. On the pre-specified primary endpoint of Average Itch Visual Analog Scale (VAS), tradipitant showed improvement over placebo, but this improvement was not significant due to high placebo effect and the lack of sensitivity of this measure.
In June 2018, we initiated EPIONE, a Phase III study of tradipitant for pruritus in atopic dermatitis. In October 2019, we began enrolling patients in EPIONE 2, a second Phase III clinical study of tradipitant in atopic dermatitis. We announced results of EPIONE in February 2020. The EPIONE study did not meet its primary endpoint in reduction of pruritus across the overall study population. However, the antipruritic effect of tradipitant was robust in the mild atopic dermatitis population. The EPIONE study continued to demonstrate that tradipitant is safe and well-tolerated. We plan to reassess the ongoing EPIONE 2 study of tradipitant in atopic dermatitis.
Atopic dermatitis is a chronic, relapsing inflammatory skin disorder characterized by the symptom of intense and persistent pruritus or itch. Other clinical features include erythema, excoriation, edema, lichenification, oozing and xerosis. It is a common skin disorder affecting millions of people worldwide. Currently, there are very few safe systemic treatments available for atopic dermatitis, representing a significant unmet medical need in this population. A 2015 Decision Resources Group report estimated that 9.8 million individuals were diagnosed with atopic dermatitis in the U.S., of which approximately 6.4 million were drug-treated atopic dermatitis patients.

7

Tradipitant for Gastroparesis
We announced results in December 2018 from a randomized clinical study (2301) of tradipitant as a monotherapy in the treatment of gastroparesis. Several symptom severity scales were used to assess gastroparesis symptoms, including the Gastroparesis Symptom Index (GCSI), Patients Assessment of Upper Gastrointestinal Disorders-Symptoms (PAGI-​SYM), and Patient Global Impression of Change (PGI-C) as well as a Clinician Global Impression of Severity (CGI-S). Tradipitant met the primary endpoint of the study of change in nausea score as measured by patient daily diaries and also met the related endpoint of improvement in the number of nausea free days. Tradipitant also showed significant improvement in most of the secondary endpoints studied, including several key scales reflecting overall gastroparesis symptoms, specifically GCSI, PAGI-SYM, CGI-S, and PGI-C.
Gastroparesis is a serious medical condition characterized by delayed gastric emptying associated with the symptoms of nausea, vomiting, bloating, fullness after meals and abdominal pain, along with significant impairment of social and occupational functioning. A paper by Rey et al published in the January 2012 Journal of Neurogastroenterology and Motility estimated the prevalence of gastroparesis in the U.S. to be over 5 million patients, many of whom remain undiagnosed.
In April 2018, we submitted a protocol amendment to the FDA, proposing a 52-week open-label extension (OLE) period for patients who had completed the tradipitant Phase II clinical study (2301) in gastroparesis. In May 2018, based on feedback from the FDA, we amended the protocol limiting the duration of treatment in the 2301 study to a total of three months, while continuing to seek further dialogue with the FDA on extending the study duration to 52-weeks. As a part of this negotiation process, in September 2018, we submitted a new follow-on 52-week OLE protocol to the FDA (2302) for patients who had completed the 2301 study. While waiting for further feedback, no patients were ever enrolled in any study beyond 12 weeks. On December 19, 2018, the FDA imposed a partial clinical hold (PCH) on the two proposed studies, stating that we are required first to conduct additional chronic toxicity studies in canines, monkeys or minipigs before allowing patients access in any clinical protocol beyond 12 weeks. At that time, the FDA informed us that the original PCH was not based on any safety or efficacy data related to tradipitant, but rather that these additional toxicity studies were required by a guidance document. Subsequently, the FDA has taken the position that an additional study was required in order for the FDA to have adequate toxicology data to undertake a risk analysis of tradipitant.
On February 5, 2019, we filed a lawsuit against the FDA in the U.S. District Court for the District of Columbia (DC District Court), challenging the FDA’s legal authority to issue the PCH, and seeking an order to set it aside. In February 2019, the FDA filed a Motion for Voluntary Remand to the Agency and for a Stay of the Case. In March 2019, the DC District Court granted the FDA’s request for voluntary remand and returned the matter to the FDA for further consideration. In April 2019, the FDA provided its remand response, in which it indicated that, upon review of scientific literature and tradipitant data, it believes that a PCH continues to be appropriate until we have safety data from a nine-month non-rodent toxicity study. In May 2019, we filed an amended complaint, and in July 2019, we filed a Motion for Summary Judgment based on our continuing belief after review of the FDA’s remand response that additional chronic toxicity studies are unjustified, and that we have provided the FDA with sufficient information regarding the safety of tradipitant to justify the continued study of tradipitant in patients beyond 12 weeks, in accordance with applicable law and FDA regulations. The FDA filed a reply and cross-motion for summary judgment in October 2019 and an oral hearing was held on December 13, 2019. On January 31, 2020, the Court granted the FDA's cross-motion for summary judgment and granted judgment in favor of the FDA on our claims. We are evaluating our options, including a potential appeal, and we intend to continue vigorously pursuing our interests in the matter. (see Part I, Item 3, Legal Proceedings of this Annual Report for additional information).
We do not expect the PCH to have a material impact on our ongoing clinical studies in atopic dermatitis, gastroparesis or motion sickness, each of which is under 12 weeks in duration and are not subject to the PCH. Nor do we expect the PCH to impact the potential timing of the submission of a New Drug Application (NDA) with the FDA. If the matter has not been fully resolved prior to the date on which we are ready to submit the first NDA for tradipitant, then we may choose to submit with the safety data we have available at that time. We may pursue additional studies of durations in excess of 12 weeks in countries where the conduct of such studies may be permitted (or we may choose to file for approval of a limited indication). If the FDA continues to recommend that we conduct a long-term safety study of 12 months duration in humans, and determines that our NDA does not contain safety data sufficient for approval, it may not accept the NDA for filing. We will continue to reassess the situation on an ongoing basis.

8

Enrollment in the Phase III study of tradipitant in gastroparesis is ongoing.
Tradipitant for Motion Sickness
In July 2019, we reported tradipitant was effective in treating motion sickness in a Phase II clinical study conducted in the Pacific Ocean. In the study, 126 people with a prior history of motion sickness were subjected to sea travel in the Pacific Ocean. Study participants were randomized to receive either tradipitant or placebo in a blinded fashion. The study had two primary endpoints: percentage of participants vomiting, and Motion Sickness Severity Scale (MSSS) Worst score. In the overall population, a significantly higher percentage of participants experienced vomiting in the placebo arm as compared to the tradipitant arm. The MSSS Worst score endpoint also favored tradipitant, but the difference did not reach statistical significance.
Motion sickness is a disorder that arises often as a response to real or perceived movement, as occurring during vehicular travel. Vomiting is the most disturbing symptom of motion sickness, although the disorder is often accompanied by a constellation of symptoms that includes nausea, sweating, pallor, headache and anorexia. Motion sickness is one of the most prevalent episodic disorders in the world, whose prevalence has dramatically increased with world population mobility over the last 100 years. It is reported that approximately 30% of the general population suffers from Motion Sickness under ordinary travel conditions that include sea, air and land travel.
We plan to complete the Phase III program of tradipitant in motion sickness and expect to file an NDA with the FDA in 2020.
VTR-297
VTR-297 is a small molecule HDAC inhibitor with potential use as a treatment for several oncology indications. The FDA accepted an Investigational New Drug (IND) application for VTR-297 in 2017 and provided authorization to proceed with the treatment of patients with relapsed and/or refractory hematologic malignancies. We initiated a clinical study in patients with hematologic malignancies in the fourth quarter of 2018. Enrollment in the Phase I clinical study (1101) of VTR-297 in hematologic malignancies is ongoing.
Other Products
VQW-765
VQW-765 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist that we licensed from Novartis on December 31, 2014 pursuant to a settlement agreement. The FDA accepted an Investigational New Drug (IND) application for VQW-765 in January 2020 and provided authorization to proceed with clinical development. We are evaluating VQW-765 for the treatment of psychiatric disorders.
Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors
An early stage CFTR activator program is planned for the treatment of dry eye and ocular inflammation. In addition, an early stage CFTR inhibitor program is planned for the treatment of secretory diarrhea disorders, including cholera.
For more detailed information regarding our clinical trial results and regulatory activities for our products please refer to our SEC filings and press releases, which can be found on the SEC Edgar system and on our website www.vandapharma.com.
License Agreements
Our rights to develop and commercialize our products are subject to the terms and conditions of licenses granted to us by other pharmaceutical companies.
HETLIOZ® 
In February 2004, we entered into a license agreement with Bristol-Myers Squibb (BMS) under which we received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize HETLIOZ®. To date, we have paid BMS $37.5 million in upfront fees and milestone obligations. We have no remaining milestone obligations to BMS. Additionally, we are obligated to make royalty payments on HETLIOZ® net sales to BMS in any territory where we commercialize HETLIOZ® for a period equal to the greater of 10 years following the first

9

commercial sale in the territory or the expiry of the new chemical entity (NCE) patent in that territory. During the period prior to the expiry of the NCE patent in a territory, we are obligated to pay a 10% royalty on net sales in that territory. The royalty rate is decreased by half for countries in which no NCE patent existed or for the remainder of the 10 years after the expiry of the NCE patent. We are also obligated under the license agreement to pay BMS a percentage of any sublicense fees, upfront payments and milestone and other payments (excluding royalties) that we receive from a third-party in connection with any sublicensing arrangement, at a rate which is in the mid-twenties. We have agreed with BMS in the license agreement for HETLIOZ® to use commercially reasonable efforts to develop and commercialize HETLIOZ®.
Either party may terminate the HETLIOZ® license agreement under certain circumstances, including a material breach of the agreement by the other. In the event we terminate our license, or if BMS terminates our license due to our breach, all rights licensed and developed by us under this agreement will revert or otherwise be licensed back to BMS on an exclusive basis.
Fanapt® 
Pursuant to the terms of a settlement agreement with Novartis, Novartis transferred all U.S. and Canadian rights in the Fanapt® franchise to us on December 31, 2014. We paid directly to Sanofi S.A. (Sanofi) a fixed royalty of 3% of net sales through December 2019 related to manufacturing know-how. No further royalties on manufacturing know-how are payable by us. We are also obligated to pay Sanofi a fixed royalty on Fanapt® net sales equal up to 6% on Sanofi know-how not related to manufacturing under certain conditions for a period of up to 10 years in markets where the NCE patent has expired or was not issued. We are obligated to pay this 6% royalty on net sales in the U.S. through November 2026. No further royalties on know-how not related to manufacturing will be payable by us for net sales in the U.S. after November 2026. We may lose our rights to develop and commercialize Fanapt® if we fail to comply with certain requirements in the Titan license agreement regarding our financial condition, or if we fail to comply with certain diligence obligations regarding our development or commercialization activities.
Tradipitant (VLY-686)
In April 2012, we entered into a license agreement with Eli Lilly and Company (Lilly) pursuant to which we acquired an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize an NK-1R antagonist, tradipitant, for all human indications. Lilly is eligible to receive future payments based upon achievement of specified development, regulatory approval and commercialization milestones as well as tiered-royalties on net sales at percentage rates up to the low double digits. To date, we have paid Lilly $3.0 million in upfront fees and development milestones, including a $2.0 million milestone payment as a result of enrolling the first subject into a Phase III study for tradipitant in July 2018. As of December 31, 2019, remaining milestones include a $2.0 million development milestone due upon the filing of the first marketing authorization for tradipitant in either the U.S. or the E.U, $10.0 million and $5.0 million for the first approval of a marketing authorization for tradipitant in the U.S. and E.U., respectively, and up to $80.0 million for sales milestones. We are obligated to use commercially reasonable efforts to develop and commercialize tradipitant.
Either party may terminate the agreement under certain circumstances, including a material breach of the agreement by the other. In the event that we terminate the agreement, or if Lilly terminates the agreement due to our breach or for certain other reasons set forth in the agreement, all rights licensed and developed by us under the agreement will revert or otherwise be licensed back to Lilly on an exclusive basis, subject to payment by Lilly to us of a royalty on net sales of products that contain tradipitant.
VQW-765
In connection with the settlement agreement with Novartis relating to Fanapt®, we received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. Pursuant to the license agreement, we are obligated to use commercially reasonable efforts to develop and commercialize VQW-765 and are responsible for all development costs. We have no milestone obligations, but Novartis is eligible to receive tiered-royalties on net sales at percentage rates up to the mid-teens.
Either party may terminate the agreement under certain circumstances, including a material breach of the agreement by the other. In the event that we terminate the agreement, or if Novartis terminates the agreement due to our breach or for certain other reasons set forth in the agreement, all rights licensed and developed by us under the agreement will revert or

10

otherwise be licensed back to Novartis on an exclusive basis, subject to payment by Novartis to us of a royalty on net sales of products that contain VQW-765.
Portfolio of CFTR activators and inhibitors
In March 2017, we entered into a license agreement with the University of California San Francisco (UCSF), under which we acquired an exclusive worldwide license to develop and commercialize a portfolio of CFTR activators and inhibitors. Pursuant to the license agreement, we will develop and commercialize the CFTR activators and inhibitors and are responsible for all development costs under the license agreement, including current pre-investigational new drug development work. UCSF is eligible to receive future payments based upon achievement of specified development, regulatory approval and commercialization milestones as well as single-digit tiered-royalties on net sales. To date, we have paid UCSF $1.2 million in upfront fees and development milestones, including an upfront license fee payment of $1.0 million in 2017 and a $0.2 million development milestone payment in March 2019. As of December 31, 2019, remaining milestones include $12.2 million for development milestones and $33.0 million for future regulatory approval and sales milestones. Included in the $12.2 million in development milestones is a $350,000 milestone due upon the conclusion of a Phase I study for each licensed product but not to exceed $1.1 million in total for the CFTR portfolio.
Either party may terminate the agreement under certain circumstances. In the event that we terminate the agreement, or if UCSF terminates the agreement due to our breach or for certain other reasons set forth in the agreement, all rights licensed and developed by us under the agreement will revert or otherwise be licensed back to UCSF. Termination will not relieve us of our obligation to pay royalties or other payments owed, if any, to UCSF under the terms of the agreement.
Patents and proprietary rights; Hatch-Waxman protection
We will be able to protect our products from unauthorized use by others only to the extent that our products are covered through regulatory protections or by valid and enforceable patents, either licensed to us by others or generated through our activities internally, that give us sufficient proprietary rights. Accordingly, securing patents, regulatory data package protection, and other proprietary rights is an essential element of our business strategies.
HETLIOZ®, tradipitant and VQW-765 are covered by NCE and other patents and patent applications related to their respective medicinal uses. In addition, NCE patent protection has been sought for VTR-297 and CFTR. Patent applications for these active ingredients remain pending. While the NCE patents protecting Fanapt® have expired, Fanapt® remains protected by medicinal patents. For more on the license and sublicense arrangements related to these active ingredients, see License Agreements above. In addition, we have filed for patents based on our own discoveries that seek to provide additional protection for HETLIOZ® and Fanapt®.

11

The table below is a summary of patents listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) for our commercial products. Members of these patent families are also issued or pending in a number of territories, such as Europe and Japan.
Product
 
Number
  
Type
HETLIOZ®
 
US 5,856,529
  
New chemical entity
 
 
US 9,060,995
  
Method of treatment
 
 
US 9,539,234
  
Method of treatment
 
 
US 9,549,913
  
Method of treatment
 
 
US 9,730,910
  
Method of treatment
 
 
US 9,855,241
  
Method of treatment
 
 
US RE46604
  
Method of treatment
 
 
US 10,071,977
 
Drug substance
 
 
US 10,149,829
 
Method of treatment
 
 
US 10,376,487
 
Method of treatment
 
 
US 10,449,176
 
Method of treatment
Fanapt®
 
US 8,586,610
  
Method of treatment
 
 
US 8,652,776
  
Method of treatment
 
 
US 8,999,638
  
Method of treatment
 
 
US 9,072,742
  
Method of treatment
 
 
US 9,074,254
  
Method of treatment
 
 
US 9,074,255
  
Method of treatment
 
 
US 9,074,256
  
Method of treatment
 
 
US 9,138,432
  
Method of treatment
 
 
US 9,157,121
  
Method of treatment
HETLIOZ® 
Our rights to the NCE patent covering HETLIOZ® and related intellectual property have been acquired through a license with BMS. HETLIOZ® and its formulations, genetic markers and uses are the subject of numerous patent filings for which protection has been sought in selected countries worldwide. The NCE patent covering HETLIOZ® expires in December 2022 in the U.S., which is inclusive of a five-year extension granted under the Hatch-Waxman Act in October 2018. Corresponding NCE patent protection has expired in most other markets. The U.S. Patent and Trademark Office has issued nine method of use patents for HETLIOZ® that will expire between 2033 and 2035 and one drug substance patent that will expire in 2035.
In Europe, the law provides for ten years of data exclusivity (with the potential for an additional year if a medicine is developed for a significant new indication). In addition, Europe provides for ten years of market exclusivity for orphan indications. As such, in Europe, data or market exclusivity will provide protection for HETLIOZ® for at least ten years from approval. It is also possible that the protection through a basic patent (i.e., a patent which protects a product as such, a process to obtain a product, or an application of a product) in Europe could be extended for up to five years by the issuance of a supplementary protection certificate (SPC). A completed Pediatric Investigation Plan (PIP) could further extend SPC protection for an additional six months or the market exclusivity in an orphan indication for two additional years. Thus, a PIP could provide a total of 12 years of market exclusivity for an orphan indication. The European Patent Office has granted our patent application directed to the 20 mg/day dose. This patent will expire in 2027 and provides the basis for an SPC. Other pending patent applications in Europe, if granted, may offer additional protection for HETLIOZ®.
Outside the U.S. and Europe, data exclusivity will protect HETLIOZ® from generic competition for varying numbers of years depending on the country.
Additional patent applications directed to specific sleep disorders and to methods of treating patients with HETLIOZ®, if issued, would provide exclusivity for such indications and methods of treatment, potentially extending the effective patent protection period in the U.S., Europe, and other markets.

12

Fanapt® 
The NCE patent for Fanapt®, which expired in 2016 in the U.S. and in 2010 in other countries, was owned by Sanofi. Other patents and patent applications relating to Fanapt® are owned by Vanda.
Fanapt® metabolites, formulations, genetic markers and uses are the subject of numerous patent filings in which protection has been sought in the U.S., Europe, and other markets. In November 2013, a U.S. patent (U.S. 8,586,610) directed to a method of treating patients with Fanapt® based on genotype was issued to us by the U.S. Patent and Trademark Office. This patent, which was listed in the Orange Book in January 2015, is set to expire in 2027, potentially further extending the U.S. marketing exclusivity for Fanapt®. Additional method of treatment patents have been issued in the U.S. and listed in the Orange Book, with the latest expiration date in December 2031.
We have also filed and plan on filing additional patent applications covering the use of iloperidone (Fanapt® active ingredient) LAI formulations. Patents for the microsphere LAI formulation of Fanapt® expire in 2024 in the U.S. and 2022 in some markets in Europe. Patents for the aqueous microcrystals LAI formulation of Fanapt® expire in 2023 in the U.S. and in some markets in Europe. We have pending patent applications covering the use of iloperidone and plan on filing additional applications based on discoveries made throughout the development plan of this molecule.
In Europe, the law provides for ten years of regulatory exclusivity (with the potential for an additional year if the drug is developed for a significant new indication). No generic versions of Fanapt® would be permitted to be marketed or sold during the applicable regulatory exclusivity period in most European countries. Outside the U.S. and Europe, similar regulatory package protection periods may be available and could protect Fanapt® from generic competition for varying numbers of years depending upon the country.
Tradipitant
Lilly owns an NCE patent as well as patent applications directed to polymorphic forms of, and methods of making tradipitant. This patent protection was sought in the U.S. and in other countries worldwide. These patents and patent applications have been licensed to us. The NCE patent covering tradipitant expires in April 2023, except in the U.S., where it expires normally in June 2024, subject to any extension that may be received under Hatch-Waxman. We have filed additional patent applications based on discoveries made during recent studies with tradipitant.
VTR-297
VTR-297 is a small molecule HDAC inhibitor with potential use as a treatment for several oncology indications. We have pending patent applications covering the use of VTR-297 and plan on filing additional applications based on discoveries made throughout the development plan of this molecule.
VQW-765
Novartis owns an NCE patent as well as patent applications directed to methods of using VQW-765, VQW-765 formulations, and combinations of VQW-765 with other active pharmaceutical ingredients. In connection with the settlement agreement with Novartis relating to Fanapt®, we received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. The NCE patent expires normally in 2023 in the U.S., Europe, and other markets.
Portfolio of CFTR activators and inhibitors
Our portfolio of CFTR activators and inhibitors may have broad applicability in addressing a number of high unmet medical needs, including chronic dry eye, constipation, polycystic kidney disease, cholestasis and secretory diarrheas. We plan on filing applications based on discoveries made throughout the development plan of these compounds.
Other Patents
Aside from the NCE patents and other in-licensed patents discussed above, we have obtained or filed numerous patents and patent applications, most of which have been filed in key markets including the U.S., relating to our products and development compounds. In addition, we have filed numerous other patent applications relating to drugs not presently in clinical studies. The claims in these various patents and patent applications are directed to compositions of matter, including claims covering other products, pharmaceutical compositions and methods of use.

13

Proprietary Know-how
For proprietary know-how that is not appropriate for patent protection, processes for which patents are difficult to enforce and any other elements of our discovery process that involve proprietary know-how and technology that are not covered by patent applications, we generally rely on trade secret protection and confidentiality agreements to protect our interests. We require all of our employees, relevant consultants and advisors to enter into confidentiality agreements. Where it is necessary to share our proprietary information or data with outside parties, our policy is to make available only that information and data required to accomplish the desired purpose and only pursuant to a duty of confidentiality on the part of those parties.
Marketing and Sales
HETLIOZ® was approved in the U.S. for the treatment of Non-24 in January 2014 and commercially launched in the U.S. in April 2014. Additionally, HETLIOZ® was approved in the E.U. for the treatment of Non-24 in totally blind adults in July 2015. We commercially launched HETLIOZ® in Germany in August 2016. Given the range of potential indications for HETLIOZ®, we may pursue one or more partnerships for the development and commercialization of HETLIOZ® worldwide.
Fanapt® was approved in the U.S. for the treatment of schizophrenia in May 2009 and commercially launched in the U.S. in January 2010. We continue to explore the regulatory path and commercial opportunity for Fanapt® oral formulation in other regions.
Manufacturing
We currently utilize a virtual supply manufacturing and distribution chain in which we do not have our own facilities to manufacture commercial or clinical trial supplies of drugs and we do not have our own distribution facilities. Additionally, we do not intend to develop such facilities for any product in the near future. Instead, we contract with third parties for the manufacture, warehousing, order management, billing and collection and distribution of our products and product candidates.
We expect to continue to rely solely on third-party manufacturers to manufacture drug substance and final drug products for both clinical development and commercial sale. However, there are numerous factors that could cause interruptions in the supply of our products, including regulatory reviews, changes in our sources for manufacturing, disputes with a manufacturer, or financial instability of manufacturers, all of which could negatively impact our operation and our financial results.
We have agreements in place with Patheon Pharmaceuticals Inc. and Patheon Inc. (collectively, Patheon), subsidiaries of Thermo Fisher Scientific, for the manufacture of HETLIOZ® and Fanapt®.
In January 2014, we entered into a manufacturing agreement with Patheon for the manufacture of commercial supplies of HETLIOZ® 20 mg capsules at Patheon’s Cincinnati, Ohio manufacturing site. Under the HETLIOZ® manufacturing agreement, we are responsible for supplying the active pharmaceutical ingredient (tasimelteon) for HETLIOZ® to Patheon and have agreed to order from Patheon at least 80% of the total expected yearly production of new units of HETLIOZ® capsules. Patheon is responsible for manufacturing the HETLIOZ® 20 mg capsules, conducting quality control and stability testing, and packaging the HETLIOZ® capsules. The HETLIOZ® manufacturing agreement had an initial term of five years and automatically renews after the initial term for successive terms of one year each, unless either party gives notice of its intention to terminate the agreement at least 12 months prior to the end of the then current term. Either party may terminate the HETLIOZ® manufacturing agreement under certain circumstances upon specified written notice to the other party.
As part of a settlement agreement in 2014, we assumed Novartis’ manufacturing agreement with Patheon for the manufacture of commercial supplies of Fanapt®. In May 2016, we entered into a new manufacturing agreement with Patheon for the manufacture of commercial supplies of Fanapt® 1, 2, 4, 6, 8, 10 and 12 mg tablets at Patheon’s Mississauga, Ontario, Canada manufacturing site. Under the Fanapt® manufacturing agreement, we are responsible for sourcing the supply of the active pharmaceutical ingredient (iloperidone), and have agreed to order from Patheon at least 70% of the total expected yearly production of new units of Fanapt® tablets for the U.S. and other specified countries each year for the term of the agreement. Patheon is responsible for manufacturing the Fanapt® 1, 2, 4, 6, 8, 10 and 12 mg tablets, conducting quality control and stability testing, and packaging the Fanapt® tablets. The Fanapt® manufacturing agreement has an initial term of five years and will automatically renew after the initial term for successive terms of one year each, unless either party gives notice of its intention to terminate the agreement at least 12 months prior to the end of the then current term. Either party may terminate the Fanapt® manufacturing agreement under certain circumstances upon specified written notice to the other party.


14

Research and Development
We have built a research and development organization that includes extensive expertise in the scientific disciplines of pharmacogenetics and pharmacogenomics. We operate cross-functionally and are led by an experienced research and development management team. We use rigorous project management techniques to assist us in making disciplined strategic research and development program decisions and to help limit the risk profile of our product pipeline. We also access relevant market information and key opinion leaders in creating target product profiles and, when appropriate, as we advance our programs towards commercialization. We engage third parties to conduct portions of our preclinical research. In addition, we utilize multiple clinical sites to conduct our clinical trials; however, we are not substantially dependent upon any one of these sites for our clinical trials nor do any of them conduct a major portion of our clinical trials.
Major Customers
Our revenues are generated from product sales and are concentrated with specialty pharmacies, including Diplomat Pharmacy, Inc. (a subsidiary of UnitedHealth Group) and Accredo (a subsidiary of Express Scripts), and wholesalers, including Cardinal Health, Inc., AmerisourceBergen Drug Corporation, and McKesson Corporation. These 5 major customers each accounted for more than 10% of total revenues and, as a group, represented 96% of total revenues for the year ended December 31, 2019.
Competition
The pharmaceutical industry, in particular, is highly competitive and includes a number of established large and mid-sized companies with greater financial, technical and personnel resources than we have and significantly greater commercial infrastructures than we have. Our market segment also includes several smaller emerging companies whose activities are directly focused on our target markets and areas of expertise. Our products, once approved for commercial use, will compete with numerous therapeutic treatments offered by these competitors. While we believe that our products will have certain favorable features, existing and new treatments may also possess advantages. Additionally, the development of other drug technologies and methods of disease prevention are occurring at a rapid pace. These developments may render our products or technologies obsolete or noncompetitive.
We believe the primary competitors for HETLIOZ® and Fanapt® are as follows:
 
•
For HETLIOZ® in the treatment of Non-24, there are no FDA approved direct competitors. Sedative-Hypnotic treatments for certain sleep related disorders include, Ambien® (zolpidem) by Sanofi (including Ambien CR®), Lunesta® (eszopiclone) by Sunovion Pharmaceuticals Inc., Sonata® (zaleplon) by Pfizer Inc., Rozerem® (ramelteon) by Takeda Pharmaceuticals Company Limited, Silenor® (doxepin) by Pernix Therapeutics, Belsomra® (suvorexant) by Merck & Co., Inc., generic products such as zolpidem, trazodone and doxepin, and over-the-counter remedies such as Benadryl® and Tylenol PM®. The class of melatonin agonists includes Rozerem® (ramelteon) by Takeda Pharmaceuticals Company Limited, Valdoxan® (agomelatine) by Servier, Circadin® (long-acting melatonin) by Neurim Pharmaceuticals Ltd. and the food supplement melatonin. Shift work and excessive sleepiness disorder treatments include Nuvigil® (armodafinil) and Provigil® (modafinil) both by Teva Pharmaceutical Industries Ltd.
•
For Fanapt® in the treatment of schizophrenia, the atypical antipsychotics competitors are Risperdal® (risperidone), including the LAI formulation Risperdal Consta® and Invega® (paliperidone), including the LAI formulation Invega® Sustenna®, each by Ortho-McNeil-Janssen Pharmaceuticals, Inc., Zyprexa® (olanzapine), including the LAI formulation Zyprexa® RelprevvTM, each by Lilly, Seroquel® and Seroquel XR® (quetiapine) by AstraZeneca PLC, Abilify® (aripiprazole) by Otsuka America Pharmaceutical Inc., Abilify Maintena® (the LAI formulation of Abilify®) by Lundbeck/Otsuka America Pharmaceutical Inc., Geodon® (ziprasidone) by Pfizer Inc., Saphris® (asenapine) by Allergan plc, Latuda® (lurasidone) by Sunovion Pharmaceuticals Inc., Rexulti® (brexpiprazole) by Lundbeck/Otsuka America Pharmaceutical, Inc., AristadaTM (aripiprazole lauroxil) extended-release injectable suspension by Alkermes, Inc., VraylarTM (cariprazine) by Teva Pharmaceutical Industries Ltd., CALYPTA® (lumapteperone) by Intra-Cellular Therapies, and generic clozapine, as well as the typical antipsychotics haloperidol, chlorpromazine, thioridazine, and sulpiride (all of which are generic).
Our ability to compete successfully will depend in part on our ability to utilize our pharmacogenetics and pharmacogenomics and drug development expertise to identify, develop, secure rights to and obtain regulatory approvals for promising pharmaceutical products before others are able to develop competitive products. Our ability to compete successfully will also depend on our ability to attract and retain skilled and experienced personnel. Additionally, our ability to compete may

15

be affected because insurers and other third-party payors in some cases seek to encourage the use of cheaper, generic products, which could make our products less attractive.
Government Regulation
United States government regulation
Exclusivity
The FDA provides periods of regulatory exclusivity, which provides the holder of an approved NDA limited protection from new competition in the marketplace for the innovation represented by its approved drug for a period of three or five years following the FDA’s approval of the NDA. Five years of exclusivity are available to NCEs. An NCE is a drug that contains no active moiety that has been approved by the FDA in any other NDA. An active moiety is the molecule or ion, excluding those appended portions of the molecule that cause the drug to be an ester, salt, including a salt with hydrogen or coordination bonds, or other noncovalent, or not involving the sharing of electron pairs between atoms, derivatives, such as a complex (i.e., formed by the chemical interaction of two compounds), chelate (i.e., a chemical compound), or clathrate (i.e., a polymer framework that traps molecules), of the molecule, responsible for the therapeutic activity of the drug substance. During the exclusivity period, the FDA may not accept for review or approve an abbreviated new drug application (ANDA) or a 505(b)(2) NDA submitted by another company that contains the previously approved active moiety. An ANDA or 505(b)(2) application, however, may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed. If a product is not eligible for the NCE exclusivity, it may be eligible for three years of exclusivity. Three-year exclusivity is available to the holder of an NDA, including a 505(b)(2) NDA, for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials, other than bioavailability or bioequivalence trials, was essential to the approval of the application and was conducted or sponsored by the applicant. This three-year exclusivity period protects against FDA approval of ANDAs and 505(b)(2) NDAs for the condition of the new drug’s approval. As a general matter, three-year exclusivity does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for generic versions of the original, unmodified drug product. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and efficacy.
Orphan Drug Act
Under the Orphan Drug Act, the FDA may grant Orphan Drug Designation to drugs intended to treat a rare disease or condition, generally a disease or condition that affects fewer than 200,000 individuals in the U.S. Orphan Drug Designation must be requested before submitting an NDA. After the FDA grants Orphan Drug Designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan Drug Designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA Orphan Drug Designation is entitled to a seven-year exclusive marketing period in the United States for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of Orphan Drug Designation are tax credits for certain research and development expenses and a waiver of the NDA application user fee.
Fast Track and Breakthrough Therapy Designations
The FDA is required to facilitate the development and expedite the review of drugs that are intended for the treatment of a serious or life-threatening condition for which there is no effective treatment, and which demonstrate the potential to address unmet medical needs for the condition. Under the Fast Track program, the sponsor of a new product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the submission of the IND for the product candidate. The FDA must determine if the product candidate qualifies for Fast Track and Breakthrough Therapy designations within 60 days after receipt of the sponsor’s request. For Fast Track and Breakthrough Therapy products, the sponsor may have more frequent interactions with the FDA and the FDA may initiate review of sections of a Fast Track or Breakthrough Therapy product’s NDA before the application is complete. This rolling review is available if the applicant provides and the FDA approves a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA’s time period goal for reviewing a Fast Track or Breakthrough Therapy application does not begin until the last section of the NDA is submitted. In addition, the Fast Track and Breakthrough Therapy designations may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in

16

the clinical trial process. A Fast Track and Breakthrough Therapy designated product candidate would ordinarily meet the FDA’s criteria for priority review.
NDA Submission and Review by the FDA
Assuming successful completion of the required clinical trials and preclinical testing, among other items, the results of product development, including chemistry, manufacture and controls, nonclinical studies and clinical trials are submitted to the FDA, along with proposed labeling, as part of an NDA. The submission of an NDA requires payment of a substantial user fee to the FDA. These user fees must be paid at the time of the first submission of the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions are available in some circumstances. One basis for a waiver of the application user fee is if the applicant employs fewer than 500 employees, including employees of affiliates, the applicant does not have an approved marketing application for a product that has been introduced or delivered for introduction into interstate commerce, and the applicant, including its affiliates, is submitting its first marketing application.
In addition, under the Pediatric Research Equity Act (PREA), an NDA or supplement to an NDA for a new active ingredient, indication, dosage form, dosage regimen or route of administration must contain data that are adequate to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults or full or partial waivers from the pediatric data requirements.
The FDA may refer applications for drugs that contain active ingredients, including any ester or salt of the active ingredients that have not previously been approved by the FDA to an advisory committee or provide in an action letter a summary of the reasons for not referring it to an advisory committee. The FDA may also refer drugs which present difficult questions of safety, purity or potency to an advisory committee. An advisory committee is typically a panel that includes clinicians and other experts who review, evaluate and make a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.
The FDA reviews applications to determine, among other things, whether a product is safe and effective for its intended use and whether the manufacturing controls are adequate to assure and preserve the product’s identity, strength, quality and purity. Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities, including contract manufacturers and subcontracts, are in compliance with current Good Manufacturing Practices (cGMP) requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with Good Clinical Practices (GCPs).
Once the FDA receives an application, it has 60 days to review the NDA to determine if it is substantially complete to permit a substantive review, before it accepts the application for filing. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA. The FDA’s NDA review times may differ based on whether the application is a standard review or priority review application. The FDA may give a priority review designation to drugs that are intended to treat serious conditions and provide significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act (PDUFA), the FDA has set the review goal of 10 months from the 60-day filing date to complete its initial review of a standard NDA for a new molecular entity (NME) and make a decision on the application. For non-NME standard applications, the FDA has set the review goal of 10 months from the submission date to complete its initial review and to make a decision on the application. For priority review applications, the FDA has set the review goal of reviewing NME NDAs within six months of the 60-day filing date and non-NME applications within six months of the submission date. Such deadlines are referred to as the PDUFA date. The PDUFA date is only a goal and the FDA does not always meet its PDUFA dates. The review process and the PDUFA date may also be extended if the FDA requests or the NDA sponsor otherwise provides additional information or clarification regarding the submission.
Once the FDA’s review of the application is complete, the FDA will issue either a Complete Response Letter, or CRL, or approval letter. A CRL indicates that the review cycle of the application is complete, and the application is not ready for approval. A CRL generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing, or other information or analyses in order for the FDA to reconsider the application. The FDA has the goal of reviewing 90% of application resubmissions in either two or six months of the resubmission date, depending on the kind of resubmission. Even with the submission of additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions

17

have been met to the FDA’s satisfaction, the FDA may issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.
The FDA may delay or refuse approval of an NDA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product, or impose other conditions, including distribution restrictions or other risk management mechanisms. For example, the FDA may require a risk evaluation and mitigation strategy (REMS), as a condition of approval or following approval to mitigate any identified or suspected serious risks and ensure safe use of the drug. The FDA may prevent or limit further marketing of a product, or impose additional post-marketing requirements, based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements, FDA notification and FDA review and approval. Further, should new safety information arise, additional testing, product labeling or FDA notification may be required.
If regulatory approval of a product is granted, such approval may entail limitations on the indicated uses for which such product may be marketed or may include contraindications, warnings or precautions in the product labeling, which has resulted in a boxed warning. The FDA also may not approve the inclusion of labeling claims necessary for successful marketing. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. In addition, the FDA may require Phase IV post-marketing studies to monitor the effect of approved products and may limit further marketing of the product based on the results of these post-marketing studies.
Post-approval Requirements
Any products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including manufacturing, periodic reporting, product sampling and distribution, advertising, promotion, drug shortage reporting, compliance with any post-approval requirements imposed as a conditional of approval such as Phase 4 clinical trials, Risk Evaluation and Mitigation Strategy (REMS) and surveillance, recordkeeping and reporting requirements, including adverse experiences.
After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual program user fee requirements for any approved products, as well as new application fees for supplemental applications with clinical data.
Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and to list their drug products and are subject to periodic announced and unannounced inspections by the FDA and these state agencies for compliance with cGMPs and other requirements, which impose procedural and documentation requirements upon us and our third-party manufacturers. We cannot be certain that we or our present or future suppliers will be able to comply with the cGMP regulations and other FDA regulatory requirements.
Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented, or FDA notification. FDA regulations also require investigation and correction of any deviations from cGMPs and specifications and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.
Later discovery of previously unknown problems with a product, including adverse events (AEs) of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in withdrawal of marketing approval, mandatory revisions to the approved labeling to add new safety information or other limitations, imposition of post-market studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a REMS program, among other consequences.
The FDA closely regulates the marketing and promotion of drugs. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA. Physicians, in their independent professional medical judgement, may prescribe legally available products for uses that are not described in the product’s labeling and that differ from those tested by us and approved by the FDA. We, however, are prohibited from marketing or promoting drugs for uses outside of the approved labeling but may share truthful and not misleading information that is otherwise consistent with the product’s approved labeling.

18

In addition, the distribution of prescription pharmaceutical products, including samples, is subject to the Prescription Drug Marketing Act (PDMA), which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. The Drug Supply Chain Security Act also imposes obligations on manufacturers of pharmaceutical products related to product and tracking and tracing.
Failure to comply with any of the FDA’s requirements could result in significant adverse enforcement actions. These include a variety of administrative or judicial sanctions, such as refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, imposition of a clinical hold or termination of clinical trials, warning letters, untitled letters, cyber letters, modification of promotional materials or labeling, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production or distribution, debarment, injunctions, fines, consent decrees, corporate integrity agreements, refusals of government contracts and new orders under existing contracts, exclusion from participation in federal and state healthcare programs, restitution, disgorgement or civil or criminal penalties, including fines and imprisonment. Any of these sanctions could result in adverse publicity, among other adverse consequences.
The Hatch-Waxman Act
In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent with claims that cover the applicant’s drug. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA’s Orange Book. Drugs listed in the Orange Book can, in turn be cited by potential competitors in support of approval of an ANDA. An ANDA provides for marketing of a drug that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. ANDA applicants are not required to conduct or submit results of preclinical or clinical tests to prove the safety or effectiveness of their drug, other than the requirement for bioequivalence testing. Drugs approved in this way are commonly referred to as “generic equivalents” to the listed drug, and can often be substituted by pharmacists under prescriptions written for the original listed drug.
The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved drug in the Orange Book. Specifically, the applicant must certify that: (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or (iv) the listed patent is invalid or will not be infringed by the new drug. A certification that the new drug will not infringe the already approved drug’s listed patents or that such patents are invalid is called a Paragraph IV certification. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced drug have expired.
If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant.
The ANDA application also will not be approved until any non-patent exclusivity, such as exclusivity for obtaining approval of a NCE, listed in the Orange Book for the referenced drug has expired. The U.S. Drug Price Competition and Patent Term Restoration Act of 1984, more commonly known as the “Hatch-Waxman Act,” provides a period of five years following approval of a drug containing no previously approved active ingredients, during which ANDAs for generic versions of those drugs cannot be submitted unless the submission contains a Paragraph IV challenge to a listed patent, in which case the submission may be made four years following the original drug approval. Federal law provides for a period of three years of exclusivity following approval of a listed drug that contains previously approved active ingredients but is approved in a new dosage form, route of administration or combination, or for a new use, the approval of which was required to be supported by new clinical trials conducted by or for the sponsor, during which FDA cannot grant effective approval of an ANDA based on that listed drug.
Foreign regulation
Regardless of whether we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval.

19

The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement also vary greatly from country to country. Although governed by the applicable country, clinical trials conducted outside of the U.S. typically are administered with the three-Phase sequential process that is discussed above under “United States government regulation.” However, the foreign equivalent of an IND is not a prerequisite to performing pilot studies or Phase I clinical trials.
Under E.U. regulatory systems, we may submit Marketing Authorization Applications (MAAs) either under a centralized or decentralized procedure. The centralized procedure, which is available for drugs produced by biotechnology or which are highly innovative, provides for the grant of a single marketing authorization that is valid for all E.U. member states. This authorization is a marketing authorization approval. The decentralized procedure provides for mutual recognition of national approval decisions. Under this procedure, the holder of a national marketing authorization may submit an application to the remaining member states. Within 90 days of receiving the applications and assessment report, each member state must decide whether to recognize approval. This procedure is referred to as the mutual recognition procedure. In addition, regulatory approval of prices is required in most countries other than the U.S. We face the risk that the resulting prices would be insufficient to generate an acceptable return to us.
Pharmaceutical Coverage, Pricing and Reimbursement
Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Sales of products will depend, in part, on the extent to which the costs of the products will be covered by third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may also limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication.
In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. A payor’s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development.
The containment of healthcare costs has become a priority of federal, state and foreign governments and the prices of drugs have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company’s revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future. In the E.U., pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular drug candidate to currently available therapies, or so called health technology assessments, in order to obtain reimbursement or pricing approval. For example, the E.U. provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. E.U. member states may approve a specific price for a drug product or may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations for drug products may not provide favorable reimbursement and pricing arrangements.
A primary trend in the U.S. healthcare industry and elsewhere is cost containment. There have been a number of federal and state proposals during the last several years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the U.S.

20

The U.S. and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. By way of example, the 2010 Affordable Care Act (ACA), among other things, includes changes to the coverage and payment for products under government health care programs. Among the provisions of the ACA of importance to potential drug candidates are:
•
an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs, although this fee does not apply to sales of certain products approved exclusively for orphan indications;
•
expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer’s Medicaid rebate liability;
•
expanded manufacturers’ rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and generic drugs and revising the definition of “average manufacturer price,” or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices and extending rebate liability to prescriptions for individuals enrolled in Medicaid managed care plans;
•
addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;
•
expanded the types of entities eligible for the 340B drug discount program;
•
established the Medicare Part D coverage gap discount program by requiring manufacturers to provide a 50% point‑of‑sale‑discount off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturers’ outpatient drugs to be covered under Medicare Part D. The Bipartisan Budget Act of 2018 increased the manufacturer discount from 50% to 70% effective in 2019;
•
established a new Patient‑Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;
•
established the Independent Payment Advisory Board (IPAB), which has authority to recommend certain changes to the Medicare program to reduce expenditures by the program that could result in reduced payments for prescription drugs. However, the IPAB implementation has been not been clearly defined. The ACA provided that under certain circumstances, IPAB recommendations will become law unless Congress enacts legislation that will achieve the same or greater Medicare cost savings; and
•
established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. Funding has been allocated to support the mission of the Center for Medicare and Medicaid Innovation from 2011 to 2019.
Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include the Budget Control Act of 2011, which, among other things, led to aggregate reductions to Medicare payments to providers of up to 2% per fiscal year that started in 2013 and will stay in effect through 2024 unless additional congressional action is taken, and the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. Further, there have been several recent U.S. congressional inquiries and proposed state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products.
These healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price for any approved product and/or the level of reimbursement physicians receive for administering any approved product. Reductions in reimbursement levels may negatively impact the prices we can charge or the frequency with which products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Since enactment of the ACA, there have been numerous legal challenges and congressional actions to repeal and replace provisions of the law. Various pieces of

21

legislation have been proposed and/or passed by each of the chambers of Congress to achieve those objectives, but to date, few of these measures have been implemented.
The current presidential administration has also taken executive actions to undermine or delay implementation of the ACA. In January 2017, the President signed an Executive Order directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. In October 2017, the President signed a second Executive Order allowing for the use of association health plans and short-term health insurance, which may provide fewer health benefits than the plans sold through the ACA exchanges. At the same time, the Administration announced that it will discontinue the payment of cost-sharing reduction (CSR) payments to insurance companies until Congress approves the appropriation of funds for such CSR payments. The loss of the CSR payments is expected to increase premiums on certain policies issued by qualified health plans under the ACA and is currently being challenged in court.
More recently, with enactment of the Tax Cuts and Jobs Act of 2017 (TCJA), Congress repealed the “individual mandate.” The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective on January 1, 2019. According to the Congressional Budget Office, the repeal of the individual mandate will cause 13 million fewer Americans to be insured in 2027 and premiums in insurance markets may rise. Additionally, in January 2018, the President signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including the so-called “Cadillac” tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices.  In December 2018, a federal district court judge in Texas found the ACA to be unconstitutional, although the ruling was stayed while the case is appealed.
Further, there have been several recent U.S. congressional inquiries and both federal and state legislation, proposed or enacted, designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, Congress and the current presidential administration have each indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. In May 2018, the Administration issued "American Patients First," a multi-faceted blueprint to lower drug prices. The Administration has taken administrative steps to implement the blueprint, including through proposing sweeping demonstration projects aimed at putting downward pressure on drug prices. At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing.
Employees
We had 284 full-time employees as of December 31, 2019, compared with 270 employees as of December 31, 2018. None of our employees are represented by a labor union. We have not experienced any work stoppages and consider our employee relations to be good.
Corporate Information
We were incorporated in Delaware in 2002. Our principal executive offices are located at 2200 Pennsylvania Avenue NW, Suite 300E, Washington D.C. 20037, and our telephone number is (202) 734-3400. Our website address is www.vandapharma.com and the information contained in, or that can be accessed through, our website is not part of this Annual Report and should not be considered part of this Annual Report.
Available Information
We file annual, quarterly, and current reports, proxy statements, and other documents with the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934 (Exchange Act). The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers, including us, that file electronically with the SEC.

22

We also make available free of charge on our Internet website at www.vandapharma.com our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and, if applicable, amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.
Our code of ethics, other corporate policies and procedures, and the charters of our Audit Committee, Compensation Committee and Nominating/Corporate Governance Committee are available through our Internet website at www.vandapharma.com.
ITEM 1A.
RISK FACTORS
Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described below, any one or more of which could, directly or indirectly, cause our actual operating results and financial condition to vary materially from past, or anticipated future, operating results and financial condition. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results and the price of our common stock.
The following discussion of risk factors contains forward-looking statements. These risk factors may be important to understanding any statement in this Annual Report or elsewhere. The following information should be read in conjunction with the consolidated financial statements and related notes in Part II, Item 8, Financial Statements and Supplementary Data and Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Because of the following factors, as well as other factors affecting our financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.
Risks related to our business and industry
We are dependent on the commercial success of HETLIOZ® and Fanapt®.
Our future success is currently substantially dependent upon the commercial success of HETLIOZ® for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and Fanapt® for the treatment of schizophrenia.
In January 2014, the U.S. Food and Drug Administration (FDA) approved our New Drug Application (NDA) for HETLIOZ® for the treatment of Non-24 and in April 2014, we commenced the U.S. commercial launch of HETLIOZ®. In July 2015, the European Commission (EC) granted centralized marketing authorization with unified labeling for HETLIOZ® for the treatment of Non-24 in totally blind adults, and in August 2016 we commenced the commercial launch of HETLIOZ® in Germany. This authorization is valid in the 27 countries that are members of the European Union (E.U.), as well as European Economic Area members Iceland, Liechtenstein and Norway. We have applied for renewal of this marketing authorization which expires in the ordinary course in July 2020.
In the fourth quarter of 2014, we acquired the U.S. commercial rights to Fanapt®, and began selling, marketing and distributing Fanapt® in the U.S.
Our ability to generate significant product revenue from sales of HETLIOZ® and Fanapt®, both in the U.S. and abroad, in the near term will depend on, among other things, our ability to:
 
•
defend our patents and intellectual property from generic competition;
•
maintain commercial manufacturing arrangements with third-party manufacturers;
•
produce, through a validated process, sufficiently large quantities of inventory of our products to meet demand;
•
continue to maintain and grow a wide variety of internal sales, distribution and marketing capabilities sufficient to sustain growth in sales of our products;
•
gain broad acceptance of our products from physicians, health care payors, patients, pharmacists and the medical community;
•
properly price and obtain adequate coverage and reimbursement of these products by governmental authorities, private health insurers, managed care organizations and other third-party payors;

23

•
maintain compliance with ongoing labeling, packaging, storage, advertising, promotion, recordkeeping, safety and other post-market requirements;
•
obtain regulatory approval to expand the labeling of our approved products for additional indications;
•
obtain regulatory approval for HETLIOZ® or Fanapt® in additional countries;
•
renew and maintain our existing regulatory approval for HETLIOZ® in Europe;
•
adequately protect against and effectively respond to any claims by holders of patents and other intellectual property rights that our products infringe their rights; and
•
adequately protect against and effectively respond to any unanticipated adverse effects or unfavorable publicity that develops in respect to our products, as well as the emergence of new or existing competitive products, which may be proven to be more clinically effective and cost-effective.
We expect to continue to incur significant expenses and to utilize a substantial portion of our cash resources as we continue the commercialization of HETLIOZ® and Fanapt®, evaluate foreign market opportunities for HETLIOZ® and Fanapt® and continue to grow our operational capabilities, both domestically and abroad. This activity represents a significant investment in the commercial success of HETLIOZ® and Fanapt®, which is uncertain.
If our continued commercial efforts are not successful with respect to HETLIOZ® and Fanapt® in the U.S., Europe or other jurisdictions in which these products may be approved for sale, our ability to generate increased product sales revenue may be jeopardized.
The cost of growing and maintaining a sales, marketing and distribution organization may exceed its cost effectiveness. If we fail to continue to develop sales, marketing and distribution capabilities, if sales efforts are not effective or if costs of developing sales, marketing and distribution capabilities exceed their cost effectiveness, our business, results of operations and financial condition could be materially adversely affected.
Growth of HETLIOZ® and Fanapt® may be slow or limited for a variety of reasons including competing products or unanticipated safety issues. If either HETLIOZ® or Fanapt® is not successful in gaining broad commercial acceptance, our business would be harmed.
Any increase in sales of HETLIOZ® and Fanapt® will be dependent on several factors, including our ability to educate physicians and to increase physician awareness of the benefits of our products relative to competing products. The degree of further market acceptance of any of our products or market acceptance of approved product candidates among physicians, patients, health care payors and the medical community will depend on a number of factors, including but not limited to:
 
•
acceptable evidence of safety and efficacy;
•
relative convenience and ease of administration;
•
the prevalence and severity of any adverse side effects;
•
availability of alternative treatments; and
•
pricing and cost effectiveness.
In addition, HETLIOZ® and Fanapt® are subject to continual review by the FDA, and we cannot assure that newly discovered or reported safety issues will not arise. With the use of any newly marketed drug by a wider patient population, serious adverse events may occur from time to time that initially do not appear to relate to the drug itself. Any safety issues could cause us to suspend or cease marketing of our approved products, cause us to modify how we market our approved products, subject us to substantial liabilities and adversely affect our revenues and financial condition. In the event of a withdrawal of either HETLIOZ® or Fanapt® from the market, our revenues would decline significantly and our business would be seriously harmed.
If the FDA does not accept for filing the NDAs that we may submit for tradipitant for the treatment of atopic dermatitis, the treatment of gastroparesis, and the treatment of motion sickness, or the FDA determines that our clinical trial results for tradipitant for the treatment of atopic dermatitis, the treatment of gastroparesis or the treatment of motion sickness do not demonstrate adequate safety and efficacy, or the FDA does not approve an applicable PDUFA-VI date, continued development of tradipitant will be significantly delayed or terminated, our business will be significantly harmed, and the market price of our stock could decline.

24

In October 2019, we completed enrollment in EPIONE, a Phase III clinical study of tradipitant for the treatment of pruritus in atopic dermatitis and commenced enrollment in EPIONE 2, a second Phase III clinical study of tradipitant for the treatment of atopic dermatitis. Additionally, in the second quarter of 2019 we initiated a Phase III clinical study of tradipitant for the treatment of gastroparesis. If the results of our ongoing studies of tradipitant for the treatment of atopic dermatitis, gastroparesis and/or motion sickness are positive, we will likely submit an NDA with the FDA for these indications. Any adverse developments or results or perceived adverse developments or results with respect to our pre-NDA meeting with the FDA, our regulatory submission or the tradipitant clinical programs in any or all indications will significantly harm our business and could cause the market price of our stock to decline. Examples of such adverse developments include, but are not limited to:
•
the FDA determining that additional clinical studies are required with respect to tradipitant for the treatment of atopic dermatitis and/or the treatment of gastroparesis and/or the treatment of motion sickness;
•
safety, efficacy or other concerns arising from clinical or non-clinical studies in these programs; or
•
the FDA determining that the tradipitant clinical trial programs raise safety concerns or do not demonstrate adequate efficacy.

In April 2018, we submitted a protocol amendment to the FDA, proposing a 52-week open-label extension (OLE) period for patients who had completed the randomized clinical study (2301 study) of tradipitant as a monotherapy in the treatment of gastroparesis. In May 2018, based on feedback from the FDA, we amended the protocol to limit the duration of treatment in the 2301 study to a total of three months, while continuing to seek further dialogue with the FDA on extending the study duration to 52-weeks. As a part of this negotiation process, in September 2018, we submitted a new follow-on 52-week OLE protocol to the FDA (2302 study) for patients who had completed the 2301 study. While waiting for further feedback, we did not enroll any patients in any study beyond 12 weeks. In December 2018, the FDA imposed a partial clinical hold (PCH) on the two proposed studies, stating that we are required first to conduct additional chronic toxicity studies in canines, monkeys or minipigs before allowing patients access in any clinical protocol beyond 12 weeks. At that time, the FDA informed us that the original PCH was not based on any safety or efficacy data related to tradipitant, but rather that these additional toxicity studies were required by a guidance document. Subsequently, the FDA has taken the position that an additional study was required in order for the FDA to have adequate toxicology data to undertake a risk analysis of tradipitant.
On February 5, 2019, we filed a lawsuit against the FDA in the United States District Court for the District of Columbia (DC District Court), challenging the FDA’s legal authority to issue the PCH, and seeking an order to set it aside. In February 2019, the FDA filed a Motion for Voluntary Remand to the Agency and for a Stay of the Case. In March 2019, the DC District Court granted the FDA’s request for voluntary remand and returned the matter to the FDA for further consideration. In April 2019, the FDA provided its remand response, in which it indicated that, upon review of scientific literature and tradipitant data, it believes that a PCH continues to be appropriate until we have safety data from a nine-month non-rodent toxicity study. In May 2019, we filed an amended complaint, and in July 2019, we filed a Motion for Summary Judgment based on our continuing belief after review of the FDA’s remand response that additional chronic toxicity studies are unjustified, and that we have provided the FDA with sufficient information regarding the safety of tradipitant to justify the continued study of tradipitant in patients beyond 12 weeks, in accordance with applicable law and FDA regulations. The FDA filed a reply and cross-motion for summary judgment in October 2019 and an oral hearing was held on December 13, 2019. On January 31, 2020, the Court granted the FDA's cross-motion for summary judgment and granted judgment in favor of the FDA on our claims. We are evaluating our options, including a potential appeal, and we intend to continue vigorously pursuing our interests in the matter. (See Part I, Item 3, Legal Proceedings of this Annual Report for additional information.)
We do not expect the PCH to have a material impact on our ongoing clinical studies in atopic dermatitis, gastroparesis or motion sickness, each of which is under 12 weeks in duration and are not subject to the PCH. Nor do we expect the PCH to impact the potential timing of the submission of an NDA with the FDA. If the matter has not been fully resolved prior to the date on which we are ready to submit the first NDA for tradipitant, then we may choose to submit with the safety data we have available at that time. We may pursue additional studies of durations in excess of 12 weeks in countries where the conduct of such studies may be permitted (or we may choose to file for approval of a limited indication). If the FDA continues to recommend that we conduct a long-term safety study of 12 months duration in humans and determines that our NDA does not contain safety data sufficient for approval, it may not accept the NDA for filing. We will continue to reassess the situation as events unfold.
Even if we decide to appeal the decision and ultimately prevail, there can be no assurances that the FDA will not attempt to impose a clinical hold or PCH on other grounds. Any litigation related to this matter is subject to uncertainties and we may not prevail. Because the PCH could, however, impede our ability to conduct longer term studies of tradipitant, whether the PCH impacts the timing or approvability of NDA filings with the FDA for any indication will depend on a number of

25

factors, including whether the PCH is resolved through the potential appeals of the lawsuit described above, whether we resolve the PCH out of court through discussions with the FDA, and, in addition to the non-clinical animal studies, whether the FDA considers the clinical trials that we conduct to be sufficient. A delay in filing, or FDA delay or denial of approval of NDA filings for tradipitant for the treatment of atopic dermatitis, gastroparesis or motion sickness could materially adversely impact our business.
If the FDA does not approve our supplemental New Drug Application (sNDA) for HETLIOZ® for the treatment jet lag disorder, or does not agree to an acceptable regulatory path forward for HETLIOZ® for the treatment of Smith-Magenis Syndrome (SMS) or continued development of tasimelteon for the treatment of either jet lag disorder or SMS is significantly delayed or terminated, our business will be significantly harmed, and the market price of our stock could decline.
In December 2018, we announced that the FDA had accepted the HETLIOZ® sNDA for the treatment of jet lag disorder. We received a complete response letter in August 2019 in which the FDA asserted that the measures of the study were of unclear clinical significance and declined to approve our sNDA. We met with the FDA to discuss the complete response letter in a Post Action meeting and are in ongoing discussions with the FDA on the regulatory path forward.
For HETLIOZ® for the treatment of SMS, we met with the FDA in the fourth quarter of 2019 to discuss the HETLIOZ® SMS clinical study results. We submitted an sNDA, including data for a liquid formulation, and expect regulatory action by the FDA in 2020.
Any additional adverse developments or results or perceived adverse developments or results with respect to our regulatory submission for jet lag disorder or our meeting with the FDA to determine the regulatory path forward for HETLIOZ® for the treatment of SMS will significantly harm our business and could cause the market price of our stock to decline. Examples of such adverse developments include, but are not limited to:
•
the FDA determining that additional clinical studies are required with respect to either the SMS or jet lag disorder program;
•
safety, efficacy or other concerns arising from clinical or non-clinical studies in either the SMS or jet lag disorder program, or the manufacturing processes or facilities used for either the SMS or jet lag disorder programs; or
•
the FDA determining that either the SMS or jet lag disorder program raises safety concerns or does not demonstrate substantial evidence of efficacy.
We may enter into third party collaborations from time to time in order to develop and commercialize our products. If we are unable to identify or enter into an agreement with any material third-party collaborator, if our collaborations with any such third-party are not commercially successful or if our agreement with any such third-party is terminated or allowed to expire, we could be adversely affected financially or our business reputation could be harmed.
Our business strategy includes entering into collaborations with corporate collaborators for the commercialization of HETLIOZ®, Fanapt® and our other products. While we are not currently party to any material commercial collaborative arrangements, areas in which we may potentially enter into third-party collaboration arrangements include joint sales and marketing arrangements for sales and marketing in certain E.U. countries and elsewhere outside of the U.S., and future product development arrangements. If we are unable to identify or enter into an agreement with any material third-party collaborator, this could result in an adverse effect on our business, results of operations or financial condition. Any arrangements we do enter into may not be scientifically or commercially successful. The termination of any of these arrangements might adversely affect our ability to develop, commercialize and market our products.
The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Our collaborators will have significant discretion in determining the efforts and resources that they will apply to these collaborations. We expect that the risks which we face in connection with these future collaborations will include the following:
•
our collaboration agreements are expected to be for fixed terms and subject to termination under various circumstances, including, in many cases, on short notice without cause;
•
our collaborators may develop and commercialize, either alone or with others, products and services that are similar to or competitive with our products which are the subject of their collaboration with us; and
•
our collaborators may change the focus of their commercialization efforts.
In recent years there have been a significant number of mergers and consolidations in the pharmaceutical and biotechnology industries, some of which have resulted in the participant companies reevaluating and shifting the focus of their

26

business following the completion of these transactions. The ability of our products to reach their potential could be limited if any of our future collaborators decreases or fails to increase spending relating to such products.
Collaborations with pharmaceutical companies and other third-parties often are terminated or allowed to expire by the other party. With respect to our future collaborations, any such termination or expiration could adversely affect us financially as well as harm our business reputation.
Even after we obtain regulatory approvals of a product, acceptance of the product in the marketplace is uncertain and failure to achieve commercial acceptance will prevent or delay our ability to generate significant revenue from such product.
Even after obtaining regulatory approvals for the sale of our products, the commercial success of these products will depend, among other things, on their acceptance by physicians, patients, third-party payors and other members of the medical community as therapeutic and cost-effective alternatives to competing products and treatments. The degree of market acceptance of any product will depend on a number of factors, including the demonstration of its safety and efficacy, its cost-effectiveness, its potential advantages over other therapies, the reimbursement policies of government and third-party payors with respect to such product, our ability to attract and maintain corporate partners, including pharmaceutical companies, to assist in commercializing our products, receipt of regulatory clearance of marketing claims for the uses that we are developing and the effectiveness of our marketing and distribution capabilities. If our approved products fail to gain market acceptance or do not become widely accepted by physicians, patients, third-party payors and other members of the medical community, it is unlikely that we will ever become profitable on a sustained basis or achieve significant revenues.
We rely and will continue to rely on outsourcing arrangements for many of our activities, including preclinical and clinical development and supply of HETLIOZ®, Fanapt® and our other products.
As of December 31, 2019, we had 284 full-time employees. We rely on outsourcing arrangements for a significant portion of our activities, including distribution, preclinical and clinical research and development, data collection and analysis and manufacturing, as well as for certain functions as a public company. We have limited control over these third parties and we cannot guarantee that they will perform their obligations in an effective and timely manner.
Disruptions to our HETLIOZ® or Fanapt® supply chains could materially affect our level of success in commercializing HETLIOZ® or Fanapt®, thereby reducing our future earnings and prospects.
A loss or disruption with any one of our manufacturers or suppliers could disrupt the supply of HETLIOZ® or Fanapt®, possibly for a significant time period, and we may not have sufficient inventories to maintain supply before the manufacturer or supplier could be replaced or the disruption is resolved. In addition, marketed drugs and their contract manufacturing organizations are subject to continual review, including review and approval by regulatory authorities of their manufacturing facilities and the manufacturing processes, which can result in delays in the regulatory approval process and/or commercialization. Introducing a replacement or backup manufacturer or supplier for HETLIOZ® or Fanapt® requires a lengthy regulatory and commercial process and there can be no guarantee that we could obtain necessary regulatory approvals in a timely fashion or at all. In addition, it is difficult to identify and select qualified suppliers and manufacturers with the necessary technical capabilities, and establishing new supply and manufacturing sources involves a lengthy and technical engineering process.
Failure to comply with government regulations regarding the sale and marketing of our products could harm our business.
Pharmaceutical companies are subject to extensive government regulation and oversight by government authorities in countries in which they do business. As a result, we may become subject to governmental actions which could materially and adversely affect our business, results of operations and financial condition, certain of which are described below.
Pharmaceutical Pricing and Reimbursement
In U.S. markets, our ability to commercialize our products successfully, and to attract commercialization partners for our products, should we choose to do so, depends in significant part on the availability of adequate financial coverage and reimbursement from third-party payors, including, in the U.S., governmental payors such as the Medicare and Medicaid programs, managed care organizations, and private health insurers.

27

We participate in the Medicaid Drug Rebate Program for both HETLIOZ® and Fanapt®. Under the Medicaid Drug Rebate Program, we are required to pay a rebate to each state Medicaid program for our covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program as a condition of having our drugs eligible for coverage under Medicaid and Medicare Part B. Those rebates are based on pricing data that are reported by us on a monthly and quarterly basis to the Centers for Medicare & Medicaid Services (CMS). Federal law requires that any company that participates in the Medicaid Drug Rebate Program also participate in the Public Health Service Act’s 340B drug pricing discount program (340B program), in order for the manufacturer’s drugs to be eligible for coverage under Medicaid and Medicare Part B. The 340B program requires participating manufacturers to agree to charge statutorily-defined covered entities no more than the 340B “ceiling price” for the manufacturer’s covered outpatient drugs. The ceiling price can represent a significant discount and is based on the pricing data reporting to the Medicaid Drug Rebate Program.
The ACA expanded the 340B program to include additional entity types: certain free-standing cancer hospitals, critical access hospitals, rural referral centers and sole community hospitals, each as defined by ACA. ACA exempts drugs designated under section 526 of the FDC Act as “orphan drugs” from the ceiling price requirements for these newly-eligible entities.
ACA also obligates the Health Resources and Services Administration to create regulations and processes to improve the integrity of the 340B program and to update the agreement that manufacturers must sign to participate in the 340B program. A final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities became effective on January 1, 2019. Implementation of this final regulation and the issuance of any other final regulations and guidance could affect our obligations under the 340B program in ways we cannot anticipate. In addition, legislation may be introduced that, if passed, would further expand the 340B program to additional covered entities or would require participating manufacturers to agree to provide 340B discounted pricing on drugs used in the inpatient setting.
Federal law also requires that for a drug manufacturer’s products to be eligible for coverage under the Medicaid and Medicare Part B programs and to be purchased by certain federal agencies and grantees, the manufacturer must participate in the Department of Veterans Affairs Federal Supply Schedule (FSS), pricing program, established by Section 603 of the Veterans Health Care Act of 1992. Manufacturers that participate in the FSS pricing program must list their covered (innovator and authorized generic) drugs on an FSS contract and charge no more than Federal Ceiling Price (FCP), to the Department of Veterans Affairs, Department of Defense, Public Health Service, and Coast Guard when those agencies purchase from the FSS contract or a depot contract. FCP is calculated based on non-federal average manufacturer price data, which manufacturers must submit quarterly and annually. In addition, because our products are available in the retail and specialty pharmacy setting, we are required to provide rebates to the Department of Defense for prescriptions dispensed to Tricare beneficiaries from Tricare retail network pharmacies under the Tricare Retail Refund Program. To the extent we choose to participate in these government healthcare programs for our current and future products, these and other requirements may affect our ability to profitably sell any product for which we obtain marketing approval.
Pricing and rebate calculations vary among products and programs. The calculations are complex and will often be subject to interpretation by us, governmental or regulatory agencies and the courts. If we become aware that our reporting of pricing data for a prior quarter was incorrect, we will be obligated to resubmit the corrected data. For the Medicaid Drug Rebate Program, corrected data must be submitted for a period not to exceed 12 quarters from the quarter in which the data originally were due. Such restatements and recalculations increase our costs for complying with the laws and regulations governing the Medicaid Drug Rebate Program and other governmental pricing programs.
We may be liable for errors associated with our submission of pricing data. If we are found to have knowingly submitted false pricing data to the Medicaid program or the FSS pricing program, we may be liable for civil monetary penalties in the amount of up to $100,000 per item of false information, adjusted for inflation as applicable. Our failure to submit pricing data to the Medicaid program or the FSS pricing program on a timely basis could result in a civil monetary penalty of $10,000 per day for each day the information is late, adjusted for inflation as applicable. Such failure also could be grounds for CMS to terminate our Medicaid drug rebate agreement, which is the agreement under which we would participate in the Medicaid Drug Rebate Program. In the event that CMS terminates our rebate agreement, our products may no longer be eligible for coverage under Medicaid or Medicare Part B. There can be no assurance that our submissions will not be found to be incomplete or incorrect.
Third-party payors decide which drugs they will cover and establish reimbursement and co-pay levels. Third-party payors are increasingly challenging the prices charged for medical products and services and examining their cost effectiveness, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost effectiveness of our products. Even with such studies, any of our products that are commercialized may be considered

28

less cost-effective than other products, and third-party payors may not provide coverage and reimbursement, in whole or in part, for our products.
Political, economic and regulatory influences are subjecting the healthcare industry in the U.S. to fundamental changes. There have been, and we expect there will continue to be, legislative and regulatory proposals to change the healthcare system pharmaceutical pricing, and reimbursement systems in ways that could impact our ability to profitably sell commercialized products.
Payors also are increasingly considering new metrics as the basis for reimbursement rates. It is difficult to project the impact of these evolving reimbursement mechanics on the willingness of payors to cover any of our commercialized products.
In addition, we anticipate that a significant portion of our revenue from sales of commercialized products will be obtained through government payors, including Medicare and Medicaid. Any failure to obtain eligibility for coverage under those programs for products we are able to commercialize would have a material adverse effect on revenues and royalties from sales of such products.
Interactions with Healthcare Providers
Physicians and other healthcare providers often play a primary role in the recommendation and prescription of pharmaceutical products. Manufacturers of branded prescription drugs are subject to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which manufacturers market, sell and distribute the products for which they obtain marketing approval. Some of the laws and regulations that may affect our ability to operate are described below.
Anti-Kickback Laws
The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward the purchasing, leasing, ordering or arranging for or recommending the purchase, lease, or order of any health care item or service reimbursable under federal healthcare programs such as Medicare and Medicaid. The term “remuneration” has been broadly interpreted to include anything of value, and the government can establish a violation of the Anti-Kickback Statute without proving that a person or entity had actual knowledge of the law or specific intent to violate it. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, patients, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, however, the exceptions and safe harbors are drawn narrowly. Failure to meet all of the requirements of a particular statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute, but the legality of the arrangement will be evaluated on a case-by-case basis based on the totality of the facts and circumstances. Violations of the Anti-Kickback Statute are punishable by imprisonment, criminal fines, civil monetary penalties and exclusion from the participation in federal healthcare programs, such as Medicare and Medicaid. A number of states also have anti-kickback laws that establish similar prohibitions that may apply to items or services reimbursed by government programs, as well as any third-party payors, including commercial payors, known as "all-payor" laws.
Federal Food Drug and Cosmetic Act
The Federal Food Drug and Cosmetic Act and its implementing regulations (FDCA) apply to drug product advertising and labeling. The FDCA provides the FDA with the authority to prohibit drug manufacturers and third parties acting on their behalf from marketing drug products for off-label uses. Violations of the prohibition can result in warning letters and untitled letters, criminal and civil penalties, including imprisonment and civil monetary penalties. The U.S. Criminal Code may also apply and permit greater fines than those enumerated in the FDCA.
Prescription Drug Marketing Act
As part of the sales and marketing process, pharmaceutical companies frequently provide healthcare providers with samples of approved drugs. The Prescription Drug Marketing Act (PDMA) imposes requirements and limitations upon the distribution of drugs and drug samples, and prohibits states from licensing distributors of prescription drugs unless the state licensing program meets certain federal guidelines that include minimum standards for storage and handling, as well as record keeping and other requirements. Violations of the PDMA may result in criminal and civil penalties. In addition, ACA imposes annual reporting requirements related to sample distribution.

29

False Claims Act
The federal False Claims Act prohibits, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment of government funds and knowingly making, or causing to be made or used, a false record or statement to get a false claim paid. Certain marketing practices may implicate the False Claims Act, including promotion of pharmaceutical products for unapproved uses, providing free product to customers with the expectation that customers would bill federal programs for the product, or inflating prices reported to private price publication services used to set drug reimbursement rates under federal healthcare programs. In addition, ACA amended the Social Security Act to provide that a claim including items or services resulting from a violation of the Anti-Kickback Statute constitutes a false claim for purposes of the False Claims Act. Actions under the False Claims Act may be brought by the government or as a qui tam action by private individuals who may receive financial awards if their claims are successful. False Claims Act liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties of $5,500 to $11,000 per false claim or statement, which increased to a range of $11,181 to $22,363 in January 2018, with respect to violations occurring after November 2, 2015. Violations of the False Claims Act are also punishable by exclusion from participation in federal healthcare programs, such as Medicare and Medicaid. Pharmaceutical and other life sciences companies often resolve allegations without admissions of liability for significant and sometimes material amounts to avoid the uncertainty of treble damages and per claim penalties that may be awarded in litigation. These companies may be required, however, to enter into corporate integrity agreements with the government, which may impose substantial costs on companies to ensure compliance.
Health Insurance Portability and Accountability Act and Health Information Technology for Economic and Clinical Health Act
The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), includes federal criminal statutory provisions that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH) and their implementing regulations, impose certain requirements and restrictions on certain types of individuals and entities relating to the privacy and security of individually identifiable health information. Among other things, HITECH makes HIPAA’s privacy and security standards directly applicable not only to covered entities (e.g. health care providers and health plans), but also to business associates, i.e., independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys’ fees and costs associated with pursuing federal civil actions.
Physician Payment Sunshine Act
The federal Physician Payment Sunshine Act requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program to report annually (with certain exceptions) to CMS information related to payments or other “transfers of value” made to physicians and teaching hospitals, and requires applicable manufacturers and group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members and payments or other ‘‘transfers of value’’ to such physician owners. Failure to report relevant data may result in civil fines and/or penalties.
Foreign Corrupt Practices Act
The Foreign Corrupt Practices Act (FCPA), prohibits U.S. corporations and their representatives and intermediaries from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. Other countries have enacted similar anti-corruption laws and/or regulations. Violation of the FCPA could result in substantial civil and criminal penalties and remedies, including fines, disgorgement, and/or imprisonment.
Analogous State and Foreign Laws

30

Analogous state and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, can apply to our business practices, including but not limited to research, distribution, sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third party payors and are generally broad and are enforced by many different federal and state agencies as well as through private actions. In addition to requiring reporting transfers of value, some states have imposed price reporting requirements, and an increasing number of countries worldwide have either adopted or are considering similar laws requiring disclosure of various interactions with healthcare professionals. These state laws apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. In addition, a number of states require pharmaceutical companies to report expenses relating to the marketing and promotion of pharmaceutical products and to report gifts and payments to individual physicians in the states. Other states restrict when pharmaceutical companies may provide meals to prescribers or engage in other marketing related activities, or require pharmaceutical companies to implement compliance programs or marketing codes of conduct, and file periodic reports or disclosures with states. Compliance with these laws requires significant resources and companies that do not comply may face civil penalties or other consequences.
Many state laws govern the privacy and security of personal information in specified circumstances. For example, the California Consumer Privacy Act (CCPA), which became effective on January 1, 2020, established a new legal framework governing covered businesses' collection and use of personal information of California residents by, among other things, creating an expanded definition of covered personal information, establishing new privacy rights for California residents, imposing an opt-in standard for certain disclosures of personal information about minors, and creating a new and potentially severe statutory damages framework for businesses subject to certain data breaches resulting from the failure to implement and maintain reasonable security procedures and practices. While properly collected clinical trial data and all protected health information governed by HIPAA are exempt from the current version of the CCPA, other personal information may be applicable and possible changes to the CCPA may broaden its scope.
Outside the U.S., we are subject to similar regulations in those countries where we market and sell products, including with respect to transparency, bribery and other laws mentioned above. In some foreign countries, including major markets in the E.U. and Japan, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take nine to twelve months or longer after the receipt of regulatory marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. Our business could be materially harmed if reimbursement of our products is unavailable or limited in scope or amount or if pricing is set at unsatisfactory levels.
The collection and processing of personal data in the E.U. is governed by the General Data Protection Regulation (GDPR), which became applicable in May 2018. The GDPR implements stringent operational requirements for processors and controllers of personal data, including, for example, expanded disclosure requirements about how personal information is to be used, strengthened individual data subject rights, limitations on retention of personal data, increased requirements pertaining to health data and pseudonymised (i.e., key-coded) data, shortened mandatory data breach notification timelines and higher standards for controllers to demonstrate they have obtained valid consent for certain data processing activities. The GDPR provides that E.U. member states may make their own additional laws and regulations in relation to the processing of genetic, biometric or health data, which could result in differences between member states, limit our ability to use and share personal data or cause our costs to increase, and harm our business and financial condition. Further, the U.K.’s exit from the E.U. on January 31, 2020, with a transition period through December 31, 2020, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the U.K. During the transition period, the U.K. will continue to follow E.U. law and will negotiate with the E.U. on the terms of its relationship post-2020. In particular, it is unclear how data transfers to and from the U.K. will be regulated. We are also subject to evolving and strict rules on the transfer of personal data out of the E.U. Failure to comply with E.U. data protection laws may result in significant fines, including GDPR fines of up to the higher of €20,000,000 or 4% of our total worldwide annual turnover of the preceding financial year, and other administrative penalties, which may be onerous and adversely affect our business, financial condition, results of operations and prospects.
Efforts to ensure that our business arrangements with third parties, and our business generally, will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations.

31

Additionally, drug prices are under significant scrutiny, and along with other health care costs, continue to be subject to intense political and societal pressures, which we anticipate will continue and escalate, including on a global basis. As a result, our business and reputation may be harmed, our stock price may be adversely impacted and experience periods of volatility, and our results of operations may be adversely impacted.
Other Laws and Regulations
There are evolving legal requirements and other statutory and regulatory regimes that will continue to affect our business.
Efforts to ensure that business activities and business arrangements comply with applicable healthcare laws and regulations can be costly for manufacturers of branded prescription products. If a manufacturer’s operations, including activities conducted by its sales or marketing teams, are found to be in violation of any of these laws or any other governmental regulations that apply to the company, the company may be subject to significant civil, criminal and administrative sanctions, including imprisonment, monetary penalties, damages, fines, exclusion from participation in federal healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of operations.
We intend to seek regulatory approvals for our products in additional foreign jurisdictions, but we may not obtain any such approvals.
We intend to market our products, alone or with others, in foreign jurisdictions. In order to market our products in foreign jurisdictions, we may be required to obtain separate regulatory approvals and to comply with numerous and varying regulatory requirements. The approval procedure varies among countries and jurisdictions and can involve additional trials, and the time required to obtain approval may differ from that required to obtain FDA approval. Additionally, the foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. For all of these reasons, we may not obtain foreign regulatory approvals on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or jurisdictions or by the FDA. We may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any market. The failure to obtain these approvals could harm our business materially.
We rely on a limited number of specialty pharmacies for distribution of HETLIOZ® in the U.S., and the loss of one or more of these specialty pharmacies or their failure to distribute HETLIOZ® effectively would materially harm our business.
HETLIOZ® is available for distribution through a limited number of specialty pharmacies in the U.S. A specialty pharmacy is a pharmacy that specializes in the dispensing of medications for complex or chronic conditions, which often require a high level of patient education and ongoing management. The use of specialty pharmacies involves certain risks, including, but not limited to, risks that these specialty pharmacies will:
 
•
not provide us accurate or timely information regarding their inventories, the number of patients who are using HETLIOZ® or complaints about HETLIOZ®;
•
reduce their efforts or discontinue to sell or support or otherwise not effectively sell or support HETLIOZ®;
•
not devote the resources necessary to sell HETLIOZ® in the volumes and within the time frames that we expect;
•
be unable to satisfy financial obligations to us or others; or
•
cease operations.
In addition, if one or more of our specialty pharmacies do not fulfill their contractual obligations to us, or refuse or fail to adequately serve patients, or their agreements are terminated without adequate notice, shipments of HETLIOZ®, and associated revenues, would be adversely affected. We expect that it would take a significant amount of time if we were required to replace one or more of our specialty pharmacies.
Our revenues from Fanapt® are substantially dependent on sales through a limited number of wholesalers, and such revenues may fluctuate from quarter to quarter.
We sell Fanapt® primarily through a limited number of pharmaceutical wholesalers in the U.S. The use of pharmaceutical wholesalers involves certain risks, including, but not limited to, risks that these pharmaceutical wholesalers will:

32

 
•
not provide us accurate or timely information regarding their inventories, demand from wholesaler customers buying Fanapt® or complaints about Fanapt®;
•
reduce their efforts or discontinue to sell or support or otherwise not effectively sell or support Fanapt®;
•
not devote the resources necessary to sell Fanapt® in the volumes and within the time frames that we expect;
•
be unable to satisfy financial obligations to us or others; or
•
cease operations.
Additionally, our reliance on a small number of wholesalers could cause revenues to fluctuate from quarter to quarter based on the buying patterns of these wholesalers. In addition, if any of these wholesalers fails to pay on a timely basis or at all, our business, financial condition and results of operations could be materially adversely affected.
We face substantial competition, which may result in others developing or commercializing products before or more successfully than we do.
Our future success will depend on our ability to demonstrate and maintain a competitive advantage with respect to our products and our ability to identify and develop additional products. Large, fully integrated pharmaceutical companies, either alone or together with collaborative partners, have substantially greater financial resources and have significantly greater experience than we do in:
 
•
developing products;
•
undertaking preclinical testing and clinical trials;
•
obtaining FDA and other regulatory approvals of products; and
•
manufacturing, marketing and selling products.
These companies may invest heavily and quickly to discover and develop novel products that could make our products obsolete. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA or foreign regulatory approval or commercializing superior products or other competing products before we do. Technological developments or the FDA or foreign regulatory approval of new therapeutic indications for existing products may make our products obsolete or may make them more difficult to market successfully, any of which could have a material adverse effect on our business, results of operations and financial condition.
Our products, if successfully developed and approved for commercial sale, will compete with a number of drugs and therapies currently manufactured and marketed by major pharmaceutical and other biotechnology companies. Our products may also compete with new products currently under development by others or with products which may cost less than our products. Physicians, patients, third party payors and the medical community may not accept or utilize any of our products that may be approved. If HETLIOZ®, Fanapt® and our other products, if and when approved, do not achieve significant market acceptance, our business, results of operations and financial condition would be materially adversely affected. We believe the primary competitors for HETLIOZ® and Fanapt® are as follows:
 
•
For HETLIOZ® in the treatment of Non-24, there are no FDA approved direct competitors. Sedative-Hypnotic treatments for certain sleep related disorders include, Ambien® (zolpidem) by Sanofi (including Ambien CR®), Lunesta® (eszopiclone) by Sunovion Pharmaceuticals Inc., Sonata® (zaleplon) by Pfizer Inc., Rozerem® (ramelteon) by Takeda Pharmaceuticals Company Limited, Silenor® (doxepin) by Pernix Therapeutics, Belsomra® (suvorexant) by Merck & Co., Inc., generic products such as zolpidem, trazodone and doxepin, and over-the-counter remedies such as Benadryl® and Tylenol PM®. The class of melatonin agonists includes Rozerem® (ramelteon) by Takeda Pharmaceuticals Company Limited, Valdoxan® (agomelatine) by Servier, Circadin® (long-acting melatonin) by Neurim Pharmaceuticals Ltd. and the food supplement melatonin. Shift work and excessive sleepiness disorder treatments include Nuvigil® (armodafinil) and Provigil® (modafinil) both by Teva Pharmaceutical Industries Ltd.
•
For Fanapt® in the treatment of schizophrenia, the atypical antipsychotics competitors are Risperdal® (risperidone), including the LAI formulation Risperdal Consta® and Invega® (paliperidone), including the LAI formulation Invega® Sustenna®, each by Ortho-McNeil-Janssen Pharmaceuticals, Inc., Zyprexa® (olanzapine), including the LAI formulation Zyprexa® RelprevvTM, each by Lilly, Seroquel® and Seroquel XR® (quetiapine) by AstraZeneca PLC, Abilify® (aripiprazole) by Otsuka America Pharmaceutical Inc., Abilify Maintena® (the LAI formulation of Abilify®) by Lundbeck/Otsuka America Pharmaceutical Inc., Geodon® (ziprasidone) by Pfizer Inc.,

33

Saphris® (asenapine) by Allergan plc, Latuda® (lurasidone) by Sunovion Pharmaceuticals Inc., Rexulti® (brexpiprazole) by Lundbeck/Otsuka America Pharmaceutical, Inc., AristadaTM (aripiprazole lauroxil) extended-release injectable suspension by Alkermes, Inc., VraylarTM (cariprazine) by Teva Pharmaceutical Industries Ltd., CALYPTA® (lumapteperone) by Intra-Cellular Therapies, and generic clozapine, as well as the typical antipsychotics haloperidol, chlorpromazine, thioridazine, and sulpiride (all of which are generic).
Additionally, we may face competition from newly developed generic products. Under the Hatch-Waxman Act, newly approved drugs and indications may benefit from a statutory period of non-patent marketing exclusivity. The Hatch-Waxman Act seeks to stimulate competition by providing incentives to generic pharmaceutical manufacturers to introduce non-infringing forms of patented pharmaceutical products and to challenge patents on branded pharmaceutical products. If we are unsuccessful at challenging an ANDA, filed pursuant to the Hatch-Waxman Act, cheaper generic versions of our products, which may be favored by insurers and third-party payors, may be launched commercially, which would significantly harm our business.
To obtain an ANDA approval for a generic drug, the generic company needs to show, among other things, that its version of the product is bioequivalent to the Reference Listed Drug (RLD). This usually requires the generic company to conduct bioequivalence studies comparing its product to the RLD, and to retain sufficient samples of the RLD used in testing after a study is complete. In recent years, the U.S. federal lawmakers and the FDA have been considering proposals to facilitate the generic drug company’s access to samples and foster the generic competition. For example, in February 2019, the U.S. House and Senate lawmakers reintroduced the Creating and Restoring Equal Access to Equivalent Samples Act (CREATES Act), a bill intended to require brand drug manufacturers to provide sufficient drug samples to generic and biosimilar drug developers. The proposed legislation, if enacted, would allow a biosimilar or generic product developer to bring a civil action against a brand drug manufacturer for failing to provide samples of the brand product for comparative testing “on commercially reasonable, market-based terms.” The developer could receive injunctive relief and a monetary award “sufficient to deter the license holder from failing to provide other eligible product developers with sufficient quantities of a covered product on commercially reasonable, market-based terms” in certain cases.
Certain states have also taken similar actions. In 2018, Maine passed a new law that requires brand drug manufacturers to make samples of drugs distributed in the state available for sale in Maine at a price no greater than wholesale acquisition cost and without any restriction that would block or delay a biosimilar and generic drug application in a manner inconsistent with federal law. The state may seek injunctive relief and attorney’s fees from a drug manufacturer who fails to comply with this requirement.
FDA and foreign regulatory approval of our products is uncertain.
The research, testing, manufacturing and marketing of products such as those that we have developed or that we are developing are subject to extensive regulation by federal, state and local government authorities, including the FDA, as well as foreign regulatory authorities in jurisdictions in which we seek approval. To obtain regulatory approval of such products, we must demonstrate to the satisfaction of the applicable regulatory agency that, among other things, the product is safe and effective for its intended use. In addition, we must show that the manufacturing facilities used to produce such products are in compliance with cGMPs.
The process of obtaining FDA and other required regulatory approvals and clearances can take many years and will require us to expend substantial time and capital. Despite the time and expense expended, regulatory approval is never guaranteed. The number of preclinical and clinical trials that will be required for FDA or foreign regulatory approval varies depending on the product, the disease or condition that the product is in development for, and the requirements applicable to that particular product. The FDA or applicable foreign regulatory agency can delay, limit or deny approval of a product for many reasons, including that:
 
•
a product may not be shown to be safe or effective;
•
the FDA or foreign agency may interpret data from preclinical and clinical trials in different ways than we do;
•
the FDA or foreign agency may not approve our or our partners’ manufacturing processes or facilities;
•
a product may not be approved for all the indications we request;
•
the FDA or foreign agency may change its approval policies or adopt new regulations;
•
the FDA or foreign agency may not meet, or may extend, the PDUFA-VI date or its foreign equivalent with respect to a particular NDA or foreign application; and

34

•
the FDA or foreign agency may not agree with our regulatory approval strategies or components of the regulatory filings, such as clinical trial designs.
For example, if certain of our methods for analyzing trial data are not accepted by the FDA or the applicable foreign agency, we may fail to obtain regulatory approval for our products.
Any delay or failure to obtain regulatory approvals for our products will result in increased costs, could diminish competitive advantages that we may attain and would adversely affect the marketing and sale of our products. Other than HETLIOZ® in the U.S. and the countries in Europe covered by the centralized marketing authorization by the EC, and Fanapt® in the U.S., Mexico and Israel, we have not received, and may never receive, regulatory approval to market any of our products in any jurisdiction.
Even following regulatory approval of our products, the FDA or the applicable foreign agency may impose limitations on the indicated uses for which such products may be marketed, subsequently withdraw approval or take other actions against us, or such products that are adverse to our business. The FDA and foreign agencies generally approve drugs for particular indications. An approval for a more limited indication reduces the size of the potential market for the product. Product approvals, once granted, may be withdrawn or modified if problems occur after initial marketing.
We and our partners also are subject to numerous federal, state, local and foreign laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices, the environment and the use and disposal of hazardous substances used in connection with discovery, research and development work. In addition, we cannot predict the extent to which new governmental regulations might significantly impede the discovery, development, production and marketing of our products. We or our partners may be required to incur significant costs to comply with current or future laws or regulations, and we may be adversely affected by the cost of such compliance or the inability to comply with such laws or regulations.
If our products are determined to be unsafe or ineffective in humans, whether commercially or in clinical trials, our business will be materially harmed.
Despite the FDA’s approval of the NDA for HETLIOZ® in January 2014 and the NDA for Fanapt® in May 2009, the EC’s grant of the centralized marketing authorization for HETLIOZ® in July 2015, and the positive results of our completed trials for HETLIOZ® and Fanapt®, we are uncertain whether either of these products will ultimately prove to be effective and safe in humans long term and in all uses. Frequently, products that have shown promising results in clinical trials have suffered significant setbacks in later clinical trials or even after they are approved for commercial sale. Future uses of our products, whether in clinical trials or commercially, may reveal that the product is ineffective, unacceptably toxic, has other undesirable side effects, is difficult to manufacture on a large scale, is uneconomical, infringes on proprietary rights of another party or is otherwise not fit for further use. If our products are determined to be unsafe or ineffective in humans, our business will be materially harmed.
Clinical trials for our products are expensive and their outcomes are uncertain. Any failure or delay in completing clinical trials for our products could severely harm our business.
Preclinical studies and clinical trials required to demonstrate the safety and efficacy of our products are time-consuming and expensive and together take several years to complete. Before obtaining regulatory approvals for the commercial sale of any of our products, we must demonstrate through preclinical testing and clinical trials that such product is safe and effective for use in humans. We have incurred, and we will continue to incur, substantial expense for, and devote a significant amount of time to, preclinical testing and clinical trials.
Historically, the results from preclinical testing and early clinical trials often have not predicted results of later clinical trials. A number of new drugs have shown promising results in clinical trials, but subsequently failed to establish sufficient safety and efficacy data to obtain necessary regulatory approvals. Clinical trials conducted by us or by third parties on our behalf may not demonstrate sufficient safety and efficacy to obtain the requisite regulatory approvals for our products. Regulatory authorities may not permit us to undertake any additional clinical trials for our products, may force us to stop any ongoing clinical trials and it may be difficult to design efficacy studies for our products in new indications.
Clinical development efforts performed by us may not be successfully completed, or completed in a timely manner. Completion of clinical trials may take several years or more. The length of time can vary substantially with the type, complexity, novelty and intended use of the products and the size of the prospective patient population. Our ability to enroll

35

patients in, and the commencement and rate of completion of, clinical trials for our products may be affected by many factors, including:
 
•
the size and nature of the patient population;
•
the design of the trial protocol for our clinical trials;
•
the eligibility and exclusion criteria for the trial in question;
•
the availability of competing therapies and competing clinical trials, and physician and patient perception of our product candidates and our other product candidates being studied in relation to these other potential options;
•
the availability of raw materials and the possibility of raw materials expiring prior to their use;
•
difficulty in maintaining contact with patients after treatment, resulting in incomplete data;
•
poor effectiveness of our products during clinical trials;
•
unforeseen safety issues or side effects;
•
the number and location of clinical sites in our clinical trials;
•
the proximity and availability of clinical trial sites for prospective patients;
•
the availability of time and resources at the institutions where clinical trials are and will be conducted;
•
the availability of adequate financing to fund ongoing clinical trial expenses;
•
the study endpoints that rely on subjective patient reported outcomes; and
•
governmental or regulatory delays and changes in regulatory requirements and guidelines.
If we fail to complete successfully, or have difficulty enrolling a sufficient number of patients for, our clinical trials, we or they may not receive the regulatory approvals needed to market that product. Any such failure or difficulty could have a material adverse effect on our business.
Our products may cause undesirable side effects or have other properties that could delay, prevent or result in the revocation of their regulatory approval or limit their marketability.
Undesirable side effects caused by our products could interrupt, delay or halt clinical trials and could result in the denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications, and in turn prevent us from commercializing or continuing the commercialization of such products and generating revenues from their sale. We will continue to assess the side effect profile of our products in ongoing clinical development programs. However, we cannot predict whether the commercial use of our approved products (or our products in development, if and when they are approved for commercial use) will produce undesirable or unintended side effects that have not been evident in the use of, or in clinical trials conducted for, such products to date. Additionally, incidents of product misuse may occur. These events, among others, could result in product recalls, product liability actions or withdrawals or additional regulatory controls, all of which could have a material adverse effect on our business, results of operations and financial condition.
In addition, if after receiving marketing approval of a product, we or others identify undesirable side effects caused by such product, we could face one or more of the following:
 
•
regulatory authorities may require the addition of labeling statements, such as a “black box” warning or a contraindication;
•
regulatory authorities may withdraw their approval of the product;
•
we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product; and
•
our or the product’s reputation may suffer.
Any of these events could prevent us from achieving or maintaining market acceptance of the affected product or could substantially increase the costs and expenses of commercializing the product, which in turn could delay or prevent us from generating significant revenues from its sale.

36

We have a history of operating losses and may not be able to achieve or sustain profitability in the future.
We have been engaged in identifying and developing drug products since March 2003, which has required, and will continue to require, significant research and development expenditures. The continued commercialization of HETLIOZ® and Fanapt® will also require substantial additional expenditures.
As of December 31, 2019, we had an accumulated deficit of $220.7 million and we cannot estimate with precision the extent of our future income or loss. We may not succeed in gaining additional market acceptance of HETLIOZ® and Fanapt® in the U.S. and we may not succeed in commercializing HETLIOZ® or Fanapt® outside of the U.S. We may not be profitable even if our products are successfully commercialized. We may be unable to fully develop, obtain regulatory approval for, commercialize, manufacture, market, sell and derive revenue from our products in the timeframes we project, if at all, and our inability to do so would materially and adversely impact the market price of our common stock and our ability to raise capital and continue operations.
There can be no assurance that we will achieve sustained profitability, which depends on many factors, including but not limited to, our ability to obtain regulatory approval for our products and achieve success in commercializing them in the U.S., Europe and our other target jurisdictions, as well as other factors described in this Annual Report.
In addition, the amount we spend on developing, obtaining and maintaining regulatory approval for and commercializing our products, among other expenditures described in this Annual Report, will impact our profitability.
Our ability to use net operating loss carryforwards and tax credit carryforwards to offset future taxable income is dependent on generating future taxable income and may be limited, including as a result of transactions involving our common stock.
We have recorded deferred tax assets based on our assessment that we will be able to realize the benefits of our net operating losses and other favorable tax attributes. Realization of deferred tax assets involve significant judgments and estimates, which are subject to change and ultimately depends on generating sufficient taxable income of the appropriate character during the appropriate periods. Changes in circumstances may affect the likelihood of such realization, which in turn may trigger the need for additional valuation allowance against our deferred tax assets and adversely affect our net income and financial condition. In addition, we are potentially subject to ongoing and periodic tax examinations and audits in various jurisdictions, including with respect to the amount of our net operating losses and any limitation thereon. An adjustment to such net operating loss carryforwards, including an adjustment from a taxing authority, could result in higher tax costs, penalties and interest, thereby adversely impacting our financial condition.
In general, under Section 382 of the Internal Revenue Code of 1986,, as amended (IRC), a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-change net operating losses (NOLs) and certain other tax assets (tax attributes) to offset future taxable income. In general, an ownership change occurs if the aggregate stock ownership of certain stockholders increases by more than 50 percentage points over such stockholders’ lowest percentage ownership during the testing period (generally three years). Transactions involving our common stock, even those outside our control, such as purchases or sales by investors, within the testing period could result in an ownership change. A limitation on our ability to utilize some or all of our NOLs or credits could have a material adverse effect on our results of operations and cash flows. Ownership changes occurred in the years ending December 31, 2014 and 2008. We believe that the ownership changes in 2014 and 2008 will not impact our ability to utilize NOL and credit carryforwards; however, future ownership changes may cause our existing tax attributes to have additional limitations.
If we fail to adequately fund our research and development activities and commercialization efforts, we may be unable to continue operations or we may be forced to share our rights to commercialize our products with third parties on terms that may not be attractive to us.
Our activities will necessitate significant uses of working capital throughout 2020 and beyond. It is uncertain whether cash provided by our operating activities, together with our existing funds, will be sufficient to meet our operating needs. As of December 31, 2019, our total cash and cash equivalents and marketable securities were $312.1 million. Our long term capital requirements are expected to depend on many factors, including, among others:
 
•
our level of success in commercializing HETLIOZ® and Fanapt® globally;
•
outcomes of ongoing and potential patent litigation;
•
costs of developing and maintaining sales, marketing and distribution channels and our ability to sell our products;

37

•
market acceptance of our products;
•
costs involved in establishing and maintaining manufacturing capabilities for commercial quantities of our products;
•
the number of potential formulations and products in development;
•
progress with preclinical studies and clinical trials;
•
time and costs involved in obtaining regulatory (including FDA) approval;
•
costs involved in preparing, filing, prosecuting, maintaining and enforcing patent, trademark and other intellectual property claims;
•
competing technological and market developments;
•
costs for recruiting and retaining employees and consultants;
•
costs for training physicians; and
•
legal, accounting, insurance and other professional and business related costs.
As a result, we may need to raise additional capital to fund our anticipated operating expenses and execute on our business plans. In our capital-raising efforts, we may seek to sell debt securities or additional equity securities, obtain a bank credit facility, or enter into partnerships or other collaboration agreements. The sale of additional equity or debt securities, if convertible, could result in dilution to our stockholders and may also result in a lower price for our common stock. The incurrence of indebtedness would result in increased fixed obligations and could also result in covenants that could restrict our operations. However, we may not be able to raise additional funds on acceptable terms, or at all. If additional financing is not available when required or is not available on acceptable terms, we may be unable to fund our operations and planned growth, develop or enhance our technologies or products, take advantage of business opportunities or respond to competitive market pressures, any of which would materially harm our business, financial condition and results of operations.
If our contract research organizations (CROs) do not successfully carry out their duties or if we lose our relationships with CROs, our drug development efforts could be delayed.
Our arrangements with CROs are critical to our success in bringing our products to the market. We are dependent on CROs, third-party vendors and investigators for preclinical testing and clinical trials related to our drug discovery and development efforts and we will likely continue to depend on them to assist in our future discovery and development efforts. These parties are not our employees and we cannot control the amount or timing of resources that they devote to our programs. As such, they may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or our stated protocols. The parties with which we contract for execution of our clinical trials play a significant role in the conduct of the trials and the subsequent collection and analysis of data. If they fail to devote sufficient time and resources to our drug development programs or if their performance is substandard, it will delay the development, approval and commercialization of our products. Moreover, these parties may also have relationships with other commercial entities, some of which may compete with us. If they assist our competitors, it could harm our competitive position.
Our CROs could merge with or be acquired by other companies or experience financial or other setbacks unrelated to our collaboration that could, nevertheless, materially adversely affect our business, results of operations and financial condition.
If we lose our relationship with any one or more of these parties, we could experience a significant delay in both identifying another comparable provider and then contracting for its services. We may be unable to retain an alternative provider on reasonable terms, if at all. Even if we locate an alternative provider, it is likely that this provider may need additional time to respond to our needs and may not provide the same type or level of service as the original provider. In addition, any provider that we retain will be subject to current Good Laboratory Practices as set forth in 21 Code of Federal Regulations (C.F.R.) Part 58 and Good Clinical Practices as set forth in 21 C.F.R. Part 50, 54, 58, and 312, and similar international standards and we do not have control over compliance with these regulations by these providers. Consequently, if these practices and standards are not adhered to by these providers, the development and commercialization of our products could be delayed.

38

We rely on a limited number of third-party manufacturers to formulate and manufacture our products and our business will be seriously harmed if these manufacturers are not able to satisfy our demand and alternative sources are not available.
We do not have an in-house manufacturing capability and depend completely on a small number of third-party manufacturers and active pharmaceutical ingredient formulators for the manufacture of our products. Therefore, we are dependent on third parties for our formulation development and manufacturing of our products. This may expose us to the risk of not being able to directly oversee the production and quality of the manufacturing process and provide ample commercial supplies to successfully launch and maintain the marketing of our products. Furthermore, these third party contractors, whether foreign or domestic, may experience regulatory compliance difficulty, mechanical shut downs, employee strikes, or other unforeseeable events that may delay or limit production. Our inability to adequately establish, supervise and conduct (either ourselves or through third parties) all aspects of the formulation and manufacturing processes would have a material adverse effect on our ability to develop and commercialize our products.
We have agreements in place with Patheon Pharmaceuticals Inc. and Patheon Inc. (collectively, Patheon), subsidiaries of Thermo Fisher Scientific, for the manufacture of HETLIOZ® and Fanapt®.
In January 2014, we entered into a manufacturing agreement with Patheon for the manufacture of commercial supplies of HETLIOZ® 20 mg capsules at Patheon’s Cincinnati, Ohio manufacturing site. In May 2016, we entered into a manufacturing agreement with Patheon for the manufacture of commercial supplies of Fanapt® tablets at Patheon’s Mississauga, Ontario, Canada manufacturing site. We do not have exclusive long-term agreements with any other third-party manufacturers of our products. If our current manufacturers, or any other third-party manufacturer, is unable or unwilling to perform its obligations under our manufacturing agreements for any reason, we may not be able to locate alternative acceptable manufacturers or formulators or enter into favorable agreements with them. Any inability to acquire sufficient quantities of our products in a timely manner from these third parties could adversely affect sales of our products, delay clinical trials and prevent us from developing our products in a cost-effective manner or on a timely basis. In addition, manufacturers of our products are subject to cGMP and similar foreign standards and we do not have control over compliance with these regulations by our manufacturers. If one of our contract manufacturers fails to maintain compliance, the production of our products could be interrupted, resulting in delays and additional costs. In addition, if the facilities of such manufacturers do not pass a pre-approval or post-approval plant inspection, the FDA will not grant approval and may institute restrictions on the marketing or sale of our products.
Our manufacturing strategy presents the following additional risks:
 
•
because most of our third-party manufacturers and formulators are located outside of the U.S., there may be difficulties in importing our products or their components into the U.S. as a result of, among other things, FDA import inspections, incomplete or inaccurate import documentation or defective packaging; and
•
because of the complex nature of our products, our manufacturers may not be able to successfully manufacture our products in a cost-effective and/or timely manner.
Materials necessary to manufacture our products may not be available on commercially reasonable terms, or at all, which may delay the development, regulatory approval and commercialization of our products.
We rely on manufacturers to purchase from third-party suppliers the materials necessary to produce our products for clinical trials and commercialization. Suppliers may not sell these materials to such manufacturers at the times we need them or on commercially reasonable terms. We do not have any control over the process or timing of the acquisition of these materials by these manufacturers. Moreover, we currently do not have any agreements for the commercial production of these materials. If the manufacturers are unable to obtain these materials for our clinical trials, product testing, potential regulatory approval of our products and commercial scale manufacturing could be delayed, significantly affecting our ability to further develop and commercialize our products. If we, our manufacturers are unable to purchase these materials for our products, there would be a shortage in supply or the commercial launch of such products would be delayed, which would materially and adversely affect our ability to generate revenues from the sale of such products.
If we cannot identify, or enter into licensing arrangements for, new products, our ability to develop a diverse product portfolio will be limited.
A component of our business strategy is acquiring rights to develop and commercialize products discovered or developed by other pharmaceutical and biotechnology companies for which we may find effective uses and markets through our unique pharmacogenetics and pharmacogenomics expertise for the treatment of central nervous system disorders. Competition for the acquisition of these products is intense. If we are not able to identify opportunities to acquire rights to

39

commercialize additional products, we may not be able to develop a diverse portfolio of products. Additionally, it may take substantial human and financial resources to secure commercial rights to promising products. Moreover, if other firms develop pharmacogenetics and pharmacogenomics capabilities, we may face increased competition in identifying and acquiring additional products.
If we lose key scientists or management personnel, or if we fail to recruit additional highly skilled personnel, it will impair our ability to identify, develop, and commercialize products.
We are highly dependent on principal members of our management team and scientific staff, including our Chief Executive Officer, Mihael H. Polymeropoulos, M.D. These executives each have significant pharmaceutical industry experience. The loss of any such executives, including Dr. Polymeropoulos, or any other principal member of our management team or scientific staff, would impair our ability to identify, develop and market new products. Our management and other employees may voluntarily terminate their employment with us at any time. The loss of the services of these or other key personnel, or the inability to attract and retain additional qualified personnel, could result in delays to development or approval, loss of sales and diversion of management resources. In addition, we depend on our ability to attract and retain other highly skilled personnel, including research scientists. Competition for qualified personnel is intense, and the process of hiring and integrating such qualified personnel is often lengthy. We may be unable to recruit such personnel on a timely basis, if at all, which would negatively impact our development and commercialization programs.
Additionally, we do not currently maintain “key person” life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.
Product liability lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our products.
The risk that we may be sued on product liability claims is inherent in the development and sale of pharmaceutical products. For example, we face a risk of product liability exposure related to the testing of our products in clinical trials and will face even greater risks upon commercialization of our products. We believe that we may be at a greater risk of product liability claims relative to other pharmaceutical companies because certain of our products are intended to treat central nervous system disorders, among others, and it is possible that we may be held liable for the behavior and actions of patients who use our products. These lawsuits may divert our management from pursuing our business strategy and may be costly to defend. In addition, if we are held liable in any of these lawsuits, we may incur substantial liabilities and we may be forced to limit or forego further commercialization of one or more of our products. Although we maintain product liability insurance, our aggregate coverage limit under this insurance is $30.0 million, and while we believe this amount of insurance is sufficient to cover our product liability exposure, these limits may not be high enough to fully cover potential liabilities. As our development activities and commercialization efforts progress and we sell our products, this coverage may be inadequate, we may be unable to obtain adequate coverage at an acceptable cost or we may be unable to get adequate coverage at all or our insurer may disclaim coverage as to a future claim. This could prevent the commercialization or limit the commercial potential of our products. Even if we are able to maintain insurance that we believe is adequate, our results of operations and financial condition may be materially adversely affected by a product liability claim. Uncertainties resulting from the initiation and continuation of products liability litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Product liability litigation and other related proceedings may also require significant management time.
E.U. Member States tend to impose strict price controls, which may delay or prevent the further commercial launch or impede the commercial success of HETLIOZ® in Europe and adversely affect our future results of operations.
In the E.U., prescription drug pricing and reimbursement are subject to governmental control and reimbursement mechanisms used by private and public health insurers in the E.U. vary by Member State. For the public systems, reimbursement is determined by guidelines established by the legislature or responsible national authority. As elsewhere, inclusion in reimbursement catalogues focuses on the medical usefulness, need, quality and economic benefits to patients and the health care system. Acceptance for reimbursement comes with cost, use and often volume restrictions, which can vary by Member State. Although we have received marketing authorization for HETLIOZ® from the EC, pricing negotiations with governmental authorities may take a considerable amount of time in those Member States that impose price controls. For example, we launched HETLIOZ® commercially in Germany in August 2016, and concluded our pricing negotiations with German authorities in October 2017. In addition, to obtain reimbursement or pricing approval for HETLIOZ® in some Member States, we may be required to conduct a clinical trial that compares the cost-effectiveness of HETLIOZ®, to other available therapies.

40

Some Member States require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some Member States, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we may be subject to lengthy price regulations that delay or prevent the commercial launch of HETLIOZ® in a particular Member State and negatively impact the revenues that are generated from the sale of HETLIOZ® in that country. If reimbursement of HETLIOZ® is unavailable or limited in scope or amount, or if pricing for HETLIOZ® is set at unsatisfactory levels or takes too long to establish, or if there is competition from lower priced cross-border sales, our results of operations will be negatively affected.
We may not be able to effectively market and sell our future products, if approved, in the U.S.
We plan to continue to build our sales and marketing capabilities in the U.S. to commercialize future products, if approved. Our current sales and marketing capabilities in the U.S. may not be adequate to support the commercialization of future products and we would expect to build such capabilities by investing significant amounts of financial and management resources. Furthermore, the cost of establishing and maintaining marketing and sales capabilities may not be justifiable in light of the revenues generated by any future products.
If we are unable to establish and maintain adequate sales and marketing capabilities for future products or are unable to do so in a timely manner, we may not be able to generate product revenues from these products which may prevent us from reaching or maintaining profitability.
Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.
In the U.S., there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the ACA was passed, which substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and creates a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D.
Some of the provisions of the ACA have yet to be fully implemented, while certain provisions have been subject to judicial and Congressional challenges, as well as efforts by the Trump administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed two Executive Orders designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have been signed into law. The TCJA, includes a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment by imposed by the ACA on certain individuals who failed to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate.” Additionally, on January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including the so-called “Cadillac” tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. Further, the Bipartisan Budget Act of 2018 (BBA), among other things, amended the ACA, effective January 1, 2019, to reduce the coverage gap in most Medicare drug plans, commonly referred to as the “donut hole.” On December 14, 2018, a U.S. District Court ruled that the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the TCJA. Subsequently, the U.S. Fifth Circuit Court of Appeals upheld the U.S. District Court ruling as to the unconstitutionality of the individual mandate, but remanded the decision for further analysis of whether the unconstitutionality of one provision would render the entirety of the ACA unconstitutional. While the ruling has no immediate effect pending review by the lower court and potential appeal of the decision to the U.S. Supreme Court, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA and our business. The effect that the ACA and its possible repeal and replacement may have on our business remains unclear.
Other legislative changes have been proposed and adopted in the U.S. since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments to the

41

statute, will remain in effect through 2027 unless additional congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers.
Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for any product candidate we develop or complementary diagnostics or companion diagnostics or additional pricing pressures.
Additionally, there has been increasing legislative and enforcement interest in the U.S. with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. We expect that the healthcare reform measures that have been adopted and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private third-party payors.
Significant developments arising from changes in the political climate could have a material adverse effect on us.
Changes in U.S. social, political, regulatory and economic conditions or in laws and policies governing foreign trade, manufacturing, development and investment, and any negative sentiments towards the U.S. as a result of such changes, could adversely affect our business.
In addition, the U.K. formally withdrew from the E.U. on January 31, 2020 with a transition period through December 31, 2020. During the transition period, the U.K. will continue to follow E.U. law and will negotiate with the E.U. on the terms of its relationship post-2020. Since the regulatory framework for pharmaceutical products in the U.K. covering quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from E.U. directives and regulations, Brexit could materially impact the future regulatory regime which applies to products and the approval of product candidates in the U.K. It remains to be seen how, if at all, Brexit will impact regulatory requirements for product candidates and products in the U.K. These possible negative impacts, and others resulting from the U.K.’s withdrawal from the E.U., may adversely affect our operating results and growth prospects as well as the manner in which we conduct our business operations in Europe.
Changes to tax regulations to which we are subject could adversely affect us.
We are subject to tax laws, treaties and regulations in the countries in which we operate, and these laws and treaties are subject to interpretation. New legislation or regulation which could affect our tax burden could be enacted by any governmental authority. We cannot predict the timing or extent of such tax-related developments which could have a negative impact on our financial results. We have taken, and will continue to take, tax positions based on our interpretation of such tax laws. However, a challenge by a taxing authority, our ability to utilize tax benefits such as carryforwards or tax credits, or a deviation from other tax-related assumptions may cause actual financial results to deviate from previous estimates.
Future transactions may harm our business or the market price of our stock.
We regularly review potential transactions related to technologies, products or product rights and businesses complementary to our business. These transactions could include:
 
•
mergers;
•
acquisitions;
•
strategic alliances;
•
licensing agreements; and
•
co-promotion and similar agreements.
We may choose to enter into one or more of these transactions at any time, which may cause substantial fluctuations in the market price of our stock. Moreover, depending upon the nature of any transaction, we may experience a charge to earnings, which could also materially adversely affect our results of operations and could harm the market price of our stock.

42

We may undertake strategic acquisitions in the future, and difficulties integrating such acquisitions could damage our ability to achieve or sustain profitability.
Although we have no experience in acquiring businesses, we may acquire businesses or assets that complement or augment our existing business. If we acquire businesses with promising products or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to move one or more products through preclinical and/or clinical development to regulatory approval and commercialization. Integrating any newly acquired businesses or technologies could be expensive and time-consuming, resulting in the diversion of resources from our current business. We may not be able to integrate any acquired business successfully. We cannot assure you that, following an acquisition, we will achieve revenues, specific net income or loss levels that justify the acquisition or that the acquisition will result in increased earnings, or reduced losses, for the combined company in any future period. Moreover, we may need to raise additional funds through public or private debt or equity financing to acquire any businesses, which would result in dilution for stockholders or the incurrence of indebtedness and may not be available on terms which would otherwise be acceptable to us. We may not be able to operate acquired businesses profitably or otherwise implement our growth strategy successfully.
Our operating results may fluctuate significantly due to a number of factors which make our future results difficult to predict and could cause our operating results to fall below expectations or our guidance.
Our operating results will continue to be subject to fluctuations. The revenues we generate and our operating results will be affected by numerous factors, including:
 
•
product sales;
•
cost of product sales;
•
marketing and other expenses;
•
manufacturing or supply issues;
•
the timing and amount of royalties or milestone payments;
•
our addition or termination of development programs;
•
variations in the level of expenses related to our products or future development programs;
•
regulatory developments affecting our products or those of our competitors;
•
our execution of collaborative, licensing or other arrangements, and the timing of payments we may make or receive under these arrangements;
•
any intellectual property infringement or other lawsuit in which we may become involved; and
•
the timing and recognition of stock-based compensation expense.
If our operating results fall below the expectations of investors or securities analysts or below any guidance we may provide, the price of our common stock could decline substantially. Furthermore, any fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.
We are increasingly dependent on information technology systems, infrastructure and data. Cybersecurity breaches could expose us to liability, damage our reputation, compromise our confidential information or otherwise adversely affect our business.
We are increasingly dependent upon information technology systems, infrastructure and data. Our computer systems may be vulnerable to service interruption or destruction, malicious intrusion and random attack. Security breaches pose a risk that sensitive data, including intellectual property, trade secrets or personal information may be exposed to unauthorized persons or to the public. Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, denial-of service, social engineering and other means to affect service reliability and threaten data confidentiality, integrity and availability. Our key business partners face similar risks, and a security breach of their systems could adversely affect our security posture. While we continue to invest in data protection and information technology, there can be no assurance that our efforts will prevent service interruptions, or identify breaches in our systems, that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business or reputational harm.

43

Our internal computer systems, or those of our collaborator, CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of development programs for our product candidates.
Despite the implementation of security measures, our internal computer systems and those of our collaborators, CROs, and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Information security risks have significantly increased in recent years in part due to the proliferation of new technologies and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including foreign state actors. As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any information security breaches.
While we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our independent drug development programs. For example, the loss of clinical trial data from ongoing or future clinical trials for any of our product candidates could result in delays in regulatory approval efforts and significantly increase costs to recover or reproduce the data. Our information security systems are also subject to laws and regulations requiring that we take measures to protect the privacy and security of certain information we gather and use in our business. For example, HIPAA and its implementing regulations impose, among other requirements, certain regulatory and contractual requirements regarding the privacy and security of personal health information. In addition to HIPAA, numerous other federal and state laws, including, without limitation, state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use, disclosure and storage of personal information. To the extent that any disruption or security breach were to result in a loss of or damage to data or applications, or inappropriate disclosure of confidential or proprietary information or personal health information, we could incur substantial liability, our reputation would be damaged, and the further development of our product candidates could be delayed.
Risks related to intellectual property and other legal matters
Our rights to develop and commercialize our products are subject in part to the terms and conditions of licenses or sublicenses granted to us by other pharmaceutical companies.
Our rights to our product portfolio are based in part on patents and other intellectual property licensed from third-parties. These third parties may generally terminate the license agreements under certain circumstances, including a material breach of the agreement by the other. In the event we terminate our license, or if the third-party terminates our license due to our breach, rights to the intellectual property revert back to the licensor. Any termination or reversion of our rights to develop or commercialize our products would have a material adverse effect on our business.
If our efforts to protect the proprietary nature of the intellectual property related to our products are not adequate, we may not be able to compete effectively in our markets.
Method of treatment patents protect the use of a product for the method specified in the patent claims. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for a use that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our patented methods, physicians may prescribe these products “off-label.” Although off-label prescriptions may infringe or contribute to the infringement of method of treatment patents, such infringement may be difficult to prevent.
Our patents and patent applications may be challenged or fail to result in issued patents and our existing or future patents may be too narrow to prevent third parties from developing or designing around these patents. In addition, we generally rely on trade secret protection and confidentiality agreements to protect certain proprietary know-how that is not patentable, for processes for which patents are difficult to enforce and for any other elements of our drug development processes that involve proprietary know-how, information and technology that is not covered by patent applications. While we require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information and technology to enter into confidentiality agreements, we cannot be certain that this know-how, information and technology will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Further, the laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the U.S. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the U.S. and abroad. If we are unable to protect or defend the intellectual property related to our technologies, we will not be able to establish or maintain a competitive advantage in our market.
Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our

44

competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. Our competitors may seek to market generic versions of any approved products by submitting ANDAs to the FDA in which they claim that patents owned or licensed by us are invalid, unenforceable and/or not infringed. Alternatively, our competitors may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid and/or unenforceable. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.
The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.
We are, have been, and may continue to be, involved in lawsuits to protect or enforce our patents, which could be expensive, time-consuming and unsuccessful, and third parties may challenge the validity or enforceability of our patents and they may be successful.
Even where laws provide protection or we are able to obtain patents, costly and time-consuming litigation may be necessary to enforce and determine the scope of our proprietary rights, and the outcome of such litigation would be uncertain. Moreover, any actions we may bring to enforce our intellectual property against our competitors could provoke them to bring counterclaims against us, and some of our competitors have substantially greater intellectual property portfolios than we have. To counter infringement or unauthorized use of any patents we may obtain, we may be required to file infringement claims, which can be expensive and time-consuming to litigate. In addition, if we or one of our future collaborators were to initiate legal proceedings against a third party to enforce a patent covering one of our products, current product candidates, or one of our future products, the defendant could counterclaim that the patent is invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace and challenges to validity of patents in certain foreign jurisdictions are common as well. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the U.S. Patent and Trademark Office, or made a materially misleading statement, during prosecution. We may assert the patents in Hatch-Waxman litigation against the party filing the ANDA to keep the competing product off of the market until the patents expire but there is a risk that we will not succeed. The party filing the ANDA may also counterclaim in the litigation that our patents are not valid or unenforceable, and the court may find one or more claims of our patents invalid or unenforceable. If this occurs, a competing generic product could be marketed prior to expiration of our patents listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the “Orange Book,” which would harm our business.
We have been and continue to be involved in number of lawsuits with a variety of generic drug manufacturers who have filed ANDAs relating to certain of our patents. We have been successful in asserting that these third parties have infringed certain of our patents, but we may not be successful in such lawsuits in the future. Please see Part I, Item 3, Legal Proceedings, of this Annual Report for additional information.
If we do not obtain protection under the Hatch-Waxman Act and similar foreign legislation to extend our patents and to obtain market exclusivity for our products, our business will be harmed.
The Hatch-Waxman Act provides for an extension of patent term for drugs for a period of up to five years to compensate for time spent in development. The HETLIOZ® U.S. new chemical entity (NCE) patent (the primary patent covering the product as a new composition of matter) received the full five-year patent term extension under the Hatch-Waxman Act and so, assuming that we continue to have rights under our license agreement with respect to this product, this patent in the U.S. expires in December 2022. We also own HETLIOZ® U.S. method of treatment patents (directed to the approved method of treatment as described in the HETLIOZ® label approved by the FDA), which expire normally between 2033 and 2035, and a drug substance patent which expires in 2035. The Fanapt® U.S. NCE patent received the full five-year patent term extension under the Hatch-Waxman Act and so this patent in the U.S. expired in November 2016. In November 2013, a patent directed to a method of treating patients with Fanapt® based on genotype was issued to us by the U.S. Patent and Trademark Office. This patent, which was listed in the Orange Book in January 2015, is set to expire in 2027. Please see the

45

risk factor entitled “We are, have been, and may continue to be, involved in lawsuits to protect or enforce our patents, which could be expensive, time-consuming and unsuccessful, and third parties may challenge the validity or enforceability of our patents and they may be successful,” and Part I, Item 3, Legal Proceedings, of this Annual Report for additional information. Eight additional U.S. patents directed to methods of treating patients with Fanapt®, which are set to expire between 2025 and 2031, were issued to us in 2015.
A directive in the E.U. provides that companies that receive regulatory approval for a new medicinal product will have a 10-year period of market exclusivity for that product (with the possibility of a further one-year extension), beginning on the date of such European regulatory approval, regardless of when the European NCE patent covering such product expires. A generic version of the approved drug may not be marketed or sold in Europe during such market exclusivity period. This directive is of material importance with respect to Fanapt®, since the European NCE patent for Fanapt® has expired.
Assuming we gain a five-year patent term restoration for tradipitant, and that we continue to have rights under our license agreement with respect to this product, we would have exclusive rights to tradipitant’s U.S. NCE patent until 2029. Assuming we gain a five-year patent term restoration for VQW-765, and that we continue to have rights under our license agreement with respect to this product, we would have exclusive rights to VQW-765’s U.S. NCE patent until 2028.
However, there is no assurance that we will receive the extensions of our patents or other exclusive rights available under the Hatch-Waxman Act or similar foreign legislation. If we fail to receive such extensions or exclusive rights, our ability to prevent competitors from manufacturing, marketing and selling generic versions of our products will be materially impaired.
We may not be successful in the development of products for our own account.
In addition to our business strategy of acquiring rights to develop and commercialize products, we may develop products for our own account by applying our technologies to off-patent drugs as well as developing our own proprietary molecules. Because we will be funding the development of such programs, there is a risk that we may not be able to continue to fund all such programs to completion or to provide the support necessary to perform the clinical trials, obtain regulatory approvals or market any approved products. We expect the development of products for our own account to consume substantial resources. If we are able to develop commercial products on our own, the risks associated with these programs may be greater than those associated with our programs with collaborative partners.
Litigation or third-party claims of intellectual property infringement could require us to divert resources and may prevent or delay our drug discovery and development efforts.
Our commercial success depends in part on our not infringing the patents and proprietary rights of third parties. Third parties may assert that we are employing their proprietary technology without authorization. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents.
Furthermore, parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to develop and commercialize one or more of our products. Defense of these claims, regardless of their merit, would divert substantial financial and employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, obtain one or more licenses from third parties or pay royalties. In addition, even in the absence of litigation, we may need to obtain additional licenses from third parties to advance our research or allow commercialization of our products. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to develop and commercialize further one or more of our products.
In addition, in the future we could be required to initiate litigation to enforce our proprietary rights against infringement by third parties. Prosecution of these claims to enforce our rights against others could divert substantial financial and employee resources from our business. If we fail to enforce our proprietary rights against others, our business will be harmed.
As described elsewhere in these risk factors and in Part I, Item 3, Legal Proceedings, of this Annual Report, we have initiated lawsuits to enforce our patent rights against certain generic pharmaceutical companies.

46

Risks related to our common stock
Our stock price has been highly volatile and may be volatile in the future, and purchasers of our common stock could incur substantial losses.
The realization of any of the risks described in these risk factors or other unforeseen risks could have a dramatic and adverse effect on the market price of our common stock. Between January 1, 2019 and December 31, 2019, the high and low sale prices of our common stock as reported on The Nasdaq Global Market varied between $11.83 and $31.30. Additionally, market prices for securities of biotechnology and pharmaceutical companies, including ours, have historically been very volatile. The market for these securities has from time to time experienced significant price and volume fluctuations for reasons that were unrelated to the operating performance of any one company.
The following factors, in addition to the other risk factors described in this section, may also have a significant impact on the market price of our common stock:
 
•
our level of success in commercializing our products;
•
our level of success in executing our commercialization strategies;
•
publicity regarding actual or potential testing or trial results relating to products under development by us or our competitors;
•
the outcome of regulatory review relating to products under development by us or our competitors;
•
regulatory developments in the U.S. and foreign countries;
•
developments concerning any collaboration or other strategic transaction we may undertake;
•
publicity regarding actual or potential litigation involving us;
•
announcements of patent issuances or denials, technological innovations or new commercial products by us or our competitors;
•
safety issues with our products or those of our competitors;
•
announcements of technological innovations or new therapeutic products or methods by us or others;
•
actual or anticipated variations in our quarterly operating results;
•
changes in estimates of our financial results or recommendations by securities analysts or failure to meet such financial expectations;
•
changes in government regulations or policies;
•
changes in patent legislation or patent decisions or adverse changes to patent law;
•
additions or departures of key personnel or members of our board of directors;
•
the publication of negative research or articles about our company, our business or our products by industry analysts or others;
•
market rumors or press reports;
•
publicity regarding actual or potential transactions involving us; and
•
economic, political and other external factors beyond our control.
We have been and may in the future be subject to litigation, which could harm our stock price, business, results of operations and financial condition.
We have been the subject of litigation in the past and may be subject to litigation in the future. In the past, following periods of volatility in the market price of their stock, many companies, including us, have been the subjects of securities class action litigation. Any such litigation can result in substantial costs and diversion of management’s attention and resources and could harm our stock price, business results of operations and financial condition. As a result of these factors, holders of our common stock might be unable to sell their shares at or above the price they paid for such shares.

47

If there are substantial sales of our common stock, our stock price could decline.
A small number of institutional investors and private equity funds hold a significant number of shares of our common stock. Sales by these stockholders of a substantial number of shares, or the expectation of such sales, could cause a significant reduction in the market price of our common stock.
In addition to our outstanding common stock, as of December 31, 2019, there were a total of 6,144,430 shares of our common stock that we have registered and that we are obligated to issue upon the exercise of currently outstanding options and settlement of restricted stock unit awards granted under our 2006 and 2016 Equity Incentive Plans. Upon the exercise of these options or settlement of the shares underlying these restricted stock units, as the case may be, in accordance with their respective terms, these shares may be resold freely, subject to restrictions imposed on our affiliates under Rule 144. If significant sales of these shares occur in short periods of time, these sales could reduce the market price of our common stock. Any reduction in the trading price of our common stock could impede our ability to raise capital on attractive terms, if at all.
If securities or industry analysts do not publish research or reports or publish unfavorable research about our business, our stock price and trading volume could decline.
The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. We currently have research coverage by securities and industry analysts. If one or more of the analysts who covers us downgrades our stock, our stock price would likely decline. If one or more of these analysts ceases coverage of our company or fails to regularly publish reports on us, interest in the purchase of our stock could decrease, which could cause our stock price or trading volume to decline.
Our common stock may experience future dilution as a result of future equity offerings.
In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in previous offerings. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by investors in previous offerings, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by investors.
Our business could be negatively affected as a result of the actions of activist stockholders.
Proxy contests have been waged against many companies in the biopharmaceutical industry, including us, over the last several years. If faced with a proxy contest or other type of shareholder activism, we may not be able to respond successfully to the contest or dispute, which would be disruptive to our business. Even if we are successful, our business could be adversely affected by a proxy contest or shareholder dispute involving us because:
 
•
responding to proxy contests and other actions by activist stockholders can be costly and time-consuming, disrupting operations and diverting the attention of management and employees;
•
perceived uncertainties as to future direction may result in the loss of potential acquisitions, collaborations or in-licensing opportunities, and may make it more difficult to attract and retain qualified personnel and business partners; and
•
if individuals are elected to a board of directors with a specific agenda, it may adversely affect our ability to effectively and timely implement our strategic plan and create additional value for our stockholders.
These actions could cause our stock price to experience periods of volatility.
Anti-takeover provisions in our charter and bylaws and under Delaware law, and the adoption of a rights plan, could prevent or delay a change in control of our company.
We are a Delaware corporation and the anti-takeover provisions of Section 203 of the Delaware General Corporation Law may discourage, delay or prevent a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes an interested stockholder, even if a change of control would be beneficial to our existing stockholders. In addition, our amended and restated certificate of incorporation and bylaws may discourage, delay or prevent a change in our management or control over us that stockholders may consider favorable. Our amended and restated certificate of incorporation and bylaws:

48

•
authorize the issuance of “blank check” preferred stock that could be issued by our board of directors to thwart a takeover attempt;
•
do not provide for cumulative voting in the election of directors, which would allow holders of less than a majority of the stock to elect some directors;
•
establish a classified board of directors, as a result of which the successors to the directors whose terms have expired will be elected to serve from the time of election and qualification until the third annual meeting following their election;
•
require that directors only be removed from office for cause;
•
provide that vacancies on the board of directors, including newly-created directorships, may be filled only by a majority vote of directors then in office;
•
limit who may call special meetings of stockholders;
•
prohibit stockholder action by written consent, requiring all actions to be taken at a meeting of the stockholders; and
•
establish advance notice requirements for nominating candidates for election to the board of directors or for proposing matters that can be acted upon by stockholders at stockholder meetings.
Our board of directors previously adopted a rights agreement, the provisions of which could have had the effect of discouraging, delaying or preventing a change in or management or control over us. While there is no plan to do so at this time, our board of directors may choose to adopt a new rights plan in the future.
Global economic conditions may have an adverse effect on our business.
Financial instability or a general decline in economic conditions in the U.S. and other countries where we sell our product could adversely affect our operations. Economic conditions, and uncertainty as to the general direction of the macroeconomic environment, are beyond our control and may make any necessary debt or equity financing more difficult, more costly, and more dilutive. While we believe we have adequate capital resources to meet current working capital and capital expenditure requirements, an economic downturn or significant increase in our expenses could require additional financing on less than attractive rates or on terms that are excessively dilutive to existing stockholders. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our stock price and could require us to delay or abandon clinical development plans.
Sales of our products will be dependent, in large part, on reimbursement from government health administration authorities, private health insurers, distribution partners and other organizations. In the event of economic decline, these organizations may be unable to satisfy their reimbursement obligations or may delay payment. In addition, federal and state health authorities may reduce Medicare and Medicaid reimbursements, and private insurers may increase their scrutiny of claims. A reduction in the availability or extent of reimbursement could negatively affect our product sales and revenue.
In addition, we rely on third parties for several important aspects of our business. For example, we use third parties for sales, distribution, medical affairs and clinical research, and we rely upon several single source providers of raw materials and contract manufacturers for the manufacture of our products. During challenging and uncertain economic times and in tight credit markets, there may be a disruption or delay in the performance of our third party contractors, suppliers or partners. If such third parties are unable to satisfy their commitments to us, our business and results of operations would be adversely affected.

ITEM 1B.
UNRESOLVED STAFF COMMENTS
Not applicable.
ITEM 2.
PROPERTIES
Our headquarters office consists of a total of 43,462 square feet of office space located at 2200 Pennsylvania Avenue, N.W. in Washington, D.C. under operating leases and subleases that expire between 2026 and 2028 and are subject to renewal options. In addition, we have 2,880 square feet of office space in London, England under an operating lease that has a lease

49

term ending in 2021 and is subject to a renewal option, and other short term leases. We believe that these facilities are suitable and adequate to meet our anticipated near-term needs. We anticipate that following the expiration of the leases, additional or alternative space will be available at commercially reasonable terms.
ITEM 3.
LEGAL PROCEEDINGS
Fanapt®. We have been involved in litigation with Roxane Laboratories, Inc. (Roxane) and its affiliates, West-Ward Pharmaceuticals International Limited and West-Ward Pharmaceuticals Corp (West-Ward), since we filed a lawsuit against Roxane in the U.S. District Court for the District of Delaware (Delaware District Court) for patent infringement in June 2014. The lawsuit was filed in response to Roxane’s submission to the U.S. Food and Drug Administration (FDA) of an Abbreviated New Drug Application (ANDA) for a generic version of Fanapt® prior to the expiration of certain of our patents covering Fanapt®, including U.S. Patent No. 8,586,610 (‘610 Patent). In August 2016, the Delaware District Court ruled in our favor, permanently enjoining Roxane from manufacturing, using, selling, offering to sell, distributing or importing any generic iloperidone product described in Roxane’s ANDA until the expiration of the ‘610 Patent in November 2027, or May 2028 if we obtain pediatric exclusivity. In April 2018, following an appeal by Roxane of the Delaware District Court’s decision to the Federal Circuit Court of Appeals (Federal Circuit), the Federal Circuit affirmed the Delaware District Court’s ruling. In June 2018, West-Ward, having replaced Roxane as defendants following the acquisition of Roxane by West-Ward’s parent company, Hikma Pharmaceuticals PLC, petitioned the Federal Circuit for a rehearing en banc. In August 2018, the Federal Circuit denied West-Ward's petition. In January 2019, West-Ward filed a petition in the U.S. Supreme Court for a writ of certiorari seeking reversal of the Federal Circuit’s decision. In March 2019, the U.S. Supreme Court invited the Solicitor General of the U.S. to file a brief in the matter expressing the views of the U.S. In January 2020, the U.S. Supreme Court denied West-Ward's petition for writ of certiorari.
In 2015, we filed six separate patent infringement lawsuits in the Delaware District Court against Roxane, Inventia Healthcare Pvt. Ltd. (Inventia), Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin), Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd. (Taro), and Apotex Inc. and Apotex Corp. (Apotex, and collectively with Roxane, Inventia, Lupin and Taro, the Fanapt® Defendants). These lawsuits were filed in response to the submission to the FDA by each of the Fanapt® Defendants of ANDAs for generic versions of Fanapt® prior to the expiration of the ‘610 Patent in November 2027 or the U.S. Patent No. 9,138,432 in September 2025. We entered into separate confidential stipulations with each of Inventia and Lupin regarding any potential launch of their generic versions of Fanapt®. The parties are scheduled to provide the court with a status report in March 2020 with respect to the remaining lawsuits against the other Fanapt® Defendants.
HETLIOZ®. In April and May 2018, we filed three separate patent infringement lawsuits in the Delaware District Court against Teva Pharmaceuticals USA, Inc. (Teva), MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (MSN) and Apotex (collectively with Teva and MSN, the HETLIOZ® Defendants) after having received Paragraph IV certification notice letters (Paragraph IV Letters) from each of the HETLIOZ® Defendants alleging that certain of our patents covering HETLIOZ® (collectively, the HETLIOZ® Patents) were invalid, unenforceable and/or would not be infringed by the manufacture, use or sale of their generic versions of HETLIOZ®, as described in the ANDAs submitted to the FDA by each of the HETLIOZ® Defendants, prior to the expiration of the latest to expire of the HETLIOZ® Patents in 2034. Each of the HETLIOZ® Patents are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). In December 2018, we filed amended complaints against each of the HETLIOZ® Defendants following the receipt of additional Paragraph IV Letters from Teva and Apotex concerning our Orange Book listed '977 Patent, which expires in 2035. These lawsuits are scheduled for trial in October 2020.
In March 2019, April 2019, and May 2019, we filed three additional patent infringement lawsuits in the Delaware District Court against the HETLIOZ® Defendants following the receipt of additional Paragraph IV Letters from each concerning our Orange Book listed U.S. Patent No. 10,149,829, which expires in 2033. These lawsuits have been consolidated with the other lawsuits against the HETLIOZ® Defendants and are also scheduled for trial in October 2020.
In November and December 2019, we filed additional patent infringement lawsuits in the Delaware District Court against Apotex and Teva, respectively, for infringement of our Orange Book listed U.S. Patent No. 10,376,487 ('487 Patent) following the receipt of additional Paragraph IV Letters from Apotex and Teva regarding the '487 Patent, which expires in July 2035. Teva asserted a counterclaim for a declaratory judgment that the ‘487 Patent is invalid. We answered Teva’s counterclaim by denying their allegation that the ‘487 Patent is invalid. In January 2020, we filed two additional patent infringement lawsuits in the Delaware District Court against Teva and Apotex for infringement of our Orange Book-listed U.S. Patent No. 10,449,176 (‘176 Patent) following the receipt of additional Paragraph IV Letters from Teva and Apotex regarding the ‘176 Patent, which expires in January 2033. A trial date has not yet been scheduled for these lawsuits.

50

In January 2020, we received an additional Paragraph IV Letter from MSN concerning the '487 patent, in which MSN alleges that the ‘487 Patent is invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale offer for sale, or importation of MSN's generic version of HETLIOZ® as described in MSN's ANDA. We intend to vigorously pursue a patent infringement lawsuit permanently enjoining MSN from infringing the claims of the ‘487 Patent.
Other Matters. In April 2018, we submitted a protocol amendment to the FDA, proposing a 52-week open-label extension (OLE) period for patients who had completed the tradipitant Phase II clinical study (2301) in gastroparesis. In May 2018, based on feedback from the FDA, we amended the protocol limiting the duration of treatment in the 2301 study to a total of three months, while continuing to seek further dialogue with the FDA on extending the study duration to 52-weeks. As a part of this negotiation process, in September 2018, we submitted a new follow-on 52-week OLE protocol to the FDA (2302) for patients who had completed the 2301 study. While waiting for further feedback, we did not enroll any patients in any study beyond 12 weeks. In December 2018, the FDA imposed a partial clinical hold (PCH) on the two proposed studies, stating that we are required first to conduct additional chronic toxicity studies in canines, monkeys or minipigs before allowing patients access in any clinical protocol beyond 12 weeks. At that time, the FDA informed us that the original PCH was not based on any safety or efficacy data related to tradipitant, but, rather, that these additional toxicity studies were required by a guidance document. Subsequently, the FDA has taken the position that an additional study was required in order for the FDA to have adequate toxicology data to undertake a risk analysis of tradipitant.
On February 5, 2019, we filed a lawsuit against the FDA in the U.S. District Court for the District of Columbia (DC District Court), challenging the FDA’s legal authority to issue the PCH, and seeking an order to set it aside. In February 2019, the FDA filed a Motion for Voluntary Remand to the Agency and for a Stay of the Case. In March 2019, the DC District Court granted the FDA’s request for voluntary remand and returned the matter to the FDA for further consideration. In April 2019, the FDA provided its remand response, in which it indicated that, upon review of scientific literature and tradipitant data, it believes that a PCH continues to be appropriate until we have safety data from a nine-month non-rodent toxicity study. In May 2019, we filed an amended complaint, and in July 2019, we filed a Motion for Summary Judgment based on our continuing belief after review of the FDA’s remand response that additional chronic toxicity studies are unjustified, and that we have provided the FDA with sufficient information regarding the safety of tradipitant to justify the continued study of tradipitant in patients beyond 12 weeks, in accordance with applicable law and FDA regulations. The FDA filed a reply and cross-motion for summary judgment in October 2019 and an oral hearing was held on December 13, 2019. On January 31, 2020, the Court granted the FDA's cross-motion for summary judgment and granted judgment in favor of the FDA on our claims. We are evaluating our options, including a potential appeal, and we intend to continue vigorously pursuing our interests in the matter.
In February 2019, a qui tam action filed against us was unsealed by order of the DC District Court. The qui tam action, which was filed under seal in March 2017, was brought by a former employee of ours on behalf of the U.S., 28 states and the District of Columbia (collectively, the Plaintiff States) and the policyholders of certain insurance companies under the Federal False Claims Act and state law equivalents to the Federal False Claims Act and related state laws. The complaint alleged that we violated these laws through the promotion and marketing of our products Fanapt® and HETLIOZ® and sought, among other things, treble damages, civil penalties for each alleged false claim, and attorneys’ fees and costs. By virtue of the DC District Court having unsealed the original complaint, we learned that in January 2019, the U.S. Department of Justice (the DOJ), as well as the Plaintiff States, elected not to intervene in the qui tam action at that time. In May 2019, the plaintiff filed an amended complaint under seal repeating the same allegations and seeking the same relief. According to a filing unsealed in June 2019, the DOJ reaffirmed its decision not to intervene and incorporated its prior filing, indicating that neither the DOJ nor the Plaintiff States were intervening regarding the original complaint. Although the DOJ and the Plaintiff States have elected not to intervene, the plaintiff may litigate this action and the DOJ and the Plaintiff States may later seek to intervene in the action. In August 2019, we filed a motion to dismiss, and in October 2019 the plaintiff filed a reply. We intend to vigorously defend ourselves in the case. The Court will hear our motion to dismiss on March 20, 2020.
In February 2019, a securities class action, Gordon v. Vanda Pharmaceuticals Inc., was filed in the U.S. District Court for the Eastern District of New York naming us and certain of our officers as defendants. An amended complaint was filed in July 2019. The amended complaint, filed on behalf of a purported stockholder, asserts claims on behalf of a putative class of all persons who purchased our publicly traded securities between November 4, 2015 and February 11, 2019, for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The amended complaint alleges that the defendants made false and misleading statements and/or omissions regarding Fanapt®, HETLIOZ® and our interactions with the FDA regarding tradipitant between November 3, 2015 and February 11, 2019. We believe that we have meritorious defenses and intend to vigorously defend this lawsuit. We do not anticipate that this litigation will have a material adverse effect on our business, results of operations or financial condition. However, this lawsuit is subject to inherent uncertainties, the actual cost may be significant, and we may not prevail. We believe we are entitled to coverage under our relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient.

51

In July 2019, a shareholder derivative complaint, Samuel Williams vs. Mihael Polymeropoulos, et al., was filed in the U.S. District Court for the Eastern District of New York naming certain of our current and former directors and officers as defendants. In September 2019, a shareholder derivative complaint, Michael Bavaro v. Mihael Polymeropoulos, et al., was filed in the Delaware District Court naming certain of our current and former directors and officers as defendants. In October 2019, we filed a motion to transfer the Bavaro case to the Eastern District of New York, where the Gordon and Williams cases are pending. In February 2020, the Delaware District Court issued an order staying the Bavaro case pending the resolution of the Williams case. These complaints, filed on behalf of purported stockholders, derivatively on our behalf, assert claims for alleged breach of fiduciary duties by certain of our current and former directors and officers. We believe that we have meritorious defenses and intend to vigorously defend these lawsuits. We do not anticipate that this litigation will have a material adverse effect on our business, results of operations or financial condition. However, these lawsuits are subject to inherent uncertainties, the actual cost may be significant, and we may not prevail. We believe we are entitled to coverage under our relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient.
In July 2017, the CHMP issued a negative opinion recommending against approval of Fanaptum® (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the E.U. The CHMP was of the opinion that the benefits of Fanaptum® did not outweigh its risks and recommended against marketing authorization. In March 2018, we filed an application seeking annulment of the EMA’s negative opinion and the subsequent European Commission decision refusing marketing authorization of Fanaptum in the European General Court. In December 2019, the General Court issued its judgment dismissing the action, leaving the EMA opinion and Commission decision intact. We are considering our options to appeal the decision.
ITEM 4.
MINE SAFETY DISCLOSURES
Not applicable.
PART II
 
ITEM 5.
MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Our common stock is quoted on The Nasdaq Global Market under the symbol “VNDA.” As of February 18, 2020, there were seven holders of record of our common stock. The number of holders of record of our common stock does not reflect the number of beneficial holders whose shares are held by depositors, brokers or other nominees.
Market Price of and Dividends on the Registrant’s Common Equity and Related Stockholder Matters
The following graph shows the cumulative five-year total return on our common stock relative to the cumulative total returns of the Nasdaq Composite Index and the Nasdaq Biotechnology Index. An investment of $100 (with reinvestment of dividends) is assumed to have been made in our common stock and in each of the indexes on December 31, 2014 and its relative performance is tracked through December 31, 2019. The comparisons in the table are required by the Securities and Exchange Commission (SEC) and are not intended to forecast or be indicative of possible future performance of our common stock. We have never paid cash dividends to our stockholders and do not plan to pay dividends in the foreseeable future. The following graph and related information is being furnished solely to accompany this Annual Report pursuant to Item 201(e) of Regulation S-K and shall not be deemed “soliciting materials” or to be “filed” with the SEC (other than as provided in Item 201), nor shall such information be incorporated by reference into any of our filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, and irrespective of any general incorporation language in any such filing.

52

partiiitem5chart.jpg
Securities Authorized for Issuance under Equity Incentive Plans
Information regarding securities authorized for issuance under equity incentive plans will be contained in our Proxy Statement for the 2020 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2019, under the caption “Security Ownership of Certain Beneficial Owners and Management” and is incorporated herein by reference pursuant to General Instruction G(3) to Form 10-K.


53

ITEM 6.
SELECTED CONSOLIDATED FINANCIAL DATA
The consolidated statements of operations data for the years ended December 31, 2019, 2018 and 2017 and the consolidated balance sheet data as of December 31, 2019 and 2018 are each derived from our audited consolidated financial statements included in this Annual Report. The consolidated statements of operations data for the years ended December 31, 2016 and 2015, and the consolidated balance sheet data as of December 31, 2017, 2016 and 2015 are each derived from our audited consolidated financial statements not included herein. Our historical results for any prior period are not necessarily indicative of results to be expected in any future period.
The following data should be read together with our consolidated financial statements and accompanying notes and the section entitled Management’s Discussion and Analysis of Financial Condition and Results of Operations included in this Annual Report.
 
Year Ended December 31,
(in thousands, except for share and per share amounts)
2019 (1)
 
2018 (1)(2)
 
2017 (1)(2)
 
2016 (1)(2)
 
2015 (1)(2)
Statements of Operations Data
 
 
 
 
 
 
 
 
 
Total revenues
$
227,188

 
$
193,118

 
$
165,083

 
$
146,017

 
$
109,925

Operating expenses:
 
 
 
 
 
 
 
 
 
Cost of goods sold excluding amortization
24,488

 
20,508

 
17,848

 
24,712

 
23,462

Research and development
48,649

 
43,594

 
38,547

 
29,156

 
29,145

Selling, general and administrative
129,736

 
105,751

 
123,841

 
99,787

 
84,531

Intangible asset amortization
1,505

 
1,527

 
1,750

 
10,933

 
12,972

Total operating expenses
204,378

 
171,380

 
181,986

 
164,588

 
150,110

Income (loss) from operations
22,810

 
21,738

 
(16,903
)
 
(18,571
)
 
(40,185
)
Other income
6,218

 
3,608

 
1,472

 
665

 
320

Income (loss) before income taxes
29,028

 
25,346

 
(15,431
)
 
(17,906
)
 
(39,865
)
Provision (benefit) for income taxes
(86,525
)
 
138

 
136

 
104

 
—

Net income (loss)
$
115,553

 
$
25,208

 
$
(15,567
)
 
$
(18,010
)
 
$
(39,865
)
Net income (loss) per share:
 
 
 
 
 
 
 
 
 
Basic
$
2.17

 
$
0.50

 
$
(0.35
)
 
$
(0.41
)
 
$
(0.94
)
Diluted
$
2.11

 
$
0.48

 
$
(0.35
)
 
$
(0.41
)
 
$
(0.94
)
Weighted average shares outstanding:
 
 
 
 
 
 
 
 
 
Basic
53,137,562

 
50,859,947

 
44,735,146

 
43,449,441

 
42,250,254

Diluted
54,847,060

 
53,045,257

 
44,735,146

 
43,449,441

 
42,250,254

 
 
December 31,
(in thousands)
2019 (1)
 
2018 (1)
 
2017 (1)
 
2016 (1)
 
2015 (1)
Balance Sheet Data
 
 
 
 
 
 
 
 
 
Cash and cash equivalents
$
45,072

 
$
61,005

 
$
33,627

 
$
40,426

 
$
50,843

Marketable securities
267,057

 
196,355

 
109,786

 
100,914

 
92,337

Working capital
294,631

 
246,117

 
99,494

 
123,855

 
115,230

Total assets
483,748

 
332,130

 
205,425

 
210,374

 
213,050

Long-term liabilities
13,298

 
3,693

 
3,675

 
28,724

 
28,706

Total liabilities
72,803

 
56,708

 
74,038

 
79,044

 
80,023

Accumulated deficit
(220,665
)
 
(336,218
)
 
(361,426
)
 
(345,859
)
 
(327,849
)
Total stockholders’ equity
410,945

 
275,422

 
131,387

 
131,330

 
133,027

 
(1)
We adopted Accounting Standards Codification (ASC) Subtopic 842 Leases (ASC 842), effective January 1, 2019, using a modified retrospective transition. Results for the years ended prior to December 31, 2019 are accounted for in accordance with ASC 840.
(2)
We adopted Accounting Standards Codification (ASC) Subtopic 606 Revenue from Contracts with Customers (ASC 606), effective January 1, 2018, using the modified retrospective method to those contracts which were not completed

54

as of January 1, 2018. Results for the years ended prior to December 31, 2018 are accounted for in accordance with ASC 605.


55

ITEM 7.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following discussion and analysis of our financial condition and results of operations together with Selected Consolidated Financial Data and our consolidated financial statements and related notes appearing in this annual report on Form 10-K (Annual Report). Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report include historical information and other information with respect to our plans and strategy for our business and contain forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including but not limited to those set forth under the “Risk Factors” section of this report and elsewhere in this Annual Report.
Overview
Vanda Pharmaceuticals Inc. (we, our or Vanda) is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.
We strive to advance novel approaches to bring important, new medicines to market through responsible innovation. We are committed to the use of technologies that support sound science, including genetics and genomics, in drug discovery, clinical trials and the commercial positioning of our products.
Our commercial portfolio is currently comprised of two products, HETLIOZ® for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and Fanapt® for the treatment of schizophrenia. HETLIOZ® is the first treatment for Non-24 approved by the FDA. In addition, we have a number of drugs in development, including:
 
•
HETLIOZ® (tasimelteon) for the treatment of jet lag disorder, Smith-Magenis Syndrome (SMS), pediatric Non-24 and delayed sleep phase disorder (DSPD);
•
Fanapt® (iloperidone) for the treatment of bipolar disorder and a long acting injectable (LAI) formulation program for the treatment of schizophrenia;
•
Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis and motion sickness;
•
VTR-297, a small molecule histone deacetylase (HDAC) inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications;
•
VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist, with potential use for the treatment of psychiatric disorders; and
•
Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors for the treatment of dry eye and ocular inflammation and for the treatment of secretory diarrhea disorders, including cholera.
Operational Highlights
Tradipitant
•
Results from the EPIONE study of tradipitant in the treatment of pruritus in atopic dermatitis were reported today. We will reassess EPIONE 2 and determine next steps.
•
Enrollment in the Phase III study of tradipitant in gastroparesis (VP-VLY-686-3301) is ongoing.
•
We expect to complete the Phase III program of tradipitant in motion sickness and file an NDA with the FDA in 2020.
•
We continue to engage with the FDA over the requirement of a nine-month dog toxicity study.
HETLIOZ® 
•
We submitted an sNDA for HETLIOZ® in SMS, including data for a liquid formulation, and expect regulatory action by the FDA in 2020.
•
We continue to pursue approval for HETLIOZ® in the treatment of jet lag disorder.
•
A clinical program for HETLIOZ® in DSPD is ongoing.

56

Fanapt® 
•
A Phase III study of Fanapt® in bipolar disorder is ongoing.
•
Development of the LAI formulation of Fanapt® is ongoing.
Since we began operations, we have devoted substantially all of our resources to the in-licensing, clinical development and commercialization of our products. Our ability to generate meaningful product sales and achieve profitability largely depends on our level of success in commercializing HETLIOZ® and Fanapt® in the U.S. and Europe, on our ability, alone or with others, to complete the development of our products, and to obtain the regulatory approvals for and to manufacture, market and sell our products. The results of our operations will vary significantly from year-to-year and quarter-to-quarter and depend on a number of factors, including risks related to our business, risks related to our industry, and other risks which are detailed in Risk Factors reported in Item 1A of Part I of this Annual Report.
As described in Part I, Item 3, Legal Proceedings, of this Annual Report, we have initiated lawsuits to enforce our patent rights against certain generic pharmaceutical companies.
Critical Accounting Policies
The preparation of our consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our financial statements, as well as the reported revenues and expenses during the reported periods. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
A summary of our significant accounting policies appears in the notes to our audited consolidated financial statements for the year ended December 31, 2019 included in this Annual Report. However, we believe that the following accounting policies are important to understanding and evaluating our reported financial results, and we have accordingly included them in this discussion.
Leases. In accordance with Accounting Standards Codification (ASC) 842, Leases, effective January 1, 2019, we determine if an arrangement contains a lease at inception. Right-of-use (ROU) assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from that lease. For leases with a term greater than 12 months, ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The lease term includes the option to extend the lease when it is reasonably certain we will exercise that option. We do not combine lease and non-lease elements for office leases. For existing leases as of January 1, 2019, executory costs are excluded from lease expense, which is consistent with our accounting under ASC 840, Leases. For all leases entered into after January 1, 2019, executory costs are allocated between lease and non-lease elements based upon their relative stand-alone prices.
When available, we use the rate implicit in the lease to discount lease payments to present value; however, most of our leases do not provide a readily determinable implicit rate. Therefore, we use our incremental borrowing rate based on information available at the lease commencement date in determining the present value of lease payments. Our incremental borrowing rate is derived from information available at the lease commencement date in determining the present value of lease payments. Since we do not have outstanding debt that could provide an indication of the appropriate discount rate we used publicly available data for instruments with similar characteristics when calculating our incremental borrowing rates. In making this estimation we considered market comparable data on companies with similar credit rating, secured contracts and contract length terms. We use the lease term to determine the incremental borrowing rate.
Net Product Sales. Our net product sales consist of sales of HETLIOZ® and sales of Fanapt®. In accordance with ASC Subtopic 606 Revenue from Contracts with Customers (ASC 606), which we adopted January 1, 2018, we account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. We recognize revenue when control of the product is transferred to the customer in an amount that reflects the consideration we expect to be entitled to in exchange for those product sales, which is typically once the product physically arrives at the customer. Sales taxes, value add taxes, and usage-based taxes are excluded from revenues.
HETLIOZ® is available in the U.S. for distribution through a limited number of specialty pharmacies, and is not available in retail pharmacies. Fanapt® is available in the U.S. for distribution through a limited number of wholesalers and is

57

available in retail pharmacies. We invoice and record revenue when customers, specialty pharmacies and wholesalers, receive product from the third-party logistics warehouse which is the point at which control is transferred to the customer. Revenues and accounts receivable are concentrated with these customers. Outside the U.S., we commercially launched HETLIOZ® in Germany in August 2016. We have also entered into a distribution agreement with Megapharm Ltd. for the commercialization of Fanapt® in Israel. The Company evaluates outstanding receivables to assess collectability. In performing this evaluation, the Company analyzes economic conditions, the aging of receivables and customer specific risks.
The transaction price is determined based upon the consideration to which we will be entitled in exchange for transferring product to the customer. Our product sales are recorded net of applicable product revenue allowances for which reserves are established and include discounts, rebates, chargebacks, service fees, co-pay assistance and product returns that are applicable for various government and commercial payors. We estimate the amount of variable consideration that should be included in the transaction price utilizing the most likely amount method and update our estimate at each reporting date. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Allowances for rebates, chargebacks and co-pay assistance are based upon the insurance benefits of the end customer, which are estimated using historical activity and, where available, actual and pending prescriptions for which we have validated the insurance benefits. Reserves for variable consideration are classified as product revenue allowances on the consolidated balance sheets, with the exception of prompt-pay discounts which are classified as reductions of accounts receivable. The reserve for product returns for which the product may not be returned for a period of greater than one year from the balance sheet date is included as a component of other non-current liabilities in the consolidated balance sheets. Uncertainties related to variable consideration are generally resolved in the quarter subsequent to period end, with the exception of Medicaid rebates, which are dependent upon the timing of when states submit reimbursement claims, and product returns which are resolved during the product expiry period specified in the customer contract. We currently record sales allowances for the following:
Prompt-pay: Specialty pharmacies and wholesalers are offered discounts for prompt payment. We expect that the specialty pharmacies and wholesalers will earn prompt payment discounts and, therefore, deduct the full amount of these discounts from total product sales when revenues are recognized.
Rebates: Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program as well as contracted rebate programs with other payors. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contracted discount rates and estimated patient utilization.
Chargebacks: Chargebacks are discounts that occur when contracted indirect customers purchase directly from specialty pharmacies and wholesalers. Contracted indirect customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The specialty pharmacy or wholesaler, in turn, charges back the difference between the price initially paid by the specialty pharmacy or wholesaler and the discounted price paid to the specialty pharmacy or wholesaler by the contracted customer.
Medicare Part D Coverage Gap: Medicare Part D prescription drug benefit mandates manufacturers to fund approximately 50% of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients through 2018. Public Law No. 115-123, also known as the Bipartisan Budget Act of 2018 enacted on February 9, 2018 increased the manufacturer discount from 50% to 70% effective in 2019 for applicable drugs. We account for the Medicare Part D coverage gap using a point of sale model. Estimates for expected Medicare Part D coverage gap are based in part on historical activity and, where available, actual and pending prescriptions when we have validated the insurance benefits.
Service Fees: We receive sales order management, data and distribution services from certain customers. These fees are based on contracted terms and are known amounts. We accrue service fees at the time of revenue recognition, resulting in a reduction of product sales and the recognition of an accrued liability, unless it is a payment for a distinct good or service from the customer in which case the fair value of those distinct goods or services are recorded as selling, general and administrative expense.
Co-payment Assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Co-pay assistance utilization is based on information provided by our third-party administrator.
Product Returns: We generally offer direct customers a limited right to return as contractually defined with our customers. We consider several factors in the estimation process, including expiration dates of product shipped to customers, inventory levels within the distribution channel, product shelf life, historical return activity, including activity for product sold for which the return period has past, prescription trends and other relevant factors. We do not expect returned goods to be resalable. There was no right of return asset as of December 31, 2019 or 2018.

58

The following table summarizes sales discounts and allowance activity as of and for the years ended December 31, 2019, 2018 and 2017:
 
(in thousands)
Rebates &
Chargebacks
 
Discounts,
Returns
and Other
 
Total
Balances at December 31, 2016
$
31,202

 
$
6,458

 
$
37,660

Provision related to current period sales
53,406

 
23,751

 
77,157

Adjustments for prior period sales
(3,883
)
 
1,362

 
(2,521
)
Credits/payments made
(60,496
)
 
(24,214
)
 
(84,710
)
Balances at December 31, 2017
20,229

 
7,357

 
27,586

Provision related to current period sales
59,317

 
23,796

 
83,113

Adjustments for prior period sales
811

 
370

 
1,181

Credits/payments made
(58,223
)
 
(21,823
)
 
(80,046
)
Balances at December 31, 2018
22,134

 
9,700

 
31,834

Provision related to current period sales
59,358

 
26,872

 
86,230

Adjustments for prior period sales
(350
)
 
(399
)
 
(749
)
Credits/payments made
(58,750
)
 
(26,022
)
 
(84,772
)
Balances at December 31, 2019
$
22,392

 
$
10,151

 
$
32,543

The provision for rebates and chargebacks of $59.4 million and $59.3 million for the years ended December 31, 2019 and 2018, respectively, primarily represents Medicaid rebates applicable to sales of Fanapt® and HETLIOZ®. The provision for discounts, returns and other of $26.9 million and $23.8 million for the years ended December 31, 2019 and 2018, primarily represents wholesaler distribution fees applicable to sales of Fanapt® and, to a lesser extent, estimated product returns of Fanapt®, as well as co-pay assistance costs and prompt pay discounts applicable to the sales of both HETLIOZ® and Fanapt®.
Stock-based compensation. Compensation costs for all stock-based awards to employees and directors are measured based on the grant date fair value of those awards and recognized over the period during which the employee or director is required to perform service in exchange for the award. We use the Black-Scholes-Merton option pricing model to determine the fair value of stock options. The determination of the fair value of stock options on the date of grant using an option pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. These variables include the expected stock price volatility over the expected term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rate and expected dividends. Expected volatility rates are based on the historical volatility of our publicly traded common stock and other factors. The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. We have never paid cash dividends to our stockholders and do not plan to pay dividends in the foreseeable future. As stock-based compensation expense recognized in the consolidated statements of operations is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
Research and development expenses. Research and development expenses consist primarily of fees for services provided by third parties in connection with the clinical trials, costs of contract manufacturing services for clinical trial use, milestone payments made under licensing agreements prior to regulatory approval, costs of materials used in clinical trials and research and development, costs for regulatory consultants and filings, depreciation of capital resources used to develop products, related facilities costs, and salaries, other employee-related costs and stock-based compensation for research and development personnel. We expense research and development costs as they are incurred for products in the development stage, including manufacturing costs and milestone payments made under license agreements prior to FDA approval. Upon and subsequent to FDA approval, manufacturing and milestone payments made under license agreements are capitalized. Milestone payments are accrued when it is deemed probable that the milestone event will be achieved. Costs related to the acquisition of intellectual property are expensed as incurred if the underlying technology is developed in connection with our research and development efforts and has no alternative future use.
Clinical trials are inherently complex, often involve multiple service providers, and can include payments made to investigator physicians at study sites. Because billing for services often lags delivery of service by a substantial amount of time, we often are required to estimate a significant portion of our accrued clinical expenses. Our assessments include, but are not

59

limited to: (i) an evaluation by the project manager of the work that has been completed during the period, (ii) measurement of progress prepared internally and/or provided by the third-party service provider, (iii) analyses of data that justify the progress, and (iv) management’s judgment. In the event that we do not identify certain costs that have begun to be incurred or we under- or over-estimates the level of services performed or the costs of such services, our reported expenses for such period would be too low or too high.
Intangible Assets. Our intangible assets consist of capitalized license costs for products approved by the FDA. We amortize our intangible assets on a straight-line basis over the estimated useful economic life of the related product patents. We assess the impairment of intangible assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors we consider important which could trigger an impairment review include significant underperformance relative to expected historical or projected future operating results, a significant adverse change in legal or regulatory factors that could affect the value or patent life including our ability to defend and enforce patent claims and other intellectual property rights and significant negative industry or economic trends. When we determine that the carrying value of our intangible assets may not be recoverable based upon the existence of one or more of the indicators of impairment, we measure any impairment based on the amount that carrying value exceeds fair value. No impairments have been recognized on our intangible assets.
Income taxes. We assess the need for a valuation allowance against our deferred tax asset each quarter through the review of all available positive and negative evidence. Deferred tax assets are reduced by a tax valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. The analysis is highly dependent upon historical and projected taxable income. Projected taxable income includes significant assumptions related to revenue, commercial expenses and research and development activities. During 2019, after considering all available positive and negative evidence, including but not limited to cumulative income in recent periods, historical, current and future projected results and significant risks and uncertainties related to forecasts, we concluded that it was more likely than not that substantially all of our deferred tax assets in the U.S. are realizable in future periods. A valuation allowance has been retained against certain U.S. federal tax attributes with short carryforward periods and District of Columbia state deferred tax assets as of December 31, 2019. A full valuation allowance was recorded against all net U.S. deferred tax assets as of December 31, 2018. Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement.
Recent Accounting Pronouncements
See Note 2, Summary of Significant Accounting Policies, to the consolidated financial statements included in Part II of this Annual Report for information on recent accounting pronouncements.
Results of Operations
We anticipate that our results of operations will fluctuate for the foreseeable future due to several factors, including our and our partners’ ability to successfully commercialize our products, any possible payments made or received pursuant to license or collaboration agreements, progress of our research and development efforts, the timing and outcome of clinical trials and related possible regulatory approvals. Since our inception, we have incurred significant losses resulting in an accumulated deficit of $220.7 million as of December 31, 2019. Our total stockholders’ equity was $410.9 million as of December 31, 2019.
Year ended December 31, 2019 compared to year ended December 31, 2018
Revenues. Total revenues increased by $34.1 million, or 18%, to $227.2 million for the year ended December 31, 2019 compared to $193.1 million for the year ended December 31, 2018. Revenues were as follows:
 
 
Year Ended December 31,
(in thousands)
2019
 
2018
 
Net
Change
 
Percent
HETLIOZ® product sales, net
$
142,980

 
$
115,835

 
$
27,145

 
23
%
Fanapt® product sales, net
84,208

 
77,283

 
6,925

 
9
%
Total net product sales
$
227,188

 
$
193,118

 
$
34,070

 
18
%

60

HETLIOZ® product sales, net increased by $27.1 million, or 23%, to $143.0 million for the year ended December 31, 2019 compared to $115.8 million for the year ended December 31, 2018. The increase to net product sales was attributable to an increase in volume and an increase in price net of deductions.
Fanapt® product sales, net increased by $6.9 million, or 9%, to $84.2 million for the year ended December 31, 2019 compared to $77.3 million for the year ended December 31, 2018. The increase to net product sales was attributable to an increase in price net of deductions.
Cost of goods sold. Cost of goods sold increased by $4.0 million, or 19%, to $24.5 million for the year ended December 31, 2019 compared to $20.5 million for the year ended December 31, 2018. Cost of goods sold includes third party manufacturing costs of product sold, third party royalty costs and distribution and other costs. Third party royalty costs were 10% and 5% of net product sales of HETLIOZ® in the U.S. and Germany, respectively, and 9% of net product sales of Fanapt®. Third party royalty costs on net product sales of Fanapt® will decrease to 6% beginning January 2020.
In addition to third party royalty costs, HETLIOZ® and Fanapt® cost of goods sold as a percentage of revenue depends upon our cost to manufacture inventory at normalized production levels with our third party manufacturers. We expect that, in the future, total HETLIOZ® manufacturing costs included in cost of goods sold will continue to be less than 2% of our net HETLIOZ® product sales. We expect that, in the future, total U.S. Fanapt® manufacturing costs included in cost of goods sold will continue to be less than 3% of our net U.S. Fanapt® product sales.
Research and development expenses. Research and development expenses increased by $5.1 million, or 12%, to $48.6 million for the year ended December 31, 2019 compared to $43.6 million for the year ended December 31, 2018. The increase was primarily due to an increase in clinical trial expenses associated with the tradipitant and Fanapt programs as well as an increase in indirect project costs including stock-based compensation expense, partially offset by a decrease in expenses associated with the HETLIOZ® clinical programs. 
The following table summarizes the costs of our product development initiatives for the years ended December 31, 2019 and 2018.

 
Year Ended December 31,
(in thousands)
2019
 
2018
Direct project costs (1)
 
 
 
HETLIOZ®
$
8,672

 
$
12,709

Fanapt®
5,516

 
3,438

Tradipitant
21,290

 
16,978

VTR-297
1,609

 
2,190

CFTR
4,511

 
3,870

Other
668

 
619

 
42,266

 
39,804

Indirect project costs (1)
 
 
 
Stock-based compensation
3,207

 
1,290

Other indirect overhead
3,176

 
2,500

 
6,383

 
3,790

Total research and development expense
$
48,649

 
$
43,594

 
(1)
We record direct costs, including personnel costs and related benefits, on a project-by-project basis. Many of our research and development costs are not attributable to any individual project because we share resources across several development projects. We record indirect costs that support a number of our research and development activities in the aggregate, including stock-based compensation.
We expect to incur significant research and development expenses as we continue to develop our products. In addition, we expect to incur licensing costs in the future that could be substantial, as we continue our efforts to expand our product pipeline.

61

Selling, general and administrative expenses. Selling, general and administrative expenses increased by $24.0 million, or 23%, to $129.7 million for the year ended December 31, 2019 compared to $105.8 million for the year ended December 31, 2018. The increase was primarily the result of higher spend on legal and corporate related activities, including personnel costs, and Non-24 direct to consumer marketing.
Intangible asset amortization. Intangible asset amortization was $1.5 million for each of the years ended December 31, 2019 and 2018.
Other income. Other income was $6.2 million for the year ended December 31, 2019 compared to $3.6 million for the year ended December 31, 2018. Other income primarily relates to investment income on our marketable securities.
Provision for income taxes. An income tax benefit of $86.5 million was recorded for the year ended December 31, 2019 and a provision for income taxes of $0.1 million was recorded for the year ended December 31, 2018. The income tax benefit for 2019 was primarily due to the reduction of the tax valuation allowance against substantially all of its deferred tax assets in the U.S. Tax expense associated with U.S. income before income taxes for the years ended December 31, 2019 and 2018 was offset by a corresponding tax benefit for the reduction of the valuation allowance recorded against tax attributes that were utilized in those periods. Income tax expense was recorded related to certain U.S. state and foreign jurisdictions for the years ended December 31, 2019 and 2018. 
Liquidity and Capital Resources
As of December 31, 2019, our total cash and cash equivalents and marketable securities were $312.1 million compared to $257.4 million at December 31, 2018. Our cash and cash equivalents are deposits in operating accounts and highly liquid investments with an original maturity of 90 days or less at date of purchase and consist of investments in money market funds with commercial banks and financial institutions, and commercial paper of high-quality corporate issuers. Our marketable securities consist of investments in government sponsored and corporate enterprises and commercial paper.
Our liquidity resources as of December 31, 2019 and 2018 are summarized as follows:
 
(in thousands)
December 31, 2019
 
December 31, 2018
Cash and cash equivalents
$
45,072

 
$
61,005

Marketable securities:
 
 
 
U.S. Treasury and government agencies
88,601

 
69,270

Corporate debt
130,055

 
105,910

Asset-backed securities
48,401

 
21,175

Total marketable securities
267,057

 
196,355

Total cash, cash equivalents and marketable securities
$
312,129

 
$
257,360

As of December 31, 2019, we maintained all of our Cash in two financial institutions. Deposits held with these institutions may exceed the amount of insurance provided on such deposits, but we do not anticipate any losses with respect to such deposits.
We expect to incur substantial costs and expenses throughout 2020 and beyond in connection with our continued clinical development of tradipitant and our other products, U.S. commercial activities for HETLIOZ® and Fanapt®, the European commercial launch activities for HETLIOZ® and payments due upon achievement of milestones under our license agreements. Additionally, we continue to pursue market approval of HETLIOZ® and Fanapt® in other regions. The actual costs to advance tradipitant and our research and development projects and commercial activities for HETLIOZ® and Fanapt® are difficult to estimate and may vary significantly. We believe that our existing funds will be sufficient to meet our operating plans for at least the next twelve months. Our future capital requirements and the adequacy of our available funds will depend on many factors, primarily including our ability to generate revenue, the scope and costs of our commercial, manufacturing and process development activities, the magnitude of our discovery, preclinical and clinical development programs, and potential costs to acquire or license the rights to additional products.
We may need or desire to obtain additional capital to finance our operations through debt, equity or alternative financing arrangements. We may also seek capital through collaborations or partnerships with other companies. The issuance of debt could require us to grant liens on certain of our assets that may limit our flexibility and debt securities may be convertible

62

into common stock. If we raise additional capital by issuing equity securities, the terms and prices for these financings may be much more favorable to the new investors than the terms obtained by our existing stockholders. These financings also may significantly dilute the ownership of our existing stockholders. If we are unable to obtain additional financing, we may be required to reduce the scope of our future activities which could harm our business, financial condition and operating results. There can be no assurance that any additional financing required in the future will be available on acceptable terms, if at all.
Cash Flow
The following table summarizes our net cash flows from operating, investing and financing activities for the years ended December 31, 2019 and 2018:
 
Year Ended December 31,
(in thousands)
2019
 
2018
 
Net Change
Net cash provided by (used in):
 
 
 
 
 
Operating activities:
 
 
 
 
 
Net income
$
115,553

 
$
25,208

 
$
90,345

Non-cash charges
(72,731
)
 
12,568

 
(85,299
)
Net change in operating assets and liabilities
3,125

 
(7,790
)
 
10,915

Operating activities
45,947

 
29,986

 
15,961

Investing activities:
 
 
 
 
 
Acquisition of intangible asset
—

 
(25,000
)
 
25,000

Purchases of property and equipment
(1,019
)
 
(368
)
 
(651
)
Net purchases of marketable securities
(67,290
)
 
(84,292
)
 
17,002

Investing activities
(68,309
)
 
(109,660
)
 
41,351

Financing activities:
 
 
 
 
 
Net proceeds from offering of common stock
—

 
100,870

 
(100,870
)
Proceeds from exercise of employee stock options and other
6,264

 
6,256

 
8

Financing activities
6,264

 
107,126

 
(100,862
)
Effect of exchange rate changes on cash, cash equivalents and restricted cash
(1
)
 
(38
)
 
37

Net increase (decrease) in cash, cash equivalents and restricted cash
$
(16,099
)
 
$
27,414

 
$
(43,513
)
Operating Activities. Cash flows provided by operating activities during the year ended December 31, 2019 were $45.9 million, an increase of $16.0 million compared to $30.0 million during the year ended December 31, 2018. The increase reflects an increase of $90.3 million in net income and $10.9 million from the net change in operating assets and liabilities, partially offset by a decrease of $85.3 million in non-cash charges primarily due to the reduction of our tax valuation allowance against substantially all of our deferred tax assets in the U.S. The increase of $10.9 million from the net change in operating assets and liabilities primarily relates to a decrease in accounts receivable attributable to the timing of shipments and payments and an increase in accounts payable and other liabilities attributable to the timing of activities and payments.
Investing Activities. Cash flows used in investing activities during the year ended December 31, 2019 were $68.3 million, a decrease of $41.4 million compared to $109.7 million during the year ended December 31, 2018. Investing activities reflect continued net reinvestment of available cash and cash equivalents in our portfolio of marketable securities. Additionally, during the year ended December 31, 2018, we paid $25.0 million upon achievement of a HETLIOZ® milestone obligation.
Financing Activities. Cash flows provided by financing activities during the year ended December 31, 2019 were $6.3 million, a decrease of $100.9 million compared to $107.1 million during the year ended December 31, 2018. During the year ended December 31, 2018, we received net cash proceeds of $100.9 million from a public offering of common stock.
Off-balance sheet arrangements
We have no off-balance sheet arrangements, as defined in Item 303(a)(4) of the Securities and Exchange Commission’s Regulation S-K.


63

Contractual obligations and commitments
The following is a summary of our non-cancellable long-term contractual cash obligations as of December 31, 2019:
 
 
Cash payments due by year (3)(4)
(in thousands)
Total
 
2020
 
2021
 
2022
 
2023
 
2024
 
Thereafter
Operating leases (1)
$
20,103

 
$
2,326

 
$
2,332

 
$
2,355

 
$
2,420

 
$
2,488

 
$
8,182

Purchase commitments (2)
10,614

 
9,167

 
966

 
481

 
—

 
—

 
—

 
$
30,717

 
$
11,493

 
$
3,298

 
$
2,836

 
$
2,420

 
$
2,488

 
$
8,182

 
(1)
Operating leases include the minimum lease payments for our operating lease liabilities. This table does not include obligations under short-term lease agreements, variable payments for building maintenance and other services and executory costs associated with our operating lease agreements.
(2)
Purchase commitments include noncancellable purchase commitments for agreements longer than one year and primarily relate to commitments for media and data services. This table does not include various other long-term agreements entered into for services with other third party vendors, such as inventory purchase commitments, due to the cancelable nature of the services or variable terms within the agreement. Additionally, this table does not include rebates, chargebacks or discounts recorded as liabilities at the time that product sales are recognized as revenue.
(3)
This table does not include potential future milestone obligations under our license agreements for which we have not deemed it probable that the milestone event will occur as of December 31, 2019. See Part I, Item 1, Business, of this Annual Report, for a description of our licensing arrangements and remaining milestone obligations.
(4)
This table does not include liabilities related to uncertain tax positions taken as of December 31, 2019. Due to the uncertainties in the timing of potential tax audits, the timing associated with the resolution of these positions is also uncertain.

ITEM 7A.
QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK
 
Interest rate risks
Our exposure to market risk is currently confined to our cash and cash equivalents, marketable securities and restricted cash. We currently do not hedge interest rate exposure. We have not used derivative financial instruments for speculation or trading purposes. Because of the short-term maturities of our cash and cash equivalents and marketable securities, we do not believe that an increase in market rates would have any significant impact on the realized value of our investments.
Concentrations of credit risk
We deposit our cash with financial institutions that we consider to be of high credit quality and purchase marketable securities which are generally investment grade, liquid, short-term fixed income securities and money-market instruments denominated in U.S. dollars. Our marketable securities consist of commercial paper, corporate notes, asset-backed securities and U.S. government agency notes.
Revenues and accounts receivable are concentrated with specialty pharmacies and wholesalers. There were 5 major customers that each accounted for more than 10% of total revenues and, as a group, represented 96% of total revenues for the year ended December 31, 2019. There were 5 major customers that each accounted for more than 10% of accounts receivable and, as a group, represented 94% of total accounts receivable at December 31, 2019. We mitigate our credit risk relating to accounts receivable from customers by performing ongoing credit evaluations.
Foreign currency risk
We are exposed to risks related to changes in foreign currency exchange rates relating to our foreign operations. The functional currency of our international subsidiaries is the local currency. We are exposed to foreign currency risk to the extent that we enter into transactions denominated in currencies other than our subsidiaries’ respective functional currencies. We are also exposed to unfavorable fluctuations of the U.S. dollar, which is our reporting currency, against the currencies of our operating subsidiaries when their respective financial statements are translated into U.S. dollars for inclusion in our

64

consolidated financial statements. We do not currently hedge our foreign currency exchange rate risk. Foreign currency has not had a material impact on our results of operations.
Effects of inflation
Inflation has not had a material impact on our results of operations.
 
ITEM 8.
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The consolidated financial statements and related financial statement schedules required to be filed are listed in the Index to Consolidated Financial Statements and are incorporated in Item 15 of Part IV of this Annual Report.
 
ITEM 9.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.
 
ITEM 9A.
CONTROLS AND PROCEDURES
 
Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934 (Exchange Act)) as of December 31, 2019. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective as of December 31, 2019, the end of the period covered by this Annual Report, to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.
Management’s Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining an adequate system of internal control over financial reporting, as defined in the Exchange Act Rule 13a-15(f). Management conducted an assessment of our internal control over financial reporting based on the original framework established in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control — Integrated Framework. Based on the assessment, management concluded that, as of December 31, 2019, our internal control over financial reporting was effective. The effectiveness of our internal control over financial reporting as of December 31, 2019 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report included in this Annual Report.
Changes in Internal Control over Financial Reporting
There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fourth quarter of 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
 
ITEM 9B.
OTHER INFORMATION
 
None.
 
PART III

65

ITEM 10.
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
 
Information required under this item will be contained in our Proxy Statement for the 2020 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2019, under the captions “Election of Directors,” “Executive Officers,” “Corporate Governance,” and “Section 16(a) Beneficial Ownership Reporting Compliance” and is incorporated herein by reference pursuant to General Instruction G(3) to Form 10-K.
 
ITEM 11.
EXECUTIVE COMPENSATION
 
Information required under this item will be contained in our Proxy Statement for the 2020 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2019, under the captions “Corporate Governance” and “Compensation of Executive Officers,” and is incorporated herein by reference pursuant to General Instruction G(3) to Form 10-K, except that information required by Item 407(e)(5) of Regulation S-K will be deemed furnished in this Form 10-K and will not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate it by reference into such filing.
 
ITEM 12.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
 
Information required under this item will be contained in our Proxy Statement for the 2020 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2019, under the caption “Security Ownership of Certain Beneficial Owners and Management” and is incorporated herein by reference pursuant to General Instruction G(3) to Form 10-K.

ITEM 13.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
 
Information required under this item will be contained in our Proxy Statement for the 2020 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2019, under the caption “Corporate Governance” and is incorporated herein by reference pursuant to General Instruction G(3) to Form 10-K.
ITEM 14.
PRINCIPAL ACCOUNTANT FEES AND SERVICES
 
Information required under this item will be contained in our Proxy Statement for the 2020 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2019, under the caption “Ratification of Selection of Independent Registered Public Accounting Firm” and is incorporated herein by reference pursuant to General Instruction G (3) to Form 10-K.
PART IV
 
ITEM 15.
EXHIBITS AND FINANCIAL STATEMENTS SCHEDULES
 
The consolidated financial statements filed as part of this annual report on Form 10-K are listed in the Index to Consolidated Financial Statements. Certain schedules are omitted because they are not applicable, or not required, or because the required information is included in the consolidated financial statements or notes thereto. The Exhibits are listed in the Exhibit Index.

66

Signatures
Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this annual report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
Vanda Pharmaceuticals Inc.
 
 
 
 
 
February 26, 2020
 
By:
 
/s/ Mihael H. Polymeropoulos, M.D.
 
 
 
 
Mihael H. Polymeropoulos, M.D.
 
 
 
 
President and Chief Executive Officer
Pursuant to the requirements of the Securities Act of 1934, this annual report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Name
  
Title
  
Date
 
 
 
 
 
/s/ Mihael H. Polymeropoulos, M.D.
  
President and Chief Executive Officer and Director (principal executive officer)
  
February 26, 2020
Mihael H. Polymeropoulos, M.D.
 
 
 
 
 
 
 
/s/ James P. Kelly
  
Executive Vice President, Chief Financial Officer and Treasurer (principal financial officer and principal accounting officer)
  
February 26, 2020
James P. Kelly
  
  
 
 
 
 
 
/s/ H. Thomas Watkins
  
Chairman of the Board and
Director
  
February 26, 2020
H. Thomas Watkins
 
 
 
 
 
 
 
/s/ Anne Sempowski Ward
  
Director
  
February 26, 2020
Anne Sempowski Ward
 
 
 
 
 
 
 
/s/ Phaedra Chrousos
  
Director
  
February 26, 2020
Phaedra Chrousos
 
 
 
 
 
 
 
/s/ Richard W. Dugan
  
Director
  
February 26, 2020
Richard W. Dugan
 
 
 
 
 
 
 
 
  
Director
  
February 26, 2020
Stephen Ray Mitchell
 
 
 
 
 
 
 


67

Vanda Pharmaceuticals Inc.
Index to Consolidated Financial Statements

68

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of Vanda Pharmaceuticals Inc.
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheets of Vanda Pharmaceuticals Inc. and its subsidiaries (the “Company”) as of December 31, 2019 and 2018, and the related consolidated statements of operations, of comprehensive income (loss), of changes in stockholders’ equity and of cash flows for each of the three years in the period ended December 31, 2019, including the related notes (collectively referred to as the “consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.
Change in Accounting Principle
As discussed in Note 2 to the consolidated financial statements, the Company changed the manner in which it accounts for leases in 2019.
Basis for Opinions
The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to

69

permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
Medicaid rebates
As described in Note 2 to the consolidated financial statements, allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program as well as contracted rebate programs with other payors. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contracted discount rates and estimated patient utilization. The Company has recorded product revenue allowances of $31.9 million as of December 31, 2019, of which a significant amount relates to allowances for Medicaid rebates.
The principal considerations for our determination that performing procedures relating to Medicaid rebates is a critical audit matter are there was significant judgment by management due to the significant measurement uncertainty involved in developing the allowances, as these allowances are based on assumptions developed for estimated patient utilization, primarily payor mix, invoice lag and inventory levels within the distribution channel. This in turn led to a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating audit evidence related to management’s significant assumptions, related to the estimated patient utilization.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the allowances for Medicaid rebates, including controls over the assumptions used to estimate these rebates. These procedures also included, among others, (i) developing an independent estimate of the Medicaid rebates by utilizing third-party information related to payor mix, as well as inventory levels within the distribution channel and the historical trends of the invoice lag; (ii) comparing the independent estimate to management’s estimate; and (iii) testing rebate claims processed by the Company, including evaluating those claims for consistency with the contractual and mandated terms of the Medicaid Drug Rebate Program.
Product Returns for Fanapt
As described in Note 2 to the consolidated financial statements, the Company generally offers direct customers a limited right to return as contractually defined with the customers. The Company has recorded a reserve for product returns for Fanapt of $6.1 million as of December 31, 2019. Management considers several factors in the estimation process, including expiration dates of product shipped to customers, inventory levels within the distribution channel, product shelf life, historical return activity including activity for product sold for which the return period has past, prescription trends and other relevant factors. Management does not expect returned goods to be resalable.
The principal considerations for our determination that performing procedures relating to the product returns for Fanapt is a critical audit matter are there was significant judgment by management due to the significant measurement uncertainty involved in developing the reserve, as the reserve is based on assumptions developed using return activity with limited historical information and inventory levels within the distribution channel. This in turn led to a high degree of auditor judgment, subjectivity and effort in performing procedures relating to these significant assumptions, and evaluating audit evidence relating to the reserve for product returns for Fanapt.

70

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the reserve for product returns for Fanapt, including controls over the assumptions used to estimate this reserve. These procedures also included, among others, (i) developing an independent estimate of the returns by utilizing information related to the historical return activity and the inventory in the distribution channel, (ii) comparing the independent estimate to management’s estimate; and (iii) testing returns processed by the Company, including evaluating the returns for consistency with the contractual and mandated terms of the Company’s returns arrangements.
Valuation Allowance for Deferred Tax Assets
As described in Note 15 to the consolidated financial statements, the Company has recorded a valuation allowance on deferred tax assets of $8.2 million as of December 31, 2019. For the year ended December 31, 2019, the Company recorded income tax benefit of $86.5 million. The income tax benefit for 2019 was primarily due to the reduction of the Company's tax valuation allowance against substantially all of its deferred tax assets in the U.S. Management assesses the need for a valuation allowance against its deferred tax asset each quarter through the review of all available positive and negative evidence. Deferred tax assets are reduced by a tax valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. Management’s analysis depends on historical and projected taxable income. Projected taxable income includes significant assumptions related to revenue, commercial expenses and research and development activities.
The principal considerations for our determination that performing procedures relating to the valuation allowance for deferred tax assets is a critical audit matter are there was significant judgment by management due to the significant measurement uncertainty involved in determining the realizability of the deferred tax assets, as realizability is based on historical taxable income and projected taxable income, specifically related to assumptions developed for projected revenue, commercial expenses and research and development activities. This in turn led to a high degree of auditor judgment, subjectivity and effort in performing procedures related to evaluating management’s judgments about the Company’s ability to realize deferred tax assets, including the evaluation of significant assumptions related to the realizability of deferred tax assets, and evaluating audit evidence relating to assumptions for projected revenue, commercial expenses and research and development activities.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the valuation allowance for deferred tax assets, including controls over the assessment of the need for valuation allowances. These procedures also included, among others, (i) testing management’s process for developing projected taxable income; (ii) evaluating the appropriateness of the method for estimating projected taxable income; (iii) testing the completeness, accuracy, and relevance of underlying data used in the estimate; and (iv) evaluating the significant assumptions used by management to estimate projected revenue, commercial expenses and research and development activities. Evaluating management’s assumptions involved evaluating whether the assumptions used by management were reasonable considering (i) the current and past performance of the company, (ii) the consistency with external market and industry data, and (iii) whether these assumptions were consistent with evidence obtained in other areas of the audit.



/s/ PricewaterhouseCoopers LLP


Baltimore, Maryland
February 26, 2020
We have served as the Company’s auditor since 2003.





71

VANDA PHARMACEUTICALS INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except for share and per share amounts)
December 31, 2019
 
December 31, 2018
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
45,072

 
$
61,005

Marketable securities
267,057

 
196,355

Accounts receivable, net
26,367

 
28,780

Inventory
1,140

 
994

Prepaid expenses and other current assets
14,500

 
11,998

Total current assets
354,136

 
299,132

Property and equipment, net
3,864

 
4,417

Operating lease right-of-use assets
11,180

 
—

Intangible assets, net
23,037

 
24,542

Deferred tax assets
87,680

 
—

Non-current inventory and other
3,851

 
4,039

Total assets
$
483,748

 
$
332,130

LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable and accrued liabilities
$
27,590

 
$
21,584

Product revenue allowances
31,915

 
31,231

Milestone obligations under license agreements
—

 
200

Total current liabilities
59,505

 
53,015

Operating lease non-current liabilities
12,455

 
—

Other non-current liabilities
843

 
3,693

Total liabilities
72,803

 
56,708

Commitments and contingencies (Notes 10 and 17)

 

Stockholders’ equity:
 
 
 
Preferred stock, $0.001 par value; 20,000,000 shares authorized, and no shares issued or outstanding
—

 
—

Common stock, $0.001 par value; 150,000,000 shares authorized; 53,549,612 and 52,477,593 shares issued and outstanding at December 31, 2019 and 2018, respectively
54

 
52

Additional paid-in capital
631,307

 
611,587

Accumulated other comprehensive income
249

 
1

Accumulated deficit
(220,665
)
 
(336,218
)
Total stockholders’ equity
410,945

 
275,422

Total liabilities and stockholders’ equity
$
483,748

 
$
332,130


The accompanying notes are an integral part of these consolidated financial statements.

72

VANDA PHARMACEUTICALS INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
 
Year Ended December 31,
(in thousands, except for share and per share amounts)
2019
 
2018
 
2017
Revenues:
 
 
 
 
 
Net product sales
$
227,188

 
$
193,118

 
$
165,083

Total revenues
227,188

 
193,118

 
165,083

Operating expenses:
 
 
 
 
 
Cost of goods sold excluding amortization
24,488

 
20,508

 
17,848

Research and development
48,649

 
43,594

 
38,547

Selling, general and administrative
129,736

 
105,751

 
123,841

Intangible asset amortization
1,505

 
1,527

 
1,750

Total operating expenses
204,378

 
171,380

 
181,986

Income (loss) from operations
22,810

 
21,738

 
(16,903
)
Other income
6,218

 
3,608

 
1,472

Income (loss) before income taxes
29,028

 
25,346

 
(15,431
)
Provision (benefit) for income taxes
(86,525
)
 
138

 
136

Net income (loss)
$
115,553


$
25,208


$
(15,567
)
Net income (loss) per share:
 
 
 
 
 
Basic
$
2.17

 
$
0.50

 
$
(0.35
)
Diluted
$
2.11

 
$
0.48

 
$
(0.35
)
Weighted average shares outstanding:
 
 
 
 
 
Basic
53,137,562

 
50,859,947

 
44,735,146

Diluted
54,847,060

 
53,045,257

 
44,735,146


The accompanying notes are an integral part of these consolidated financial statements.

73

VANDA PHARMACEUTICALS INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
 
Year Ended December 31,
(in thousands)
2019
 
2018
 
2017
Net income (loss)
$
115,553

 
$
25,208

 
$
(15,567
)
Other comprehensive income (loss):
 
 
 
 
 
Net foreign currency translation gain (loss)
6

 
(22
)
 
30

Change in net unrealized gain (loss) on marketable securities
313

 
57

 
(122
)
Tax provision on other comprehensive income
(71
)
 
—

 
—

Other comprehensive income (loss), net of tax
248

 
35

 
(92
)
Comprehensive income (loss)
$
115,801


$
25,243


$
(15,659
)

The accompanying notes are an integral part of these consolidated financial statements.

74

VANDA PHARMACEUTICALS INC.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
 
Common Stock
 
Additional
 Paid-in Capital
 
Other
 Comprehensive
 Income (Loss)
 
Accumulated
 Deficit
 
Total
(in thousands, except for share amounts)
Shares
 
Par Value
 
 
 
 
Balances at December 31, 2016
44,000,614

 
$
44

 
$
477,087

 
$
58

 
$
(345,859
)
 
$
131,330

Issuance of common stock from the exercise of stock options and settlement of restricted stock units
937,519

 
1

 
5,250

 
—

 
—

 
5,251

Stock-based compensation expense
—

 
—

 
10,465

 
—

 
—

 
10,465

Net loss
—

 
—

 
—

 
—

 
(15,567
)
 
(15,567
)
Other comprehensive loss, net of tax
—

 
—

 
—

 
(92
)
 
—

 
(92
)
Balances at December 31, 2017
44,938,133


45


492,802


(34
)

(361,426
)

131,387

Net proceeds from public offering of common stock
6,325,000

 
6

 
100,864

 
—

 
—

 
100,870

Issuance of common stock from the exercise of stock options and settlement of restricted stock units
1,214,460

 
1

 
6,255

 
—

 
—

 
6,256

Stock-based compensation expense
—

 
—

 
11,666

 
—

 
—

 
11,666

Net income
—

 
—

 
—

 
—

 
25,208

 
25,208

Other comprehensive income, net of tax
—

 
—

 
—

 
35

 
—

 
35

Balances at December 31, 2018
52,477,593


52


611,587


1


(336,218
)

275,422

Issuance of common stock from the exercise of stock options and settlement of restricted stock units
1,072,019

 
2

 
6,262

 
—

 
—

 
6,264

Stock-based compensation expense
—

 
—

 
13,458

 
—

 
—

 
13,458

Net income
—

 
—

 
—

 
—

 
115,553

 
115,553

Other comprehensive income, net of tax
—

 
—

 
—

 
248

 
—

 
248

Balances at December 31, 2019
53,549,612


$
54


$
631,307


$
249


$
(220,665
)

$
410,945

The accompanying notes are an integral part of these consolidated financial statements.

75

VANDA PHARMACEUTICALS INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
 
Year Ended December 31,
(in thousands)
2019
 
2018
 
2017
Cash flows from operating activities
 
 
 
 
 
Net income (loss)
$
115,553

 
$
25,208

 
$
(15,567
)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
 
 
 
 
 
Depreciation of property and equipment
1,387

 
1,429

 
1,234

Stock-based compensation
13,458

 
11,666

 
10,465

Amortization of discounts and premiums on marketable securities
(3,099
)
 
(2,221
)
 
(426
)
Intangible asset amortization
1,505

 
1,527

 
1,750

Deferred income taxes
(87,767
)
 
—

 
—

Other non-cash adjustments, net
1,785

 
167

 
587

Changes in operating assets and liabilities:
 
 
 
 

Accounts receivable
2,342

 
(11,207
)
 
2,525

Prepaid expenses and other assets
(2,764
)
 
(4,258
)
 
3,652

Inventory
(722
)
 
70

 
(1,060
)
Accounts payable and other liabilities
3,508

 
(618
)
 
5,953

Product revenue allowances
761

 
8,223

 
(11,096
)
Net cash provided by (used in) operating activities
45,947

 
29,986

 
(1,983
)
Cash flows from investing activities
 
 
 
 
 
Acquisition of intangible asset
—

 
(25,000
)
 
—

Purchases of property and equipment
(1,019
)
 
(368
)
 
(1,664
)
Purchases of marketable securities
(394,517
)
 
(282,395
)
 
(148,135
)
Maturities of marketable securities
327,227

 
198,103

 
139,568

Net cash used in investing activities
(68,309
)

(109,660
)

(10,231
)
Cash flows from financing activities
 
 
 
 
 
Net proceeds from offering of common stock
—

 
100,870

 
—

Proceeds from exercise of employee stock options
6,264

 
6,256

 
5,251

Net cash provided by financing activities
6,264


107,126


5,251

Effect of exchange rate changes on cash, cash equivalents and restricted cash
(1
)
 
(38
)
 
42

Net increase (decrease) in cash, cash equivalents and restricted cash
(16,099
)
 
27,414

 
(6,921
)
Cash, cash equivalents and restricted cash
 
 
 
 
 
Beginning of year
61,749

 
34,335

 
41,256

End of year
$
45,650


$
61,749


$
34,335

The accompanying notes are an integral part of these consolidated financial statements.

76

VANDA PHARMACEUTICALS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
1. Business Organization and Presentation
Business organization
Vanda Pharmaceuticals Inc. (the Company) is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. The Company commenced its operations in 2003 and operates in one reporting segment.
The Company's commercial portfolio is currently comprised of two products, HETLIOZ® for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and Fanapt® for the treatment of schizophrenia. HETLIOZ® is the first treatment for Non-24 approved by the U.S. Food and Drug Administration (FDA). In addition, the Company has a number of drugs in development, including:
 
•
HETLIOZ® (tasimelteon) for the treatment of jet lag disorder, Smith-Magenis Syndrome (SMS), pediatric Non-24 and delayed sleep phase disorder (DSPD);
 
•
Fanapt® (iloperidone) for the treatment of bipolar disorder and a long acting injectable (LAI) formulation program for the treatment of schizophrenia;
 
•
Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis and motion sickness;
 
•
VTR-297, a small molecule histone deacetylase (HDAC) inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications;
 
•
VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist, with potential use for the treatment of psychiatric disorders; and
 
•
Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors for the treatment of dry eye and ocular inflammation and for the treatment of secretory diarrhea disorders, including cholera.

Basis of Presentation
The accompanying consolidated financial statements includes the accounts of Vanda Pharmaceuticals Inc. and its wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.). All intercompany accounts and transactions have been eliminated in consolidation.
2. Summary of Significant Accounting Policies
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management’s evaluation could change. Actual results could differ from those estimates.
Cash, Cash Equivalents and Restricted Cash
For purposes of the Consolidated Balance Sheets and Consolidated Statements of Cash Flows, cash equivalents represent highly-liquid investments with a maturity date of three months or less at the date of purchase. Cash and cash equivalents include investments in money market funds with commercial banks and financial institutions, and commercial paper of high-quality corporate issuers. Restricted cash relates primarily to amounts held as collateral for letters of credit for leases for office space at the Company’s Washington, D.C. headquarters. 

77

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets to the total end of period cash, cash equivalents and restricted cash reported within the Consolidated Statement of Cash Flows:
 
December 31,
(in thousands)
2019
 
2018
Cash and cash equivalents
$
45,072

 
$
61,005

Restricted cash included in:
 
 
 
Prepaid expenses and other current assets
—

 
157

Non-current inventory and other
578

 
587

Total cash, cash equivalents and restricted cash
$
45,650

 
$
61,749


Marketable Securities
The Company classifies all of its marketable securities as available-for-sale securities. The Company’s investment policy requires the selection of high-quality issuers. Available-for-sale securities are carried at fair market value, with unrealized gains and losses reported as a component of stockholders’ equity in accumulated other comprehensive income (loss). At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. If declines in the value of available for-sale securities are determined to be other-than-temporary, a loss is recorded in earnings in the current period. Interest and dividend income is recorded when earned and included in other income. Premiums and discounts on marketable securities are amortized and accreted, respectively, to earliest call date and maturity, respectively, and included in other income. The Company uses the specific identification method in computing realized gains and losses on the sale of investments, which would be included in the consolidated statements of operations when generated. All available-for-sale marketable securities are available for use in current operations and are classified as current.
Inventory
Inventory, which is recorded at the lower of cost or net realizable value, includes the cost of third-party manufacturing and other direct and indirect costs and is valued using the first-in, first-out method. The Company capitalizes inventory costs associated with its products upon regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. Inventory not expected to be sold within 12 months following the balance sheet date are classified as non-current.
Intangible Assets
Costs incurred for products not yet approved by the FDA and for which no alternative future use exists are recorded as expense. Obligations for milestone payments to other pharmaceutical companies that may result in a capitalized intangible asset are recognized when it is deemed probable that the milestone event will occur. In the event a product has been approved by the FDA or an alternative future use exists for a product, patent and license costs are capitalized and amortized on a straight-line basis over the estimated useful economic life of the of the related product patents. For intangible assets related to HETLIOZ®, the estimated useful life is the estimated economic useful life of the related product patents, the latest of which expires in July 2035. Intangible assets related Fanapt® have been fully amortized on a straight-line basis to November 2016. The useful life estimate for Fanapt® was based on the market participant methodology prescribed by ASC 805, and therefore does not reflect the impact of additional Fanapt® patents solely owned by the Company with varying expiration dates, the latest of which is December 2031.
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation. Depreciation of most property and equipment is provided on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized using a straight-line basis over the lesser of the estimated useful lives of the assets or the terms of the related leases. The costs of additions and improvements are capitalized, and repairs and maintenance costs are charged to operations in the period incurred. Upon retirement or disposition of property and equipment, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in the statement of operations for that period.

78

Leases
In accordance with Accounting Standards Codification (ASC) 842, Leases, effective January 1, 2019, the Company determines if an arrangement contains a lease at inception. Right-of-use (ROU) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from that lease. For leases with a term greater than 12 months, ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The lease term includes the option to extend the lease when it is reasonably certain the Company will exercise that option. When available, the Company uses the rate implicit in the lease to discount lease payments to present value. In the case the implicit rate is not available, the Company uses its incremental borrowing rate based on information available at the lease commencement date, including publicly available data for instruments with similar characteristics, to determine the present value of lease payments. The Company does not combine lease and non-lease elements for office leases. For existing leases as of January 1, 2019, executory costs are excluded from lease expense, which is consistent with the Company's accounting under ASC 840, Leases. For all leases entered into after January 1, 2019, executory costs are allocated between lease and non-lease elements based upon their relative stand-alone prices.
Accounts Payable and Accrued Liabilities
The Company’s management is required to estimate accrued liabilities as part of the process of preparing financial statements. The estimation of accrued liabilities involves identifying services that have been performed on the Company’s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date in the financial statements. Accrued liabilities include research and development expenses, such as accrued costs under contracts with clinical monitors, data management organizations and investigators in conjunction with clinical trials, fees to contract manufacturers in conjunction with the production of clinical materials, consulting and professional fees, such as lawyers and fees for marketing and other commercialization activities, accrued compensation and employee benefits, such as accrued bonus, royalties payable under licensing agreements, and other accrued fees. Pursuant to management’s assessment of the services that have been performed on clinical trials and other contracts, the Company recognizes these expenses as the services are provided. Such management assessments include, but are not limited to: (i) an evaluation by the project manager of the work that has been completed during the period, (ii) measurement of progress prepared internally and/or provided by the third-party service provider, (iii) analyses of data that justify the progress, and (iv) management’s judgment. In the event that the Company does not identify certain costs that have begun to be incurred or the Company under- or over-estimates the level of services performed or the costs of such services, the Company’s reported expenses for such period would be too low or too high.

Revenue Recognition
In accordance with ASC Subtopic 606 Revenue from Contracts with Customers (ASC 606), which the Company adopted January 1, 2018, the Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. The Company recognizes revenue when control of the product is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for those product sales, which is typically once the product physically arrives at the customer. Sales taxes, value add taxes, and usage-based taxes are excluded from revenues. Results for reporting period ended December 31, 2017 were not adjusted and continue to be reported in accordance with historic accounting under ASC 605. The impact to the Consolidated Statements of Operations if the Company had applied ASC 606 for the year ended December 31, 2017 is not material. 
The Company’s net product sales consist of sales of HETLIOZ® and Fanapt®. Net sales by product for the years ended December 31, 2019, 2018 and 2017 were as follows:
 
Year Ended December 31,
(in thousands)
2019
 
2018
 
2017
HETLIOZ® product sales, net
$
142,980

 
$
115,835

 
$
89,978

Fanapt® product sales, net
84,208

 
77,283

 
75,105

Total net product sales
$
227,188


$
193,118


$
165,083


HETLIOZ® is available in the U.S. for distribution through a limited number of specialty pharmacies, and is not available in retail pharmacies. Specialty pharmacy customers include Diplomat Pharmacy, Inc. (a subsidiary of UnitedHealth Group) and Accredo (a subsidiary of Express Scripts). Fanapt® is available in the U.S. for distribution through a limited number of wholesalers and is available in retail pharmacies. Wholesaler customers include Cardinal Health, Inc., AmerisourceBergen

79

Drug Corporation, and McKesson Corporation. The Company invoices and records revenue when its customers, specialty pharmacies and wholesalers, receive product from the third-party logistics warehouse which is the point at which control is transferred to the customer. Revenues and accounts receivable are concentrated with these customers. The Company evaluates outstanding receivables to assess collectability. In performing this evaluation, the Company analyzes economic conditions, the aging of receivables and customer specific risks. 
The following table presents each major customer that represented more than 10% of total revenues for the years ended December 31, 2019, 2018 and 2017:
 
Year Ended December 31,
Percent of Net Product Sales
2019
 
2018
 
2017
Distributor A
38
%
 
37
%
 
32
%
Distributor B
23
%
 
17
%
 
10
%
Distributor C
12
%
 
14
%
 
15
%
Distributor D
12
%
 
12
%
 
15
%
Distributor E
11
%
 
12
%
 
12
%
Distributor F
—
%
 
5
%
 
11
%

The following table presents each major customer that represented more than 10% of accounts receivable, net, as of December 31, 2019 and 2018:
 
December 31,
Percent of Accounts Receivable, Net
2019
 
2018
Distributor A
21
%
 
30
%
Distributor B
21
%
 
15
%
Distributor C
18
%
 
20
%
Distributor D
16
%
 
13
%
Distributor E
18
%
 
16
%

The transaction price is determined based upon the consideration to which the Company will be entitled in exchange for transferring product to the customer. The Company’s product sales are recorded net of applicable product revenue allowances for which reserves are established and include discounts, rebates, chargebacks, service fees, co-pay assistance and product returns that are applicable for various government and commercial payors. The Company estimates the amount of variable consideration that should be included in the transaction price utilizing the most likely amount method and updates its estimate at each reporting date. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Allowances for rebates, chargebacks and co-pay assistance are based upon the insurance benefits of the end customer, which are estimated using historical activity and, where available, actual and pending prescriptions for which the Company has validated the insurance benefits. Reserves for variable consideration are classified as product revenue allowances on the consolidated balance sheets, with the exception of prompt-pay discounts which are classified as reductions of accounts receivable. The reserve for product returns for which the product may not be returned for a period of greater than one year from the balance sheet date is included as a component of other non-current liabilities in the consolidated balance sheets. Uncertainties related to variable consideration are generally resolved in the quarter subsequent to period end, with the exception of Medicaid rebates, which are dependent upon the timing of when states submit reimbursement claims, and product returns which are resolved during the product expiry period specified in the customer contract. The Company currently records sales allowances for the following:
Prompt-pay: Specialty pharmacies and wholesalers are offered discounts for prompt payment. The Company expects that the specialty pharmacies and wholesalers will earn prompt payment discounts and, therefore, deducts the full amount of these discounts from total product sales when revenues are recognized.
Rebates: Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program as well as contracted rebate programs with other payors. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contracted discount rates and estimated patient utilization.

80

Chargebacks: Chargebacks are discounts that occur when contracted indirect customers purchase directly from specialty pharmacies and wholesalers. Contracted indirect customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The specialty pharmacy or wholesaler, in turn, charges back the difference between the price initially paid by the specialty pharmacy or wholesaler and the discounted price paid to the specialty pharmacy or wholesaler by the contracted customer.
Medicare Part D Coverage Gap: Medicare Part D prescription drug benefit mandates manufacturers to fund approximately 50% of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients through 2018. Public Law No. 115-123, also known as the Bipartisan Budget Act of 2018 enacted on February 9, 2018 increased the manufacturer discount from 50% to 70% effective in 2019 for applicable drugs. Vanda accounts for the Medicare Part D coverage gap using a point of sale model. Estimates for expected Medicare Part D coverage gap are based in part on historical activity and, where available, actual and pending prescriptions for which the Company has validated the insurance benefits.
Service Fees: The Company receives sales order management, data and distribution services from certain customers. These fees are based on contracted terms and are known amounts. The Company accrues service fees at the time of revenue recognition, resulting in a reduction of product sales and the recognition of an accrued liability, unless it is a payment for a distinct good or service from the customer in which case the fair value of those distinct goods or services are recorded as selling, general and administrative expense.
Co-payment Assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Co-pay assistance utilization is based on information provided by the Company’s third-party administrator.
Product Returns: The Company generally offers direct customers a limited right to return as contractually defined with the customers. The Company considers several factors in the estimation process, including expiration dates of product shipped to customers, inventory levels within the distribution channel, product shelf life, historical return activity, including activity for product sold for which the return period has past, prescription trends and other relevant factors. The Company does not expect returned goods to be resalable. There was no right of return asset as of December 31, 2019 or 2018. The following table summarizes activity for product returns as of and for the years ended December 31, 2019, 2018 and 2017, all of which relates to sales of Fanapt®:
 
(in thousands)
Reserve for Product Returns
Balances at December 31, 2016
$
3,080

Additions
5,978

Credits/payments
(4,939
)
Balances at December 31, 2017
4,119

Additions
2,684

Credits/payments
(1,616
)
Balances at December 31, 2018
5,187

Additions
3,138

Credits/payments
(2,205
)
Balances at December 31, 2019
$
6,120


Cost of Goods Sold
Cost of goods sold includes royalties payable, the cost of inventory sold, manufacturing and supply chain costs and product shipping and handling costs related to sales of HETLIOZ® and Fanapt® to the Company’s distribution partners.
Research and Development Expenses
Research and development expenses consist primarily of fees for services provided by third parties in connection with the clinical trials, costs of contract manufacturing services, milestone payments, costs of materials used in clinical trials and research and development, costs for regulatory consultants and filings, depreciation of capital resources used to develop products, related facilities costs, and salaries, other employee-related costs and stock-based compensation for research and development personnel. The Company expenses research and development costs as they are incurred for products in the

81

development stage, including manufacturing costs and milestone payments made under license agreements prior to FDA approval. Upon and subsequent to FDA approval, manufacturing and milestone payments related to license agreements are capitalized. Milestone payments are accrued when it is deemed probable that the milestone event will be achieved. Costs related to the acquisition of intellectual property are expensed as incurred if the underlying technology is developed in connection with the Company’s research and development efforts and has no alternative future use.
Selling, General and Administrative Expenses
Selling, general and administrative expenses consist of salaries, stock-based compensation, facilities and third party expenses. Selling, general and administrative expenses are associated with the activities of the corporate, finance, accounting, information technology, business development, commercial support, trade and distribution, sales, marketing, legal, medical affairs and human resource functions. Additionally, selling, general and administrative expenses included an estimate for the annual Affordable Care Act fee.
Stock-Based Compensation
Compensation costs for all stock-based awards to employees and directors are measured based on the grant date fair value of those awards and recognized over the period during which the employee or director is required to perform service in exchange for the award. The Company recognizes the expense over the award’s vesting period. The fair value of stock options granted and restricted stock units (RSUs) awarded are amortized using the straight-line method. As stock-based compensation expense recognized in the consolidated statements of operations is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
Advertising Expense
The Company expenses the costs of advertising, including branded promotional expenses, as incurred. Branded advertising expenses, recorded in selling, general and administrative expenses, were $3.2 million, $0.9 million and $1.3 million for the years ended December 31, 2019, 2018 and 2017, respectively.
Foreign Currency
The reporting currency of the Company is the U.S. dollar. The functional currency of the Company’s international subsidiaries is the local currency. Assets and liabilities denominated in foreign currencies, including intercompany balances for which settlement is anticipated in the foreseeable future, are translated at exchange rates in effect at the balance sheet date. Foreign currency equity balances are translated at historical rates. Revenues and expenses denominated in foreign currencies are translated at average exchange rates for the respective periods. Foreign currency translation adjustments are recorded in accumulated other comprehensive income (loss).
Transactions denominated in currencies other than subsidiaries’ functional currencies are recorded based on exchange rates at the time such transactions arise. Changes in exchange rates with respect to amounts recorded in the consolidated balance sheets related to these items will result in unrealized foreign currency transaction gains and losses based upon period-end exchange rates. The Company also records realized foreign currency transaction gains and losses upon settlement of the transactions. Foreign currency transaction gains and losses are included in other income and were not material for the years ended December 31, 2019, 2018 and 2017, respectively.
Income Taxes
The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. Tax rate changes are reflected in income during the period such changes are enacted. Changes in ownership may limit the amount of net operating loss (NOL) carryforwards that can be utilized in the future to offset taxable income. Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement.

82

Certain Risks and Uncertainties
The Company’s products under development require approval from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance the products will receive the necessary clearance. If the Company is denied clearance or clearance is delayed, it may have a material adverse impact on the Company.
The Company’s products are concentrated in rapidly-changing, highly-competitive markets, which are characterized by rapid technological advances, changes in customer requirements and evolving regulatory requirements and industry standards. Any failure by the Company to anticipate or to respond adequately to technological developments in its industry, changes in customer requirements or changes in regulatory requirements or industry standards or any significant delays in the development or introduction of products or services could have a material adverse effect on the Company’s business, operating results and future cash flows.
The Company depends on single source suppliers for critical raw materials for manufacturing, as well as other components required for the administration of its products. The loss of these suppliers could delay the clinical trials or prevent or delay commercialization of the products.
Concentrations of Credit Risk
Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash, cash equivalents and marketable securities. The Company places its cash, cash equivalents and marketable securities with highly-rated financial institutions. At December 31, 2019, the Company maintained all of its cash, cash equivalents and marketable securities in two financial institutions. Deposits held with these institutions may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand, and the Company believes there is minimal risk of losses on such balances.
Segment and Geographic Information
The Company operates in one reporting segment and, accordingly, no segment disclosures are presented herein. Foreign sales were not material for each of the years ended December 31, 2019, 2018 and 2017.
Recent Accounting Pronouncements
In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company is evaluating this standard to determine if adoption will have a material impact on the Company’s consolidated financial statements.
In August 2018, the U.S. Securities and Exchange Commission (SEC) adopted the final rule under SEC Release No. 33-10532, Disclosure Update and Simplification. This final rule amends certain disclosure requirements that are redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expand the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule is effective for the Company for all filings made on or after November 5, 2018. The SEC staff clarified that the first presentation of the changes in shareholders' equity may be included in the first Form 10-Q for the quarter that begins after the effective date of the amendments. The adoption of the final rule did not have a material impact on the Company’s consolidated financial statements.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses, which changes the impairment model for most financial assets and certain other financial instruments. The standard will require the use of a forward-looking “expected loss” model for instruments measured at amortized cost that generally will result in the earlier recognition of allowances for losses. The standard is effective for years beginning after December 15, 2019, and interim periods within annual periods beginning after December 15, 2019. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial results.
In February 2016, the FASB issued ASU 2016-2, Leases (Topic 842), which was further clarified by ASU 2018-10, Codification Improvements to Topic 842, Leases, and ASU 2018-11, Leases - Targeted Improvements, issued in July

83

2018. ASC 842 supersedes existing lease guidance, including ASC 840 Leases. The new leasing standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The new leasing standard requires that lessees will need to recognize an ROU asset and a lease liability for virtually all of their leases, and allows companies to make a policy election as to whether short term leases will be recognized under the requirements of the new standard. The Company elected to exclude short-term leases in the application of the new standard. The lease liability is equal to the present value of lease payments. The ROU asset is based on the liability subject to certain adjustments. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense, similar to accounting for operating leases under ASC 840, while finance leases will result in a front-loaded expense pattern, similar to accounting for capital leases under ASC 840.
The Company adopted the new leasing standard in the first quarter of 2019, using a modified retrospective transition. There was no impact to the opening balance of retained earnings as of the effective date of January 1, 2019 as a result of adoption. Prior period financial statements were not recast. The Company elected the package of transition provisions available for expired or existing contracts, which allowed it to carryforward its historical assessments of (1) whether contracts are or contain leases, (2) lease classification and (3) initial direct costs. The adoption of the new leasing standard on January 1, 2019 resulted in the recognition of $15.8 million of operating lease liabilities, $2.2 million of which were classified as current liabilities, with corresponding ROU assets of $12.2 million, net of lease prepayments and the balance of deferred lease incentives. The Company does not have any financing leases.
3. Marketable Securities
The following is a summary of the Company’s available-for-sale marketable securities as of December 31, 2019, which all have contractual maturities of less than two years:
(in thousands)
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair
Market
Value
U.S. Treasury and government agencies
$
88,535

 
$
68

 
$
(2
)
 
$
88,601

Corporate debt
129,860

 
196

 
(1
)
 
130,055

Asset-backed securities
48,355

 
49

 
(3
)
 
48,401

Total marketable securities
$
266,750


$
313


$
(6
)

$
267,057

The following is a summary of the Company’s available-for-sale marketable securities as of December 31, 2018, which all have contract maturities of less than one year:
(in thousands)
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair
Market
Value
U.S. Treasury and government agencies
$
69,275

 
$
12

 
$
(17
)
 
$
69,270

Corporate debt
105,897

 
38

 
(25
)
 
105,910

Asset-backed securities
21,189

 
—

 
(14
)
 
21,175

Total marketable securities, current
$
196,361


$
50


$
(56
)

$
196,355


 
4. Fair Value Measurements
Authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:
 
•
Level 1 — defined as observable inputs such as quoted prices in active markets
 
•
Level 2 — defined as inputs other than quoted prices in active markets that are either directly or indirectly observable
 
•
Level 3 — defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions
Marketable securities classified in Level 1 and Level 2 as of December 31, 2019 and 2018 consist of cash equivalents and available-for-sale marketable securities. The valuation of Level 1 instruments is determined using a market approach, and is based upon unadjusted quoted prices for identical assets in active markets. The valuation of investments classified in Level 2

84

also is determined using a market approach based upon quoted prices for similar assets in active markets, or other inputs that are observable for substantially the full term of the financial instrument. Level 2 securities include certificates of deposit, commercial paper, corporate notes, and asset-backed securities that use as their basis readily observable market parameters.
 
The Company held certain assets that are required to be measured at fair value on a recurring basis as of December 31, 2019, as follows:
 
 
 
Fair Value Measurement as of December 31, 2019 Using
(in thousands)
Total Fair Value
 
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
U.S. Treasury and government agencies
$
88,601

 
$
88,601

 
$
—

 
$
—

Corporate debt
137,025

 
—

 
137,025

 
—

Asset-backed securities
48,401

 
—

 
48,401

 
—

Total assets measured at fair value
$
274,027


$
88,601


$
185,426


$
—


The Company held certain assets that are required to be measured at fair value on a recurring basis as of December 31, 2018, as follows:
 
 
 
Fair Value Measurement as of December 31, 2018 Using
(in thousands)
Total Fair Value
 
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
U.S. Treasury and government agencies
$
69,270

 
$
69,270

 
$
—

 
$
—

Corporate debt
105,910

 
—

 
105,910

 
—

Asset-backed securities
21,175

 
—

 
21,175

 
—

Total assets measured at fair value
$
196,355


$
69,270


$
127,085


$
—


Total assets measured at fair value as of December 31, 2019 include $7.0 million of cash equivalents.
The Company also has financial assets and liabilities, not required to be measured at fair value on a recurring basis, which primarily consist of cash, accounts receivable, restricted cash, accounts payable and accrued liabilities, product revenue allowances, and milestone obligations under license agreements, the carrying values of which materially approximate their fair values.
5. Inventory
The Company evaluates expiry risk by evaluating current and future product demand relative to product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. Inventory levels are evaluated for the amount of inventory that would be sold within one year. At certain times, the level of inventory can exceed the forecasted level of cost of goods sold for the next twelve months. The Company classifies the estimate of such inventory as non-current. Inventory consisted of the following as of December 31, 2019 and 2018:
(in thousands)
December 31,
2019
 
December 31,
2018
Current assets
 
 
 
Work-in-process
$
—

 
$
48

Finished goods
1,140

 
946

Total inventory, current
$
1,140

 
$
994

Non-Current assets
 
 
 
Raw materials
$
659

 
$
86

Work-in-process
1,109

 
2,290

Finished goods
1,056

 
516

Total inventory, non-current
$
2,824

 
$
2,892


 

85

6. Property and Equipment
The following is a summary of the Company’s property and equipment, at cost, as of December 31, 2019 and 2018:
(in thousands)
Estimated
Useful Life
(Years)
 
December 31, 2019
 
December 31, 2018
Computer and other equipment
3
 
$
4,398

 
$
3,642

Furniture and fixtures
5 - 7
 
1,491

 
1,488

Leasehold improvements
5 - 11
 
4,587

 
4,506

Total property and equipment, gross
 
 
10,476

 
9,636

Accumulated depreciation and amortization
 
(6,612
)
 
(5,219
)
Total property and equipment, net
 
 
$
3,864

 
$
4,417


Depreciation expense was $1.4 million, $1.4 million and $1.2 million for the years ended December 31, 2019, 2018 and 2017, respectively.
 
7. Leases
The Company's long-term leases primarily include operating leases and subleases for office space in Washington, D.C. and London, England. The Company recognized ROU assets and lease liabilities related to fixed payments for these long-term operating leases in its Consolidated Balance Sheet as of December 31, 2019. The Company also has short-term leases, including office space in Berlin, Germany.
In June 2011, the Company entered into an operating lease agreement under which it leases 33,534 square feet of office space for its headquarters at 2200 Pennsylvania Avenue, N.W. in Washington, D.C. Subject to the prior rights of other tenants, the Company has the right to renew the lease for five years following its expiration in July 2028. As of December 31, 2019, the renewal period has not been included in the lease term. The Company has the right to sublease or assign all or a portion of the premises, subject to standard conditions. The lease may be terminated early by the Company or the landlord under certain circumstances.
In June 2016, the Company entered into a sublease agreement under which it subleases an additional 9,928 square feet of office space for its headquarters at 2200 Pennsylvania Avenue, N.W. in Washington, D.C. The sublease term began in January 2017 and ends in July 2026, but may be terminated earlier by either party under certain circumstances. The Company has the right to sublease or assign all or a portion of the premises, subject to standard conditions.
In May 2016, the Company entered into an operating lease agreement under which it leases 2,880 square feet of office space in London, England. The Company has the right to renew the lease for five years following its expiration in 2021. As of December 31, 2019, the renewal period has not been included in the lease term.
The following is a summary of the Company’s ROU assets and operating lease liabilities as of December 31, 2019:
(in thousands)
 
Classification on the Balance Sheet
 
December 31, 2019
Assets
 
 
 
 
Operating lease assets
 
Operating lease right-of-use assets
 
$
11,180

 
 
 
 
 
Liabilities
 
 
 
 
Operating lease current liabilities
 
Accounts payable and accrued liabilities
 
$
2,147

Operating lease non-current liabilities
 
Operating lease non-current liabilities
 
12,455

Total lease liabilities
 
 
 
$
14,602

 
 
 
 
 
Weighted average remaining lease term
 
 
 
8.1

Weighted average discount rate(1)
 
 
 
8.1
%
 
(1)
Upon adoption of the new lease standard, discount rates used for existing leases were established at January 1, 2019.


86

For the year ended December 31, 2019, the Company recognized operating lease cost of $2.3 million and short-term operating lease cost of $0.4 million. The Company also recognized $1.4 million of expense related to non-lease elements, such as building maintenance services and utilities, and executory costs associated with the operating leases. For existing leases as of January 1, 2019, executory costs are excluded from operating lease expense, which is consistent with the Company's accounting under ASC 840. For all leases entered into after January 1, 2019, executory costs are allocated between lease and non-lease elements based upon their relative stand-alone prices. For the years ended December 31, 2018 and 2017, the Company recognized $3.6 million and $3.2 million of rent expense, respectively, inclusive of lease expense, non-lease elements, and executory costs for short and long-term operating leases.
Cash paid for amounts included in the measurement of operating lease liabilities is included in operating cash flows and was $2.5 million for the year ended December 31, 2019.
The table below reconciles the Company's future cash obligations to operating lease liabilities recorded on the balance sheet as of December 31, 2019:
(in thousands)
 
Operating Leases
2020
 
$
2,326

2021
 
2,332

2022
 
2,355

2023
 
2,420

2024
 
2,488

Thereafter
 
8,182

Total minimum lease payments
 
20,103

Less: amount of lease payments representing interest
 
(5,501
)
Present value of future minimum lease payments
 
14,602

Less: current obligations under leases
 
(2,147
)
Operating lease non-current liabilities
 
$
12,455



At December 31, 2018, future minimum payments under noncancellable operating leases under ASC 840 were as follows:
 
Cash Payments Due by Year
(in thousands)
Total
 
2019
 
2020
 
2021
 
2022
 
2023
 
Thereafter
Operating leases
$
22,757

 
$
2,483

 
$
2,495

 
$
2,335

 
$
2,355

 
$
2,420

 
$
10,669


8. Intangible Assets
HETLIOZ®. In January 2014, the Company announced that the FDA had approved the New Drug Application (NDA) for HETLIOZ®. As a result of this approval, the Company met a milestone under its license agreement with Bristol-Myers Squibb (BMS) that required the Company to make a license payment of $8.0 million to BMS. The $8.0 million is being amortized on a straight-line basis over the estimated economic useful life of the related product patents, the latest of which expires in July 2035.
In April 2018, the Company met its final milestone under its license agreement when cumulative worldwide sales of HETLIOZ® reached $250.0 million. As a result of the achievement of this milestone, the Company made a payment to BMS of $25.0 million in 2018. The $25.0 million, which was capitalized as an intangible asset in the first quarter of 2015, was determined to be additional consideration for the acquisition of the HETLIOZ® intangible asset and is being amortized on a straight-line basis over the estimated economic useful life of the related product patents, the latest of which expires in July 2035.
The estimated economic useful life of both the $8.0 million and the $25.0 million intangible assets were changed from February 2035 to July 2035 based on the July 2035 expiration date of U.S. patent number 10,376,487 ('487 Patent) issued by the U.S. Patent and Trademark Office in August 2019. The estimated economic useful life of these intangible assets were

87

previously changed from May 2034 to February 2035 based on the February 2035 expiration date of U.S. patent number 10,071,977 ('977 Patent) issued by the U.S. Patent and Trademark Office in September 2018.
The following is a summary of the Company’s intangible assets as of December 31, 2019:
 
 
 
December 31, 2019
(in thousands)
Estimated
Useful Life
(Years)
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
HETLIOZ®
July 2035
 
$
33,000

 
$
9,963

 
$
23,037


The following is a summary of the Company’s intangible assets as of December 31, 2018:
 
 
 
December 31, 2018
(in thousands)
Estimated
Useful Life
(Years)
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
HETLIOZ®
February 2035
 
$
33,000

 
$
8,458

 
$
24,542


As of December 31, 2019 and 2018, the Company also had $27.9 million of fully amortized intangible assets related to Fanapt®.
Intangible assets are amortized over their estimated useful economic life using the straight-line method. Amortization expense for the years ended December 31, 2019, 2018 and 2017 was as follows:
 
Year Ended December 31,
(in thousands)
2019
 
2018
 
2017
HETLIOZ®
$
1,505

 
$
1,527

 
$
1,750


The following is a summary of the future intangible asset amortization schedule as of December 31, 2019:
(in thousands)
Total
 
2020
 
2021
 
2022
 
2023
 
2024
 
Thereafter
HETLIOZ®
$
23,037

 
$
1,478

 
$
1,478

 
$
1,478

 
$
1,478

 
$
1,478

 
$
15,647


9. Accounts Payable and Accrued Liabilities
The following is a summary of the Company’s accounts payable and accrued liabilities as of December 31, 2019 and 2018:
(in thousands)
December 31,
2019
 
December 31,
2018
Compensation and employee benefits
$
6,597

 
$
6,363

Royalties payable
5,904

 
5,172

Research and development expenses
5,893

 
5,593

Consulting and other professional fees
5,376

 
2,924

Operating lease liabilities
2,147

 
—

Other
1,673

 
1,532

Total accounts payable and accrued liabilities
$
27,590

 
$
21,584


10. Commitments and Contingencies
Guarantees and Indemnifications
The Company has entered into a number of standard intellectual property indemnification agreements in the ordinary course of its business. Pursuant to these agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company’s business partners or customers, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to the Company’s products. The term of these indemnification agreements is generally perpetual from the date of execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. Since inception, the Company has not incurred costs to defend

88

lawsuits or settle claims related to these indemnification agreements. The Company also indemnifies its officers and directors for certain events or occurrences, subject to certain conditions.
License Agreements
The Company’s rights to develop and commercialize its products are subject to the terms and conditions of licenses granted to the Company by other pharmaceutical companies.
HETLIOZ®. In February 2004, the Company entered into a license agreement with BMS under which it received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize HETLIOZ®. To date, the Company has paid BMS $37.5 million in upfront fees and milestone obligations, including $33.0 million of regulatory approval and commercial milestones capitalized as intangible assets (see Note 8). The Company has no remaining milestone obligations to BMS. Additionally, the Company is obligated to make royalty payments on HETLIOZ® net sales to BMS in any territory where the Company commercializes HETLIOZ® for a period equal to the greater of 10 years following the first commercial sale in the territory or the expiry of the new chemical entity (NCE) patent in that territory. During the period prior to the expiry of the NCE patent in a territory, the Company is obligated to pay a 10% royalty on net sales in that territory. The royalty rate is decreased by half for countries in which no NCE patent existed or for the remainder of the 10 years after the expiry of the NCE patent. The Company is also obligated under the license agreement to pay BMS a percentage of any sublicense fees, upfront payments and milestone and other payments (excluding royalties) that it receives from a third party in connection with any sublicensing arrangement, at a rate which is in the mid-twenties. The Company has agreed with BMS in the license agreement for HETLIOZ® to use its commercially reasonable efforts to develop and commercialize HETLIOZ®.
Fanapt®. Pursuant to the terms of a settlement agreement with Novartis, Novartis transferred all U.S. and Canadian rights in the Fanapt® franchise to the Company on December 31, 2014. The Company paid directly to Sanofi S.A. (Sanofi) a fixed royalty of 3% of net sales from November 16, 2016 through December 31, 2019 related to manufacturing know-how. The Company is also obligated to pay Sanofi a fixed royalty on Fanapt® net sales equal to 6% on Sanofi know-how not related to manufacturing under certain conditions for a period of up to 10 years in markets where the NCE patent has expired or was not issued. The Company is obligated to pay this 6% royalty on net sales in the U.S. through November 2026.
Tradipitant. In April 2012, the Company entered into a license agreement with Eli Lilly and Company (Lilly) pursuant to which the Company acquired an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize an NK-1R antagonist, tradipitant, for all human indications. Lilly is eligible to receive future payments based upon achievement of specified development, regulatory approval and commercialization milestones as well as tiered-royalties on net sales at percentage rates up to the low double digits. To date, the Company has paid Lilly $3.0 million in upfront fees and development milestones, including a $2.0 million milestone payment in July 2018 as a result of enrolling the first subject into a Phase III study for tradipitant. As of December 31, 2019, remaining milestone obligations include a $2.0 million development milestone due upon the filing of the first marketing authorization for tradipitant either in the U.S. or European Union (E.U.), $10.0 million and $5.0 million for the first approval of a marketing authorization for tradipitant in the U.S. and E.U., respectively, and up to $80 million for sales milestones. The Company is obligated to use its commercially reasonable efforts to develop and commercialize tradipitant.
VQW-765. In connection with a settlement agreement with Novartis relating to Fanapt®, the Company received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. Pursuant to the license agreement, the Company is obligated to use its commercially reasonable efforts to develop and commercialize VQW-765 and is responsible for all development costs. The Company has no milestone obligations; however, Novartis is eligible to receive tiered-royalties on net sales at percentage rates up to the mid-teens.
Portfolio of CFTR activators and inhibitors. In March 2017, the Company entered into a license agreement with the University of California San Francisco (UCSF), under which the Company acquired an exclusive worldwide license to develop and commercialize a portfolio of CFTR activators and inhibitors. Pursuant to the license agreement, the Company will develop and commercialize the CFTR activators and inhibitors and is responsible for all development costs under the license agreement, including current pre-investigational new drug development work. UCSF is eligible to receive future payments based upon achievement of specified development and commercialization milestones as well as single-digit royalties on net sales. To date, the Company has paid UCSF $1.2 million in upfront fees and development milestones, including an upfront license fee payment of $1.0 million in 2017 and a $0.2 million development milestone payment in the March 2019. As of December 31, 2019, remaining milestone obligations include $12.2 million for development milestones and $33.0 million for future

89

regulatory approval and sales milestones. Included in the $12.2 million in development milestones is a $350,000 milestone due upon the conclusion of a Phase I study for each licensed product but not to exceed $1.1 million in total for the CFTR portfolio.
Purchase Commitments
In the course of its business, the Company regularly enters into agreements with clinical organizations to provide services relating to clinical development and clinical manufacturing activities under fee service arrangements. The Company’s current agreements for clinical and marketing services may be terminated on generally 90 days’ notice without incurring additional charges, other than charges for work completed but not paid for through the effective date of termination and other costs incurred by the Company’s contractors in closing out work in progress as of the effective date of termination. Noncancellable long-term contractual cash obligations include noncancellable purchase commitments longer than one year and primarily relate to commitments for media and data services, of which $9.2 million, $1.0 million and $0.5 million are expected to be paid in 2020, 2021 and 2022, respectively.
11. Public Offering of Common Stock
In March 2018, the Company completed a public offering of 6,325,000 shares of its common stock, including the exercise of the underwriters’ option to purchase an additional 825,000 shares of common stock, at a price to the public of $17.00 per share. Net cash proceeds from the public offering were $100.9 million, after deducting the underwriting discounts and commissions and offering expenses.
12. Accumulated Other Comprehensive Income
The accumulated balances related to each component of other comprehensive income (loss), net of taxes, were as follows for the years ended December 31, 2019 and 2018:
(in thousands)
December 31,
2019
 
December 31,
2018
Foreign currency translation
$
13

 
$
7

Unrealized gain (loss) on marketable securities
236

 
(6
)
Accumulated other comprehensive income
$
249

 
$
1


There were no reclassifications out of accumulated other comprehensive income (loss) for the years ended December 31, 2019, 2018 and 2017.
13. Stock-Based Compensation
As of December 31, 2019, there were 6,144,430 shares that were subject to outstanding options and RSUs under the 2006 Equity Incentive Plan (2006 Plan) and the Amended and Restated 2016 Equity Incentive Plan (2016 Plan, and together with the 2006 Plan, Plans). The 2006 Plan expired by its terms on April 12, 2016, and the Company adopted the 2016 Plan. Outstanding options and RSUs under the 2006 Plan remain in effect and the terms of the 2006 Plan continue to apply, but no additional awards can be granted under the 2006 Plan. In June 2016, the Company’s stockholders approved the 2016 Plan. The 2016 Plan has been amended and restated twice to increase the number of shares reserved for issuance, among other administrative changes. Both amendments and restatements of the 2016 Plan were approved by the Company's stockholders. There are a total of 7,100,000 shares of common stock reserved for issuance under the 2016 Plan, 3,026,147 shares of which remained available for future grant as of December 31, 2019.
Stock Options
The Company has granted option awards under the Plans with service conditions (service option awards) that are subject to terms and conditions established by the compensation committee of the board of directors. Service option awards have 10-year contractual terms. Service option awards granted to employees and new directors upon their election vest and become exercisable over four years, with the first 25% of the shares subject to service option awards vesting on the first anniversary of the grant date and the remaining 75% of the shares subject to the service option awards in 36 equal monthly installments thereafter. Subsequent annual service option awards granted to directors vest and become exercisable in full on the first anniversary of the grant date. Certain service option awards to executives and directors provide for accelerated vesting if there is a change in control of the Company. Certain service option awards to employees and executives provide for accelerated vesting if the respective employee’s or executive’s service is terminated by the Company for any reason other than cause or permanent disability.

90

As of December 31, 2019, $9.8 million of unrecognized compensation costs related to unvested service option awards are expected to be recognized over a weighted average period of 1.4 years. No option awards are classified as a liability as of December 31, 2019.
The following is a summary of option activity for the 2006 Plan and the 2016 Plan for the years ended December 31, 2019, 2018, and 2017:
2006 and 2016 Plans
(in thousands, except for share and per share amounts)
Number of
Shares
 
Weighted Average
Exercise Price at Grant Date
 
Weighted Average
Remaining Term
(Years)
 
Aggregate
Intrinsic
Value
Outstanding at December 31, 2016
5,548,336

 
$
11.62

 
5.58
 
$
32,453

Granted
643,000

 
14.44

 
 
 
 
Forfeited
(290,729
)
 
10.73

 
 
 
 
Expired
(605,617
)
 
29.87

 
 
 
 
Exercised
(575,206
)
 
9.13

 
 
 
3,140

Outstanding at December 31, 2017
4,719,784

 
10.03

 
5.63
 
24,421

Granted
567,500

 
19.22

 
 
 
 
Forfeited
(232,527
)
 
13.99

 
 
 
 
Exercised
(685,715
)
 
9.12

 
 
 
5,945

Outstanding at December 31, 2018
4,369,042

 
11.15

 
5.28
 
65,438

Granted
687,500

 
18.38

 
 
 
 
Forfeited
(53
)
 
7.94

 
 
 
 
Expired
(15,000
)
 
14.78

 
 
 
 
Exercised
(546,344
)
 
11.47

 
 
 
2,482

Outstanding at December 31, 2019
4,495,145

 
12.21

 
5.58
 
22,148

Exercisable at December 31, 2019
3,371,836

 
10.31

 
4.53
 
21,200

Vested and expected to vest at December 31, 2019
4,354,708

 
12.02

 
5.46
 
22,039


The weighted average grant-date fair value of options granted was $10.19, $10.66 and $7.81 per share for the years ended December 31, 2019, 2018 and 2017, respectively. Proceeds from the exercise of stock options amounted to $6.3 million, $6.3 million and $5.3 million for the years ended December 31, 2019, 2018 and 2017, respectively.
Restricted Stock Units
An RSU is a stock award that entitles the holder to receive shares of the Company’s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company’s stock on the date of grant. The Company has granted RSUs under the Plans with service conditions (service RSUs) that vest in four equal annual installments provided that the employee remains employed with the Company. Annual service RSUs granted to directors vest on the first anniversary of the grant date.
As of December 31, 2019, $22.8 million of unrecognized compensation costs related to unvested service RSUs are expected to be recognized over a weighted average period of 1.8 years. No RSUs are classified as a liability as of December 31, 2019.

91

The following is a summary of RSU activity for the 2006 Plan and the 2016 Plan for the years ended December 31, 2019, 2018, and 2017:
RSUs
Number of
Shares
 
Weighted
Average
Grant Date Fair Value
Unvested at December 31, 2016
1,138,428

 
$
10.07

Granted
857,336

 
14.57

Forfeited
(275,613
)
 
11.41

Vested
(362,313
)
 
9.78

Unvested at December 31, 2017
1,357,838

 
12.72

Granted
714,086

 
18.93

Forfeited
(229,603
)
 
15.19

Vested
(528,745
)
 
12.69

Unvested at December 31, 2018
1,313,576

 
15.68

Granted
937,328

 
19.46

Forfeited
(75,444
)
 
18.93

Vested
(526,175
)
 
14.54

Unvested at December 31, 2019
1,649,285

 
18.04


The grant date fair value for the 526,175 shares underlying RSUs that vested during the year ended December 31, 2019 was $7.7 million.
Stock-Based Compensation Expense
Stock-based compensation expense recognized for the years ended December 31, 2019, 2018 and 2017 was allocated as follows:
 
Year Ended December 31,
(in thousands)
2019
 
2018
 
2017
Research and development
$
3,207

 
$
1,290

 
$
1,152

Selling, general and administrative
10,251

 
10,376

 
9,313

Total stock-based compensation expense
$
13,458

 
$
11,666

 
$
10,465


The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model that uses the assumptions noted in the following table. Expected volatility rates are based on the historical volatility of the Company’s publicly traded common stock and other factors. The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has never paid cash dividends to its stockholders and does not plan to pay dividends in the foreseeable future. Assumptions used in the Black-Scholes-Merton option pricing model for employee and director stock options granted during the years ended December 31, 2019, 2018 and 2017 were as follows:
 
Year Ended December 31,
 
2019
 
2018
 
2017
Expected dividend yield
—
%
 
—
%
 
—
%
Weighted average expected volatility
58
%
 
58
%
 
57
%
Weighted average expected term (years)
5.95

 
5.90

 
5.89

Weighted average risk-free rate
2.26
%
 
2.68
%
 
1.97
%

14. Employee Benefit Plan
The Company has a defined contribution plan under IRC Section 401(k). This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Currently, the Company matches fifty percent up to the first six percent of employee contributions. All matching

92

contributions have been paid by the Company. The Company match vests over a 4-year period and amounted to $0.8 million, $0.9 million and $0.8 million for the years ended December 31, 2019, 2018 and 2017, respectively.
15. Income Taxes
The following is a summary of the domestic and foreign components of income (loss) before income taxes for the years ended December 31, 2019, 2018 and 2017:
 
Year Ended December 31,
(in thousands)
2019
 
2018
 
2017
Domestic
$
28,794

 
$
25,123

 
$
(15,693
)
Foreign
234

 
223

 
262

Total income (loss) before income taxes
$
29,028

 
$
25,346

 
$
(15,431
)

The following is a summary of the provision (benefit) for income taxes for the years ended December 31, 2019, 2018 and 2017:
 
Year Ended December 31,
(in thousands)
2019
 
2018
 
2017
Current:
 
 
 
 
 
Federal
$
—

 
$
—

 
$
—

State
1,161

 
53

 
65

Foreign
81

 
99

 
(66
)
Deferred:
 
 
 
 
 
Federal
(85,624
)
 
—

 
—

State
(2,127
)
 
—

 
—

Foreign
(16
)
 
(14
)
 
137

Provision (benefit) for income taxes
$
(86,525
)
 
$
138

 
$
136


The Company assesses the need for a valuation allowance against its deferred tax asset each quarter through the review of all available positive and negative evidence. Deferred tax assets are reduced by a tax valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. The analysis depends on historical and projected taxable income. Projected taxable income includes significant assumptions related to revenue, commercial expenses and research and development activities. During 2019, after considering all available positive and negative evidence, including but not limited to cumulative income in recent periods, historical, current and future projected results and significant risks and uncertainties related to forecasts, the Company concluded that it was more likely than not that substantially all of its deferred tax assets in the U.S. are realizable in future periods. A valuation allowance has been retained against certain U.S. federal tax attributes with short carryforward periods and District of Columbia state deferred tax assets as of December 31, 2019. A full valuation allowance was recorded against all net U.S. deferred tax assets as of December 31, 2018.

93

The income tax benefit for 2019 was primarily due to the reduction of the Company's valuation allowance against substantially all of its deferred tax assets in the U.S. Tax expense associated with U.S. income before income taxes for the years ended December 31, 2019 and 2018 was offset by a corresponding tax benefit for the reduction of the valuation allowance recorded against tax attributes that were utilized in those periods. Tax benefit associated with U.S. loss before income taxes for the year ended December 31, 2017 was offset by a corresponding tax expense for the increase of the valuation allowance recorded against tax attributes that were generated in that period. The following is reconciliation between the federal statutory tax rate and the Company’s effective tax rate for the years ended December 31, 2019, 2018 and 2017:
 
Year Ended December 31,
 
2019
 
2018
 
2017
Federal tax at statutory rate
21.0
 %
 
21.0
 %
 
35.0
 %
State taxes
1.8
 %
 
1.7
 %
 
1.7
 %
U.S. Tax Cuts and Job Act (1)
—
 %
 
—
 %
 
(262.6
)%
Change in valuation allowance - U.S. Tax Cuts and Jobs Act
—
 %
 
—
 %
 
262.6
 %
Other change in valuation allowance (2)
(357.6
)%
 
(16.4
)%
 
(47.8
)%
Research and development credit (3)
(10.9
)%
 
(9.1
)%
 
9.0
 %
Orphan drug credit (3)
17.1
 %
 
(2.7
)%
 
6.3
 %
Section 162(m) limitation
2.7
 %
 
3.1
 %
 
8.1
 %
Other tax rate changes
(0.5
)%
 
(0.7
)%
 
(2.6
)%
Other changes in state deferred taxes (4)
—
 %
 
5.9
 %
 
5.1
 %
Uncertain tax positions (5)
26.3
 %
 
—
 %
 
—
 %
Stock-based compensation
(1.0
)%
 
(3.9
)%
 
(13.0
)%
Other items
3.0
 %
 
1.6
 %
 
(2.7
)%
Effective tax rate
(298.1
)%

0.5
 %

(0.9
)%
 
(1)
Includes the effect of the Tax Cuts and Jobs Act, which primarily relates to the remeasurement of existing deferred taxes as a result of the change to the U.S. federal tax rate.
(2)
Reductions in 2019 valuation allowances include $7.5 million related to 2019 U.S. income before income taxes, $10.7 related to adjustments for prior period credit carryforwards and uncertain tax positions and $85.6 million related to a change in beginning-of-the-year balances that resulted from a change in circumstances that caused a change in judgment about the realizability of U.S. deferred tax assets in future years. Reductions in 2018 valuation allowances are attributable to 2018 income before income taxes.
(3)
2019 activity includes adjustments to prior year credit carryforwards. As a result of the tax valuation allowance previously recorded against deferred tax assets in the U.S., these adjustments resulted in no change in tax expense.
(4)
Includes adjustments to state deferred taxes based on changes to filing jurisdictions.
(5)
2019 activity includes adjustments to prior year tax positions. As a result of the tax valuation allowance previously recorded against deferred tax assets in the U.S., these adjustments resulted in no change in tax expense.

94

The following is a summary of the components of the Company’s deferred tax assets (liabilities) and the related tax valuation allowance as of December 31, 2019 and 2018:
(in thousands)
December 31,
2019
 
December 31,
2018
Deferred tax assets:
 
 
 
Net operating loss carryforwards
$
52,034

 
$
55,742

Stock-based compensation
5,298

 
5,202

Accrued and deferred expenses
2,101

 
2,096

Allowance for returns and uncollectable receivables
1,468

 
1,247

Research and development and orphan drug credit carryforwards
36,041

 
48,066

Other
1,301

 
1,405

Total deferred tax assets
98,243

 
113,758

Deferred tax liabilities:
 
 
 
Intangible assets
(1,994
)
 
(1,247
)
Other
(414
)
 
(576
)
Total deferred tax liabilities
(2,408
)
 
(1,823
)
Deferred tax assets, net
95,835

 
111,935

Less: Valuation allowance
8,155

 
111,950

Net deferred tax assets (liabilities)
$
87,680

 
$
(15
)

The Company’s net deferred tax liability of less than $0.1 million as of December 31, 2018 is included as a component of other non-current liabilities.
The following is a summary of changes in the Company’s tax valuation allowance for the years ended December 31, 2019, 2018 and 2017:
(in thousands)
Balance at
Beginning
of Year
 
Additions
 
Reductions
 
Balance at
End of
Year
Year Ended:
 
 
 
 
 
 
 
December 31, 2019
$
111,950

 
$
—

 
$
(103,795
)
 
$
8,155

December 31, 2018
116,110

 
4,036

 
(8,196
)
 
111,950

December 31, 2017
146,012

 
12,403

 
(42,305
)
 
116,110


The Company has NOL and other tax credit carryforwards in several jurisdictions. As of December 31, 2019, the Company has $43.3 million of deferred tax assets relating to U.S. federal NOL carryforwards, along with deferred tax assets of $12.0 million and $24.0 million related to U.S. federal research and development credits and orphan drug credits, respectively. These tax attributes will begin to expire in 2031, 2024 and 2030, respectively. In addition, the Company has $8.7 million of deferred tax assets relating to U.S. state NOL carryforwards, which primarily relate to the District of Columbia. State NOLs for the District of Columbia will begin to expire in 2031 and other state NOLs will begin to expire in 2021.
Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement.

A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:

 
Year Ended December 31,
(in thousands)
2019
 
2018
 
2017
Unrecognized tax benefits at the beginning of the year
$
—

 
$
—

 
$
—

Increases related to prior year tax positions
8,223

 
—

 
—

Increases related to current year tax positions
1,518

 
—

 
—

Unrecognized tax benefits at the end of the year
$
9,741

 
$
—

 
$
—



95


The amount of uncertain tax benefits that, if recognized, would impact the effective tax rate is $9.7 million. No material income tax interest or penalties have been recorded, and unrecognized tax benefits are not expected to change materially over the next 12 months. Income tax returns filed by the Company for all periods are open to examination by tax jurisdictions. As of December 31, 2019, the Company is not under examination by any federal or state tax jurisdiction.
Certain tax attributes of the Company, including NOLs and credits, would be subject to a limitation should an ownership change as defined under the Internal Revenue Code of 1986, as amended (IRC), Section 382, occur. The limitations resulting from a change in ownership could affect the Company’s ability to utilize its NOLs and credit carryforward (tax attributes). Ownership changes occurred in the years ending December 31, 2014 and December 31, 2008. The Company believes that the ownership changes in 2014 and 2008 will not impact its ability to utilize NOL and credit carryforwards; however, future ownership changes may cause the Company’s existing tax attributes to have additional limitations.
The Tax Cuts and Jobs Act (TCJA) was enacted in December 2017. The TCJA reduces the U.S. federal corporate tax rate from 35% to 21%, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously deferred and creates new taxes on certain foreign sourced earnings. During the fourth quarter of 2018, the Company completed its accounting for the tax effects of the TCJA. Effects of the TCJA resulted in no tax expense in 2018 or 2017 as they were fully offset by a change in the Company's tax valuation allowance.
16. Earnings per Share
Basic earnings per share (EPS) is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding. Diluted EPS is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding, plus potential outstanding common stock for the period. Potential outstanding common stock includes stock options and shares underlying RSUs, but only to the extent that their inclusion is dilutive.
The following table presents the calculation of basic and diluted net income (loss) per share of common stock for the years ended December 31, 2019, 2018 and 2017:
 
Year Ended December 31,
(in thousands, except for share and per share amounts)
2019
 
2018
 
2017
Numerator:
 
 
 
 
 
Net income (loss)
$
115,553

 
$
25,208

 
$
(15,567
)
Denominator:
 
 
 
 
 
Weighted average shares outstanding, basic
53,137,562

 
50,859,947

 
44,735,146

Effect of dilutive securities
1,709,498

 
2,185,310

 
—

Weighted average shares outstanding, diluted
54,847,060

 
53,045,257

 
44,735,146

Net income (loss) per share, basic and diluted:
 
 
 
 
 
Basic
$
2.17

 
$
0.50

 
$
(0.35
)
Diluted
$
2.11

 
$
0.48

 
$
(0.35
)
Antidilutive securities excluded from calculations of diluted net income (loss) per share
1,932,024

 
903,265

 
3,136,515


The Company incurred a net loss for the year ended December 31, 2017 causing inclusion of any potentially dilutive securities to have an anti-dilutive effect, resulting in dilutive loss per share and basic loss per share attributable to common stockholders being equivalent.
17. Legal Matters
Fanapt®. The Company has been involved in litigation with Roxane Laboratories, Inc. (Roxane) and its affiliates, West-Ward Pharmaceuticals International Limited and West-Ward Pharmaceuticals Corp (West-Ward), since the Company filed a lawsuit against Roxane in the U.S. District Court for the District of Delaware (Delaware District Court) for patent infringement in June 2014. The lawsuit was filed in response to Roxane’s submission to the U.S. Food and Drug Administration (FDA) of an Abbreviated New Drug Application (ANDA) for a generic version of Fanapt® prior to the expiration of certain of the Company’s patents covering Fanapt®, including U.S. Patent No. 8,586,610 (‘610 Patent). In August 2016, the Delaware District Court ruled in the Company’s favor, permanently enjoining Roxane from manufacturing, using,

96

selling, offering to sell, distributing or importing any generic iloperidone product described in Roxane’s ANDA until the expiration of the ‘610 Patent in November 2027, or May 2028 if the Company obtains pediatric exclusivity. In April 2018, following an appeal by Roxane of the Delaware District Court’s decision to the Federal Circuit Court of Appeals (Federal Circuit), the Federal Circuit affirmed the Delaware District Court’s ruling. In June 2018, West-Ward, having replaced Roxane as defendants following the acquisition of Roxane by West-Ward’s parent company, Hikma Pharmaceuticals PLC, petitioned the Federal Circuit for a rehearing en banc. In August 2018, the Federal Circuit denied West-Ward's petition. In January 2019, West-Ward filed a petition in the U.S. Supreme Court for a writ of certiorari seeking reversal of the Federal Circuit’s decision. In March 2019, the U.S. Supreme Court invited the Solicitor General of the U.S. to file a brief in the matter expressing the views of the U.S. In January 2020, the U.S. Supreme Court denied West-Ward's petition for writ of certiorari.
In 2015, the Company filed six separate patent infringement lawsuits in the Delaware District Court against Roxane, Inventia Healthcare Pvt. Ltd. (Inventia), Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin), Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd. (Taro), and Apotex Inc. and Apotex Corp. (Apotex, and collectively with Roxane, Inventia, Lupin and Taro, the Fanapt® Defendants). These lawsuits were filed in response to the submission to the FDA by each of the Fanapt® Defendants of ANDAs for generic versions of Fanapt® prior to the expiration of the ‘610 Patent in November 2027 or the U.S. Patent No. 9,138,432 in September 2025. The Company entered into separate confidential stipulations with each of Inventia and Lupin regarding any potential launch of their generic versions of Fanapt®. The parties are scheduled to provide the court with a status report in March 2020 with respect to the remaining lawsuits against the other Fanapt® Defendants.
HETLIOZ®. In April and May 2018, the Company filed three separate patent infringement lawsuits in the Delaware District Court against Teva Pharmaceuticals USA, Inc. (Teva), MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (MSN) and Apotex (collectively with Teva and MSN, the HETLIOZ® Defendants) after having received Paragraph IV certification notice letters (Paragraph IV Letters) from each of the HETLIOZ® Defendants alleging that certain of the Company's patents covering HETLIOZ® (collectively, the HETLIOZ® Patents) were invalid, unenforceable and/or would not be infringed by the manufacture, use or sale of their generic versions of HETLIOZ®, as described in the ANDAs submitted to the FDA by each of the HETLIOZ® Defendants, prior to the expiration of the latest to expire of the HETLIOZ® Patents in 2034. Each of the HETLIOZ® Patents are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). In December 2018, the Company filed amended complaints against each of the HETLIOZ® Defendants following the receipt of additional Paragraph IV Letters from Teva and Apotex concerning its Orange Book listed '977 Patent, which expires in 2035. These lawsuits are scheduled for trial in October 2020.
In March 2019, April 2019, and May 2019, the Company filed three additional patent infringement lawsuits in the Delaware District Court against the HETLIOZ® Defendants following the receipt of additional Paragraph IV Letters from each concerning its Orange Book listed U.S. Patent No. 10,149,829, which expires in 2033. These lawsuits have been consolidated with the other lawsuits against the HETLIOZ® Defendants and are also scheduled for trial in October 2020.
In November and December 2019, the Company filed additional patent infringement lawsuits in the Delaware District Court against Apotex and Teva, respectively, for infringement of its Orange Book listed U.S. Patent No. 10,376,487 ('487 Patent) following the receipt of additional Paragraph IV Letters from Apotex and Teva regarding the '487 Patent, which expires in July 2035. Teva asserted a counterclaim for a declaratory judgment that the ‘487 Patent is invalid. The Company answered Teva’s counterclaim by denying their allegation that the ‘487 Patent is invalid. In January 2020, the Company filed two additional patent infringement lawsuits in the Delaware District Court against Teva and Apotex for infringement of its Orange Book-listed U.S. Patent No. 10,449,176 (‘176 Patent) following the receipt of additional Paragraph IV Letters from Teva and Apotex regarding the ‘176 Patent, which expires in January 2033. A trial date has not yet been scheduled for these lawsuits.
In January 2020, the Company received an additional Paragraph IV Letter from MSN concerning the '487 patent, in which MSN alleges that the ‘487 Patent is invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale offer for sale, or importation of MSN's generic version of HETLIOZ® as described in MSN's ANDA. The Company intends to vigorously pursue a patent infringement lawsuit permanently enjoining MSN from infringing the claims of the ‘487 Patent.
Other Matters. In April 2018, the Company submitted a protocol amendment to the FDA, proposing a 52-week open-label extension (OLE) period for patients who had completed the tradipitant Phase II clinical study (2301) in gastroparesis. In May 2018, based on feedback from the FDA, the Company amended the protocol limiting the duration of treatment in the 2301 study to a total of three months, while continuing to seek further dialogue with the FDA on extending the study duration to 52-weeks. As a part of this negotiation process, in September 2018, the Company submitted a new follow-on 52-week OLE protocol to the FDA (2302) for patients who had completed the 2301 study. While waiting for further feedback, the Company did not enroll any patients in any study beyond 12 weeks. In December 2018, the FDA imposed a partial clinical hold (PCH) on

97

the two proposed studies, stating that the Company is required first to conduct additional chronic toxicity studies in canines, monkeys or minipigs before allowing patients access in any clinical protocol beyond 12 weeks. At that time, the FDA informed the Company that the original PCH was not based on any safety or efficacy data related to tradipitant, but, rather. that these additional toxicity studies were required by a guidance document. Subsequently, the FDA has taken the position that an additional study was required in order for the FDA to have adequate toxicology data to undertake a risk analysis of tradipitant.
On February 5, 2019, the Company filed a lawsuit against the FDA in the U.S. District Court for the District of Columbia (DC District Court), challenging the FDA’s legal authority to issue the PCH, and seeking an order to set it aside. In February 2019, the FDA filed a Motion for Voluntary Remand to the Agency and for a Stay of the Case. In March 2019, the DC District Court granted the FDA’s request for voluntary remand and returned the matter to the FDA for further consideration. In April 2019, the FDA provided its remand response, in which it indicated that, upon review of scientific literature and tradipitant data, it believes that a PCH continues to be appropriate until the Company has adequate safety data from a nine-month non-rodent toxicity study. In May 2019, the Company filed an amended complaint, and in July 2019, the Company filed a Motion for Summary Judgment based on its continuing belief after review of the FDA’s remand response that additional chronic toxicity studies are unjustified, and that it has provided the FDA with sufficient information regarding the safety of tradipitant to justify the continued study of tradipitant in patients beyond 12 weeks, in accordance with applicable law and FDA regulations. The FDA filed a reply and cross-motion for summary judgment in October 2019 and an oral hearing was held on December 13, 2019. On January 31, 2020, the Court granted the FDA's cross-motion for summary judgment and granted judgment in favor of the FDA on the Company's claims. The Company is evaluating its options, including a potential appeal, and the Company intends to continue vigorously pursuing its interests in the matter.
In February 2019, a qui tam action filed against the Company was unsealed by order of the DC District Court. The qui tam action, which was filed under seal in March 2017, was brought by a former Company employee on behalf of the U.S., 28 states and the District of Columbia (collectively, the Plaintiff States) and the policyholders of certain insurance companies under the Federal False Claims Act and state law equivalents to the Federal False Claims Act and related state laws. The complaint alleged that the Company violated these laws through the promotion and marketing of its products Fanapt® and HETLIOZ® and sought, among other things, treble damages, civil penalties for each alleged false claim, and attorneys’ fees and costs. By virtue of the DC District Court having unsealed the original complaint, the Company learned that in January 2019, the U.S. Department of Justice (the DOJ), as well as the Plaintiff States, elected not to intervene in the qui tam action at that time. In May 2019, the plaintiff filed an amended complaint under seal repeating the same allegations and seeking the same relief. According to a filing unsealed in June 2019, the DOJ reaffirmed its decision not to intervene and incorporated its prior filing, indicating that neither the DOJ nor the Plaintiff States were intervening regarding the original complaint. Although the DOJ and the Plaintiff States have elected not to intervene, the plaintiff may litigate this action and the DOJ and the Plaintiff States may later seek to intervene in the action. In August 2019, the Company filed a motion to dismiss, and in October 2019 the plaintiff filed a reply. The Company intends to vigorously defend itself in the case. The Court will hear the Company's motion to dismiss on March 20, 2020.
In February 2019, a securities class action, Gordon v. Vanda Pharmaceuticals Inc., was filed in the U.S. District Court for the Eastern District of New York naming the Company and certain of its officers as defendants. An amended complaint was filed in July 2019. The amended complaint, filed on behalf of a purported stockholder, asserts claims on behalf of a putative class of all persons who purchased the Company’s publicly traded securities between November 4, 2015 and February 11, 2019, for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The amended complaint alleges that the defendants made false and misleading statements and/or omissions regarding Fanapt®, HETLIOZ® and the Company’s interactions with the FDA regarding tradipitant between November 3, 2015 and February 11, 2019. The Company believes that it has meritorious defenses and intends to vigorously defend this lawsuit. The Company does not anticipate that this litigation will have a material adverse effect on its business, results of operations or financial condition. However, this lawsuit is subject to inherent uncertainties, the actual cost may be significant, and the Company may not prevail. The Company believes it is entitled to coverage under its relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient.
In July 2019, a shareholder derivative complaint, Samuel Williams vs. Mihael Polymeropoulos, et al., was filed in the U.S. District Court for the Eastern District of New York naming certain current and former Company directors and officers as defendants. In September 2019, a shareholder derivative complaint, Michael Bavaro v. Mihael Polymeropoulos, et al., was filed in the Delaware District Court naming certain current and former Company directors and officers as defendants. In October 2019, the Company filed a motion to transfer the Bavaro case to the Eastern District of New York, where the Gordon and Williams cases are pending. In February 2020, the Delaware District Court issued an order staying the Bavaro case pending the resolution of the Williams case. These complaints, filed on behalf of purported stockholders, derivatively on behalf of the Company, assert claims for alleged breach of fiduciary duties by certain of the Company’s current and former directors and officers. The Company believes that it has meritorious defenses and intends to vigorously defend these lawsuits. The Company

98

does not anticipate that this litigation will have a material adverse effect on its business, results of operations or financial condition. However, these lawsuits are subject to inherent uncertainties, the actual cost may be significant, and the Company may not prevail. The Company believes it is entitled to coverage under its relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient.
In July 2017, the CHMP issued a negative opinion recommending against approval of Fanaptum® (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the E.U. The CHMP was of the opinion that the benefits of Fanaptum® did not outweigh its risks and recommended against marketing authorization. In March 2018, the Company filed an application seeking annulment of the EMA’s negative opinion and the subsequent European Commission decision refusing marketing authorization of Fanaptum in the European General Court. In December 2019, the General Court issued its judgment dismissing the action, leaving the EMA opinion and Commission decision intact. The Company is considering its options to appeal the decision.
18. Quarterly Financial Data (Unaudited)
The following is a summary of quarterly financial data for the years ended December 31, 2019 and 2018:
(in thousands, except for per share amounts)
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
Year Ended December 31, 2019
 
 
 
 
 
 
 
Revenues
$
47,713

 
$
59,060

 
$
59,485

 
$
60,930

Gross profit (1)
42,220

 
52,313

 
52,327

 
54,335

Income (loss) from operations
(2,087
)
 
9,895

 
10,759

 
4,243

Net income (loss)
(612
)
 
11,526

 
100,423

 
4,216

Net income (loss) per share, basic
$
(0.01
)
 
$
0.22

 
$
1.88

 
$
0.08

Net income (loss) per share, diluted
$
(0.01
)
 
$
0.21

 
$
1.84

 
$
0.08

Year Ended December 31, 2018
 
 
 
 
 
 
 
Revenues
$
43,592

 
$
47,350

 
$
49,135

 
$
53,041

Gross profit (1)
38,680

 
41,739

 
43,670

 
46,994

Income from operations
2,442

 
3,913

 
6,233

 
9,150

Net income
3,066

 
4,611

 
7,171

 
10,360

Net income per share, basic
$
0.07

 
$
0.09

 
$
0.14

 
$
0.20

Net income per share, diluted
$
0.06

 
$
0.09

 
$
0.13

 
$
0.19

 
(1)
Gross profit includes revenues less cost of goods sold, excluding amortization, and less intangible asset amortization.

99

VANDA PHARMACEUTICALS INC.
EXHIBIT INDEX
 
Exhibit
Number
  
Description
 
 
 
3.1
  
 
 
 
3.2
  
 
 
 
4.1
  
 
 
 
10.1#
  
 
 
 
10.2
  
 
 
 
10.3†
  
 
 
 
10.4†
  
 
 
 
10.5†
  
 
 
 
10.6†
  
 
 
 
10.7
  
 
 
 
10.8
  
 
 
 
10.9
  
 
 
 
10.10
  
 
 
 
10.11#
  
 
 
 
10.12
  

100

Exhibit
Number
  
Description
 
 
 
10.13#
  
 
 
 
10.14
  
 
 
 
10.15
  
 
 
 
10.16#
  
 
 
 
10.17#
  
 
 
 
10.18#
  
 
 
 
10.19#
  
 
 
 
10.20#
  
 
 
 
10.21
  
 
 
 
10.22#
  
 
 
 
10.23†
  
 
 
 
10.24
  
 
 
 
10.25†
  
 
 
 
10.26†
  
 
 
 
10.27†
  
 
 
 
10.28†
  
 
 
 
10.29†
  
 
 
 

101

Exhibit
Number
  
Description
10.30†
  
 
 
 
10.31#
  
 
 
 
10.32
  
 
 
 
10.33
  
 
 
 
10.34#
  
 
 
 
10.35#
  
 
 
 
10.36
 
 
 
 
10.37
 
 
 
 
10.38†
 
 
 
 
10.39†
 
 
 
 
10.40†
 
 
 
 
10.41†
 
 
 
 
21.1
  
 
 
 
23.1*
  
 
 
 
31.1*
  
 
 
 
31.2*
  
 
 
 
32.1*
  
 
 
 
101*
  
The following financial information from this annual report on Form 10-K for the fiscal year ended December 31, 2019, formatted in Inline Extensible Business Reporting Language (iXBRL) and furnished electronically herewith: (i) Consolidated Balance Sheets as of December 31, 2019 and 2018; (ii) Consolidated Statements of Operations for the years ended December 31, 2019, 2018 and 2017; (iii) Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2019, 2018 and 2017; (iv) Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2019, 2018 and 2017; (v) Consolidated Statements of Cash Flows for the years ended December 31, 2019, 2018 and 2017; and (vi) Notes to the Consolidated Financial Statements.
 
 
 

102

Exhibit
Number
  
Description
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document).
 
 
 
†
 
Indicates management contract or compensatory plan.
 
 
 
#
 
Confidential treatment has been granted with respect to certain provisions of this exhibit.
 
 
 
*
 
Filed herewith.


103
 EX-23.1 2 vnda12312019ex231.htm EXHIBIT 23.1 Exhibit


Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-133368, No. 333-138070, No. 333-141571, No. 333-148924, No. 333-156995, No. 333-164567, No. 333-171962, No. 333-179265, No. 333-186509, No. 333-193614, No. 333-201754, No. 333-209144, No. 333-212255, No. 333-218774 and No. 333-225599) of Vanda Pharmaceuticals Inc. of our report dated February 26, 2020 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Baltimore, Maryland
February 26, 2020


EX-31.1 3 vnda12312019ex311.htm EXHIBIT 31.1 Exhibit


EXHIBIT 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Mihael H. Polymeropoulos, certify that:
1.
I have reviewed this annual report on Form 10-K of Vanda Pharmaceuticals Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

February 26, 2020
  
/s/ Mihael H. Polymeropoulos, M.D.
 
  
Mihael H. Polymeropoulos, M.D.
 
  
President and Chief Executive Officer
(Principal Executive Officer)


 EX-31.2 4 vnda12312019ex312.htm EXHIBIT 31.2 Exhibit


EXHIBIT 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, James P. Kelly, certify that:
1.
I have reviewed this annual report on Form 10-K of Vanda Pharmaceuticals Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

February 26, 2020
  
/s/ James P. Kelly
 
  
James P. Kelly
Executive Vice President, Chief Financial Officer and Treasurer
(Principal Financial Officer and Principal Accounting Officer)


 EX-32.1 5 vnda12312019ex321.htm EXHIBIT 32.1 Exhibit


EXHIBIT 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Vanda Pharmaceuticals Inc., (the “Company”), does hereby certify, to the best of such officer’s knowledge, that:
The Annual Report on Form 10-K for the year ended December 31, 2019 (the Form 10-K) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the consolidated financial condition and results of operations of the Company.

February 26, 2020
  
/s/ Mihael H. Polymeropoulos, M.D.
 
  
Mihael H. Polymeropoulos, M.D.
President and Chief Executive Officer
(Principal Executive Officer)
 
 
 
February 26, 2020
  
/s/ James P. Kelly
 
  
James P. Kelly
Executive Vice President, Chief Financial Officer and Treasurer
(Principal Financial Officer and Principal Accounting Officer)
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission (SEC) or its staff upon request. This certification “accompanies” the Form 10-K to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.


 EX-101.SCH 6 vnda-20191231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2118100 - Disclosure - Accounts Payable and Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - Accounts Payable and Accrued Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2318301 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2126100 - Disclosure - Accumulated Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 2426403 - Disclosure - Accumulated Other Comprehensive Income - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2426402 - Disclosure - Accumulated Other Comprehensive Income - Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss) (Detail) link:presentationLink link:calculationLink link:definitionLink 2326301 - Disclosure - Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Business Organization and Presentation link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Business Organization and Presentation (Detail) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2419404 - Disclosure - Commitments and Contingencies - CFTR Activators and Inhibitors - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Commitments and Contingencies - Fanapt - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2419401 - Disclosure - Commitments and Contingencies - HETLIOZ - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2419405 - Disclosure - Commitments and Contingencies - Purchase Commitments (Detail) link:presentationLink link:calculationLink link:definitionLink 2419405 - Disclosure - Commitments and Contingencies - Purchase Commitments (Detail) link:presentationLink link:calculationLink link:definitionLink 2419403 - Disclosure - Commitments and Contingencies - Tradipitant - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2140100 - Disclosure - Earnings per Share link:presentationLink link:calculationLink link:definitionLink 2440402 - Disclosure - Earnings per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 2340301 - Disclosure - Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2133100 - Disclosure - Employee Benefit Plan link:presentationLink link:calculationLink link:definitionLink 2433401 - Disclosure - Employee Benefit Plan (Detail) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2139100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2439402 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2439406 - Disclosure - Income Taxes - Components of Deferred Tax Assets, Net and Related Valuation Allowance (Detail) link:presentationLink link:calculationLink link:definitionLink 2439405 - Disclosure - Income Taxes - Reconciliation Between Statutory Tax Rate and Effective Tax Rate (Detail) link:presentationLink link:calculationLink link:definitionLink 2439403 - Disclosure - Income Taxes - Summary of Domestic and Foreign Components of Income (loss) Before Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2439408 - Disclosure - Income Taxes - Summary of Gross Unrecognized Income Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 2439404 - Disclosure - Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail) link:presentationLink link:calculationLink link:definitionLink 2339301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2439407 - Disclosure - Income Taxes - Valuation Allowance Activity on Deferred Tax Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Intangible Assets - Fanapt - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Intangible Assets - HETLIOZ - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2416405 - Disclosure - Intangible Assets - Summary of Amortization Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 2416406 - Disclosure - Intangible Assets - Summary of Future Intangible Asset Amortization (Detail) link:presentationLink link:calculationLink link:definitionLink 2416404 - Disclosure - Intangible Assets - Summary of Intangible Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Inventory (Detail) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - Leases - Lease Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2414404 - Disclosure - Leases - Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2414405 - Disclosure - Leases - Maturities under ASC 840 (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2141100 - Disclosure - Legal Matters link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Marketable Securities - Available-For-Sale Marketable Securities (Detail) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - Property and Equipment - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Property and Equipment - Property and Equipment-at Cost (Detail) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2124100 - Disclosure - Public Offering of Common Stock link:presentationLink link:calculationLink link:definitionLink 2424401 - Disclosure - Public Offering of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2142100 - Disclosure - Quarterly Financial Data (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2442402 - Disclosure - Quarterly Financial Data (Unaudited) (Detail) link:presentationLink link:calculationLink link:definitionLink 2342301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 2131100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2431402 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2431408 - Disclosure - Stock-Based Compensation - Black-Scholes-Merton Option Pricing Model for Stock Options Granted (Detail) link:presentationLink link:calculationLink link:definitionLink 2431404 - Disclosure - Stock-Based Compensation - RSU - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2431403 - Disclosure - Stock-Based Compensation - Stock Option - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2431405 - Disclosure - Stock-Based Compensation - Summary of Option Activity for 2006 Plan and the 2016 Plan (Detail) link:presentationLink link:calculationLink link:definitionLink 2431406 - Disclosure - Stock-Based Compensation - Summary of RSU Activity Plan (Detail) link:presentationLink link:calculationLink link:definitionLink 2331301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2431407 - Disclosure - Stock-Based Compensation - Total Stock-Based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2401405 - Disclosure - Summary of Significant Accounting Policies - Net Sales by Product (Detail) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - Summary of Significant Accounting Policies - Reconciliation Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2401407 - Disclosure - Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Accounts Receivable, Net (Detail) link:presentationLink link:calculationLink link:definitionLink 2401406 - Disclosure - Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Total Revenues (Detail) link:presentationLink link:calculationLink link:definitionLink 2401408 - Disclosure - Summary of Significant Accounting Policies - Summary of Product Return Allowance (Detail) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 vnda-20191231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 vnda-20191231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 vnda-20191231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Payables and Accruals [Abstract] Summary of Accounts Payable and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Accounting Policies [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Reserve for Product Returns SEC Schedule, 12-09, Allowance, Product Returns [Member] SEC Schedule, 12-09, Allowance, Product Returns [Member] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Beginning balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Additions SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Credits/payments SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Ending balance Income Tax Disclosure [Abstract] Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Income (loss) before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2006 Plan and 2016 Plan Two Thousand Six Plan and Two Thousand Sixteen Plan [Member] Two Thousand Six Plan and Two Thousand Sixteen Plan [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Beginning balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Ending balance (in shares) Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Vested and expected to vest at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Weighted Average Exercise Price at Grant Date Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Beginning balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Forfeited (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expired (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Ending balance (in dollars per share) Exercisable (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Vested and expected to vest at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted Average Remaining Term (Years) Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract] Weighted Average Remaining Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Vested and expected to vest at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Beginning balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Ending balance Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Vested and expected to vest at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Valuation Allowance [Table] Valuation Allowance [Table] Valuation Allowance by Deferred Tax Asset [Axis] Valuation Allowance by Deferred Tax Asset [Axis] Deferred Tax Asset [Domain] Deferred Tax Asset [Domain] Income Before Income Taxes, Current Year Income Before Income Taxes, Current Year [Member] Income Before Income Taxes, Current Year [Member] Income Tax Credit Carryforwards and Uncertain Tax Positions Income Tax Credit Carryforwards and Uncertain Tax Positions [Member] Income Tax Credit Carryforwards and Uncertain Tax Positions [Member] Estimated Realizability of Deferred Tax Asset Estimated Realizability of Deferred Tax Asset [Member] Estimated Realizability of Deferred Tax Asset [Member] Valuation Allowance [Line Items] Valuation Allowance [Line Items] Reduction in valuation allowances Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Federal tax at statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent State taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent U.S. Tax Cuts and Job Act Effective Income Tax Rate Reconciliation, Tax Cuts And Job Act Rate Effective income tax rate reconciliation, tax cuts and job act rate. Change in valuation allowance - U.S. Tax Cuts and Jobs Act Effective Income Tax Rate Reconciliation Tax Cuts And Job Act Of 2017 Change In Valuation Allowance Effective Income Tax Rate Reconciliation Tax Cuts And Job Act Of 2017 Change In Valuation Allowance Other change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Research and development credit Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Orphan drug credit Effective Income Tax Rate Reconciliation Tax Credits Orphan Drug Effective Income Tax Rate Reconciliation Tax Credits Orphan Drug Section 162(m) limitation Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Other tax rate changes Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Other changes in state deferred taxes Effective Income Tax Rate Reconciliation, Effective Tax Rate Adjustment Effective Income Tax Rate Reconciliation, Effective Tax Rate Adjustment Uncertain tax positions Effective Income Tax Rate Reconciliation, Uncertain Tax Positions, Percent Effective Income Tax Rate Reconciliation, Uncertain Tax Positions, Percent Stock-based compensation Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Percent Other items Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent Effective tax rate Effective Income Tax Rate Reconciliation, Percent Statement of Comprehensive Income [Abstract] Net income (loss) Net Income (Loss) Attributable to Parent Other comprehensive income (loss): Other Comprehensive Income (Loss), before Tax [Abstract] Net foreign currency translation gain (loss) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax Change in net unrealized gain (loss) on marketable securities Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax Tax provision on other comprehensive income Other Comprehensive Income (Loss), Tax Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Service option awards Service Option Awards [Member] Service Option Awards [Member] Share based compensation option awards contractual term Share Based Compensation Option Awards Contractual Term Contractual term of stock option awards. Vesting period for subsequent stock options granted to directors Share Based Compensation Arrangement by Share Based Payment Annual Award Vesting Period Employees and New Directors Period which an employee and new director's right to exercise an annual option award is no longer contingent on satisfaction of either a service, market or a performance condition. Portion of initial stock options granted to employees that vests on employee's first anniversary Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Share Subject To Option Awards Percentage of new hire stock option award that vests after one year of service. Portion of initial stock options granted to employees that vests ratably over three years after completion of first year of service Share Based Compensation Arrangement By Share Based Payment Award Remaining Percentage Of Share Subject To Option Awards Percentage of new hire stock option award that vests monthly after one year of service. Number of vesting equal installments Share-based Compensation Arrangement by Share-Based Payment Award, Options, Vesting Period, Number Of Equal Monthly Installments Share-based Compensation Arrangement by Share-Based Payment Award, Options, Vesting Period, Number Of Equal Monthly Installments Unrecognized compensation expenses Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unrecognized compensation expenses, weighted average period Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Options granted, weighted average fair value per share (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Proceeds from exercise of employee stock options Proceeds from Stock Options Exercised Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] HETLIOZ® Hetlioz [Member] Hetlioz [Member] Fanapt® Fanapt [Member] Fanapt. Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Net product sales Revenue from Contract with Customer, Excluding Assessed Tax Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Acquisition of intangible assets Payments to Acquire Intangible Assets Intangible assets, estimated future useful life Finite Lived Intangible Assets Useful Future Life End Month and Year The month and year that finite lived intangible assets are expected to be amortized through. Cumulative worldwide sales milestone Cumulative Net Sales To Achieve Milestone Net cumulative worldwide sales to achieve milestone and trigger payment of milestone obligation. Milestone obligation under license agreement Milestone Obligation Under License Agreement Current Carrying value as of the balance sheet date for accrued current liability relating to obligations to make a probable future milestone payments that would become due and payable when the related milestones are achieved. Leases [Abstract] Leases Lessee, Operating Leases [Text Block] 2016 Plan Two Thousand Sixteen Plan [Member] Two Thousand Sixteen Plan [Member] Outstanding options and RSUs granted (RSUs) Stock Options and Restricted Stock Units (RSUs) [Member] Stock Options and Restricted Stock Units (RSUs) [Member] Shares subject to outstanding options and RSUs (in shares) Share Based Compensation Arrangement by Share Based Payment Award Options and Restricted Stock Units (RSUs) Outstanding Number Number of options outstanding, including vested and non-vested options, as of the balance sheet, plus the number of non-vested restricted stock units outstanding as of the balance sheet date. Number of shares of common stock reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Number of shares of common stock available for future grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Gross Carrying Amount Finite-Lived Intangible Assets, Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Net Carrying Amount Finite-Lived Intangible Assets, Net Schedule of Future Minimum Rental Payments for Operating Leases Schedule Of Lease Assets And Liabilities [Table Text Block] Schedule Of Lease Assets And Liabilities [Table Text Block] Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of Lease Assets and Liabilities Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Income Taxes Income Tax Disclosure [Text Block] Restricted Stock Units (RSU) Restricted Stock Units (RSUs) [Member] Unrecognized compensation expenses related to unvested RSUs Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Grant date fair value of common stock vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Grant date fair value of common stock vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Equity [Abstract] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] Public Offering Public Offering [Member] Public Offering [Member] Over-Allotment Option Over-Allotment Option [Member] Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Public offering of common stock (in shares) Stock Issued During Period, Shares, New Issues Public offering of common stock (in dollars per shares) Sale of Stock, Price Per Share Net proceeds from public offering Proceeds from Issuance of Common Stock Inventory Disclosure [Abstract] Current assets Inventory, Net [Abstract] Work-in-process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Total inventory, current Inventory, Net Non-Current assets Inventory, Noncurrent [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves, Non Current Raw materials inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle. Work-in-process Inventory, Work in Process, Net of Reserves, Non Current Work in process inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle. Finished goods Inventory, Finished Goods, Net of Reserves, Non Current Finished goods inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle. Total inventory, non-current Inventory, Noncurrent Quarterly Financial Information Disclosure [Abstract] Revenues Revenues Gross profit Gross Profit Income (loss) from operations Operating Income (Loss) Net income (loss) per share, basic (in dollars per share) Earnings Per Share, Basic Net income (loss) per share, diluted (in dollars per share) Earnings Per Share, Diluted Intangible Assets Intangible Assets Disclosure [Text Block] Statement of Financial Position [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Earnings Per Share [Abstract] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Denominator: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Weighted average shares outstanding, basic (shares) Weighted Average Number of Shares Outstanding, Basic Effect of dilutive securities (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Weighted average shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Net income (loss) per share, basic and diluted: Earnings Per Share, Basic and Diluted [Abstract] Basic (in dollars per share) Diluted (in dollars per share) Antidilutive securities excluded from calculations of diluted net income (loss) per share (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2020 Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2023 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2024 Finite-Lived Intangible Assets, Amortization Expense, Year Five Thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five Business organization Description of Business [Policy Text Block] Description of Business Basis of presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Marketable Securities Marketable Securities, Policy [Policy Text Block] Inventory Inventory, Policy [Policy Text Block] Intangible Assets Intangible Assets, Finite-Lived, Policy [Policy Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Leases Lessee, Leases [Policy Text Block] Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities [Policy Text Block] Accounts Payable and Accrued Liabilities [Policy Text Block] Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Major Customers Major Customers, Policy [Policy Text Block] Reserves for Variable Consideration Reserves for Variable Consideration [Policy Text Block] Reserves for variable consideration policy. Cost of Goods Sold Cost of Sales, Policy [Policy Text Block] Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Selling, General and Administrative Expenses Selling, General and Administrative Expenses, Policy [Policy Text Block] Stock-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Advertising Expense Advertising Costs, Policy [Policy Text Block] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Earnings per Share Earnings Per Share, Policy [Policy Text Block] Summary of the Domestic and Foreign Components of Income (loss) Before Income Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Summary of Provision (Benefit) for Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Reconciliation Between Statutory Tax Rate and Effective Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Components of Deferred Tax Assets, Net, and Related Valuation Allowance Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Summary of Changes in Tax Valuation Allowance Summary of Valuation Allowance [Table Text Block] Reconciliation of Gross Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Number of operating segments Number of Operating Segments Number of products in portfolio Number Of Products In Portfolio Number Of Products In Portfolio Income Taxes [Table] Income Taxes [Table] Income Taxes [Table] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other Non-current Liabilities Other Noncurrent Liabilities [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] District of Columbia DISTRICT OF COLUMBIA Range [Axis] Range [Axis] Range [Domain] Range [Domain] Maximum Maximum [Member] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] U.S. Federal Domestic Tax Authority [Member] Orphan Drug Orphan Drug [Member] Orphan Drug [Member] Income Taxes [Line Items] Income Taxes [Line Items] Income Taxes [Line Items] Provision (benefit) for income taxes Income Tax Expense (Benefit) Income tax benefit associated with the loss before income taxes Current Federal Tax Expense (Benefit) Net deferred tax assets Deferred Tax Assets, Net Net deferred tax liability Deferred Tax Liabilities, Net Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Domestic Deferred tax assets related to U.S. federal research and development credits Deferred Tax Assets, Tax Credit Carryforwards, Research Net operating loss carryforwards beginning expiration year Operating Loss Carryforwards, Beginning Expiration Year The year in which operating loss carryforwards begin to expire. U.S. research and development credit beginning expiration year Research and Development, Credit Beginning, Expiration Year Research and Development, Credit Beginning, Expiration Year Orphan drug credit beginning expiration year Orphan Drug Credit , Beginning Expiration Year Orphan Drug Credit , Beginning Expiration Year Deferred tax assets relating to U.S. state NOL carryforwards Deferred Tax Assets, Operating Loss Carryforwards, State and Local Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Balance at Beginning of Year Deferred Tax Assets, Valuation Allowance Additions Deferred Tax Assets Valuation Allowance, Increase Amount of increase in the period related to valuation allowance for deferred tax assets. Reductions Deferred Tax Assets Valuation Allowance, Decrease Amount of decrease in the period related to valuation allowance for deferred tax assets. Balance at End of Year Commitments and Contingencies Disclosure [Abstract] Legal Matters Legal Matters and Contingencies [Text Block] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Percentage of insurance coverage gap allocated for prescription drugs under Medicare Part D Percentage of Responsibility for Patients Cost of Branded Prescription under Medicare Part D Represents the percentage of responsibility for patient's cost of branded prescription taken by the manufacturers under Medicare Part D. Advertising expenses Advertising Expense Number of reportable segments Number of Reportable Segments Total lease liabilities Operating Lease, Liability Operating lease current liabilities Operating Lease, Liability, Current Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Public Offering of Common Stock Public Offering Of Common Stock [Text Block] Public Offering Of Common Stock [Text Block] Commitments and Contingencies [Table] Commitments and Contingencies [Table] Commitments and contingencies. Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Regulatory Approval Milestone Regulatory Approval Milestone [Member] Regulatory Approval Milestone [Member] Future Regulatory Approval And Sales Milestones Future Regulatory Approval And Sales Milestones [Member] Future Regulatory Approval And Sales Milestones [Member] Development And Milestone Payment, Conclusion Of Phase I Study Development And Milestone Payment, Conclusion Of Phase I Study [Member] Development And Milestone Payment, Conclusion Of Phase I Study [Member] CFTR Activators and Inhibitors CFTR activators and inhibitors [Member] CFTR activators and inhibitors [Member] Commitments and Contingencies [Line Items] Commitments and Contingencies [Line Items] Commitments and contingencies. CFTR activators and inhibitors CFTR activators and inhibitors [Abstract] CFTR activators and inhibitors [Abstract] Possible future milestone payments Development And Milestone Payments Potentially Due To Third Party Total amount potentially due to third party under license agreement based on achievement of pre-new drug application approval milestones. Tiered royalties payable on future net sales Tiered Royalties Payable on Future Net Sales Tiered royalties potentially due to third party under license agreement based on future net sales. Development and milestone payments to third party Development And Milestone Obligations Paid To Third Party Development And Milestone Obligations Paid To Third Party Summary of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Summary of Amortization Expense Finite-lived Intangible Assets Amortization Expense [Table Text Block] Summary of Future Intangible Asset Amortization Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification Out of Accumulated Other Comprehensive Income (Loss) Reclassification out of Accumulated Other Comprehensive Income [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Reclassifications out of accumulated other comprehensive income (loss) Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent UNITED STATES UNITED STATES Europe Europe [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Tradipitant Tradipitant [Member] Tradipitant [Member] Pre-NDA Approval Milestones Pre-NDA Approval Milestones [Member] Pre-NDA Approval Milestones [Member] Sales Milestone Sales Milestone [Member] Sales Milestone [Member] Future percentage of royalty payments based net sales Future Percentage Of Royalty Payments Based On Net Sales Future Percentage Of Royalty Payments Based On Net Sales. Possible future milestone payment Milestone obligation under license agreement Milestone Obligation Under License Agreement Carrying value as of the balance sheet for accrued current liability relating to an obligation to make a probable future milestone payment that would become due and payable when cumulative sales of a product reaches a certain agreed upon sales threshold. Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] 2020 Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three 2023 Lessee, Operating Lease, Liability, Payments, Due Year Four 2024 Lessee, Operating Lease, Liability, Payments, Due Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total minimum lease payments Lessee, Operating Lease, Liability, Payments, Due Less: amount of lease payments representing interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Present value of future minimum lease payments Less: current obligations under leases Operating lease non-current liabilities Operating Lease, Liability, Noncurrent Accumulated Other Comprehensive Income Comprehensive Income (Loss) Note [Text Block] Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Weighted average expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Weighted average expected term (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Weighted average risk-free rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Investments, Debt and Equity Securities [Abstract] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Noncurrent investments Noncurrent Investments [Member] Noncurrent Investments [Member] Current investments Current Investment [Member] Current investments. Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] U.S. Treasury and government agencies US Treasury and Government [Member] Corporate debt Corporate Debt Securities [Member] Asset-backed securities Asset-backed Securities [Member] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Fair Market Value Debt Securities, Available-for-sale HETLIOZ Hetlioz [Abstract] Hetlioz [Abstract] Intangible assets capitalized Finite-Lived Intangible Assets, Period Increase (Decrease) Royalty payable percentage on net sales Royalty Payable On Net Sales Percentage Royalty payable percentage under a contractual arrangement for use of technology or intellectual property. Percentage of future sublicense fees payable to third-party Percentage Of Future Sublicense Fees Payable Percentage of sublicense fees payable to third party under a contractual arrangement for use of technology or intellectual property. Royalty payment period Royalty Period Royalty Period Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Retirement Benefits [Abstract] Defined contribution plan employer matching percent Defined Contribution Plan, Employer Matching Contribution, Percent of Match Defined contribution plan maximum employee contribution percent Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Defined contribution plan vesting period Defined Contribution Plan Vesting Period Period which an employee's right to employer matching contribution to defined contribution plan is no longer contingent on satisfaction of a service condition. Defined contribution plan matching amount Defined Contribution Plan, Cost ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Marketable securities Debt Securities, Available-for-sale, Current Accounts receivable, net Accounts Receivable, Net, Current Inventory Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Intangible assets, net Deferred tax assets Deferred Income Tax Assets, Net Non-current inventory and other Inventory and Other Non Current Carrying amount as of the balance sheet date of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle and other non current assets. Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Product revenue allowances Product Revenue Allowances, Current Product Revenue Allowances, Current Milestone obligations under license agreements Total current liabilities Liabilities, Current Operating lease non-current liabilities Other non-current liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies (Notes 10 and 17) Commitments and Contingencies Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.001 par value; 20,000,000 shares authorized, and no shares issued or outstanding Preferred Stock, Value, Issued Common stock, $0.001 par value; 150,000,000 shares authorized; 53,549,612 and 52,477,593 shares issued and outstanding at December 31, 2019 and 2018, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity Statement of Cash Flows [Abstract] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation of property and equipment Depreciation Stock-based compensation Share-based Compensation Amortization of discounts and premiums on marketable securities Investment Income, Net, Amortization of Discount and Premium Intangible asset amortization Amortization of Intangible Assets Deferred income taxes Deferred Income Tax Expense (Benefit) Other non-cash adjustments, net Other Noncash Income (Expense) Changes in operating assets and liabilities: Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Inventory Increase (Decrease) in Inventories Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Product revenue allowances Increase (Decrease) Product Revenue Allowances The increase (decrease) during the reporting period in the amount of obligations and expenses incurred but not paid for product revenue allowances. Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Acquisition of intangible asset Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-sale Maturities of marketable securities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Net proceeds from offering of common stock Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, cash equivalents and restricted cash Cash and Cash Equivalents, at Carrying Value [Abstract] Beginning of year Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents End of year Basic and Diluted Net Income (Loss) Per Share of Common Stock Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Sublease Sublease [Member] Sublease [Member] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Domain] Lease Arrangement, Type [Domain] Washington DC Leases and Sublease Washington DC Lease [Member] Washington DC Lease [Member] London Lease London Lease [Member] London Lease [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Leased square footage Area of Real Estate Property Renewal term of lease agreement Lessee, Operating Lease, Renewal Term Operating lease cost Operating Lease, Cost Short-term lease cost Short-term Lease, Cost Non-lease component expense Operating Lease, Non-Lease Component Expense Operating Lease, Non-Lease Component Expense Rent expense Operating Leases, Rent Expense Operating lease, payments Operating Lease, Payments Income Statement [Abstract] Revenues: Revenues [Abstract] Total revenues Operating expenses: Costs and Expenses [Abstract] Cost of goods sold excluding amortization Cost of Goods Sold, Excluding Depreciation, Depletion, and Amortization Research and development Research and Development Expense Selling, general and administrative Selling, General and Administrative Expense Total operating expenses Costs and Expenses Income (loss) from operations Other income Other Income Net income (loss) Net income (loss) per share: Weighted average shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (in shares) Diluted (in shares) Property, Plant and Equipment [Abstract] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Accumulated Deficit Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Beginning balance (in shares) Beginning balance Net proceeds from public offering of common stock Stock Issued During Period, Value, New Issues Net proceeds from public offering of common stock (in shares) Issuance of common stock from the exercise of stock options and settlement of restricted stock units Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Issuance of common stock from the exercise of stock options and settlement of restricted stock units (in shares) Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Stock-based compensation expense Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Other comprehensive income (loss), net of tax Ending balance (in shares) Ending balance Reconciliation of Cash, Cash Equivalents and Restricted Cash Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Net Product Sales Revenue from External Customers by Products and Services [Table Text Block] Schedule of Major Customers that Represented More Than 10% of Total Revenues Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Schedule of Major Customers that Represented More Than 10% of Accounts Receivable, Net Schedule Of Accounts Receivable By Major Customers By Reporting Segments [Table Text Block] Schedule Of Accounts Receivable By Major Customers By Reporting Segments [Table Text Block] Summary of Product Return Allowance SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Cash Equivalents Cash Equivalents [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Corporate debt Asset-backed securities Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets measured at fair value Assets, Fair Value Disclosure Agreements for clinical and marketing services, termination notice period Agreements For Clinical And Marketing Services, Termination Notice Period Agreements For Clinical And Marketing Services, Termination Notice Period Purchase commitments Purchase Obligation, Fiscal Year Maturity [Abstract] 2020 Purchase Obligation, Due in Next Twelve Months 2021 Purchase Obligation, Due in Second Year 2022 Purchase Obligation, Due in Third Year Unrecognized tax benefits at the beginning of the year Unrecognized Tax Benefits Increases related to prior year tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Increases related to current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Unrecognized tax benefits at the end of the year Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Computer and other equipment Computer Hardware and Other Equipment [Member] Computer Hardware and Other Equipment [Member] Furniture and fixtures Furniture and Fixtures [Member] Leasehold improvements Leasehold Improvements [Member] Minimum Minimum [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Estimated Useful Life (Years) Property, Plant and Equipment, Useful Life Property and equipment, gross Property, Plant and Equipment, Gross Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Operating lease assets Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Inventory Schedule Of Inventories [Table Text Block] Schedule of inventories. Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Research and development Research and Development Expense [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Stock-based compensation expense Allocated Share-based Compensation Expense Inventory Inventory Disclosure [Text Block] Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Deferred tax assets: Deferred Tax Assets, Gross [Abstract] Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Accrued and deferred expenses Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities Allowance for returns and uncollectable receivables Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts Research and development and orphan drug credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards, Research and Other Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit and other tax credit carryforwards. Other Deferred Tax Assets, Tax Deferred Expense, Other Total deferred tax assets Deferred Tax Assets, Gross Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Intangible assets Deferred Tax Liabilities, Intangible Assets Other Deferred Tax Liabilities, Other Total deferred tax liabilities Deferred Tax Liabilities, Gross Deferred tax assets, net Deferred Tax Assets Liabilities Before Valuation Allowance Net Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences. Less: Valuation allowance Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Net deferred tax liabilities Total Operating Leases, Future Minimum Payments Due 2019 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2020 Operating Leases, Future Minimum Payments, Due in Two Years 2021 Operating Leases, Future Minimum Payments, Due in Three Years 2022 Operating Leases, Future Minimum Payments, Due in Four Years 2023 Operating Leases, Future Minimum Payments, Due in Five Years Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Statement, Scenario Secondary [Axis] Statement, Scenario Secondary [Axis] Statement, Scenario Secondary [Axis] Statement, Scenario Secondary [Domain] Statement, Scenario Secondary [Domain] Statement, Scenario Secondary [Domain] November 16,2016 through December 31,2019 Scenario 4 [Member] Scenario 4 [Member] Fanapt Fanapt [Abstract] Fanapt [Abstract] Compensation and employee benefits Employee-related Liabilities, Current Royalties payable Accrued Royalties, Current Research and development expenses Accrued Research And Development Expense Carrying value as of the balance sheet date of obligations incurred and payable for research and development expenses (due within one year or within the normal operating cycle if longer). Consulting and other professional fees Accrued Professional Fees, Current Operating lease liabilities Other Other Accrued Liabilities, Current Total accounts payable and accrued liabilities Intangible assets Summary of Option Activity Plan Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of RSU Activity for 2006 Plan and 2016 Plan Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Stock-Based Compensation Expense Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Black-Scholes-Merton Option Pricing Model for Employee and Director Stock Options Granted Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Concentration Risk [Table] Concentration Risk [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Credit Concentration Risk Credit Concentration Risk [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Accounts Receivable Accounts Receivable [Member] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] Distributor A Customer 1 [Member] Customer 1 [Member] Distributor B Customer 2 [Member] Customer 2 [Member] Distributor C Customer 3 [Member] Customer 3 [Member] Distributor D Customer 5 [Member] Customer 5 [Member] Distributor E Customer 4 [Member] Customer 4 [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Concentration risk, percentage Concentration Risk, Percentage Cover page. Document Type Document Type Document Annual Report Document Annual Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Public Float Entity Public Float Depreciation expense Current: Current Federal, State and Local, Tax Expense (Benefit) [Abstract] Federal State Current State and Local Tax Expense (Benefit) Foreign Current Foreign Tax Expense (Benefit) Deferred: Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) State Deferred State and Local Income Tax Expense (Benefit) Foreign Deferred Foreign Income Tax Expense (Benefit) Provision for income taxes Business Organization and Presentation Business Description and Basis of Presentation [Text Block] Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Summary of Property and Equipment-at Cost Property, Plant and Equipment [Table Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table] Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table] Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table] Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items] Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items] Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items] Number of Shares Unvested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Beginning balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Vested (in shares) Ending balance (in shares) Weighted Average Price/Share Unvested Share based Compensation Arrangement by Share based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value [Abstract] Share based Compensation Arrangement by Share based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value [Abstract] Beginning balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Ending balance (in dollars per share) Earnings per Share Earnings Per Share [Text Block] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Customer Concentration Risk Customer Concentration Risk [Member] Sales Revenue, Net Sales Revenue, Net [Member] Distributor F Customer 6 [Member] Customer 6 [Member] Revenue, Major Customer [Line Items] Revenue, Major Customer [Line Items] Assets Measured at Fair Value on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Foreign currency translation Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Unrealized gain (loss) on marketable securities Accumulated Other Comprehensive Income (Loss), Debt Securities, Available-for-sale, Adjustment, after Tax Accumulated other comprehensive income Summary of Available-for-Sale Marketable Securities Debt Securities, Available-for-sale [Table Text Block] Quarterly Financial Data Quarterly Financial Information [Table Text Block] Employee Benefit Plan Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block] Schedule of Cash and Cash Equivalents [Table] Schedule of Cash and Cash Equivalents [Table] Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Non-current inventory and other Noncurrent Inventory and Other [Member] Noncurrent Inventory and Other [Member] Cash and Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] Restricted cash included in: Restricted Cash and Cash Equivalents [Abstract] Restricted Cash and Cash Equivalents Restricted Cash and Cash Equivalents Total cash, cash equivalents and restricted cash Quarterly Financial Data (Unaudited) Quarterly Financial Information [Text Block] EX-101.PRE 10 vnda-20191231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 fanapt.gif begin 644 fanapt.gif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end GRAPHIC 12 hetlioz.gif begin 644 hetlioz.gif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end GRAPHIC 13 partiiitem5chart.jpg begin 644 partiiitem5chart.jpg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end GRAPHIC 14 researchanddevelopment.jpg begin 644 researchanddevelopment.jpg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htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Dec. 31, 2019
Dec. 31, 2018
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 20,000,000 20,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 150,000,000 150,000,000
Common stock, shares issued (in shares) 53,549,612 52,477,593
Common stock, shares outstanding (in shares) 53,549,612 52,477,593

XML 16 R47.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Marketable Securities - Available-For-Sale Marketable Securities (Detail) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Noncurrent investments    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost $ 266,750  
Gross Unrealized Gains 313  
Gross Unrealized Losses (6)  
Fair Market Value 267,057  
Noncurrent investments | U.S. Treasury and government agencies    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 88,535  
Gross Unrealized Gains 68  
Gross Unrealized Losses (2)  
Fair Market Value 88,601  
Noncurrent investments | Corporate debt    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 129,860  
Gross Unrealized Gains 196  
Gross Unrealized Losses (1)  
Fair Market Value 130,055  
Noncurrent investments | Asset-backed securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 48,355  
Gross Unrealized Gains 49  
Gross Unrealized Losses (3)  
Fair Market Value $ 48,401  
Current investments    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost   $ 196,361
Gross Unrealized Gains   50
Gross Unrealized Losses   (56)
Fair Market Value   196,355
Current investments | U.S. Treasury and government agencies    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost   69,275
Gross Unrealized Gains   12
Gross Unrealized Losses   (17)
Fair Market Value   69,270
Current investments | Corporate debt    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost   105,897
Gross Unrealized Gains   38
Gross Unrealized Losses   (25)
Fair Market Value   105,910
Current investments | Asset-backed securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost   21,189
Gross Unrealized Gains   0
Gross Unrealized Losses   (14)
Fair Market Value   $ 21,175
XML 17 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Summary of Significant Accounting Policies - Net Sales by Product (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Revenue from External Customer [Line Items]      
Net product sales $ 227,188 $ 193,118 $ 165,083
HETLIOZ®      
Revenue from External Customer [Line Items]      
Net product sales 142,980 115,835 89,978
Fanapt®      
Revenue from External Customer [Line Items]      
Net product sales $ 84,208 $ 77,283 $ 75,105
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Cash flows from operating activities      
Net income (loss) $ 115,553 $ 25,208 $ (15,567)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:      
Depreciation of property and equipment 1,387 1,429 1,234
Stock-based compensation 13,458 11,666 10,465
Amortization of discounts and premiums on marketable securities (3,099) (2,221) (426)
Intangible asset amortization 1,505 1,527 1,750
Deferred income taxes (87,767) 0 0
Other non-cash adjustments, net 1,785 167 587
Changes in operating assets and liabilities:      
Accounts receivable 2,342 (11,207) 2,525
Prepaid expenses and other assets (2,764) (4,258) 3,652
Inventory (722) 70 (1,060)
Accounts payable and other liabilities 3,508 (618) 5,953
Product revenue allowances 761 8,223 (11,096)
Net cash provided by (used in) operating activities 45,947 29,986 (1,983)
Cash flows from investing activities      
Acquisition of intangible asset 0 (25,000) 0
Purchases of property and equipment (1,019) (368) (1,664)
Purchases of marketable securities (394,517) (282,395) (148,135)
Maturities of marketable securities 327,227 198,103 139,568
Net cash used in investing activities (68,309) (109,660) (10,231)
Cash flows from financing activities      
Net proceeds from offering of common stock 0 100,870 0
Proceeds from exercise of employee stock options 6,264 6,256 5,251
Net cash provided by financing activities 6,264 107,126 5,251
Effect of exchange rate changes on cash, cash equivalents and restricted cash (1) (38) 42
Net increase (decrease) in cash, cash equivalents and restricted cash (16,099) 27,414 (6,921)
Cash, cash equivalents and restricted cash      
Beginning of year 61,749 34,335 41,256
End of year $ 45,650 $ 61,749 $ 34,335
XML 19 R60.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets - Summary of Future Intangible Asset Amortization (Detail) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]    
Net Carrying Amount $ 23,037 $ 24,542
HETLIOZ®    
Finite-Lived Intangible Assets [Line Items]    
Net Carrying Amount 23,037 $ 24,542
2020 1,478  
2021 1,478  
2022 1,478  
2023 1,478  
2024 1,478  
Thereafter $ 15,647  
XML 20 R64.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments and Contingencies - Tradipitant - Additional Information (Detail) - Tradipitant - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Jul. 31, 2018
Dec. 31, 2019
Commitments and Contingencies [Line Items]    
Future percentage of royalty payments based net sales   low double digits
Development and milestone payments to third party $ 2.0 $ 3.0
Pre-NDA Approval Milestones    
Commitments and Contingencies [Line Items]    
Milestone obligation under license agreement   2.0
Sales Milestone    
Commitments and Contingencies [Line Items]    
Possible future milestone payment   80.0
UNITED STATES | Regulatory Approval Milestone    
Commitments and Contingencies [Line Items]    
Possible future milestone payment   10.0
Europe | Regulatory Approval Milestone    
Commitments and Contingencies [Line Items]    
Possible future milestone payment   $ 5.0
XML 21 R68.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accumulated Other Comprehensive Income - Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss) (Detail) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]    
Foreign currency translation $ 13 $ 7
Unrealized gain (loss) on marketable securities 236 (6)
Accumulated other comprehensive income $ 249 $ 1
XML 22 R22.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes
 12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The following is a summary of the domestic and foreign components of income (loss) before income taxes for the years ended December 31, 2019, 2018 and 2017:
 
Year Ended December 31,
(in thousands)
2019
 
2018
 
2017
Domestic
$
28,794

 
$
25,123

 
$
(15,693
)
Foreign
234

 
223

 
262

Total income (loss) before income taxes
$
29,028

 
$
25,346

 
$
(15,431
)

The following is a summary of the provision (benefit) for income taxes for the years ended December 31, 2019, 2018 and 2017:
 
Year Ended December 31,
(in thousands)
2019
 
2018
 
2017
Current:
 
 
 
 
 
Federal
$
—

 
$
—

 
$
—

State
1,161

 
53

 
65

Foreign
81

 
99

 
(66
)
Deferred:
 
 
 
 
 
Federal
(85,624
)
 
—

 
—

State
(2,127
)
 
—

 
—

Foreign
(16
)
 
(14
)
 
137

Provision (benefit) for income taxes
$
(86,525
)
 
$
138

 
$
136


The Company assesses the need for a valuation allowance against its deferred tax asset each quarter through the review of all available positive and negative evidence. Deferred tax assets are reduced by a tax valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. The analysis depends on historical and projected taxable income. Projected taxable income includes significant assumptions related to revenue, commercial expenses and research and development activities. During 2019, after considering all available positive and negative evidence, including but not limited to cumulative income in recent periods, historical, current and future projected results and significant risks and uncertainties related to forecasts, the Company concluded that it was more likely than not that substantially all of its deferred tax assets in the U.S. are realizable in future periods. A valuation allowance has been retained against certain U.S. federal tax attributes with short carryforward periods and District of Columbia state deferred tax assets as of December 31, 2019. A full valuation allowance was recorded against all net U.S. deferred tax assets as of December 31, 2018.
The income tax benefit for 2019 was primarily due to the reduction of the Company's valuation allowance against substantially all of its deferred tax assets in the U.S. Tax expense associated with U.S. income before income taxes for the years ended December 31, 2019 and 2018 was offset by a corresponding tax benefit for the reduction of the valuation allowance recorded against tax attributes that were utilized in those periods. Tax benefit associated with U.S. loss before income taxes for the year ended December 31, 2017 was offset by a corresponding tax expense for the increase of the valuation allowance recorded against tax attributes that were generated in that period. The following is reconciliation between the federal statutory tax rate and the Company’s effective tax rate for the years ended December 31, 2019, 2018 and 2017:
 
Year Ended December 31,
 
2019
 
2018
 
2017
Federal tax at statutory rate
21.0
 %
 
21.0
 %
 
35.0
 %
State taxes
1.8
 %
 
1.7
 %
 
1.7
 %
U.S. Tax Cuts and Job Act (1)
—
 %
 
—
 %
 
(262.6
)%
Change in valuation allowance - U.S. Tax Cuts and Jobs Act
—
 %
 
—
 %
 
262.6
 %
Other change in valuation allowance (2)
(357.6
)%
 
(16.4
)%
 
(47.8
)%
Research and development credit (3)
(10.9
)%
 
(9.1
)%
 
9.0
 %
Orphan drug credit (3)
17.1
 %
 
(2.7
)%
 
6.3
 %
Section 162(m) limitation
2.7
 %
 
3.1
 %
 
8.1
 %
Other tax rate changes
(0.5
)%
 
(0.7
)%
 
(2.6
)%
Other changes in state deferred taxes (4)
—
 %
 
5.9
 %
 
5.1
 %
Uncertain tax positions (5)
26.3
 %
 
—
 %
 
—
 %
Stock-based compensation
(1.0
)%
 
(3.9
)%
 
(13.0
)%
Other items
3.0
 %
 
1.6
 %
 
(2.7
)%
Effective tax rate
(298.1
)%

0.5
 %

(0.9
)%
 
(1)
Includes the effect of the Tax Cuts and Jobs Act, which primarily relates to the remeasurement of existing deferred taxes as a result of the change to the U.S. federal tax rate.
(2)
Reductions in 2019 valuation allowances include $7.5 million related to 2019 U.S. income before income taxes, $10.7 related to adjustments for prior period credit carryforwards and uncertain tax positions and $85.6 million related to a change in beginning-of-the-year balances that resulted from a change in circumstances that caused a change in judgment about the realizability of U.S. deferred tax assets in future years. Reductions in 2018 valuation allowances are attributable to 2018 income before income taxes.
(3)
2019 activity includes adjustments to prior year credit carryforwards. As a result of the tax valuation allowance previously recorded against deferred tax assets in the U.S., these adjustments resulted in no change in tax expense.
(4)
Includes adjustments to state deferred taxes based on changes to filing jurisdictions.
(5)
2019 activity includes adjustments to prior year tax positions. As a result of the tax valuation allowance previously recorded against deferred tax assets in the U.S., these adjustments resulted in no change in tax expense.
The following is a summary of the components of the Company’s deferred tax assets (liabilities) and the related tax valuation allowance as of December 31, 2019 and 2018:
(in thousands)
December 31,
2019
 
December 31,
2018
Deferred tax assets:
 
 
 
Net operating loss carryforwards
$
52,034

 
$
55,742

Stock-based compensation
5,298

 
5,202

Accrued and deferred expenses
2,101

 
2,096

Allowance for returns and uncollectable receivables
1,468

 
1,247

Research and development and orphan drug credit carryforwards
36,041

 
48,066

Other
1,301

 
1,405

Total deferred tax assets
98,243

 
113,758

Deferred tax liabilities:
 
 
 
Intangible assets
(1,994
)
 
(1,247
)
Other
(414
)
 
(576
)
Total deferred tax liabilities
(2,408
)
 
(1,823
)
Deferred tax assets, net
95,835

 
111,935

Less: Valuation allowance
8,155

 
111,950

Net deferred tax assets (liabilities)
$
87,680

 
$
(15
)

The Company’s net deferred tax liability of less than $0.1 million as of December 31, 2018 is included as a component of other non-current liabilities.
The following is a summary of changes in the Company’s tax valuation allowance for the years ended December 31, 2019, 2018 and 2017:
(in thousands)
Balance at
Beginning
of Year
 
Additions
 
Reductions
 
Balance at
End of
Year
Year Ended:
 
 
 
 
 
 
 
December 31, 2019
$
111,950

 
$
—

 
$
(103,795
)
 
$
8,155

December 31, 2018
116,110

 
4,036

 
(8,196
)
 
111,950

December 31, 2017
146,012

 
12,403

 
(42,305
)
 
116,110


The Company has NOL and other tax credit carryforwards in several jurisdictions. As of December 31, 2019, the Company has $43.3 million of deferred tax assets relating to U.S. federal NOL carryforwards, along with deferred tax assets of $12.0 million and $24.0 million related to U.S. federal research and development credits and orphan drug credits, respectively. These tax attributes will begin to expire in 2031, 2024 and 2030, respectively. In addition, the Company has $8.7 million of deferred tax assets relating to U.S. state NOL carryforwards, which primarily relate to the District of Columbia. State NOLs for the District of Columbia will begin to expire in 2031 and other state NOLs will begin to expire in 2021.
Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement.

A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:

 
Year Ended December 31,
(in thousands)
2019
 
2018
 
2017
Unrecognized tax benefits at the beginning of the year
$
—

 
$
—

 
$
—

Increases related to prior year tax positions
8,223

 
—

 
—

Increases related to current year tax positions
1,518

 
—

 
—

Unrecognized tax benefits at the end of the year
$
9,741

 
$
—

 
$
—



The amount of uncertain tax benefits that, if recognized, would impact the effective tax rate is $9.7 million. No material income tax interest or penalties have been recorded, and unrecognized tax benefits are not expected to change materially over the next 12 months. Income tax returns filed by the Company for all periods are open to examination by tax jurisdictions. As of December 31, 2019, the Company is not under examination by any federal or state tax jurisdiction.
Certain tax attributes of the Company, including NOLs and credits, would be subject to a limitation should an ownership change as defined under the Internal Revenue Code of 1986, as amended (IRC), Section 382, occur. The limitations resulting from a change in ownership could affect the Company’s ability to utilize its NOLs and credit carryforward (tax attributes). Ownership changes occurred in the years ending December 31, 2014 and December 31, 2008. The Company believes that the ownership changes in 2014 and 2008 will not impact its ability to utilize NOL and credit carryforwards; however, future ownership changes may cause the Company’s existing tax attributes to have additional limitations.
The Tax Cuts and Jobs Act (TCJA) was enacted in December 2017. The TCJA reduces the U.S. federal corporate tax rate from 35% to 21%, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously deferred and creates new taxes on certain foreign sourced earnings. During the fourth quarter of 2018, the Company completed its accounting for the tax effects of the TCJA. Effects of the TCJA resulted in no tax expense in 2018 or 2017 as they were fully offset by a change in the Company's tax valuation allowance.
XML 23 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Business organization
Business organization
Vanda Pharmaceuticals Inc. (the Company) is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. The Company commenced its operations in 2003 and operates in one reporting segment.
The Company's commercial portfolio is currently comprised of two products, HETLIOZ® for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and Fanapt® for the treatment of schizophrenia. HETLIOZ® is the first treatment for Non-24 approved by the U.S. Food and Drug Administration (FDA). In addition, the Company has a number of drugs in development, including:
 
•
HETLIOZ® (tasimelteon) for the treatment of jet lag disorder, Smith-Magenis Syndrome (SMS), pediatric Non-24 and delayed sleep phase disorder (DSPD);
 
•
Fanapt® (iloperidone) for the treatment of bipolar disorder and a long acting injectable (LAI) formulation program for the treatment of schizophrenia;
 
•
Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis and motion sickness;
Basis of presentation
Basis of Presentation
The accompanying consolidated financial statements includes the accounts of Vanda Pharmaceuticals Inc. and its wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.). All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management’s evaluation could change. Actual results could differ from those estimates.
Cash and Cash Equivalents
Cash, Cash Equivalents and Restricted Cash
For purposes of the Consolidated Balance Sheets and Consolidated Statements of Cash Flows, cash equivalents represent highly-liquid investments with a maturity date of three months or less at the date of purchase. Cash and cash equivalents include investments in money market funds with commercial banks and financial institutions, and commercial paper of high-quality corporate issuers. Restricted cash relates primarily to amounts held as collateral for letters of credit for leases for office space at the Company’s Washington, D.C. headquarters. 
Marketable Securities
Marketable Securities
The Company classifies all of its marketable securities as available-for-sale securities. The Company’s investment policy requires the selection of high-quality issuers. Available-for-sale securities are carried at fair market value, with unrealized gains and losses reported as a component of stockholders’ equity in accumulated other comprehensive income (loss). At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. If declines in the value of available for-sale securities are determined to be other-than-temporary, a loss is recorded in earnings in the current period. Interest and dividend income is recorded when earned and included in other income. Premiums and discounts on marketable securities are amortized and accreted, respectively, to earliest call date and maturity, respectively, and included in other income. The Company uses the specific identification method in computing realized gains and losses on the sale of investments, which would be included in the consolidated statements of operations when generated. All available-for-sale marketable securities are available for use in current operations and are classified as current.
Inventory
Inventory
Inventory, which is recorded at the lower of cost or net realizable value, includes the cost of third-party manufacturing and other direct and indirect costs and is valued using the first-in, first-out method. The Company capitalizes inventory costs associated with its products upon regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. Inventory not expected to be sold within 12 months following the balance sheet date are classified as non-current.
Intangible Assets
Intangible Assets
Costs incurred for products not yet approved by the FDA and for which no alternative future use exists are recorded as expense. Obligations for milestone payments to other pharmaceutical companies that may result in a capitalized intangible asset are recognized when it is deemed probable that the milestone event will occur. In the event a product has been approved by the FDA or an alternative future use exists for a product, patent and license costs are capitalized and amortized on a straight-line basis over the estimated useful economic life of the of the related product patents. For intangible assets related to HETLIOZ®, the estimated useful life is the estimated economic useful life of the related product patents, the latest of which expires in July 2035. Intangible assets related Fanapt® have been fully amortized on a straight-line basis to November 2016. The useful life estimate for Fanapt® was based on the market participant methodology prescribed by ASC 805, and therefore does not reflect the impact of additional Fanapt® patents solely owned by the Company with varying expiration dates, the latest of which is December 2031.
Property and Equipment
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation. Depreciation of most property and equipment is provided on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized using a straight-line basis over the lesser of the estimated useful lives of the assets or the terms of the related leases. The costs of additions and improvements are capitalized, and repairs and maintenance costs are charged to operations in the period incurred. Upon retirement or disposition of property and equipment, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in the statement of operations for that period.
Leases
Leases
In accordance with Accounting Standards Codification (ASC) 842, Leases, effective January 1, 2019, the Company determines if an arrangement contains a lease at inception. Right-of-use (ROU) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from that lease. For leases with a term greater than 12 months, ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The lease term includes the option to extend the lease when it is reasonably certain the Company will exercise that option. When available, the Company uses the rate implicit in the lease to discount lease payments to present value. In the case the implicit rate is not available, the Company uses its incremental borrowing rate based on information available at the lease commencement date, including publicly available data for instruments with similar characteristics, to determine the present value of lease payments. The Company does not combine lease and non-lease elements for office leases. For existing leases as of January 1, 2019, executory costs are excluded from lease expense, which is consistent with the Company's accounting under ASC 840, Leases. For all leases entered into after January 1, 2019, executory costs are allocated between lease and non-lease elements based upon their relative stand-alone prices.
Accounts Payable and Accrued Liabilities
Accounts Payable and Accrued Liabilities
The Company’s management is required to estimate accrued liabilities as part of the process of preparing financial statements. The estimation of accrued liabilities involves identifying services that have been performed on the Company’s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date in the financial statements. Accrued liabilities include research and development expenses, such as accrued costs under contracts with clinical monitors, data management organizations and investigators in conjunction with clinical trials, fees to contract manufacturers in conjunction with the production of clinical materials, consulting and professional fees, such as lawyers and fees for marketing and other commercialization activities, accrued compensation and employee benefits, such as accrued bonus, royalties payable under licensing agreements, and other accrued fees. Pursuant to management’s assessment of the services that have been performed on clinical trials and other contracts, the Company recognizes these expenses as the services are provided. Such management assessments include, but are not limited to: (i) an evaluation by the project manager of the work that has been completed during the period, (ii) measurement of progress prepared internally and/or provided by the third-party service provider, (iii) analyses of data that justify the progress, and (iv) management’s judgment. In the event that the Company does not identify certain costs that have begun to be incurred or the Company under- or over-estimates the level of services performed or the costs of such services, the Company’s reported expenses for such period would be too low or too high.
Revenue Recognition
Revenue Recognition
In accordance with ASC Subtopic 606 Revenue from Contracts with Customers (ASC 606), which the Company adopted January 1, 2018, the Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. The Company recognizes revenue when control of the product is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for those product sales, which is typically once the product physically arrives at the customer. Sales taxes, value add taxes, and usage-based taxes are excluded from revenues.
Major Customers
HETLIOZ® is available in the U.S. for distribution through a limited number of specialty pharmacies, and is not available in retail pharmacies. Specialty pharmacy customers include Diplomat Pharmacy, Inc. (a subsidiary of UnitedHealth Group) and Accredo (a subsidiary of Express Scripts). Fanapt® is available in the U.S. for distribution through a limited number of wholesalers and is available in retail pharmacies. Wholesaler customers include Cardinal Health, Inc., AmerisourceBergen
Drug Corporation, and McKesson Corporation. The Company invoices and records revenue when its customers, specialty pharmacies and wholesalers, receive product from the third-party logistics warehouse which is the point at which control is transferred to the customer. Revenues and accounts receivable are concentrated with these customers. The Company evaluates outstanding receivables to assess collectability. In performing this evaluation, the Company analyzes economic conditions, the aging of receivables and customer specific risks. 
Reserves for Variable Consideration
The transaction price is determined based upon the consideration to which the Company will be entitled in exchange for transferring product to the customer. The Company’s product sales are recorded net of applicable product revenue allowances for which reserves are established and include discounts, rebates, chargebacks, service fees, co-pay assistance and product returns that are applicable for various government and commercial payors. The Company estimates the amount of variable consideration that should be included in the transaction price utilizing the most likely amount method and updates its estimate at each reporting date. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Allowances for rebates, chargebacks and co-pay assistance are based upon the insurance benefits of the end customer, which are estimated using historical activity and, where available, actual and pending prescriptions for which the Company has validated the insurance benefits. Reserves for variable consideration are classified as product revenue allowances on the consolidated balance sheets, with the exception of prompt-pay discounts which are classified as reductions of accounts receivable. The reserve for product returns for which the product may not be returned for a period of greater than one year from the balance sheet date is included as a component of other non-current liabilities in the consolidated balance sheets. Uncertainties related to variable consideration are generally resolved in the quarter subsequent to period end, with the exception of Medicaid rebates, which are dependent upon the timing of when states submit reimbursement claims, and product returns which are resolved during the product expiry period specified in the customer contract. The Company currently records sales allowances for the following:
Prompt-pay: Specialty pharmacies and wholesalers are offered discounts for prompt payment. The Company expects that the specialty pharmacies and wholesalers will earn prompt payment discounts and, therefore, deducts the full amount of these discounts from total product sales when revenues are recognized.
Rebates: Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program as well as contracted rebate programs with other payors. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contracted discount rates and estimated patient utilization.
Chargebacks: Chargebacks are discounts that occur when contracted indirect customers purchase directly from specialty pharmacies and wholesalers. Contracted indirect customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The specialty pharmacy or wholesaler, in turn, charges back the difference between the price initially paid by the specialty pharmacy or wholesaler and the discounted price paid to the specialty pharmacy or wholesaler by the contracted customer.
Medicare Part D Coverage Gap: Medicare Part D prescription drug benefit mandates manufacturers to fund approximately 50% of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients through 2018. Public Law No. 115-123, also known as the Bipartisan Budget Act of 2018 enacted on February 9, 2018 increased the manufacturer discount from 50% to 70% effective in 2019 for applicable drugs. Vanda accounts for the Medicare Part D coverage gap using a point of sale model. Estimates for expected Medicare Part D coverage gap are based in part on historical activity and, where available, actual and pending prescriptions for which the Company has validated the insurance benefits.
Service Fees: The Company receives sales order management, data and distribution services from certain customers. These fees are based on contracted terms and are known amounts. The Company accrues service fees at the time of revenue recognition, resulting in a reduction of product sales and the recognition of an accrued liability, unless it is a payment for a distinct good or service from the customer in which case the fair value of those distinct goods or services are recorded as selling, general and administrative expense.
Co-payment Assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Co-pay assistance utilization is based on information provided by the Company’s third-party administrator.
Product Returns: The Company generally offers direct customers a limited right to return as contractually defined with the customers. The Company considers several factors in the estimation process, including expiration dates of product shipped to customers, inventory levels within the distribution channel, product shelf life, historical return activity, including activity for product sold for which the return period has past, prescription trends and other relevant factors. The Company does not expect returned goods to be resalable. There was no right of return asset as of December 31, 2019 or 2018.
Cost of Goods Sold
Cost of Goods Sold
Cost of goods sold includes royalties payable, the cost of inventory sold, manufacturing and supply chain costs and product shipping and handling costs related to sales of HETLIOZ® and Fanapt® to the Company’s distribution partners.
Research and Development Expenses
Research and Development Expenses
Research and development expenses consist primarily of fees for services provided by third parties in connection with the clinical trials, costs of contract manufacturing services, milestone payments, costs of materials used in clinical trials and research and development, costs for regulatory consultants and filings, depreciation of capital resources used to develop products, related facilities costs, and salaries, other employee-related costs and stock-based compensation for research and development personnel. The Company expenses research and development costs as they are incurred for products in the
development stage, including manufacturing costs and milestone payments made under license agreements prior to FDA approval. Upon and subsequent to FDA approval, manufacturing and milestone payments related to license agreements are capitalized. Milestone payments are accrued when it is deemed probable that the milestone event will be achieved. Costs related to the acquisition of intellectual property are expensed as incurred if the underlying technology is developed in connection with the Company’s research and development efforts and has no alternative future use.
Selling, General and Administrative Expenses
Selling, General and Administrative Expenses
Selling, general and administrative expenses consist of salaries, stock-based compensation, facilities and third party expenses. Selling, general and administrative expenses are associated with the activities of the corporate, finance, accounting, information technology, business development, commercial support, trade and distribution, sales, marketing, legal, medical affairs and human resource functions. Additionally, selling, general and administrative expenses included an estimate for the annual Affordable Care Act fee.
Stock-Based Compensation
Stock-Based Compensation
Compensation costs for all stock-based awards to employees and directors are measured based on the grant date fair value of those awards and recognized over the period during which the employee or director is required to perform service in exchange for the award. The Company recognizes the expense over the award’s vesting period. The fair value of stock options granted and restricted stock units (RSUs) awarded are amortized using the straight-line method. As stock-based compensation expense recognized in the consolidated statements of operations is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
Advertising Expense
Advertising Expense
The Company expenses the costs of advertising, including branded promotional expenses, as incurred. Branded advertising expenses, recorded in selling, general and administrative expenses, were $3.2 million, $0.9 million and $1.3 million for the years ended December 31, 2019, 2018 and 2017, respectively.
Foreign Currency
Foreign Currency
The reporting currency of the Company is the U.S. dollar. The functional currency of the Company’s international subsidiaries is the local currency. Assets and liabilities denominated in foreign currencies, including intercompany balances for which settlement is anticipated in the foreseeable future, are translated at exchange rates in effect at the balance sheet date. Foreign currency equity balances are translated at historical rates. Revenues and expenses denominated in foreign currencies are translated at average exchange rates for the respective periods. Foreign currency translation adjustments are recorded in accumulated other comprehensive income (loss).
Transactions denominated in currencies other than subsidiaries’ functional currencies are recorded based on exchange rates at the time such transactions arise. Changes in exchange rates with respect to amounts recorded in the consolidated balance sheets related to these items will result in unrealized foreign currency transaction gains and losses based upon period-end exchange rates. The Company also records realized foreign currency transaction gains and losses upon settlement of the transactions.
Income Taxes
Income Taxes
The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. Tax rate changes are reflected in income during the period such changes are enacted. Changes in ownership may limit the amount of net operating loss (NOL) carryforwards that can be utilized in the future to offset taxable income.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company is evaluating this standard to determine if adoption will have a material impact on the Company’s consolidated financial statements.
In August 2018, the U.S. Securities and Exchange Commission (SEC) adopted the final rule under SEC Release No. 33-10532, Disclosure Update and Simplification. This final rule amends certain disclosure requirements that are redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expand the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule is effective for the Company for all filings made on or after November 5, 2018. The SEC staff clarified that the first presentation of the changes in shareholders' equity may be included in the first Form 10-Q for the quarter that begins after the effective date of the amendments. The adoption of the final rule did not have a material impact on the Company’s consolidated financial statements.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses, which changes the impairment model for most financial assets and certain other financial instruments. The standard will require the use of a forward-looking “expected loss” model for instruments measured at amortized cost that generally will result in the earlier recognition of allowances for losses. The standard is effective for years beginning after December 15, 2019, and interim periods within annual periods beginning after December 15, 2019. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial results.
In February 2016, the FASB issued ASU 2016-2, Leases (Topic 842), which was further clarified by ASU 2018-10, Codification Improvements to Topic 842, Leases, and ASU 2018-11, Leases - Targeted Improvements, issued in July
2018. ASC 842 supersedes existing lease guidance, including ASC 840 Leases. The new leasing standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The new leasing standard requires that lessees will need to recognize an ROU asset and a lease liability for virtually all of their leases, and allows companies to make a policy election as to whether short term leases will be recognized under the requirements of the new standard. The Company elected to exclude short-term leases in the application of the new standard. The lease liability is equal to the present value of lease payments. The ROU asset is based on the liability subject to certain adjustments. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense, similar to accounting for operating leases under ASC 840, while finance leases will result in a front-loaded expense pattern, similar to accounting for capital leases under ASC 840.
The Company adopted the new leasing standard in the first quarter of 2019, using a modified retrospective transition. There was no impact to the opening balance of retained earnings as of the effective date of January 1, 2019 as a result of adoption. Prior period financial statements were not recast. The Company elected the package of transition provisions available for expired or existing contracts, which allowed it to carryforward its historical assessments of (1) whether contracts are or contain leases, (2) lease classification and (3) initial direct costs. The adoption of the new leasing standard on January 1, 2019 resulted in the recognition of $15.8 million of operating lease liabilities, $2.2 million of which were classified as current liabilities, with corresponding ROU assets of $12.2 million, net of lease prepayments and the balance of deferred lease incentives. The Company does not have any financing leases.
Earnings per Share Earnings per Share
Basic earnings per share (EPS) is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding. Diluted EPS is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding, plus potential outstanding common stock for the period. Potential outstanding common stock includes stock options and shares underlying RSUs, but only to the extent that their inclusion is dilutive.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Marketable Securities
 12 Months Ended
Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities Marketable Securities
The following is a summary of the Company’s available-for-sale marketable securities as of December 31, 2019, which all have contractual maturities of less than two years:
(in thousands)
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair
Market
Value
U.S. Treasury and government agencies
$
88,535

 
$
68

 
$
(2
)
 
$
88,601

Corporate debt
129,860

 
196

 
(1
)
 
130,055

Asset-backed securities
48,355

 
49

 
(3
)
 
48,401

Total marketable securities
$
266,750


$
313


$
(6
)

$
267,057

The following is a summary of the Company’s available-for-sale marketable securities as of December 31, 2018, which all have contract maturities of less than one year:
(in thousands)
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair
Market
Value
U.S. Treasury and government agencies
$
69,275

 
$
12

 
$
(17
)
 
$
69,270

Corporate debt
105,897

 
38

 
(25
)
 
105,910

Asset-backed securities
21,189

 
—

 
(14
)
 
21,175

Total marketable securities, current
$
196,361


$
50


$
(56
)

$
196,355
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases
 12 Months Ended
Dec. 31, 2019
Leases [Abstract]  
Leases Leases
The Company's long-term leases primarily include operating leases and subleases for office space in Washington, D.C. and London, England. The Company recognized ROU assets and lease liabilities related to fixed payments for these long-term operating leases in its Consolidated Balance Sheet as of December 31, 2019. The Company also has short-term leases, including office space in Berlin, Germany.
In June 2011, the Company entered into an operating lease agreement under which it leases 33,534 square feet of office space for its headquarters at 2200 Pennsylvania Avenue, N.W. in Washington, D.C. Subject to the prior rights of other tenants, the Company has the right to renew the lease for five years following its expiration in July 2028. As of December 31, 2019, the renewal period has not been included in the lease term. The Company has the right to sublease or assign all or a portion of the premises, subject to standard conditions. The lease may be terminated early by the Company or the landlord under certain circumstances.
In June 2016, the Company entered into a sublease agreement under which it subleases an additional 9,928 square feet of office space for its headquarters at 2200 Pennsylvania Avenue, N.W. in Washington, D.C. The sublease term began in January 2017 and ends in July 2026, but may be terminated earlier by either party under certain circumstances. The Company has the right to sublease or assign all or a portion of the premises, subject to standard conditions.
In May 2016, the Company entered into an operating lease agreement under which it leases 2,880 square feet of office space in London, England. The Company has the right to renew the lease for five years following its expiration in 2021. As of December 31, 2019, the renewal period has not been included in the lease term.
The following is a summary of the Company’s ROU assets and operating lease liabilities as of December 31, 2019:
(in thousands)
 
Classification on the Balance Sheet
 
December 31, 2019
Assets
 
 
 
 
Operating lease assets
 
Operating lease right-of-use assets
 
$
11,180

 
 
 
 
 
Liabilities
 
 
 
 
Operating lease current liabilities
 
Accounts payable and accrued liabilities
 
$
2,147

Operating lease non-current liabilities
 
Operating lease non-current liabilities
 
12,455

Total lease liabilities
 
 
 
$
14,602

 
 
 
 
 
Weighted average remaining lease term
 
 
 
8.1

Weighted average discount rate(1)
 
 
 
8.1
%
 
(1)
Upon adoption of the new lease standard, discount rates used for existing leases were established at January 1, 2019.

For the year ended December 31, 2019, the Company recognized operating lease cost of $2.3 million and short-term operating lease cost of $0.4 million. The Company also recognized $1.4 million of expense related to non-lease elements, such as building maintenance services and utilities, and executory costs associated with the operating leases. For existing leases as of January 1, 2019, executory costs are excluded from operating lease expense, which is consistent with the Company's accounting under ASC 840. For all leases entered into after January 1, 2019, executory costs are allocated between lease and non-lease elements based upon their relative stand-alone prices. For the years ended December 31, 2018 and 2017, the Company recognized $3.6 million and $3.2 million of rent expense, respectively, inclusive of lease expense, non-lease elements, and executory costs for short and long-term operating leases.
Cash paid for amounts included in the measurement of operating lease liabilities is included in operating cash flows and was $2.5 million for the year ended December 31, 2019.
The table below reconciles the Company's future cash obligations to operating lease liabilities recorded on the balance sheet as of December 31, 2019:
(in thousands)
 
Operating Leases
2020
 
$
2,326

2021
 
2,332

2022
 
2,355

2023
 
2,420

2024
 
2,488

Thereafter
 
8,182

Total minimum lease payments
 
20,103

Less: amount of lease payments representing interest
 
(5,501
)
Present value of future minimum lease payments
 
14,602

Less: current obligations under leases
 
(2,147
)
Operating lease non-current liabilities
 
$
12,455



At December 31, 2018, future minimum payments under noncancellable operating leases under ASC 840 were as follows:
 
Cash Payments Due by Year
(in thousands)
Total
 
2019
 
2020
 
2021
 
2022
 
2023
 
Thereafter
Operating leases
$
22,757

 
$
2,483

 
$
2,495

 
$
2,335

 
$
2,355

 
$
2,420

 
$
10,669
XML 26 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Public Offering of Common Stock
 12 Months Ended
Dec. 31, 2019
Equity [Abstract]  
Public Offering of Common Stock Public Offering of Common Stock
In March 2018, the Company completed a public offering of 6,325,000 shares of its common stock, including the exercise of the underwriters’ option to purchase an additional 825,000 shares of common stock, at a price to the public of $17.00 per share. Net cash proceeds from the public offering were $100.9 million, after deducting the underwriting discounts and commissions and offering expenses.
XML 27 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Summary of the Domestic and Foreign Components of Income (loss) Before Income Taxes
The following is a summary of the domestic and foreign components of income (loss) before income taxes for the years ended December 31, 2019, 2018 and 2017:
 
Year Ended December 31,
(in thousands)
2019
 
2018
 
2017
Domestic
$
28,794

 
$
25,123

 
$
(15,693
)
Foreign
234

 
223

 
262

Total income (loss) before income taxes
$
29,028

 
$
25,346

 
$
(15,431
)
Summary of Provision (Benefit) for Income Taxes
The following is a summary of the provision (benefit) for income taxes for the years ended December 31, 2019, 2018 and 2017:
 
Year Ended December 31,
(in thousands)
2019
 
2018
 
2017
Current:
 
 
 
 
 
Federal
$
—

 
$
—

 
$
—

State
1,161

 
53

 
65

Foreign
81

 
99

 
(66
)
Deferred:
 
 
 
 
 
Federal
(85,624
)
 
—

 
—

State
(2,127
)
 
—

 
—

Foreign
(16
)
 
(14
)
 
137

Provision (benefit) for income taxes
$
(86,525
)
 
$
138

 
$
136
Reconciliation Between Statutory Tax Rate and Effective Tax Rate The following is reconciliation between the federal statutory tax rate and the Company’s effective tax rate for the years ended December 31, 2019, 2018 and 2017:
 
Year Ended December 31,
 
2019
 
2018
 
2017
Federal tax at statutory rate
21.0
 %
 
21.0
 %
 
35.0
 %
State taxes
1.8
 %
 
1.7
 %
 
1.7
 %
U.S. Tax Cuts and Job Act (1)
—
 %
 
—
 %
 
(262.6
)%
Change in valuation allowance - U.S. Tax Cuts and Jobs Act
—
 %
 
—
 %
 
262.6
 %
Other change in valuation allowance (2)
(357.6
)%
 
(16.4
)%
 
(47.8
)%
Research and development credit (3)
(10.9
)%
 
(9.1
)%
 
9.0
 %
Orphan drug credit (3)
17.1
 %
 
(2.7
)%
 
6.3
 %
Section 162(m) limitation
2.7
 %
 
3.1
 %
 
8.1
 %
Other tax rate changes
(0.5
)%
 
(0.7
)%
 
(2.6
)%
Other changes in state deferred taxes (4)
—
 %
 
5.9
 %
 
5.1
 %
Uncertain tax positions (5)
26.3
 %
 
—
 %
 
—
 %
Stock-based compensation
(1.0
)%
 
(3.9
)%
 
(13.0
)%
Other items
3.0
 %
 
1.6
 %
 
(2.7
)%
Effective tax rate
(298.1
)%

0.5
 %

(0.9
)%
 
(1)
Includes the effect of the Tax Cuts and Jobs Act, which primarily relates to the remeasurement of existing deferred taxes as a result of the change to the U.S. federal tax rate.
(2)
Reductions in 2019 valuation allowances include $7.5 million related to 2019 U.S. income before income taxes, $10.7 related to adjustments for prior period credit carryforwards and uncertain tax positions and $85.6 million related to a change in beginning-of-the-year balances that resulted from a change in circumstances that caused a change in judgment about the realizability of U.S. deferred tax assets in future years. Reductions in 2018 valuation allowances are attributable to 2018 income before income taxes.
(3)
2019 activity includes adjustments to prior year credit carryforwards. As a result of the tax valuation allowance previously recorded against deferred tax assets in the U.S., these adjustments resulted in no change in tax expense.
(4)
Includes adjustments to state deferred taxes based on changes to filing jurisdictions.
(5)
2019 activity includes adjustments to prior year tax positions. As a result of the tax valuation allowance previously recorded against deferred tax assets in the U.S., these adjustments resulted in no change in tax expense.
Components of Deferred Tax Assets, Net, and Related Valuation Allowance
The following is a summary of the components of the Company’s deferred tax assets (liabilities) and the related tax valuation allowance as of December 31, 2019 and 2018:
(in thousands)
December 31,
2019
 
December 31,
2018
Deferred tax assets:
 
 
 
Net operating loss carryforwards
$
52,034

 
$
55,742

Stock-based compensation
5,298

 
5,202

Accrued and deferred expenses
2,101

 
2,096

Allowance for returns and uncollectable receivables
1,468

 
1,247

Research and development and orphan drug credit carryforwards
36,041

 
48,066

Other
1,301

 
1,405

Total deferred tax assets
98,243

 
113,758

Deferred tax liabilities:
 
 
 
Intangible assets
(1,994
)
 
(1,247
)
Other
(414
)
 
(576
)
Total deferred tax liabilities
(2,408
)
 
(1,823
)
Deferred tax assets, net
95,835

 
111,935

Less: Valuation allowance
8,155

 
111,950

Net deferred tax assets (liabilities)
$
87,680

 
$
(15
)
Summary of Changes in Tax Valuation Allowance
The following is a summary of changes in the Company’s tax valuation allowance for the years ended December 31, 2019, 2018 and 2017:
(in thousands)
Balance at
Beginning
of Year
 
Additions
 
Reductions
 
Balance at
End of
Year
Year Ended:
 
 
 
 
 
 
 
December 31, 2019
$
111,950

 
$
—

 
$
(103,795
)
 
$
8,155

December 31, 2018
116,110

 
4,036

 
(8,196
)
 
111,950

December 31, 2017
146,012

 
12,403

 
(42,305
)
 
116,110
Reconciliation of Gross Unrecognized Tax Benefits
A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:

 
Year Ended December 31,
(in thousands)
2019
 
2018
 
2017
Unrecognized tax benefits at the beginning of the year
$
—

 
$
—

 
$
—

Increases related to prior year tax positions
8,223

 
—

 
—

Increases related to current year tax positions
1,518

 
—

 
—

Unrecognized tax benefits at the end of the year
$
9,741

 
$
—

 
$
—
XML 28 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Summary of Intangible Assets
The following is a summary of the Company’s intangible assets as of December 31, 2019:
 
 
 
December 31, 2019
(in thousands)
Estimated
Useful Life
(Years)
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
HETLIOZ®
July 2035
 
$
33,000

 
$
9,963

 
$
23,037


The following is a summary of the Company’s intangible assets as of December 31, 2018:
 
 
 
December 31, 2018
(in thousands)
Estimated
Useful Life
(Years)
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
HETLIOZ®
February 2035
 
$
33,000

 
$
8,458

 
$
24,542
Summary of Amortization Expense Amortization expense for the years ended December 31, 2019, 2018 and 2017 was as follows:
 
Year Ended December 31,
(in thousands)
2019
 
2018
 
2017
HETLIOZ®
$
1,505

 
$
1,527

 
$
1,750
Summary of Future Intangible Asset Amortization
The following is a summary of the future intangible asset amortization schedule as of December 31, 2019:
(in thousands)
Total
 
2020
 
2021
 
2022
 
2023
 
2024
 
Thereafter
HETLIOZ®
$
23,037

 
$
1,478

 
$
1,478

 
$
1,478

 
$
1,478

 
$
1,478

 
$
15,647
XML 29 R52.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Additional Information (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2019
USD ($)
ft²
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Operating lease cost $ 2.3    
Short-term lease cost 0.4    
Non-lease component expense 1.4    
Rent expense   $ 3.6 $ 3.2
Operating lease, payments $ 2.5    
Washington DC Leases and Sublease      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Leased square footage | ft² 33,534    
Renewal term of lease agreement 5 years    
London Lease      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Leased square footage | ft² 2,880    
Renewal term of lease agreement 5 years    
Sublease | Washington DC Leases and Sublease      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Leased square footage | ft² 9,928    
XML 30 R56.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets - HETLIOZ - Additional Information (Detail) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended 191 Months Ended
Apr. 30, 2018
Jan. 31, 2014
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]            
Acquisition of intangible assets     $ 0 $ 25,000 $ 0  
Milestone obligation under license agreement     $ 0 200   $ 0
HETLIOZ®            
Finite-Lived Intangible Assets [Line Items]            
Acquisition of intangible assets   $ 8,000   $ 25,000   $ 37,500
Intangible assets, estimated future useful life   2034-05 2035-07 2035-02    
Cumulative worldwide sales milestone $ 250,000          
Milestone obligation under license agreement       $ 25,000    
XML 31 R79.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Summary of Domestic and Foreign Components of Income (loss) Before Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Tax Disclosure [Abstract]      
Domestic $ 28,794 $ 25,123 $ (15,693)
Foreign 234 223 262
Income (loss) before income taxes $ 29,028 $ 25,346 $ (15,431)
XML 32 R85.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings per Share (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Numerator:                      
Net income (loss) $ 4,216 $ 100,423 $ 11,526 $ (612) $ 10,360 $ 7,171 $ 4,611 $ 3,066 $ 115,553 $ 25,208 $ (15,567)
Denominator:                      
Weighted average shares outstanding, basic (shares)                 53,137,562 50,859,947 44,735,146
Effect of dilutive securities (in shares)                 1,709,498 2,185,310 0
Weighted average shares outstanding, diluted (in shares)                 54,847,060 53,045,257 44,735,146
Net income (loss) per share, basic and diluted:                      
Basic (in dollars per share) $ 0.08 $ 1.88 $ 0.22 $ (0.01) $ 0.20 $ 0.14 $ 0.09 $ 0.07 $ 2.17 $ 0.50 $ (0.35)
Diluted (in dollars per share) $ 0.08 $ 1.84 $ 0.21 $ (0.01) $ 0.19 $ 0.13 $ 0.09 $ 0.06 $ 2.11 $ 0.48 $ (0.35)
Antidilutive securities excluded from calculations of diluted net income (loss) per share (shares)                 1,932,024 903,265 3,136,515
XML 33 R75.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock-Based Compensation - Total Stock-Based Compensation Expense (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Stock-based compensation expense $ 13,458 $ 11,666 $ 10,465
Research and development      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Stock-based compensation expense 3,207 1,290 1,152
Selling, general and administrative      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Stock-based compensation expense $ 10,251 $ 10,376 $ 9,313
XML 34 R71.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock-Based Compensation - Stock Option - Additional Information (Detail)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2019
USD ($)
installment
$ / shares
Dec. 31, 2018
USD ($)
$ / shares
Dec. 31, 2017
USD ($)
$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share based compensation option awards contractual term 10 years    
Vesting period for subsequent stock options granted to directors 4 years    
Portion of initial stock options granted to employees that vests on employee's first anniversary 25.00%    
Portion of initial stock options granted to employees that vests ratably over three years after completion of first year of service 75.00%    
Number of vesting equal installments | installment 36    
Options granted, weighted average fair value per share (in dollars per share) | $ / shares $ 10.19 $ 10.66 $ 7.81
Proceeds from exercise of employee stock options $ 6,264 $ 6,256 $ 5,251
Service option awards      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized compensation expenses $ 9,800    
Unrecognized compensation expenses, weighted average period 1 year 4 months 24 days    
XML 35 R81.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Reconciliation Between Statutory Tax Rate and Effective Tax Rate (Detail) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Valuation Allowance [Line Items]      
Federal tax at statutory rate 21.00% 21.00% 35.00%
State taxes 1.80% 1.70% 1.70%
U.S. Tax Cuts and Job Act 0.00% 0.00% (262.60%)
Change in valuation allowance - U.S. Tax Cuts and Jobs Act 0.00% 0.00% 262.60%
Other change in valuation allowance (357.60%) (16.40%) (47.80%)
Research and development credit (10.90%) (9.10%) 9.00%
Orphan drug credit 17.10% (2.70%) 6.30%
Section 162(m) limitation 2.70% 3.10% 8.10%
Other tax rate changes (0.50%) (0.70%) (2.60%)
Other changes in state deferred taxes 0.00% 5.90% 5.10%
Uncertain tax positions 26.30% 0.00% 0.00%
Stock-based compensation (1.00%) (3.90%) (13.00%)
Other items 3.00% 1.60% (2.70%)
Effective tax rate (298.10%) 0.50% (0.90%)
Income Before Income Taxes, Current Year      
Valuation Allowance [Line Items]      
Reduction in valuation allowances $ 7.5    
Income Tax Credit Carryforwards and Uncertain Tax Positions      
Valuation Allowance [Line Items]      
Reduction in valuation allowances 10.7    
Estimated Realizability of Deferred Tax Asset      
Valuation Allowance [Line Items]      
Reduction in valuation allowances $ 85.6    
XML 36 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accumulated Other Comprehensive Income
 12 Months Ended
Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income
The accumulated balances related to each component of other comprehensive income (loss), net of taxes, were as follows for the years ended December 31, 2019 and 2018:
(in thousands)
December 31,
2019
 
December 31,
2018
Foreign currency translation
$
13

 
$
7

Unrealized gain (loss) on marketable securities
236

 
(6
)
Accumulated other comprehensive income
$
249

 
$
1


There were no reclassifications out of accumulated other comprehensive income (loss) for the years ended December 31, 2019, 2018 and 2017.
XML 37 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measurements
 12 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
Authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:
 
•
Level 1 — defined as observable inputs such as quoted prices in active markets
 
•
Level 2 — defined as inputs other than quoted prices in active markets that are either directly or indirectly observable
 
•
Level 3 — defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions
Marketable securities classified in Level 1 and Level 2 as of December 31, 2019 and 2018 consist of cash equivalents and available-for-sale marketable securities. The valuation of Level 1 instruments is determined using a market approach, and is based upon unadjusted quoted prices for identical assets in active markets. The valuation of investments classified in Level 2
also is determined using a market approach based upon quoted prices for similar assets in active markets, or other inputs that are observable for substantially the full term of the financial instrument. Level 2 securities include certificates of deposit, commercial paper, corporate notes, and asset-backed securities that use as their basis readily observable market parameters.
 
The Company held certain assets that are required to be measured at fair value on a recurring basis as of December 31, 2019, as follows:
 
 
 
Fair Value Measurement as of December 31, 2019 Using
(in thousands)
Total Fair Value
 
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
U.S. Treasury and government agencies
$
88,601

 
$
88,601

 
$
—

 
$
—

Corporate debt
137,025

 
—

 
137,025

 
—

Asset-backed securities
48,401

 
—

 
48,401

 
—

Total assets measured at fair value
$
274,027


$
88,601


$
185,426


$
—


The Company held certain assets that are required to be measured at fair value on a recurring basis as of December 31, 2018, as follows:
 
 
 
Fair Value Measurement as of December 31, 2018 Using
(in thousands)
Total Fair Value
 
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
U.S. Treasury and government agencies
$
69,270

 
$
69,270

 
$
—

 
$
—

Corporate debt
105,910

 
—

 
105,910

 
—

Asset-backed securities
21,175

 
—

 
21,175

 
—

Total assets measured at fair value
$
196,355


$
69,270


$
127,085


$
—


Total assets measured at fair value as of December 31, 2019 include $7.0 million of cash equivalents.
The Company also has financial assets and liabilities, not required to be measured at fair value on a recurring basis, which primarily consist of cash, accounts receivable, restricted cash, accounts payable and accrued liabilities, product revenue allowances, and milestone obligations under license agreements, the carrying values of which materially approximate their fair values.
XML 38 R15.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets
 12 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Intangible Assets
HETLIOZ®. In January 2014, the Company announced that the FDA had approved the New Drug Application (NDA) for HETLIOZ®. As a result of this approval, the Company met a milestone under its license agreement with Bristol-Myers Squibb (BMS) that required the Company to make a license payment of $8.0 million to BMS. The $8.0 million is being amortized on a straight-line basis over the estimated economic useful life of the related product patents, the latest of which expires in July 2035.
In April 2018, the Company met its final milestone under its license agreement when cumulative worldwide sales of HETLIOZ® reached $250.0 million. As a result of the achievement of this milestone, the Company made a payment to BMS of $25.0 million in 2018. The $25.0 million, which was capitalized as an intangible asset in the first quarter of 2015, was determined to be additional consideration for the acquisition of the HETLIOZ® intangible asset and is being amortized on a straight-line basis over the estimated economic useful life of the related product patents, the latest of which expires in July 2035.
The estimated economic useful life of both the $8.0 million and the $25.0 million intangible assets were changed from February 2035 to July 2035 based on the July 2035 expiration date of U.S. patent number 10,376,487 ('487 Patent) issued by the U.S. Patent and Trademark Office in August 2019. The estimated economic useful life of these intangible assets were
previously changed from May 2034 to February 2035 based on the February 2035 expiration date of U.S. patent number 10,071,977 ('977 Patent) issued by the U.S. Patent and Trademark Office in September 2018.
The following is a summary of the Company’s intangible assets as of December 31, 2019:
 
 
 
December 31, 2019
(in thousands)
Estimated
Useful Life
(Years)
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
HETLIOZ®
July 2035
 
$
33,000

 
$
9,963

 
$
23,037


The following is a summary of the Company’s intangible assets as of December 31, 2018:
 
 
 
December 31, 2018
(in thousands)
Estimated
Useful Life
(Years)
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
HETLIOZ®
February 2035
 
$
33,000

 
$
8,458

 
$
24,542


As of December 31, 2019 and 2018, the Company also had $27.9 million of fully amortized intangible assets related to Fanapt®.
Intangible assets are amortized over their estimated useful economic life using the straight-line method. Amortization expense for the years ended December 31, 2019, 2018 and 2017 was as follows:
 
Year Ended December 31,
(in thousands)
2019
 
2018
 
2017
HETLIOZ®
$
1,505

 
$
1,527

 
$
1,750


The following is a summary of the future intangible asset amortization schedule as of December 31, 2019:
(in thousands)
Total
 
2020
 
2021
 
2022
 
2023
 
2024
 
Thereafter
HETLIOZ®
$
23,037

 
$
1,478

 
$
1,478

 
$
1,478

 
$
1,478

 
$
1,478

 
$
15,647
XML 40 R36.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Summary of Option Activity Plan
The following is a summary of option activity for the 2006 Plan and the 2016 Plan for the years ended December 31, 2019, 2018, and 2017:
2006 and 2016 Plans
(in thousands, except for share and per share amounts)
Number of
Shares
 
Weighted Average
Exercise Price at Grant Date
 
Weighted Average
Remaining Term
(Years)
 
Aggregate
Intrinsic
Value
Outstanding at December 31, 2016
5,548,336

 
$
11.62

 
5.58
 
$
32,453

Granted
643,000

 
14.44

 
 
 
 
Forfeited
(290,729
)
 
10.73

 
 
 
 
Expired
(605,617
)
 
29.87

 
 
 
 
Exercised
(575,206
)
 
9.13

 
 
 
3,140

Outstanding at December 31, 2017
4,719,784

 
10.03

 
5.63
 
24,421

Granted
567,500

 
19.22

 
 
 
 
Forfeited
(232,527
)
 
13.99

 
 
 
 
Exercised
(685,715
)
 
9.12

 
 
 
5,945

Outstanding at December 31, 2018
4,369,042

 
11.15

 
5.28
 
65,438

Granted
687,500

 
18.38

 
 
 
 
Forfeited
(53
)
 
7.94

 
 
 
 
Expired
(15,000
)
 
14.78

 
 
 
 
Exercised
(546,344
)
 
11.47

 
 
 
2,482

Outstanding at December 31, 2019
4,495,145

 
12.21

 
5.58
 
22,148

Exercisable at December 31, 2019
3,371,836

 
10.31

 
4.53
 
21,200

Vested and expected to vest at December 31, 2019
4,354,708

 
12.02

 
5.46
 
22,039
Summary of RSU Activity for 2006 Plan and 2016 Plan
The following is a summary of RSU activity for the 2006 Plan and the 2016 Plan for the years ended December 31, 2019, 2018, and 2017:
RSUs
Number of
Shares
 
Weighted
Average
Grant Date Fair Value
Unvested at December 31, 2016
1,138,428

 
$
10.07

Granted
857,336

 
14.57

Forfeited
(275,613
)
 
11.41

Vested
(362,313
)
 
9.78

Unvested at December 31, 2017
1,357,838

 
12.72

Granted
714,086

 
18.93

Forfeited
(229,603
)
 
15.19

Vested
(528,745
)
 
12.69

Unvested at December 31, 2018
1,313,576

 
15.68

Granted
937,328

 
19.46

Forfeited
(75,444
)
 
18.93

Vested
(526,175
)
 
14.54

Unvested at December 31, 2019
1,649,285

 
18.04
Stock-Based Compensation Expense
Stock-based compensation expense recognized for the years ended December 31, 2019, 2018 and 2017 was allocated as follows:
 
Year Ended December 31,
(in thousands)
2019
 
2018
 
2017
Research and development
$
3,207

 
$
1,290

 
$
1,152

Selling, general and administrative
10,251

 
10,376

 
9,313

Total stock-based compensation expense
$
13,458

 
$
11,666

 
$
10,465
Black-Scholes-Merton Option Pricing Model for Employee and Director Stock Options Granted Assumptions used in the Black-Scholes-Merton option pricing model for employee and director stock options granted during the years ended December 31, 2019, 2018 and 2017 were as follows:
 
Year Ended December 31,
 
2019
 
2018
 
2017
Expected dividend yield
—
%
 
—
%
 
—
%
Weighted average expected volatility
58
%
 
58
%
 
57
%
Weighted average expected term (years)
5.95

 
5.90

 
5.89

Weighted average risk-free rate
2.26
%
 
2.68
%
 
1.97
%
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases (Tables)
 12 Months Ended
Dec. 31, 2019
Leases [Abstract]  
Schedule of Future Minimum Rental Payments for Operating Leases
The following is a summary of the Company’s ROU assets and operating lease liabilities as of December 31, 2019:
(in thousands)
 
Classification on the Balance Sheet
 
December 31, 2019
Assets
 
 
 
 
Operating lease assets
 
Operating lease right-of-use assets
 
$
11,180

 
 
 
 
 
Liabilities
 
 
 
 
Operating lease current liabilities
 
Accounts payable and accrued liabilities
 
$
2,147

Operating lease non-current liabilities
 
Operating lease non-current liabilities
 
12,455

Total lease liabilities
 
 
 
$
14,602

 
 
 
 
 
Weighted average remaining lease term
 
 
 
8.1

Weighted average discount rate(1)
 
 
 
8.1
%
 
(1)
Upon adoption of the new lease standard, discount rates used for existing leases were established at January 1, 2019.
Lessee, Operating Lease, Liability, Maturity
The table below reconciles the Company's future cash obligations to operating lease liabilities recorded on the balance sheet as of December 31, 2019:
(in thousands)
 
Operating Leases
2020
 
$
2,326

2021
 
2,332

2022
 
2,355

2023
 
2,420

2024
 
2,488

Thereafter
 
8,182

Total minimum lease payments
 
20,103

Less: amount of lease payments representing interest
 
(5,501
)
Present value of future minimum lease payments
 
14,602

Less: current obligations under leases
 
(2,147
)
Operating lease non-current liabilities
 
$
12,455
Schedule of Lease Assets and Liabilities
At December 31, 2018, future minimum payments under noncancellable operating leases under ASC 840 were as follows:
 
Cash Payments Due by Year
(in thousands)
Total
 
2019
 
2020
 
2021
 
2022
 
2023
 
Thereafter
Operating leases
$
22,757

 
$
2,483

 
$
2,495

 
$
2,335

 
$
2,355

 
$
2,420

 
$
10,669
XML 42 R53.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Lease Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Leases [Abstract]    
Operating lease assets $ 11,180 $ 0
Operating lease current liabilities 2,147 0
Operating lease non-current liabilities 12,455 $ 0
Total lease liabilities $ 14,602  
Weighted average remaining lease term 8 years 1 month 6 days  
Weighted average discount rate 8.10%  
XML 43 R57.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets - Fanapt - Additional Information (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]      
Acquisition of intangible assets $ 0 $ 25,000 $ 0
Fanapt®      
Finite-Lived Intangible Assets [Line Items]      
Intangible assets $ 27,900 $ 27,900  
XML 44 R84.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Summary of Gross Unrecognized Income Tax Benefits (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Tax Disclosure [Abstract]      
Unrecognized tax benefits at the beginning of the year $ 0 $ 0 $ 0
Increases related to prior year tax positions 8,223 0 0
Increases related to current year tax positions 1,518 0 0
Unrecognized tax benefits at the end of the year $ 9,741 $ 0 $ 0
XML 45 R74.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock-Based Compensation - Summary of RSU Activity Plan (Detail) - Restricted Stock Units (RSU) - $ / shares
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Number of Shares Unvested      
Beginning balance (in shares) 1,313,576 1,357,838 1,138,428
Granted (in shares) 937,328 714,086 857,336
Forfeited (in shares) (75,444) (229,603) (275,613)
Vested (in shares) (526,175) (528,745) (362,313)
Ending balance (in shares) 1,649,285 1,313,576 1,357,838
Weighted Average Price/Share Unvested      
Beginning balance (in dollars per share) $ 15.68 $ 12.72 $ 10.07
Granted (in dollars per share) 19.46 18.93 14.57
Forfeited (in dollars per share) 18.93 15.19 11.41
Vested (in dollars per share) 14.54 12.69 9.78
Ending balance (in dollars per share) $ 18.04 $ 15.68 $ 12.72
XML 46 R70.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock-Based Compensation - Additional Information (Detail)
 12 Months Ended
Dec. 31, 2019
shares
2006 Plan and 2016 Plan | Outstanding options and RSUs granted (RSUs)  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Shares subject to outstanding options and RSUs (in shares) 6,144,430
2016 Plan  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of shares of common stock reserved for issuance (in shares) 7,100,000
Number of shares of common stock available for future grant (in shares) 3,026,147
XML 47 R80.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Current:      
Federal $ 0 $ 0 $ 0
State 1,161 53 65
Foreign 81 99 (66)
Deferred:      
Federal (85,624) 0 0
State (2,127) 0 0
Foreign (16) (14) 137
Provision for income taxes $ (86,525) $ 138 $ 136
JSON 48 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vnda1231201910k.htm": { "axisCustom": 1, "axisStandard": 24, "contextCount": 205, "dts": { "calculationLink": { "local": [ "vnda-20191231_cal.xml" ] }, "definitionLink": { "local": [ "vnda-20191231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml" ] }, "inline": { "local": [ "vnda1231201910k.htm" ] }, "labelLink": { "local": [ "vnda-20191231_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-doc-2018-01-31.xml" ] }, "presentationLink": { "local": [ "vnda-20191231_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-ref-2018-01-31.xml" ] }, "schema": { "local": [ "vnda-20191231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd" ] } }, "elementCount": 583, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 23, "http://www.vandapharmaceuticals.com/20191231": 4, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 32 }, "keyCustom": 48, "keyStandard": 384, "memberCustom": 33, "memberStandard": 31, "nsprefix": "vnda", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.vandapharmaceuticals.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Marketable Securities", "role": "http://www.vandapharmaceuticals.com/role/MarketableSecurities", "shortName": "Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Fair Value Measurements", "role": "http://www.vandapharmaceuticals.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - Inventory", "role": "http://www.vandapharmaceuticals.com/role/Inventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - Property and Equipment", "role": "http://www.vandapharmaceuticals.com/role/PropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - Leases", "role": "http://www.vandapharmaceuticals.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - Intangible Assets", "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118100 - Disclosure - Accounts Payable and Accrued Liabilities", "role": "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilities", "shortName": "Accounts Payable and Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119100 - Disclosure - Commitments and Contingencies", "role": "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "vnda:PublicOfferingOfCommonStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124100 - Disclosure - Public Offering of Common Stock", "role": "http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStock", "shortName": "Public Offering of Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "vnda:PublicOfferingOfCommonStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126100 - Disclosure - Accumulated Other Comprehensive Income", "role": "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome", "shortName": "Accumulated Other Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2131100 - Disclosure - Stock-Based Compensation", "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133100 - Disclosure - Employee Benefit Plan", "role": "http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlan", "shortName": "Employee Benefit Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2139100 - Disclosure - Income Taxes", "role": "http://www.vandapharmaceuticals.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140100 - Disclosure - Earnings per Share", "role": "http://www.vandapharmaceuticals.com/role/EarningsPerShare", "shortName": "Earnings per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2141100 - Disclosure - Legal Matters", "role": "http://www.vandapharmaceuticals.com/role/LegalMatters", "shortName": "Legal Matters", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2142100 - Disclosure - Quarterly Financial Data (Unaudited)", "role": "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnaudited", "shortName": "Quarterly Financial Data (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "vnda:DescriptionOfBusinessPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "vnda:DescriptionOfBusinessPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2301302 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Marketable Securities (Tables)", "role": "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables", "shortName": "Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "vnda:ScheduleOfInventoriesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - Inventory (Tables)", "role": "http://www.vandapharmaceuticals.com/role/InventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "vnda:ScheduleOfInventoriesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - Property and Equipment (Tables)", "role": "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "vnda:ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - Leases (Tables)", "role": "http://www.vandapharmaceuticals.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "vnda:ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316301 - Disclosure - Intangible Assets (Tables)", "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318301 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)", "role": "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesTables", "shortName": "Accounts Payable and Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2326301 - Disclosure - Accumulated Other Comprehensive Income (Tables)", "role": "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables", "shortName": "Accumulated Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331301 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2339301 - Disclosure - Income Taxes (Tables)", "role": "http://www.vandapharmaceuticals.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2340301 - Disclosure - Earnings per Share (Tables)", "role": "http://www.vandapharmaceuticals.com/role/EarningsPerShareTables", "shortName": "Earnings per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2342301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)", "role": "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedTables", "shortName": "Quarterly Financial Data (Unaudited) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "vnda:DescriptionOfBusinessPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401401 - Disclosure - Business Organization and Presentation (Detail)", "role": "http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentationDetail", "shortName": "Business Organization and Presentation (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "vnda:DescriptionOfBusinessPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Segment", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "D2018Q1Jan1Feb8", "decimals": "2", "first": true, "lang": null, "name": "vnda:PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401403 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "role": "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "D2018Q1Jan1Feb8", "decimals": "2", "first": true, "lang": null, "name": "vnda:PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401404 - Disclosure - Summary of Significant Accounting Policies - Reconciliation Cash, Cash Equivalents and Restricted Cash (Details)", "role": "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesReconciliationCashCashEquivalentsAndRestrictedCashDetails", "shortName": "Summary of Significant Accounting Policies - Reconciliation Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember", "decimals": "-3", "lang": null, "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401405 - Disclosure - Summary of Significant Accounting Policies - Net Sales by Product (Detail)", "role": "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail", "shortName": "Summary of Significant Accounting Policies - Net Sales by Product (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD_srt_ProductOrServiceAxis_vnda_HetliozMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD_srt_MajorCustomersAxis_vnda_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401406 - Disclosure - Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Total Revenues (Detail)", "role": "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfTotalRevenuesDetail", "shortName": "Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Total Revenues (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD_srt_MajorCustomersAxis_vnda_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "vnda:ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD_srt_MajorCustomersAxis_vnda_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401407 - Disclosure - Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Accounts Receivable, Net (Detail)", "role": "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfAccountsReceivableNetDetail", "shortName": "Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Accounts Receivable, Net (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "vnda:ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD_srt_MajorCustomersAxis_vnda_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_vnda_SECSchedule1209AllowanceProductReturnsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401408 - Disclosure - Summary of Significant Accounting Policies - Summary of Product Return Allowance (Detail)", "role": "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfProductReturnAllowanceDetail", "shortName": "Summary of Significant Accounting Policies - Summary of Product Return Allowance (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_vnda_SECSchedule1209AllowanceProductReturnsMember", "decimals": "-3", "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Marketable Securities - Available-For-Sale Marketable Securities (Detail)", "role": "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail", "shortName": "Marketable Securities - Available-For-Sale Marketable Securities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Detail)", "role": "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail", "shortName": "Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryWorkInProcessNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - Inventory (Detail)", "role": "http://www.vandapharmaceuticals.com/role/InventoryDetail", "shortName": "Inventory (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryWorkInProcessNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "role": "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - Property and Equipment - Property and Equipment-at Cost (Detail)", "role": "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentPropertyAndEquipmentAtCostDetail", "shortName": "Property and Equipment - Property and Equipment-at Cost (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413403 - Disclosure - Property and Equipment - Additional Information (Detail)", "role": "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentAdditionalInformationDetail", "shortName": "Property and Equipment - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - Leases - Additional Information (Details)", "role": "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "vnda:ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414403 - Disclosure - Leases - Lease Assets and Liabilities (Details)", "role": "http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsAndLiabilitiesDetails", "shortName": "Leases - Lease Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "vnda:ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414404 - Disclosure - Leases - Maturities (Details)", "role": "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails", "shortName": "Leases - Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414405 - Disclosure - Leases - Maturities under ASC 840 (Details)", "role": "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesUnderAsc840Details", "shortName": "Leases - Maturities under ASC 840 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416402 - Disclosure - Intangible Assets - HETLIOZ - Additional Information (Detail)", "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail", "shortName": "Intangible Assets - HETLIOZ - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "D2018Q2Apr_srt_ProductOrServiceAxis_vnda_HetliozMember", "decimals": "-5", "lang": null, "name": "vnda:CumulativeNetSalesToAchieveMilestone", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416403 - Disclosure - Intangible Assets - Fanapt - Additional Information (Detail)", "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail", "shortName": "Intangible Assets - Fanapt - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416404 - Disclosure - Intangible Assets - Summary of Intangible Assets (Detail)", "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail", "shortName": "Intangible Assets - Summary of Intangible Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4_srt_ProductOrServiceAxis_vnda_HetliozMember", "decimals": "-3", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416405 - Disclosure - Intangible Assets - Summary of Amortization Expense (Detail)", "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail", "shortName": "Intangible Assets - Summary of Amortization Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD_srt_ProductOrServiceAxis_vnda_HetliozMember", "decimals": "-3", "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "role": "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416406 - Disclosure - Intangible Assets - Summary of Future Intangible Asset Amortization (Detail)", "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail", "shortName": "Intangible Assets - Summary of Future Intangible Asset Amortization (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4_srt_ProductOrServiceAxis_vnda_HetliozMember", "decimals": "-3", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418402 - Disclosure - Accounts Payable and Accrued Liabilities (Detail)", "role": "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail", "shortName": "Accounts Payable and Accrued Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419401 - Disclosure - Commitments and Contingencies - HETLIOZ - Additional Information (Detail)", "role": "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail", "shortName": "Commitments and Contingencies - HETLIOZ - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "lang": "en-US", "name": "vnda:PercentageOfFutureSublicenseFeesPayable", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "D2019Q4Nov2016-Dec2019_vnda_StatementScenarioSecondaryAxis_vnda_ScenarioFourMember", "decimals": "2", "first": true, "lang": null, "name": "vnda:RoyaltyPayableOnNetSalesPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419402 - Disclosure - Commitments and Contingencies - Fanapt - Additional Information (Detail)", "role": "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Fanapt - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "D2019Q4Nov2016-Dec2019_vnda_StatementScenarioSecondaryAxis_vnda_ScenarioFourMember", "decimals": "2", "first": true, "lang": null, "name": "vnda:RoyaltyPayableOnNetSalesPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember", "decimals": null, "first": true, "lang": "en-US", "name": "vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419403 - Disclosure - Commitments and Contingencies - Tradipitant - Additional Information (Detail)", "role": "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Tradipitant - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember", "decimals": null, "first": true, "lang": "en-US", "name": "vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember", "decimals": null, "first": true, "lang": "en-US", "name": "vnda:TieredRoyaltiesPayableOnFutureNetSales", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419404 - Disclosure - Commitments and Contingencies - CFTR Activators and Inhibitors - Additional Information (Detail)", "role": "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail", "shortName": "Commitments and Contingencies - CFTR Activators and Inhibitors - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember", "decimals": null, "first": true, "lang": "en-US", "name": "vnda:TieredRoyaltiesPayableOnFutureNetSales", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "vnda:AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419405 - Disclosure - Commitments and Contingencies - Purchase Commitments (Detail)", "role": "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetail", "shortName": "Commitments and Contingencies - Purchase Commitments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "vnda:AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424401 - Disclosure - Public Offering of Common Stock (Details)", "role": "http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStockDetails", "shortName": "Public Offering of Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "D2018Q1Mar_us-gaap_SubsidiarySaleOfStockAxis_vnda_PublicOfferingMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426402 - Disclosure - Accumulated Other Comprehensive Income - Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss) (Detail)", "role": "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail", "shortName": "Accumulated Other Comprehensive Income - Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss) (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426403 - Disclosure - Accumulated Other Comprehensive Income - Additional Information (Detail)", "role": "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail", "shortName": "Accumulated Other Comprehensive Income - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember", "decimals": "INF", "first": true, "lang": null, "name": "vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431402 - Disclosure - Stock-Based Compensation - Additional Information (Detail)", "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail", "shortName": "Stock-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember", "decimals": "INF", "first": true, "lang": null, "name": "vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "vnda:ShareBasedCompensationOptionAwardsContractualTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431403 - Disclosure - Stock-Based Compensation - Stock Option - Additional Information (Detail)", "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail", "shortName": "Stock-Based Compensation - Stock Option - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "vnda:ShareBasedCompensationOptionAwardsContractualTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "vnda:SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments", "reportCount": 1, "unitRef": "installment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431404 - Disclosure - Stock-Based Compensation - RSU - Additional Information (Detail)", "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail", "shortName": "Stock-Based Compensation - RSU - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "INF", "lang": null, "name": "vnda:SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments", "reportCount": 1, "unique": true, "unitRef": "installment", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2018Q4_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431405 - Disclosure - Stock-Based Compensation - Summary of Option Activity for 2006 Plan and the 2016 Plan (Detail)", "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail", "shortName": "Stock-Based Compensation - Summary of Option Activity for 2006 Plan and the 2016 Plan (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431406 - Disclosure - Stock-Based Compensation - Summary of RSU Activity Plan (Detail)", "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail", "shortName": "Stock-Based Compensation - Summary of RSU Activity Plan (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431407 - Disclosure - Stock-Based Compensation - Total Stock-Based Compensation Expense (Detail)", "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail", "shortName": "Stock-Based Compensation - Total Stock-Based Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431408 - Disclosure - Stock-Based Compensation - Black-Scholes-Merton Option Pricing Model for Stock Options Granted (Detail)", "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail", "shortName": "Stock-Based Compensation - Black-Scholes-Merton Option Pricing Model for Stock Options Granted (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433401 - Disclosure - Employee Benefit Plan (Detail)", "role": "http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlanDetail", "shortName": "Employee Benefit Plan (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439402 - Disclosure - Income Taxes - Additional Information (Detail)", "role": "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": "-5", "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439403 - Disclosure - Income Taxes - Summary of Domestic and Foreign Components of Income (loss) Before Income Taxes (Details)", "role": "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails", "shortName": "Income Taxes - Summary of Domestic and Foreign Components of Income (loss) Before Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Business Organization and Presentation", "role": "http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentation", "shortName": "Business Organization and Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439404 - Disclosure - Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail)", "role": "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail", "shortName": "Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439405 - Disclosure - Income Taxes - Reconciliation Between Statutory Tax Rate and Effective Tax Rate (Detail)", "role": "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail", "shortName": "Income Taxes - Reconciliation Between Statutory Tax Rate and Effective Tax Rate (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439406 - Disclosure - Income Taxes - Components of Deferred Tax Assets, Net and Related Valuation Allowance (Detail)", "role": "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail", "shortName": "Income Taxes - Components of Deferred Tax Assets, Net and Related Valuation Allowance (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439407 - Disclosure - Income Taxes - Valuation Allowance Activity on Deferred Tax Assets (Detail)", "role": "http://www.vandapharmaceuticals.com/role/IncomeTaxesValuationAllowanceActivityOnDeferredTaxAssetsDetail", "shortName": "Income Taxes - Valuation Allowance Activity on Deferred Tax Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "vnda:DeferredTaxAssetsValuationAllowanceIncrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439408 - Disclosure - Income Taxes - Summary of Gross Unrecognized Income Tax Benefits (Details)", "role": "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfGrossUnrecognizedIncomeTaxBenefitsDetails", "shortName": "Income Taxes - Summary of Gross Unrecognized Income Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FI2016Q4", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440402 - Disclosure - Earnings per Share (Detail)", "role": "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail", "shortName": "Earnings per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": "0", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442402 - Disclosure - Quarterly Financial Data (Unaudited) (Detail)", "role": "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail", "shortName": "Quarterly Financial Data (Unaudited) (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "vnda1231201910k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 64, "tag": { "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r348" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r347" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r349" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r349" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r349" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r350" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r349" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r349" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r349" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r349" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r344" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r346" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Continent of Europe.", "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r128", "r175", "r179" ], "lang": { "en-US": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfAccountsReceivableNetDetail", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfTotalRevenuesDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentPropertyAndEquipmentAtCostDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentPropertyAndEquipmentAtCostDetail" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfAccountsReceivableNetDetail", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfTotalRevenuesDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r126", "r175", "r177", "r333" ], "lang": { "en-US": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by range, including, but not limited to, upper and lower bounds.", "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentPropertyAndEquipmentAtCostDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extent of variation, for example, but not limited to, upper and lower bounds.", "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentPropertyAndEquipmentAtCostDetail" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r88", "r353" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "terseLabel": "Summary of Product Return Allowance" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r127", "r175", "r178", "r340", "r342", "r351", "r352" ], "lang": { "en-US": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfProductReturnAllowanceDetail" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r88", "r353" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfProductReturnAllowanceDetail" ], "xbrltype": "stringItemType" }, "stpr_DC": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "DISTRICT OF COLUMBIA", "terseLabel": "District of Columbia" } } }, "localname": "DC", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r290" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities", "totalLabel": "Total accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail", "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfAccountsReceivableNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r16", "r176" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheetsCalc2": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r5", "r6", "r33" ], "calculation": { "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Consulting and other professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r5", "r6", "r33" ], "calculation": { "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Royalties payable" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r29", "r163" ], "calculation": { "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentPropertyAndEquipmentAtCostDetail": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentPropertyAndEquipmentAtCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r44", "r46", "r48", "r49" ], "calculation": { "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail": { "order": 2.0, "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss), after tax, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Accumulated Other Comprehensive Income (Loss), Debt Securities, Available-for-sale, Adjustment, after Tax", "terseLabel": "Unrealized gain (loss) on marketable securities" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [ "r43", "r46", "r48", "r49", "r284", "r286" ], "calculation": { "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail": { "order": 1.0, "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r46", "r48", "r49" ], "calculation": { "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income", "totalLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail", "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r45", "r49", "r50", "r268" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r17" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r90" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r187", "r189", "r222", "r223" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r82", "r152", "r153" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements.", "label": "Advertising Costs, Policy [Policy Text Block]", "terseLabel": "Advertising Expense" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r226" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising expenses" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r189", "r216", "r221" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r76", "r154", "r158" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Intangible asset amortization" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r100" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from calculations of diluted net income (loss) per share (shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Leased square footage" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.", "label": "Arrangements and Non-arrangement Transactions [Domain]", "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r140", "r182" ], "lang": { "en-US": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Asset-backed securities", "verboseLabel": "Asset-backed securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail", "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r124", "r312", "r324" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r4", "r42" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheetsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r272" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r136" ], "calculation": { "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r137" ], "calculation": { "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r134" ], "calculation": { "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r131", "r135" ], "calculation": { "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Fair Market Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r133" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheetsCalc2": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "verboseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r191", "r218" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail", "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesReconciliationCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r269", "r270" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail", "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesReconciliationCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r0", "r89", "r120" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Business Organization and Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r26", "r78" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheetsCalc2": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesReconciliationCashCashEquivalentsAndRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesReconciliationCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]", "terseLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValueAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Cash and Cash Equivalents [Line Items]", "terseLabel": "Cash and Cash Equivalents [Line Items]" } } }, "localname": "CashAndCashEquivalentsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesReconciliationCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r9", "r79", "r82", "r129" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r73", "r78", "r80" ], "calculation": { "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesReconciliationCashCashEquivalentsAndRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "End of year", "periodStartLabel": "Beginning of year", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesReconciliationCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r73", "r283" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash Equivalents" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r36", "r168", "r316", "r329" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Notes 10 and 17)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r167", "r169" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r37" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Number of shares of common stock reserved for issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r170" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 150,000,000 shares authorized; 53,549,612 and 52,477,593 shares issued and outstanding at December 31, 2019 and 2018, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": { "auth_ref": [ "r180", "r181", "r186" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]", "terseLabel": "Employee Benefit Plan" } } }, "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r53", "r55", "r56" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r67" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r114", "r115", "r278", "r279" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfAccountsReceivableNetDetail", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfTotalRevenuesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r114", "r115", "r278", "r279", "r334" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfAccountsReceivableNetDetail", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfTotalRevenuesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r114", "r115", "r278", "r279", "r334" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfAccountsReceivableNetDetail", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfTotalRevenuesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfAccountsReceivableNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r114", "r115", "r278", "r279" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfAccountsReceivableNetDetail", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfTotalRevenuesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r112", "r114", "r115", "r116", "r278", "r280" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfAccountsReceivableNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r114", "r115", "r278", "r279" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfAccountsReceivableNetDetail", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfTotalRevenuesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r182", "r184" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt", "verboseLabel": "Corporate debt" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail", "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization": { "auth_ref": [], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate cost of goods produced and sold during the reporting period, excluding depreciation, depletion, and amortization.", "label": "Cost of Goods Sold, Excluding Depreciation, Depletion, and Amortization", "terseLabel": "Cost of goods sold excluding amortization" } } }, "localname": "CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r63", "r82" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.", "label": "Cost of Sales, Policy [Policy Text Block]", "terseLabel": "Cost of Goods Sold" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r60" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CreditConcentrationRiskMember": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.", "label": "Credit Concentration Risk [Member]", "terseLabel": "Credit Concentration Risk" } } }, "localname": "CreditConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfAccountsReceivableNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r84", "r256", "r261" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal", "verboseLabel": "Income tax benefit associated with the loss before income taxes" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r87", "r258" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r84", "r256", "r261" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfTotalRevenuesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r145" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Summary of Available-for-Sale Marketable Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r84", "r257", "r261" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r84", "r257", "r261" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r251" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r76", "r84", "r257", "r261" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r12", "r13", "r247", "r313", "r323" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail": { "order": 2.0, "parentTag": "vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r84", "r257", "r261" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetDomain": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.", "label": "Deferred Tax Asset [Domain]", "terseLabel": "Deferred Tax Asset [Domain]" } } }, "localname": "DeferredTaxAssetDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r248" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail": { "order": 1.0, "parentTag": "vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Assets, Gross [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r251" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "terseLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r249" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "auth_ref": [ "r230", "r254", "r255" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r230", "r254", "r255" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local", "terseLabel": "Deferred tax assets relating to U.S. state NOL carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r253", "r254", "r255" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "Deferred tax assets related to U.S. federal research and development credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "auth_ref": [ "r230", "r254", "r255" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "terseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": { "auth_ref": [ "r231", "r254", "r255" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseOther", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r230", "r254", "r255" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "terseLabel": "Accrued and deferred expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "auth_ref": [ "r230", "r254", "r255" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts", "terseLabel": "Allowance for returns and uncollectable receivables" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r250" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "periodEndLabel": "Balance at End of Year", "periodStartLabel": "Balance at Beginning of Year", "terseLabel": "Less: Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail", "http://www.vandapharmaceuticals.com/role/IncomeTaxesValuationAllowanceActivityOnDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r236", "r251" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net deferred tax liabilities", "terseLabel": "Net deferred tax liability" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r231", "r254", "r255" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "negatedTerseLabel": "Intangible assets" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r231", "r254", "r255" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "negatedTerseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r185" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Defined contribution plan matching amount" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlanDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Defined contribution plan employer matching percent" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlanDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "terseLabel": "Defined contribution plan maximum employee contribution percent" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlanDetail" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r76", "r161" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense", "verboseLabel": "Depreciation of property and equipment" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r172", "r224" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "U.S. Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income (loss) per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r59", "r91", "r96", "r97", "r98", "r99", "r103", "r318", "r331" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Net income (loss) per share, basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations", "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail", "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Net income (loss) per share, basic and diluted:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r59", "r91", "r96", "r97", "r98", "r99", "r103", "r318", "r331" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Net income (loss) per share, diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations", "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail", "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r82", "r100", "r101", "r102" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r104" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r283" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r86", "r237", "r238" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r237", "r238", "r260" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal tax at statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r237", "r238", "r260" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Other change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r237", "r238", "r260" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail": { "order": 9.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "terseLabel": "Other tax rate changes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "auth_ref": [ "r237", "r238", "r260" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail": { "order": 12.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent", "terseLabel": "Other items" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r237", "r238", "r260" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Section 162(m) limitation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "auth_ref": [ "r237" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail": { "order": 11.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to excess tax benefit for share-based compensation cost.", "label": "Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Percent", "terseLabel": "Stock-based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r237", "r238", "r260" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State taxes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r237", "r238", "r260" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "negatedLabel": "Research and development credit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Compensation and employee benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation expenses, weighted average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r217" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options", "terseLabel": "Unrecognized compensation expenses related to unvested RSUs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r217" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized cost of unvested options awarded to employees as compensation.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "terseLabel": "Unrecognized compensation expenses" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EntityWideRevenueMajorCustomerLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Major Customer [Line Items]", "terseLabel": "Revenue, Major Customer [Line Items]" } } }, "localname": "EntityWideRevenueMajorCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfTotalRevenuesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r170" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r271", "r272", "r273", "r274", "r275", "r276" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r271", "r272", "r273" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Assets Measured at Fair Value on Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r182", "r183", "r184", "r273", "r304" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r182", "r183", "r184", "r273", "r305" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r182", "r183", "r184", "r273", "r306" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r182", "r183", "r184", "r273", "r307" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail", "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r157" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r159" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]", "terseLabel": "Summary of Amortization Expense" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r159" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r159" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r159" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r159" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r157", "r309" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount", "verboseLabel": "Intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r157" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net", "totalLabel": "Net Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)", "terseLabel": "Intangible assets capitalized" } } }, "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r82", "r282", "r286" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentPropertyAndEquipmentAtCostDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r62" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r85" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "verboseLabel": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r85" ], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r85" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations", "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r266" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r84", "r123", "r263" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision (benefit) for income taxes", "totalLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations", "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r82", "r234", "r235", "r245", "r246", "r252", "r265", "r341" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r233", "r237", "r238" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "negatedTerseLabel": "Reduction in valuation allowances" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r75" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r75" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r75" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r75" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r160" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r82", "r156" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r151" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/Inventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r22", "r150" ], "calculation": { "http://www.vandapharmaceuticals.com/role/InventoryDetail": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/InventoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r2", "r39", "r147" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheetsCalc2": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.vandapharmaceuticals.com/role/InventoryDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Total inventory, current" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets", "http://www.vandapharmaceuticals.com/role/InventoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Current assets" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/InventoryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.vandapharmaceuticals.com/role/InventoryDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Noncurrent", "totalLabel": "Total inventory, non-current" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/InventoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Noncurrent [Abstract]", "terseLabel": "Non-Current assets" } } }, "localname": "InventoryNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/InventoryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r8", "r40", "r82", "r105", "r148", "r149" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r23", "r150" ], "calculation": { "http://www.vandapharmaceuticals.com/role/InventoryDetail": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/InventoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "auth_ref": [ "r65" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.", "label": "Investment Income, Net, Amortization of Discount and Premium", "negatedLabel": "Amortization of discounts and premiums on marketable securities" } } }, "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r335", "r336", "r337", "r338" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r335", "r336", "r337", "r338" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r145", "r310", "r322", "r339" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/MarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "terseLabel": "Rent expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseArrangementTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement, Type [Axis]", "terseLabel": "Lease Arrangement, Type [Axis]" } } }, "localname": "LeaseArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseArrangementTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement, Type [Domain]", "terseLabel": "Lease Arrangement, Type [Domain]" } } }, "localname": "LeaseArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentPropertyAndEquipmentAtCostDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r169" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Legal Matters" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LegalMatters" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r294" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Lessee, Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r301" ], "calculation": { "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r301" ], "calculation": { "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: amount of lease payments representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Renewal term of lease agreement" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r303" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r32" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r21", "r314", "r327" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MajorCustomersPolicyPolicyTextBlock": { "auth_ref": [ "r112", "r114", "r115", "r128" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.", "label": "Major Customers, Policy [Policy Text Block]", "terseLabel": "Major Customers" } } }, "localname": "MajorCustomersPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r321" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r73" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r73" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r73", "r74", "r77" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r51", "r54", "r58", "r77", "r101", "r317", "r330" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations", "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail", "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r90", "r92", "r93" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Income (loss) from operations", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations", "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r296", "r302" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r292" ], "calculation": { "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total lease liabilities", "totalLabel": "Present value of future minimum lease payments" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsAndLiabilitiesDetails", "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r292" ], "calculation": { "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 }, "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedLabel": "Less: current obligations under leases", "terseLabel": "Operating lease current liabilities", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail", "http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsAndLiabilitiesDetails", "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r292" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease non-current liabilities", "verboseLabel": "Operating lease non-current liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets", "http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsAndLiabilitiesDetails", "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r293", "r298" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating lease, payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r291" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease assets", "verboseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets", "http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsAndLiabilitiesDetails", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r300", "r302" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r299", "r302" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r287", "r288" ], "calculation": { "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesUnderAsc840Details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r287", "r288" ], "calculation": { "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesUnderAsc840Details": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2019" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r287", "r288" ], "calculation": { "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesUnderAsc840Details": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r287", "r288" ], "calculation": { "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesUnderAsc840Details": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r287", "r288" ], "calculation": { "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesUnderAsc840Details": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r287", "r288" ], "calculation": { "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesUnderAsc840Details": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r287", "r288" ], "calculation": { "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesUnderAsc840Details": { "order": 6.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "verboseLabel": "Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r5", "r6", "r7", "r33" ], "calculation": { "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": { "auth_ref": [ "r44" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax, after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax", "terseLabel": "Change in net unrealized gain (loss) on marketable securities" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), before Tax [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "auth_ref": [ "r43", "r46", "r281", "r285" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax", "terseLabel": "Net foreign currency translation gain (loss)" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r52", "r55", "r57", "r170" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss), net of tax", "totalLabel": "Other comprehensive income (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r47", "r262", "r264" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "negatedLabel": "Tax provision on other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r332" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income", "terseLabel": "Other income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r77" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other non-cash adjustments, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Non-current Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r68", "r70", "r132" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r71" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Acquisition of intangible asset", "terseLabel": "Acquisition of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r71" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r191", "r218" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r14" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value; 20,000,000 shares authorized, and no shares issued or outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r3", "r24", "r25" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheetsCalc2": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesReconciliationCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r72" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Net proceeds from offering of common stock", "verboseLabel": "Net proceeds from public offering" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r68", "r69", "r132" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale", "terseLabel": "Maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r72", "r219" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of employee stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r29", "r164" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentPropertyAndEquipmentAtCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r166" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r28", "r162" ], "calculation": { "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentPropertyAndEquipmentAtCostDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentPropertyAndEquipmentAtCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentPropertyAndEquipmentAtCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r10", "r11", "r164", "r328" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentPropertyAndEquipmentAtCostDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets", "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentPropertyAndEquipmentAtCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r27", "r82", "r164" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r10", "r164" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of Property and Equipment-at Cost" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r10", "r162" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentPropertyAndEquipmentAtCostDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated Useful Life (Years)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentPropertyAndEquipmentAtCostDetail" ], "xbrltype": "durationItemType" }, "us-gaap_PurchaseObligationDueInNextTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount of purchase arrangement maturing in the next fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.", "label": "Purchase Obligation, Due in Next Twelve Months", "terseLabel": "2020" } } }, "localname": "PurchaseObligationDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInSecondYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount of purchase arrangement maturing in the second fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.", "label": "Purchase Obligation, Due in Second Year", "terseLabel": "2021" } } }, "localname": "PurchaseObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInThirdYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount of purchase arrangement maturing in the third fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.", "label": "Purchase Obligation, Due in Third Year", "terseLabel": "2022" } } }, "localname": "PurchaseObligationDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Purchase Obligation, Fiscal Year Maturity [Abstract]", "terseLabel": "Purchase commitments" } } }, "localname": "PurchaseObligationFiscalYearMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r107" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Quarterly Financial Data (Unaudited)" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r49", "r57" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "terseLabel": "Reclassifications out of accumulated other comprehensive income (loss)" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification Out of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r228", "r229" ], "lang": { "en-US": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r228", "r229" ], "lang": { "en-US": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r227", "r343" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r82", "r227" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r9", "r78", "r80", "r311", "r325" ], "calculation": { "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesReconciliationCashCashEquivalentsAndRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesReconciliationCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restricted Cash and Cash Equivalents [Abstract]", "terseLabel": "Restricted cash included in:" } } }, "localname": "RestrictedCashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesReconciliationCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSU)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r18", "r171", "r326" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r173", "r174", "r175" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net product sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r81", "r82", "r83" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.", "label": "Revenue Recognition, Policy [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r61", "r121", "r122", "r125" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenues", "totalLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations", "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Public offering of common stock (in dollars per shares)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue from sale of goods and services rendered, in the normal course of business, after sales returns and allowances, and sales discounts, when it serves as a benchmark in a concentration of risk calculation.", "label": "Sales Revenue, Net [Member]", "terseLabel": "Sales Revenue, Net" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfTotalRevenuesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Summary of Accounts Payable and Accrued Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r49" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r138", "r139", "r141", "r142", "r143", "r144", "r319", "r320" ], "lang": { "en-US": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.", "label": "Schedule of Cash and Cash Equivalents [Table]", "terseLabel": "Schedule of Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesReconciliationCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Summary of Provision (Benefit) for Income Taxes" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r251" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Components of Deferred Tax Assets, Net, and Related Valuation Allowance" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r101" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Basic and Diluted Net Income (Loss) Per Share of Common Stock" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Reconciliation Between Statutory Tax Rate and Effective Tax Rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r189", "r215", "r221" ], "lang": { "en-US": { "role": { "documentation": "Schedule that sets forth the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]", "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r189", "r215", "r221" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Net Product Sales" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": { "auth_ref": [ "r128" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.", "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]", "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]" } } }, "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfTotalRevenuesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r155", "r156" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r155", "r156" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Summary of Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r289" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of Lease Assets and Liabilities" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r85" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Summary of the Domestic and Foreign Components of Income (loss) Before Income Taxes" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r29", "r164" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentPropertyAndEquipmentAtCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r106" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Quarterly Financial Data" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.", "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]", "terseLabel": "Schedule of Major Customers that Represented More Than 10% of Total Revenues" } } }, "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r191", "r218" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r194" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]", "terseLabel": "Summary of RSU Activity for 2006 Plan and 2016 Plan" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r194", "r205", "r208" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Summary of Option Activity Plan" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Black-Scholes-Merton Option Pricing Model for Employee and Director Stock Options Granted" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r244", "r259" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Reconciliation of Gross Unrecognized Tax Benefits" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Summary of Future Intangible Asset Amortization" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r64", "r146" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r66" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "auth_ref": [ "r82", "r225" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.", "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "terseLabel": "Selling, General and Administrative Expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r75" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r204" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r202" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r202" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r201" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Shares Unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r201" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)", "terseLabel": "Grant date fair value of common stock vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r207" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Grant date fair value of common stock vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r214" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Weighted average risk-free rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "Weighted average expected volatility rate of share-based compensation awards.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "terseLabel": "Weighted average expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares of common stock available for future grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r207" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r200" ], "lang": { "en-US": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Options granted, weighted average fair value per share (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r218" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r196", "r218" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price at Grant Date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r208" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest at end of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest at end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest at end of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r188", "r192" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r82", "r191", "r193" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.", "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r211", "r220" ], "lang": { "en-US": { "role": { "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Weighted average expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r218" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest at end of period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r297", "r302" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r89" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r38", "r170" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r14", "r15", "r170", "r171" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Net proceeds from public offering of common stock (in shares)", "verboseLabel": "Public offering of common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r14", "r15", "r170", "r171" ], "lang": { "en-US": { "role": { "documentation": "Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.", "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures", "terseLabel": "Issuance of common stock from the exercise of stock options and settlement of restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r14", "r15", "r170", "r171", "r198" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r14", "r15", "r170", "r171" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Net proceeds from public offering of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r14", "r15", "r171", "r190", "r206" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.", "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures", "terseLabel": "Issuance of common stock from the exercise of stock options and settlement of restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r19", "r20", "r130" ], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets", "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.", "label": "Summary of Valuation Allowance [Table Text Block]", "terseLabel": "Summary of Changes in Tax Valuation Allowance" } } }, "localname": "SummaryOfValuationAllowanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r308" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail", "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.", "label": "Type of Arrangement and Non-arrangement Transactions [Axis]", "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r182", "r315" ], "lang": { "en-US": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "U.S. Treasury and government agencies" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail", "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r232", "r240" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized tax benefits at the end of the year", "periodStartLabel": "Unrecognized tax benefits at the beginning of the year" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfGrossUnrecognizedIncomeTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increases related to current year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfGrossUnrecognizedIncomeTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r241" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Increases related to prior year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfGrossUnrecognizedIncomeTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r243" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r108", "r109", "r110", "r111", "r117", "r118", "r119" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.", "label": "Valuation Allowance by Deferred Tax Asset [Axis]", "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]" } } }, "localname": "ValuationAllowanceByDeferredTaxAssetAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationAllowanceLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Valuation Allowance [Line Items]", "terseLabel": "Valuation Allowance [Line Items]" } } }, "localname": "ValuationAllowanceLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationAllowanceTable": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "A listing of an entity's valuation allowances to reduce deferred tax assets to amounts which it is more likely than not will not be realized, including a description of the deferred tax assets for which the valuation allowance has been recorded and the amount of the valuation allowance.", "label": "Valuation Allowance [Table]", "terseLabel": "Valuation Allowance [Table]" } } }, "localname": "ValuationAllowanceTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r88" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfProductReturnAllowanceDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r88" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "Additions" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfProductReturnAllowanceDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r88" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedLabel": "Credits/payments" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfProductReturnAllowanceDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfProductReturnAllowanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r88" ], "lang": { "en-US": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfProductReturnAllowanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r99" ], "calculation": { "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Effect of dilutive securities (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r95", "r99" ], "calculation": { "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations", "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r94", "r99" ], "calculation": { "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average shares outstanding, basic (shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations", "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail" ], "xbrltype": "sharesItemType" }, "vnda_AccountsPayableAndAccruedLiabilitiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accounts Payable and Accrued Liabilities [Policy Text Block]", "label": "Accounts Payable and Accrued Liabilities [Policy Text Block]", "terseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesPolicyTextBlock", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vnda_AccruedResearchAndDevelopmentExpense": { "auth_ref": [], "calculation": { "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for research and development expenses (due within one year or within the normal operating cycle if longer).", "label": "Accrued Research And Development Expense", "terseLabel": "Research and development expenses" } } }, "localname": "AccruedResearchAndDevelopmentExpense", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agreements For Clinical And Marketing Services, Termination Notice Period", "label": "Agreements For Clinical And Marketing Services, Termination Notice Period", "terseLabel": "Agreements for clinical and marketing services, termination notice period" } } }, "localname": "AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetail" ], "xbrltype": "durationItemType" }, "vnda_CftrActivatorsAndInhibitorsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CFTR activators and inhibitors [Abstract]", "label": "CFTR activators and inhibitors [Abstract]", "terseLabel": "CFTR activators and inhibitors" } } }, "localname": "CftrActivatorsAndInhibitorsAbstract", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vnda_CftrActivatorsAndInhibitorsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CFTR activators and inhibitors [Member]", "label": "CFTR activators and inhibitors [Member]", "terseLabel": "CFTR Activators and Inhibitors" } } }, "localname": "CftrActivatorsAndInhibitorsMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vnda_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments and Contingencies [Line Items]", "terseLabel": "Commitments and Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vnda_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments and Contingencies [Table]", "terseLabel": "Commitments and Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vnda_ComputerHardwareAndOtherEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Computer Hardware and Other Equipment [Member]", "label": "Computer Hardware and Other Equipment [Member]", "terseLabel": "Computer and other equipment" } } }, "localname": "ComputerHardwareAndOtherEquipmentMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentPropertyAndEquipmentAtCostDetail" ], "xbrltype": "domainItemType" }, "vnda_CumulativeNetSalesToAchieveMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net cumulative worldwide sales to achieve milestone and trigger payment of milestone obligation.", "label": "Cumulative Net Sales To Achieve Milestone", "terseLabel": "Cumulative worldwide sales milestone" } } }, "localname": "CumulativeNetSalesToAchieveMilestone", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vnda_CurrentInvestmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Current investments.", "label": "Current Investment [Member]", "terseLabel": "Current investments" } } }, "localname": "CurrentInvestmentMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" ], "xbrltype": "domainItemType" }, "vnda_CustomerFiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer 5 [Member]", "label": "Customer 5 [Member]", "terseLabel": "Distributor D" } } }, "localname": "CustomerFiveMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfAccountsReceivableNetDetail", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfTotalRevenuesDetail" ], "xbrltype": "domainItemType" }, "vnda_CustomerFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer 4 [Member]", "label": "Customer 4 [Member]", "terseLabel": "Distributor E" } } }, "localname": "CustomerFourMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfAccountsReceivableNetDetail", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfTotalRevenuesDetail" ], "xbrltype": "domainItemType" }, "vnda_CustomerOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer 1 [Member]", "label": "Customer 1 [Member]", "terseLabel": "Distributor A" } } }, "localname": "CustomerOneMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfAccountsReceivableNetDetail", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfTotalRevenuesDetail" ], "xbrltype": "domainItemType" }, "vnda_CustomerSixMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer 6 [Member]", "label": "Customer 6 [Member]", "terseLabel": "Distributor F" } } }, "localname": "CustomerSixMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfTotalRevenuesDetail" ], "xbrltype": "domainItemType" }, "vnda_CustomerThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer 3 [Member]", "label": "Customer 3 [Member]", "terseLabel": "Distributor C" } } }, "localname": "CustomerThreeMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfAccountsReceivableNetDetail", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfTotalRevenuesDetail" ], "xbrltype": "domainItemType" }, "vnda_CustomerTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer 2 [Member]", "label": "Customer 2 [Member]", "terseLabel": "Distributor B" } } }, "localname": "CustomerTwoMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfAccountsReceivableNetDetail", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfTotalRevenuesDetail" ], "xbrltype": "domainItemType" }, "vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet": { "auth_ref": [], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Assets Liabilities Before Valuation Allowance Net", "totalLabel": "Deferred tax assets, net" } } }, "localname": "DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail" ], "xbrltype": "monetaryItemType" }, "vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther": { "auth_ref": [], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit and other tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research and Other", "terseLabel": "Research and development and orphan drug credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail" ], "xbrltype": "monetaryItemType" }, "vnda_DeferredTaxAssetsValuationAllowanceDecrease": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in the period related to valuation allowance for deferred tax assets.", "label": "Deferred Tax Assets Valuation Allowance, Decrease", "negatedLabel": "Reductions" } } }, "localname": "DeferredTaxAssetsValuationAllowanceDecrease", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesValuationAllowanceActivityOnDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "vnda_DeferredTaxAssetsValuationAllowanceIncrease": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in the period related to valuation allowance for deferred tax assets.", "label": "Deferred Tax Assets Valuation Allowance, Increase", "terseLabel": "Additions" } } }, "localname": "DeferredTaxAssetsValuationAllowanceIncrease", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesValuationAllowanceActivityOnDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "vnda_DefinedContributionPlanVestingPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period which an employee's right to employer matching contribution to defined contribution plan is no longer contingent on satisfaction of a service condition.", "label": "Defined Contribution Plan Vesting Period", "terseLabel": "Defined contribution plan vesting period" } } }, "localname": "DefinedContributionPlanVestingPeriod", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlanDetail" ], "xbrltype": "durationItemType" }, "vnda_DescriptionOfBusinessPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of Business", "label": "Description of Business [Policy Text Block]", "terseLabel": "Business organization" } } }, "localname": "DescriptionOfBusinessPolicyTextBlock", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Development And Milestone Obligations Paid To Third Party", "label": "Development And Milestone Obligations Paid To Third Party", "terseLabel": "Development and milestone payments to third party" } } }, "localname": "DevelopmentAndMilestoneObligationsPaidToThirdParty", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Development And Milestone Payment, Conclusion Of Phase I Study [Member]", "label": "Development And Milestone Payment, Conclusion Of Phase I Study [Member]", "terseLabel": "Development And Milestone Payment, Conclusion Of Phase I Study" } } }, "localname": "DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total amount potentially due to third party under license agreement based on achievement of pre-new drug application approval milestones.", "label": "Development And Milestone Payments Potentially Due To Third Party", "terseLabel": "Possible future milestone payment", "verboseLabel": "Possible future milestone payments" } } }, "localname": "DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment": { "auth_ref": [], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail": { "order": 10.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Effective Tax Rate Adjustment", "label": "Effective Income Tax Rate Reconciliation, Effective Tax Rate Adjustment", "terseLabel": "Other changes in state deferred taxes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "percentItemType" }, "vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug": { "auth_ref": [], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation Tax Credits Orphan Drug", "label": "Effective Income Tax Rate Reconciliation Tax Credits Orphan Drug", "terseLabel": "Orphan drug credit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "percentItemType" }, "vnda_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobActOf2017ChangeInValuationAllowance": { "auth_ref": [], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation Tax Cuts And Job Act Of 2017 Change In Valuation Allowance", "label": "Effective Income Tax Rate Reconciliation Tax Cuts And Job Act Of 2017 Change In Valuation Allowance", "terseLabel": "Change in valuation allowance - U.S. Tax Cuts and Jobs Act" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobActOf2017ChangeInValuationAllowance", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "percentItemType" }, "vnda_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobActRate": { "auth_ref": [], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Effective income tax rate reconciliation, tax cuts and job act rate.", "label": "Effective Income Tax Rate Reconciliation, Tax Cuts And Job Act Rate", "terseLabel": "U.S. Tax Cuts and Job Act" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobActRate", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "percentItemType" }, "vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent": { "auth_ref": [], "calculation": { "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail": { "order": 13.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Uncertain Tax Positions, Percent", "label": "Effective Income Tax Rate Reconciliation, Uncertain Tax Positions, Percent", "terseLabel": "Uncertain tax positions" } } }, "localname": "EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "percentItemType" }, "vnda_EstimatedRealizabilityofDeferredTaxAssetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Estimated Realizability of Deferred Tax Asset [Member]", "label": "Estimated Realizability of Deferred Tax Asset [Member]", "terseLabel": "Estimated Realizability of Deferred Tax Asset" } } }, "localname": "EstimatedRealizabilityofDeferredTaxAssetMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "domainItemType" }, "vnda_FanaptAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fanapt [Abstract]", "label": "Fanapt [Abstract]", "terseLabel": "Fanapt" } } }, "localname": "FanaptAbstract", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vnda_FanaptMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fanapt.", "label": "Fanapt [Member]", "verboseLabel": "Fanapt\u00ae" } } }, "localname": "FanaptMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" ], "xbrltype": "domainItemType" }, "vnda_FiniteLivedIntangibleAssetsUsefulFutureLifeEndMonthAndYear": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The month and year that finite lived intangible assets are expected to be amortized through.", "label": "Finite Lived Intangible Assets Useful Future Life End Month and Year", "terseLabel": "Intangible assets, estimated future useful life" } } }, "localname": "FiniteLivedIntangibleAssetsUsefulFutureLifeEndMonthAndYear", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail" ], "xbrltype": "gYearMonthItemType" }, "vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Future Percentage Of Royalty Payments Based On Net Sales.", "label": "Future Percentage Of Royalty Payments Based On Net Sales", "terseLabel": "Future percentage of royalty payments based net sales" } } }, "localname": "FuturePercentageOfRoyaltyPaymentsBasedOnNetSales", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vnda_FutureRegulatoryApprovalAndSalesMilestonesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Future Regulatory Approval And Sales Milestones [Member]", "label": "Future Regulatory Approval And Sales Milestones [Member]", "terseLabel": "Future Regulatory Approval And Sales Milestones" } } }, "localname": "FutureRegulatoryApprovalAndSalesMilestonesMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vnda_HetliozAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Hetlioz [Abstract]", "label": "Hetlioz [Abstract]", "terseLabel": "HETLIOZ" } } }, "localname": "HetliozAbstract", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vnda_HetliozMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Hetlioz [Member]", "label": "Hetlioz [Member]", "verboseLabel": "HETLIOZ\u00ae" } } }, "localname": "HetliozMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" ], "xbrltype": "domainItemType" }, "vnda_IncomeBeforeIncomeTaxesCurrentYearMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Income Before Income Taxes, Current Year [Member]", "label": "Income Before Income Taxes, Current Year [Member]", "terseLabel": "Income Before Income Taxes, Current Year" } } }, "localname": "IncomeBeforeIncomeTaxesCurrentYearMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "domainItemType" }, "vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Income Tax Credit Carryforwards and Uncertain Tax Positions [Member]", "label": "Income Tax Credit Carryforwards and Uncertain Tax Positions [Member]", "terseLabel": "Income Tax Credit Carryforwards and Uncertain Tax Positions" } } }, "localname": "IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail" ], "xbrltype": "domainItemType" }, "vnda_IncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Income Taxes [Line Items]", "label": "Income Taxes [Line Items]", "terseLabel": "Income Taxes [Line Items]" } } }, "localname": "IncomeTaxesLineItems", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vnda_IncomeTaxesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Income Taxes [Table]", "label": "Income Taxes [Table]", "terseLabel": "Income Taxes [Table]" } } }, "localname": "IncomeTaxesTable", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vnda_IncreaseDecreaseProductRevenueAllowances": { "auth_ref": [], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of obligations and expenses incurred but not paid for product revenue allowances.", "label": "Increase (Decrease) Product Revenue Allowances", "terseLabel": "Product revenue allowances" } } }, "localname": "IncreaseDecreaseProductRevenueAllowances", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vnda_InventoryAndOtherNonCurrent": { "auth_ref": [], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle and other non current assets.", "label": "Inventory and Other Non Current", "terseLabel": "Non-current inventory and other" } } }, "localname": "InventoryAndOtherNonCurrent", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "vnda_InventoryFinishedGoodsNetOfReservesNonCurrent": { "auth_ref": [], "calculation": { "http://www.vandapharmaceuticals.com/role/InventoryDetail": { "order": 3.0, "parentTag": "us-gaap_InventoryNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Finished goods inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Finished Goods, Net of Reserves, Non Current", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReservesNonCurrent", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/InventoryDetail" ], "xbrltype": "monetaryItemType" }, "vnda_InventoryRawMaterialsNetOfReservesNonCurrent": { "auth_ref": [], "calculation": { "http://www.vandapharmaceuticals.com/role/InventoryDetail": { "order": 1.0, "parentTag": "us-gaap_InventoryNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Raw materials inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Raw Materials, Net of Reserves, Non Current", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReservesNonCurrent", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/InventoryDetail" ], "xbrltype": "monetaryItemType" }, "vnda_InventoryWorkInProcessNetOfReservesNonCurrent": { "auth_ref": [], "calculation": { "http://www.vandapharmaceuticals.com/role/InventoryDetail": { "order": 2.0, "parentTag": "us-gaap_InventoryNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Work in process inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Work in Process, Net of Reserves, Non Current", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReservesNonCurrent", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/InventoryDetail" ], "xbrltype": "monetaryItemType" }, "vnda_LondonLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "London Lease [Member]", "label": "London Lease [Member]", "terseLabel": "London Lease" } } }, "localname": "LondonLeaseMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vnda_MilestoneObligationUnderLicenseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet for accrued current liability relating to an obligation to make a probable future milestone payment that would become due and payable when cumulative sales of a product reaches a certain agreed upon sales threshold.", "label": "Milestone Obligation Under License Agreement", "terseLabel": "Milestone obligation under license agreement" } } }, "localname": "MilestoneObligationUnderLicenseAgreement", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vnda_MilestoneObligationUnderLicenseAgreementCurrent": { "auth_ref": [], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date for accrued current liability relating to obligations to make a probable future milestone payments that would become due and payable when the related milestones are achieved.", "label": "Milestone Obligation Under License Agreement Current", "terseLabel": "Milestone obligation under license agreement", "verboseLabel": "Milestone obligations under license agreements" } } }, "localname": "MilestoneObligationUnderLicenseAgreementCurrent", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vnda_NoncurrentInventoryAndOtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Noncurrent Inventory and Other [Member]", "label": "Noncurrent Inventory and Other [Member]", "terseLabel": "Non-current inventory and other" } } }, "localname": "NoncurrentInventoryAndOtherMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesReconciliationCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "domainItemType" }, "vnda_NoncurrentInvestmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Noncurrent Investments [Member]", "label": "Noncurrent Investments [Member]", "terseLabel": "Noncurrent investments" } } }, "localname": "NoncurrentInvestmentsMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" ], "xbrltype": "domainItemType" }, "vnda_NumberOfProductsInPortfolio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Products In Portfolio", "label": "Number Of Products In Portfolio", "terseLabel": "Number of products in portfolio" } } }, "localname": "NumberOfProductsInPortfolio", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentationDetail" ], "xbrltype": "integerItemType" }, "vnda_OperatingLeaseNonLeaseComponentExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating Lease, Non-Lease Component Expense", "label": "Operating Lease, Non-Lease Component Expense", "terseLabel": "Non-lease component expense" } } }, "localname": "OperatingLeaseNonLeaseComponentExpense", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vnda_OperatingLossCarryforwardsBeginningExpirationYear": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The year in which operating loss carryforwards begin to expire.", "label": "Operating Loss Carryforwards, Beginning Expiration Year", "terseLabel": "Net operating loss carryforwards beginning expiration year" } } }, "localname": "OperatingLossCarryforwardsBeginningExpirationYear", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "vnda_OrphanDrugCreditBeginningExpirationYear": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Orphan Drug Credit , Beginning Expiration Year", "label": "Orphan Drug Credit , Beginning Expiration Year", "terseLabel": "Orphan drug credit beginning expiration year" } } }, "localname": "OrphanDrugCreditBeginningExpirationYear", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "vnda_OrphanDrugMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Orphan Drug [Member]", "label": "Orphan Drug [Member]", "terseLabel": "Orphan Drug" } } }, "localname": "OrphanDrugMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vnda_PercentageOfFutureSublicenseFeesPayable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of sublicense fees payable to third party under a contractual arrangement for use of technology or intellectual property.", "label": "Percentage Of Future Sublicense Fees Payable", "terseLabel": "Percentage of future sublicense fees payable to third-party" } } }, "localname": "PercentageOfFutureSublicenseFeesPayable", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vnda_PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the percentage of responsibility for patient's cost of branded prescription taken by the manufacturers under Medicare Part D.", "label": "Percentage of Responsibility for Patients Cost of Branded Prescription under Medicare Part D", "terseLabel": "Percentage of insurance coverage gap allocated for prescription drugs under Medicare Part D" } } }, "localname": "PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "vnda_PreNDAApprovalMilestonesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pre-NDA Approval Milestones [Member]", "label": "Pre-NDA Approval Milestones [Member]", "terseLabel": "Pre-NDA Approval Milestones" } } }, "localname": "PreNDAApprovalMilestonesMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vnda_ProductRevenueAllowancesCurrent": { "auth_ref": [], "calculation": { "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Product Revenue Allowances, Current", "label": "Product Revenue Allowances, Current", "terseLabel": "Product revenue allowances" } } }, "localname": "ProductRevenueAllowancesCurrent", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "vnda_PublicOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Public Offering [Member]", "label": "Public Offering [Member]", "terseLabel": "Public Offering" } } }, "localname": "PublicOfferingMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "vnda_PublicOfferingOfCommonStockTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Public Offering Of Common Stock [Text Block]", "label": "Public Offering Of Common Stock [Text Block]", "terseLabel": "Public Offering of Common Stock" } } }, "localname": "PublicOfferingOfCommonStockTextBlock", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStock" ], "xbrltype": "textBlockItemType" }, "vnda_RegulatoryApprovalMilestoneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Regulatory Approval Milestone [Member]", "label": "Regulatory Approval Milestone [Member]", "terseLabel": "Regulatory Approval Milestone" } } }, "localname": "RegulatoryApprovalMilestoneMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vnda_ResearchAndDevelopmentCreditBeginningExpirationYear": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Research and Development, Credit Beginning, Expiration Year", "label": "Research and Development, Credit Beginning, Expiration Year", "terseLabel": "U.S. research and development credit beginning expiration year" } } }, "localname": "ResearchAndDevelopmentCreditBeginningExpirationYear", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "vnda_ReservesForVariableConsiderationPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reserves for variable consideration policy.", "label": "Reserves for Variable Consideration [Policy Text Block]", "terseLabel": "Reserves for Variable Consideration" } } }, "localname": "ReservesForVariableConsiderationPolicyTextBlock", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vnda_RoyaltyPayableOnNetSalesPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Royalty payable percentage under a contractual arrangement for use of technology or intellectual property.", "label": "Royalty Payable On Net Sales Percentage", "terseLabel": "Royalty payable percentage on net sales" } } }, "localname": "RoyaltyPayableOnNetSalesPercentage", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "vnda_RoyaltyPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Royalty Period", "label": "Royalty Period", "terseLabel": "Royalty payment period" } } }, "localname": "RoyaltyPeriod", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "vnda_SECSchedule1209AllowanceProductReturnsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "SEC Schedule, 12-09, Allowance, Product Returns [Member]", "label": "SEC Schedule, 12-09, Allowance, Product Returns [Member]", "terseLabel": "Reserve for Product Returns" } } }, "localname": "SECSchedule1209AllowanceProductReturnsMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfProductReturnAllowanceDetail" ], "xbrltype": "domainItemType" }, "vnda_SalesMilestoneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales Milestone [Member]", "label": "Sales Milestone [Member]", "terseLabel": "Sales Milestone" } } }, "localname": "SalesMilestoneMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vnda_ScenarioFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Scenario 4 [Member]", "label": "Scenario 4 [Member]", "terseLabel": "November 16,2016 through December 31,2019" } } }, "localname": "ScenarioFourMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vnda_ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Accounts Receivable By Major Customers By Reporting Segments [Table Text Block]", "label": "Schedule Of Accounts Receivable By Major Customers By Reporting Segments [Table Text Block]", "terseLabel": "Schedule of Major Customers that Represented More Than 10% of Accounts Receivable, Net" } } }, "localname": "ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "vnda_ScheduleOfInventoriesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of inventories.", "label": "Schedule Of Inventories [Table Text Block]", "terseLabel": "Inventory" } } }, "localname": "ScheduleOfInventoriesTableTextBlock", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Lease Assets And Liabilities [Table Text Block]", "label": "Schedule Of Lease Assets And Liabilities [Table Text Block]", "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases" } } }, "localname": "ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]", "label": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]", "terseLabel": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" ], "xbrltype": "stringItemType" }, "vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table]", "label": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table]", "terseLabel": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" ], "xbrltype": "stringItemType" }, "vnda_ServiceOptionAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Service Option Awards [Member]", "label": "Service Option Awards [Member]", "terseLabel": "Service option awards" } } }, "localname": "ServiceOptionAwardsMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based Compensation Arrangement by Share based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value [Abstract]", "label": "Share based Compensation Arrangement by Share based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Price/Share Unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" ], "xbrltype": "stringItemType" }, "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "stringItemType" }, "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including vested and non-vested options, as of the balance sheet, plus the number of non-vested restricted stock units outstanding as of the balance sheet date.", "label": "Share Based Compensation Arrangement by Share Based Payment Award Options and Restricted Stock Units (RSUs) Outstanding Number", "terseLabel": "Shares subject to outstanding options and RSUs (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]", "terseLabel": "Weighted Average Remaining Term (Years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "stringItemType" }, "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of new hire stock option award that vests after one year of service.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Share Subject To Option Awards", "terseLabel": "Portion of initial stock options granted to employees that vests on employee's first anniversary" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of new hire stock option award that vests monthly after one year of service.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Remaining Percentage Of Share Subject To Option Awards", "terseLabel": "Portion of initial stock options granted to employees that vests ratably over three years after completion of first year of service" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period which an employee and new director's right to exercise an annual option award is no longer contingent on satisfaction of either a service, market or a performance condition.", "label": "Share Based Compensation Arrangement by Share Based Payment Annual Award Vesting Period Employees and New Directors", "terseLabel": "Vesting period for subsequent stock options granted to directors" } } }, "localname": "ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "vnda_ShareBasedCompensationOptionAwardsContractualTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contractual term of stock option awards.", "label": "Share Based Compensation Option Awards Contractual Term", "terseLabel": "Share based compensation option awards contractual term" } } }, "localname": "ShareBasedCompensationOptionAwardsContractualTerm", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-Based Payment Award, Options, Vesting Period, Number Of Equal Monthly Installments", "label": "Share-based Compensation Arrangement by Share-Based Payment Award, Options, Vesting Period, Number Of Equal Monthly Installments", "terseLabel": "Number of vesting equal installments" } } }, "localname": "SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "vnda_StatementScenarioSecondaryAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statement, Scenario Secondary [Axis]", "label": "Statement, Scenario Secondary [Axis]", "terseLabel": "Statement, Scenario Secondary [Axis]" } } }, "localname": "StatementScenarioSecondaryAxis", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vnda_StatementScenarioSecondaryDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statement, Scenario Secondary [Domain]", "label": "Statement, Scenario Secondary [Domain]", "terseLabel": "Statement, Scenario Secondary [Domain]" } } }, "localname": "StatementScenarioSecondaryDomain", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vnda_StockOptionsAndRestrictedStockUnitsRSUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Options and Restricted Stock Units (RSUs) [Member]", "label": "Stock Options and Restricted Stock Units (RSUs) [Member]", "terseLabel": "Outstanding options and RSUs granted (RSUs)" } } }, "localname": "StockOptionsAndRestrictedStockUnitsRSUsMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vnda_SubleaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sublease [Member]", "label": "Sublease [Member]", "terseLabel": "Sublease" } } }, "localname": "SubleaseMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vnda_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summary Of Significant Accounting Policies [Line Items]", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vnda_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vnda_TieredRoyaltiesPayableOnFutureNetSales": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tiered royalties potentially due to third party under license agreement based on future net sales.", "label": "Tiered Royalties Payable on Future Net Sales", "terseLabel": "Tiered royalties payable on future net sales" } } }, "localname": "TieredRoyaltiesPayableOnFutureNetSales", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vnda_TradipitantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tradipitant [Member]", "label": "Tradipitant [Member]", "terseLabel": "Tradipitant" } } }, "localname": "TradipitantMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Thousand Six Plan and Two Thousand Sixteen Plan [Member]", "label": "Two Thousand Six Plan and Two Thousand Sixteen Plan [Member]", "terseLabel": "2006 Plan and 2016 Plan" } } }, "localname": "TwoThousandSixPlanAndTwoThousandSixteenPlanMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" ], "xbrltype": "domainItemType" }, "vnda_TwoThousandSixteenPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Thousand Sixteen Plan [Member]", "label": "Two Thousand Sixteen Plan [Member]", "terseLabel": "2016 Plan" } } }, "localname": "TwoThousandSixteenPlanMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vnda_WashingtonDcLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Washington DC Lease [Member]", "label": "Washington DC Lease [Member]", "terseLabel": "Washington DC Leases and Sublease" } } }, "localname": "WashingtonDcLeaseMember", "nsuri": "http://www.vandapharmaceuticals.com/20191231", "presentation": [ "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e543-108305" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=109225645&loc=d3e1280-108306" }, "r107": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "305", "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26626-111562" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27232-111563" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27340-111563" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r151": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=84159346&loc=d3e8275-108329" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68054294&loc=d3e8384-108330" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r166": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r167": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r169": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r172": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/subtopic&trid=2208855" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r181": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=SL37586934-109318" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32123-109318" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238393&loc=d3e36027-109320" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e39076-109324" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r266": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258" }, "r277": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=82918529&loc=d3e30304-110892" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32022-110900" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32211-110900" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=113997351&loc=SL77916155-209984" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r303": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62652-112803" }, "r322": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(2)(i))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r339": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r344": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r345": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r346": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r347": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r348": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r349": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r351": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r352": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r353": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(d))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e640-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" } }, "version": "2.1" } XML 49 R78.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Additional Information (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Taxes [Line Items]      
Provision (benefit) for income taxes $ (86,525) $ 138 $ 136
Domestic 28,794 25,123 (15,693)
Foreign 234 223 262
Income tax benefit associated with the loss before income taxes 0 0 $ 0
Net deferred tax liability   15  
Net operating loss carryforwards 52,034 55,742  
Deferred tax assets related to U.S. federal research and development credits $ 12,000    
Net operating loss carryforwards beginning expiration year 2031    
U.S. research and development credit beginning expiration year 2024    
Orphan drug credit beginning expiration year 2030    
Deferred tax assets relating to U.S. state NOL carryforwards $ 8,700    
Unrecognized tax benefits that would impact effective tax rate 9,700    
U.S. Federal      
Income Taxes [Line Items]      
Net operating loss carryforwards 43,300    
Orphan Drug      
Income Taxes [Line Items]      
Net deferred tax assets $ 24,000    
District of Columbia      
Income Taxes [Line Items]      
Net operating loss carryforwards beginning expiration year 2031    
Other Non-current Liabilities | Maximum      
Income Taxes [Line Items]      
Net deferred tax liability   $ 100  
XML 50 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 45,072 $ 61,005
Marketable securities 267,057 196,355
Accounts receivable, net 26,367 28,780
Inventory 1,140 994
Prepaid expenses and other current assets 14,500 11,998
Total current assets 354,136 299,132
Property and equipment, net 3,864 4,417
Operating lease right-of-use assets 11,180 0
Intangible assets, net 23,037 24,542
Deferred tax assets 87,680 0
Non-current inventory and other 3,851 4,039
Total assets 483,748 332,130
Current liabilities:    
Accounts payable and accrued liabilities 27,590 21,584
Product revenue allowances 31,915 31,231
Milestone obligations under license agreements 0 200
Total current liabilities 59,505 53,015
Operating lease non-current liabilities 12,455 0
Other non-current liabilities 843 3,693
Total liabilities 72,803 56,708
Commitments and contingencies (Notes 10 and 17)
Stockholders’ equity:    
Preferred stock, $0.001 par value; 20,000,000 shares authorized, and no shares issued or outstanding 0 0
Common stock, $0.001 par value; 150,000,000 shares authorized; 53,549,612 and 52,477,593 shares issued and outstanding at December 31, 2019 and 2018, respectively 54 52
Additional paid-in capital 631,307 611,587
Accumulated other comprehensive income 249 1
Accumulated deficit (220,665) (336,218)
Total stockholders’ equity 410,945 275,422
Total liabilities and stockholders’ equity $ 483,748 $ 332,130
XML 51 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Summary of Significant Accounting Policies - Summary of Product Return Allowance (Detail) - Reserve for Product Returns - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]      
Beginning balance $ 5,187 $ 4,119 $ 3,080
Additions 3,138 2,684 5,978
Credits/payments (2,205) (1,616) (4,939)
Ending balance $ 6,120 $ 5,187 $ 4,119
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Summary of Significant Accounting Policies - Reconciliation Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Cash and Cash Equivalents [Line Items]        
Cash and cash equivalents $ 45,072 $ 61,005    
Restricted cash included in:        
Total cash, cash equivalents and restricted cash 45,650 61,749 $ 34,335 $ 41,256
Prepaid expenses and other current assets        
Restricted cash included in:        
Restricted Cash and Cash Equivalents 0 157    
Non-current inventory and other        
Restricted cash included in:        
Restricted Cash and Cash Equivalents $ 578 $ 587    
XML 53 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2016   44,000,614      
Beginning balance at Dec. 31, 2016 $ 131,330 $ 44 $ 477,087 $ 58 $ (345,859)
Issuance of common stock from the exercise of stock options and settlement of restricted stock units 5,251 $ 1 5,250    
Issuance of common stock from the exercise of stock options and settlement of restricted stock units (in shares)   937,519      
Stock-based compensation expense 10,465   10,465    
Net income (loss) (15,567)       (15,567)
Other comprehensive income (loss), net of tax (92)     (92)  
Ending balance (in shares) at Dec. 31, 2017   44,938,133      
Ending balance at Dec. 31, 2017 131,387 $ 45 492,802 (34) (361,426)
Net proceeds from public offering of common stock 100,870 $ 6 100,864    
Net proceeds from public offering of common stock (in shares)   6,325,000      
Issuance of common stock from the exercise of stock options and settlement of restricted stock units 6,256 $ 1 6,255    
Issuance of common stock from the exercise of stock options and settlement of restricted stock units (in shares)   1,214,460      
Stock-based compensation expense 11,666   11,666    
Net income (loss) 25,208       25,208
Other comprehensive income (loss), net of tax $ 35     35  
Ending balance (in shares) at Dec. 31, 2018 52,477,593 52,477,593      
Ending balance at Dec. 31, 2018 $ 275,422 $ 52 611,587 1 (336,218)
Issuance of common stock from the exercise of stock options and settlement of restricted stock units 6,264 $ 2 6,262    
Issuance of common stock from the exercise of stock options and settlement of restricted stock units (in shares)   1,072,019      
Stock-based compensation expense 13,458   13,458    
Net income (loss) 115,553       115,553
Other comprehensive income (loss), net of tax $ 248     248  
Ending balance (in shares) at Dec. 31, 2019 53,549,612 53,549,612      
Ending balance at Dec. 31, 2019 $ 410,945 $ 54 $ 631,307 $ 249 $ (220,665)
XML 54 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 R69.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accumulated Other Comprehensive Income - Additional Information (Detail) - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Reclassification Out of Accumulated Other Comprehensive Income (Loss)      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Reclassifications out of accumulated other comprehensive income (loss) $ 0 $ 0 $ 0
XML 56 R61.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accounts Payable and Accrued Liabilities (Detail) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Payables and Accruals [Abstract]    
Compensation and employee benefits $ 6,597 $ 6,363
Royalties payable 5,904 5,172
Research and development expenses 5,893 5,593
Consulting and other professional fees 5,376 2,924
Operating lease liabilities 2,147 0
Other 1,673 1,532
Total accounts payable and accrued liabilities $ 27,590 $ 21,584
XML 57 R65.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments and Contingencies - CFTR Activators and Inhibitors - Additional Information (Detail) - CFTR Activators and Inhibitors - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Mar. 31, 2019
Dec. 31, 2019
Dec. 31, 2017
CFTR activators and inhibitors      
Tiered royalties payable on future net sales   single-digit  
Development and milestone payments to third party   $ 1,200  
Regulatory Approval Milestone      
CFTR activators and inhibitors      
Possible future milestone payments   12,200  
Future Regulatory Approval And Sales Milestones      
CFTR activators and inhibitors      
Possible future milestone payments   33,000  
Development And Milestone Payment, Conclusion Of Phase I Study      
CFTR activators and inhibitors      
Possible future milestone payments   350  
Development and milestone payments to third party $ 200   $ 1,000
Maximum | Development And Milestone Payment, Conclusion Of Phase I Study      
CFTR activators and inhibitors      
Possible future milestone payments   $ 1,100  
ZIP 59 0001347178-20-000003-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001347178-20-000003-xbrl.zip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�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htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings per Share
 12 Months Ended
Dec. 31, 2019
Earnings Per Share [Abstract]  
Earnings per Share Earnings per Share
Basic earnings per share (EPS) is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding. Diluted EPS is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding, plus potential outstanding common stock for the period. Potential outstanding common stock includes stock options and shares underlying RSUs, but only to the extent that their inclusion is dilutive.
The following table presents the calculation of basic and diluted net income (loss) per share of common stock for the years ended December 31, 2019, 2018 and 2017:
 
Year Ended December 31,
(in thousands, except for share and per share amounts)
2019
 
2018
 
2017
Numerator:
 
 
 
 
 
Net income (loss)
$
115,553

 
$
25,208

 
$
(15,567
)
Denominator:
 
 
 
 
 
Weighted average shares outstanding, basic
53,137,562

 
50,859,947

 
44,735,146

Effect of dilutive securities
1,709,498

 
2,185,310

 
—

Weighted average shares outstanding, diluted
54,847,060

 
53,045,257

 
44,735,146

Net income (loss) per share, basic and diluted:
 
 
 
 
 
Basic
$
2.17

 
$
0.50

 
$
(0.35
)
Diluted
$
2.11

 
$
0.48

 
$
(0.35
)
Antidilutive securities excluded from calculations of diluted net income (loss) per share
1,932,024

 
903,265

 
3,136,515


The Company incurred a net loss for the year ended December 31, 2017 causing inclusion of any potentially dilutive securities to have an anti-dilutive effect, resulting in dilutive loss per share and basic loss per share attributable to common stockholders being equivalent.

XML 61 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Reconciliation of Cash, Cash Equivalents and Restricted Cash
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets to the total end of period cash, cash equivalents and restricted cash reported within the Consolidated Statement of Cash Flows:
 
December 31,
(in thousands)
2019
 
2018
Cash and cash equivalents
$
45,072

 
$
61,005

Restricted cash included in:
 
 
 
Prepaid expenses and other current assets
—

 
157

Non-current inventory and other
578

 
587

Total cash, cash equivalents and restricted cash
$
45,650

 
$
61,749
Net Product Sales
The Company’s net product sales consist of sales of HETLIOZ® and Fanapt®. Net sales by product for the years ended December 31, 2019, 2018 and 2017 were as follows:
 
Year Ended December 31,
(in thousands)
2019
 
2018
 
2017
HETLIOZ® product sales, net
$
142,980

 
$
115,835

 
$
89,978

Fanapt® product sales, net
84,208

 
77,283

 
75,105

Total net product sales
$
227,188


$
193,118


$
165,083
Schedule of Major Customers that Represented More Than 10% of Total Revenues
The following table presents each major customer that represented more than 10% of total revenues for the years ended December 31, 2019, 2018 and 2017:
 
Year Ended December 31,
Percent of Net Product Sales
2019
 
2018
 
2017
Distributor A
38
%
 
37
%
 
32
%
Distributor B
23
%
 
17
%
 
10
%
Distributor C
12
%
 
14
%
 
15
%
Distributor D
12
%
 
12
%
 
15
%
Distributor E
11
%
 
12
%
 
12
%
Distributor F
—
%
 
5
%
 
11
%
Schedule of Major Customers that Represented More Than 10% of Accounts Receivable, Net
The following table presents each major customer that represented more than 10% of accounts receivable, net, as of December 31, 2019 and 2018:
 
December 31,
Percent of Accounts Receivable, Net
2019
 
2018
Distributor A
21
%
 
30
%
Distributor B
21
%
 
15
%
Distributor C
18
%
 
20
%
Distributor D
16
%
 
13
%
Distributor E
18
%
 
16
%
Summary of Product Return Allowance The following table summarizes activity for product returns as of and for the years ended December 31, 2019, 2018 and 2017, all of which relates to sales of Fanapt®:
 
(in thousands)
Reserve for Product Returns
Balances at December 31, 2016
$
3,080

Additions
5,978

Credits/payments
(4,939
)
Balances at December 31, 2017
4,119

Additions
2,684

Credits/payments
(1,616
)
Balances at December 31, 2018
5,187

Additions
3,138

Credits/payments
(2,205
)
Balances at December 31, 2019
$
6,120
XML 62 R38.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings per Share (Tables)
 12 Months Ended
Dec. 31, 2019
Earnings Per Share [Abstract]  
Basic and Diluted Net Income (Loss) Per Share of Common Stock
The following table presents the calculation of basic and diluted net income (loss) per share of common stock for the years ended December 31, 2019, 2018 and 2017:
 
Year Ended December 31,
(in thousands, except for share and per share amounts)
2019
 
2018
 
2017
Numerator:
 
 
 
 
 
Net income (loss)
$
115,553

 
$
25,208

 
$
(15,567
)
Denominator:
 
 
 
 
 
Weighted average shares outstanding, basic
53,137,562

 
50,859,947

 
44,735,146

Effect of dilutive securities
1,709,498

 
2,185,310

 
—

Weighted average shares outstanding, diluted
54,847,060

 
53,045,257

 
44,735,146

Net income (loss) per share, basic and diluted:
 
 
 
 
 
Basic
$
2.17

 
$
0.50

 
$
(0.35
)
Diluted
$
2.11

 
$
0.48

 
$
(0.35
)
Antidilutive securities excluded from calculations of diluted net income (loss) per share
1,932,024

 
903,265

 
3,136,515
XML 63 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accounts Payable and Accrued Liabilities (Tables)
 12 Months Ended
Dec. 31, 2019
Payables and Accruals [Abstract]  
Summary of Accounts Payable and Accrued Liabilities
The following is a summary of the Company’s accounts payable and accrued liabilities as of December 31, 2019 and 2018:
(in thousands)
December 31,
2019
 
December 31,
2018
Compensation and employee benefits
$
6,597

 
$
6,363

Royalties payable
5,904

 
5,172

Research and development expenses
5,893

 
5,593

Consulting and other professional fees
5,376

 
2,924

Operating lease liabilities
2,147

 
—

Other
1,673

 
1,532

Total accounts payable and accrued liabilities
$
27,590

 
$
21,584
XML 64 R30.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Inventory (Tables)
 12 Months Ended
Dec. 31, 2019
Inventory Disclosure [Abstract]  
Inventory Inventory consisted of the following as of December 31, 2019 and 2018:
(in thousands)
December 31,
2019
 
December 31,
2018
Current assets
 
 
 
Work-in-process
$
—

 
$
48

Finished goods
1,140

 
946

Total inventory, current
$
1,140

 
$
994

Non-Current assets
 
 
 
Raw materials
$
659

 
$
86

Work-in-process
1,109

 
2,290

Finished goods
1,056

 
516

Total inventory, non-current
$
2,824

 
$
2,892
XML 65 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Property and Equipment
 12 Months Ended
Dec. 31, 2019
Property, Plant and Equipment [Abstract]  
Property and Equipment Property and Equipment
The following is a summary of the Company’s property and equipment, at cost, as of December 31, 2019 and 2018:
(in thousands)
Estimated
Useful Life
(Years)
 
December 31, 2019
 
December 31, 2018
Computer and other equipment
3
 
$
4,398

 
$
3,642

Furniture and fixtures
5 - 7
 
1,491

 
1,488

Leasehold improvements
5 - 11
 
4,587

 
4,506

Total property and equipment, gross
 
 
10,476

 
9,636

Accumulated depreciation and amortization
 
(6,612
)
 
(5,219
)
Total property and equipment, net
 
 
$
3,864

 
$
4,417


Depreciation expense was $1.4 million, $1.4 million and $1.2 million for the years ended December 31, 2019, 2018 and 2017, respectively.
XML 66 R17.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Guarantees and Indemnifications
The Company has entered into a number of standard intellectual property indemnification agreements in the ordinary course of its business. Pursuant to these agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company’s business partners or customers, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to the Company’s products. The term of these indemnification agreements is generally perpetual from the date of execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. Since inception, the Company has not incurred costs to defend
lawsuits or settle claims related to these indemnification agreements. The Company also indemnifies its officers and directors for certain events or occurrences, subject to certain conditions.
License Agreements
The Company’s rights to develop and commercialize its products are subject to the terms and conditions of licenses granted to the Company by other pharmaceutical companies.
HETLIOZ®. In February 2004, the Company entered into a license agreement with BMS under which it received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize HETLIOZ®. To date, the Company has paid BMS $37.5 million in upfront fees and milestone obligations, including $33.0 million of regulatory approval and commercial milestones capitalized as intangible assets (see Note 8). The Company has no remaining milestone obligations to BMS. Additionally, the Company is obligated to make royalty payments on HETLIOZ® net sales to BMS in any territory where the Company commercializes HETLIOZ® for a period equal to the greater of 10 years following the first commercial sale in the territory or the expiry of the new chemical entity (NCE) patent in that territory. During the period prior to the expiry of the NCE patent in a territory, the Company is obligated to pay a 10% royalty on net sales in that territory. The royalty rate is decreased by half for countries in which no NCE patent existed or for the remainder of the 10 years after the expiry of the NCE patent. The Company is also obligated under the license agreement to pay BMS a percentage of any sublicense fees, upfront payments and milestone and other payments (excluding royalties) that it receives from a third party in connection with any sublicensing arrangement, at a rate which is in the mid-twenties. The Company has agreed with BMS in the license agreement for HETLIOZ® to use its commercially reasonable efforts to develop and commercialize HETLIOZ®.
Fanapt®. Pursuant to the terms of a settlement agreement with Novartis, Novartis transferred all U.S. and Canadian rights in the Fanapt® franchise to the Company on December 31, 2014. The Company paid directly to Sanofi S.A. (Sanofi) a fixed royalty of 3% of net sales from November 16, 2016 through December 31, 2019 related to manufacturing know-how. The Company is also obligated to pay Sanofi a fixed royalty on Fanapt® net sales equal to 6% on Sanofi know-how not related to manufacturing under certain conditions for a period of up to 10 years in markets where the NCE patent has expired or was not issued. The Company is obligated to pay this 6% royalty on net sales in the U.S. through November 2026.
Tradipitant. In April 2012, the Company entered into a license agreement with Eli Lilly and Company (Lilly) pursuant to which the Company acquired an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize an NK-1R antagonist, tradipitant, for all human indications. Lilly is eligible to receive future payments based upon achievement of specified development, regulatory approval and commercialization milestones as well as tiered-royalties on net sales at percentage rates up to the low double digits. To date, the Company has paid Lilly $3.0 million in upfront fees and development milestones, including a $2.0 million milestone payment in July 2018 as a result of enrolling the first subject into a Phase III study for tradipitant. As of December 31, 2019, remaining milestone obligations include a $2.0 million development milestone due upon the filing of the first marketing authorization for tradipitant either in the U.S. or European Union (E.U.), $10.0 million and $5.0 million for the first approval of a marketing authorization for tradipitant in the U.S. and E.U., respectively, and up to $80 million for sales milestones. The Company is obligated to use its commercially reasonable efforts to develop and commercialize tradipitant.
VQW-765. In connection with a settlement agreement with Novartis relating to Fanapt®, the Company received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. Pursuant to the license agreement, the Company is obligated to use its commercially reasonable efforts to develop and commercialize VQW-765 and is responsible for all development costs. The Company has no milestone obligations; however, Novartis is eligible to receive tiered-royalties on net sales at percentage rates up to the mid-teens.
Portfolio of CFTR activators and inhibitors. In March 2017, the Company entered into a license agreement with the University of California San Francisco (UCSF), under which the Company acquired an exclusive worldwide license to develop and commercialize a portfolio of CFTR activators and inhibitors. Pursuant to the license agreement, the Company will develop and commercialize the CFTR activators and inhibitors and is responsible for all development costs under the license agreement, including current pre-investigational new drug development work. UCSF is eligible to receive future payments based upon achievement of specified development and commercialization milestones as well as single-digit royalties on net sales. To date, the Company has paid UCSF $1.2 million in upfront fees and development milestones, including an upfront license fee payment of $1.0 million in 2017 and a $0.2 million development milestone payment in the March 2019. As of December 31, 2019, remaining milestone obligations include $12.2 million for development milestones and $33.0 million for future
regulatory approval and sales milestones. Included in the $12.2 million in development milestones is a $350,000 milestone due upon the conclusion of a Phase I study for each licensed product but not to exceed $1.1 million in total for the CFTR portfolio.
Purchase Commitments
In the course of its business, the Company regularly enters into agreements with clinical organizations to provide services relating to clinical development and clinical manufacturing activities under fee service arrangements. The Company’s current agreements for clinical and marketing services may be terminated on generally 90 days’ notice without incurring additional charges, other than charges for work completed but not paid for through the effective date of termination and other costs incurred by the Company’s contractors in closing out work in progress as of the effective date of termination. Noncancellable long-term contractual cash obligations include noncancellable purchase commitments longer than one year and primarily relate to commitments for media and data services, of which $9.2 million, $1.0 million and $0.5 million are expected to be paid in 2020, 2021 and 2022, respectively.
XML 67 R86.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Quarterly Financial Data (Unaudited) (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]                      
Revenues $ 60,930 $ 59,485 $ 59,060 $ 47,713 $ 53,041 $ 49,135 $ 47,350 $ 43,592 $ 227,188 $ 193,118 $ 165,083
Gross profit 54,335 52,327 52,313 42,220 46,994 43,670 41,739 38,680      
Income (loss) from operations 4,243 10,759 9,895 (2,087) 9,150 6,233 3,913 2,442 22,810 21,738 (16,903)
Net income (loss) $ 4,216 $ 100,423 $ 11,526 $ (612) $ 10,360 $ 7,171 $ 4,611 $ 3,066 $ 115,553 $ 25,208 $ (15,567)
Net income (loss) per share, basic (in dollars per share) $ 0.08 $ 1.88 $ 0.22 $ (0.01) $ 0.20 $ 0.14 $ 0.09 $ 0.07 $ 2.17 $ 0.50 $ (0.35)
Net income (loss) per share, diluted (in dollars per share) $ 0.08 $ 1.84 $ 0.21 $ (0.01) $ 0.19 $ 0.13 $ 0.09 $ 0.06 $ 2.11 $ 0.48 $ (0.35)
XML 68 R76.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock-Based Compensation - Black-Scholes-Merton Option Pricing Model for Stock Options Granted (Detail)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]      
Expected dividend yield 0.00% 0.00% 0.00%
Weighted average expected volatility 58.00% 58.00% 57.00%
Weighted average expected term (years) 5 years 11 months 12 days 5 years 10 months 24 days 5 years 10 months 20 days
Weighted average risk-free rate 2.26% 2.68% 1.97%
XML 69 R72.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock-Based Compensation - RSU - Additional Information (Detail)
$ in Millions
 12 Months Ended
Dec. 31, 2019
USD ($)
installment
shares
Dec. 31, 2018
shares
Dec. 31, 2017
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of vesting equal installments | installment 36    
Restricted Stock Units (RSU)      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of vesting equal installments | installment 4    
Unrecognized compensation expenses related to unvested RSUs | $ $ 22.8    
Unrecognized compensation expenses, weighted average period 1 year 9 months 18 days    
Grant date fair value of common stock vested (in shares) | shares 526,175 528,745 362,313
Grant date fair value of common stock vested | $ $ 7.7    
XML 70 R82.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Components of Deferred Tax Assets, Net and Related Valuation Allowance (Detail) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Deferred tax assets:        
Net operating loss carryforwards $ 52,034 $ 55,742    
Stock-based compensation 5,298 5,202    
Accrued and deferred expenses 2,101 2,096    
Allowance for returns and uncollectable receivables 1,468 1,247    
Research and development and orphan drug credit carryforwards 36,041 48,066    
Other 1,301 1,405    
Total deferred tax assets 98,243 113,758    
Deferred tax liabilities:        
Intangible assets (1,994) (1,247)    
Other (414) (576)    
Total deferred tax liabilities (2,408) (1,823)    
Deferred tax assets, net 95,835 111,935    
Less: Valuation allowance 8,155 111,950 $ 116,110 $ 146,012
Net deferred tax assets $ 87,680      
Net deferred tax liabilities   $ (15)    
XML 71 R51.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Property and Equipment - Additional Information (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Property, Plant and Equipment [Abstract]      
Depreciation expense $ 1,387 $ 1,429 $ 1,234
XML 72 R55.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Maturities under ASC 840 (Details)
$ in Thousands
Dec. 31, 2018
USD ($)
Leases [Abstract]  
Total $ 22,757
2019 2,483
2020 2,495
2021 2,335
2022 2,355
2023 2,420
Thereafter $ 10,669
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets - Summary of Amortization Expense (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]      
Intangible asset amortization $ 1,505 $ 1,527 $ 1,750
HETLIOZ®      
Finite-Lived Intangible Assets [Line Items]      
Intangible asset amortization $ 1,505 $ 1,527 $ 1,750
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments and Contingencies - Fanapt - Additional Information (Detail)
 12 Months Ended 38 Months Ended
Dec. 31, 2019
Dec. 31, 2019
November 16,2016 through December 31,2019    
Fanapt    
Royalty payable percentage on net sales   3.00%
Fanapt®    
Fanapt    
Royalty payable percentage on net sales 6.00%  
Royalty payment period 10 years  
XML 75 R67.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Public Offering of Common Stock (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Subsidiary, Sale of Stock [Line Items]        
Net proceeds from public offering   $ 0 $ 100,870 $ 0
Public Offering        
Subsidiary, Sale of Stock [Line Items]        
Public offering of common stock (in shares) 6,325,000      
Public offering of common stock (in dollars per shares) $ 17.00      
Net proceeds from public offering $ 100,900      
Over-Allotment Option        
Subsidiary, Sale of Stock [Line Items]        
Public offering of common stock (in shares) 825,000      
XML 76 R48.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Detail) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value $ 274,027 $ 196,355
U.S. Treasury and government agencies    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 88,601 69,270
Corporate debt    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 137,025 105,910
Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 48,401 21,175
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 88,601 69,270
Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. Treasury and government agencies    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 88,601 69,270
Quoted Prices in Active Markets for Identical Assets (Level 1) | Corporate debt    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 0 0
Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 185,426 127,085
Significant Other Observable Inputs (Level 2) | U.S. Treasury and government agencies    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 0 0
Significant Other Observable Inputs (Level 2) | Corporate debt    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 137,025 105,910
Significant Other Observable Inputs (Level 2) | Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 48,401 21,175
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 0 0
Significant Unobservable Inputs (Level 3) | U.S. Treasury and government agencies    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 0 0
Significant Unobservable Inputs (Level 3) | Corporate debt    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 0 0
Significant Unobservable Inputs (Level 3) | Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 0 $ 0
Cash Equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value $ 7,000  
XML 77 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Business Organization and Presentation
 12 Months Ended
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Business Organization and Presentation Business Organization and Presentation
Business organization
Vanda Pharmaceuticals Inc. (the Company) is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. The Company commenced its operations in 2003 and operates in one reporting segment.
The Company's commercial portfolio is currently comprised of two products, HETLIOZ® for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and Fanapt® for the treatment of schizophrenia. HETLIOZ® is the first treatment for Non-24 approved by the U.S. Food and Drug Administration (FDA). In addition, the Company has a number of drugs in development, including:
 
•
HETLIOZ® (tasimelteon) for the treatment of jet lag disorder, Smith-Magenis Syndrome (SMS), pediatric Non-24 and delayed sleep phase disorder (DSPD);
 
•
Fanapt® (iloperidone) for the treatment of bipolar disorder and a long acting injectable (LAI) formulation program for the treatment of schizophrenia;
 
•
Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis and motion sickness;
 
•
VTR-297, a small molecule histone deacetylase (HDAC) inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications;
 
•
VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist, with potential use for the treatment of psychiatric disorders; and
 
•
Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors for the treatment of dry eye and ocular inflammation and for the treatment of secretory diarrhea disorders, including cholera.

Basis of Presentation
The accompanying consolidated financial statements includes the accounts of Vanda Pharmaceuticals Inc. and its wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.). All intercompany accounts and transactions have been eliminated in consolidation.
XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 205 432 1 false 64 0 false 8 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.vandapharmaceuticals.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.vandapharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1003000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 5 false false R6.htm 1004000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Sheet http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.vandapharmaceuticals.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 2101100 - Disclosure - Business Organization and Presentation Sheet http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentation Business Organization and Presentation Notes 8 false false R9.htm 2101100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2103100 - Disclosure - Marketable Securities Sheet http://www.vandapharmaceuticals.com/role/MarketableSecurities Marketable Securities Notes 10 false false R11.htm 2104100 - Disclosure - Fair Value Measurements Sheet http://www.vandapharmaceuticals.com/role/FairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 2111100 - Disclosure - Inventory Sheet http://www.vandapharmaceuticals.com/role/Inventory Inventory Notes 12 false false R13.htm 2113100 - Disclosure - Property and Equipment Sheet http://www.vandapharmaceuticals.com/role/PropertyAndEquipment Property and Equipment Notes 13 false false R14.htm 2114100 - Disclosure - Leases Sheet http://www.vandapharmaceuticals.com/role/Leases Leases Notes 14 false false R15.htm 2116100 - Disclosure - Intangible Assets Sheet http://www.vandapharmaceuticals.com/role/IntangibleAssets Intangible Assets Notes 15 false false R16.htm 2118100 - Disclosure - Accounts Payable and Accrued Liabilities Sheet http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilities Accounts Payable and Accrued Liabilities Notes 16 false false R17.htm 2119100 - Disclosure - Commitments and Contingencies Sheet http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 2124100 - Disclosure - Public Offering of Common Stock Sheet http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStock Public Offering of Common Stock Notes 18 false false R19.htm 2126100 - Disclosure - Accumulated Other Comprehensive Income Sheet http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome Accumulated Other Comprehensive Income Notes 19 false false R20.htm 2131100 - Disclosure - Stock-Based Compensation Sheet http://www.vandapharmaceuticals.com/role/StockBasedCompensation Stock-Based Compensation Notes 20 false false R21.htm 2133100 - Disclosure - Employee Benefit Plan Sheet http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlan Employee Benefit Plan Notes 21 false false R22.htm 2139100 - Disclosure - Income Taxes Sheet http://www.vandapharmaceuticals.com/role/IncomeTaxes Income Taxes Notes 22 false false R23.htm 2140100 - Disclosure - Earnings per Share Sheet http://www.vandapharmaceuticals.com/role/EarningsPerShare Earnings per Share Notes 23 false false R24.htm 2141100 - Disclosure - Legal Matters Sheet http://www.vandapharmaceuticals.com/role/LegalMatters Legal Matters Notes 24 false false R25.htm 2142100 - Disclosure - Quarterly Financial Data (Unaudited) Sheet http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnaudited Quarterly Financial Data (Unaudited) Notes 25 false false R26.htm 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies 26 false false R27.htm 2301302 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies 27 false false R28.htm 2303301 - Disclosure - Marketable Securities (Tables) Sheet http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.vandapharmaceuticals.com/role/MarketableSecurities 28 false false R29.htm 2304301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.vandapharmaceuticals.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.vandapharmaceuticals.com/role/FairValueMeasurements 29 false false R30.htm 2311301 - Disclosure - Inventory (Tables) Sheet http://www.vandapharmaceuticals.com/role/InventoryTables Inventory (Tables) Tables http://www.vandapharmaceuticals.com/role/Inventory 30 false false R31.htm 2313301 - Disclosure - Property and Equipment (Tables) Sheet http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.vandapharmaceuticals.com/role/PropertyAndEquipment 31 false false R32.htm 2314301 - Disclosure - Leases (Tables) Sheet http://www.vandapharmaceuticals.com/role/LeasesTables Leases (Tables) Tables http://www.vandapharmaceuticals.com/role/Leases 32 false false R33.htm 2316301 - Disclosure - Intangible Assets (Tables) Sheet http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://www.vandapharmaceuticals.com/role/IntangibleAssets 33 false false R34.htm 2318301 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) Sheet http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesTables Accounts Payable and Accrued Liabilities (Tables) Tables http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilities 34 false false R35.htm 2326301 - Disclosure - Accumulated Other Comprehensive Income (Tables) Sheet http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables Accumulated Other Comprehensive Income (Tables) Tables http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome 35 false false R36.htm 2331301 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.vandapharmaceuticals.com/role/StockBasedCompensation 36 false false R37.htm 2339301 - Disclosure - Income Taxes (Tables) Sheet http://www.vandapharmaceuticals.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.vandapharmaceuticals.com/role/IncomeTaxes 37 false false R38.htm 2340301 - Disclosure - Earnings per Share (Tables) Sheet http://www.vandapharmaceuticals.com/role/EarningsPerShareTables Earnings per Share (Tables) Tables http://www.vandapharmaceuticals.com/role/EarningsPerShare 38 false false R39.htm 2342301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables) Sheet http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedTables Quarterly Financial Data (Unaudited) (Tables) Tables http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnaudited 39 false false R40.htm 2401401 - Disclosure - Business Organization and Presentation (Detail) Sheet http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentationDetail Business Organization and Presentation (Detail) Details http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentation 40 false false R41.htm 2401403 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 41 false false R42.htm 2401404 - Disclosure - Summary of Significant Accounting Policies - Reconciliation Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesReconciliationCashCashEquivalentsAndRestrictedCashDetails Summary of Significant Accounting Policies - Reconciliation Cash, Cash Equivalents and Restricted Cash (Details) Details 42 false false R43.htm 2401405 - Disclosure - Summary of Significant Accounting Policies - Net Sales by Product (Detail) Sheet http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail Summary of Significant Accounting Policies - Net Sales by Product (Detail) Details 43 false false R44.htm 2401406 - Disclosure - Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Total Revenues (Detail) Sheet http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfTotalRevenuesDetail Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Total Revenues (Detail) Details 44 false false R45.htm 2401407 - Disclosure - Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Accounts Receivable, Net (Detail) Sheet http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfMajorCustomersThatRepresentedMoreThan10OfAccountsReceivableNetDetail Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Accounts Receivable, Net (Detail) Details 45 false false R46.htm 2401408 - Disclosure - Summary of Significant Accounting Policies - Summary of Product Return Allowance (Detail) Sheet http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfProductReturnAllowanceDetail Summary of Significant Accounting Policies - Summary of Product Return Allowance (Detail) Details 46 false false R47.htm 2403402 - Disclosure - Marketable Securities - Available-For-Sale Marketable Securities (Detail) Sheet http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail Marketable Securities - Available-For-Sale Marketable Securities (Detail) Details 47 false false R48.htm 2404402 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Detail) Sheet http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Detail) Details 48 false false R49.htm 2411402 - Disclosure - Inventory (Detail) Sheet http://www.vandapharmaceuticals.com/role/InventoryDetail Inventory (Detail) Details http://www.vandapharmaceuticals.com/role/InventoryTables 49 false false R50.htm 2413402 - Disclosure - Property and Equipment - Property and Equipment-at Cost (Detail) Sheet http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentPropertyAndEquipmentAtCostDetail Property and Equipment - Property and Equipment-at Cost (Detail) Details 50 false false R51.htm 2413403 - Disclosure - Property and Equipment - Additional Information (Detail) Sheet http://www.vandapharmaceuticals.com/role/PropertyAndEquipmentAdditionalInformationDetail Property and Equipment - Additional Information (Detail) Details 51 false false R52.htm 2414402 - Disclosure - Leases - Additional Information (Details) Sheet http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 52 false false R53.htm 2414403 - Disclosure - Leases - Lease Assets and Liabilities (Details) Sheet http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsAndLiabilitiesDetails Leases - Lease Assets and Liabilities (Details) Details 53 false false R54.htm 2414404 - Disclosure - Leases - Maturities (Details) Sheet http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails Leases - Maturities (Details) Details 54 false false R55.htm 2414405 - Disclosure - Leases - Maturities under ASC 840 (Details) Sheet http://www.vandapharmaceuticals.com/role/LeasesMaturitiesUnderAsc840Details Leases - Maturities under ASC 840 (Details) Details 55 false false R56.htm 2416402 - Disclosure - Intangible Assets - HETLIOZ - Additional Information (Detail) Sheet http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail Intangible Assets - HETLIOZ - Additional Information (Detail) Details 56 false false R57.htm 2416403 - Disclosure - Intangible Assets - Fanapt - Additional Information (Detail) Sheet http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail Intangible Assets - Fanapt - Additional Information (Detail) Details 57 false false R58.htm 2416404 - Disclosure - Intangible Assets - Summary of Intangible Assets (Detail) Sheet http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail Intangible Assets - Summary of Intangible Assets (Detail) Details 58 false false R59.htm 2416405 - Disclosure - Intangible Assets - Summary of Amortization Expense (Detail) Sheet http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfAmortizationExpenseDetail Intangible Assets - Summary of Amortization Expense (Detail) Details 59 false false R60.htm 2416406 - Disclosure - Intangible Assets - Summary of Future Intangible Asset Amortization (Detail) Sheet http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail Intangible Assets - Summary of Future Intangible Asset Amortization (Detail) Details 60 false false R61.htm 2418402 - Disclosure - Accounts Payable and Accrued Liabilities (Detail) Sheet http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail Accounts Payable and Accrued Liabilities (Detail) Details http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesTables 61 false false R62.htm 2419401 - Disclosure - Commitments and Contingencies - HETLIOZ - Additional Information (Detail) Sheet http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail Commitments and Contingencies - HETLIOZ - Additional Information (Detail) Details 62 false false R63.htm 2419402 - Disclosure - Commitments and Contingencies - Fanapt - Additional Information (Detail) Sheet http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail Commitments and Contingencies - Fanapt - Additional Information (Detail) Details 63 false false R64.htm 2419403 - Disclosure - Commitments and Contingencies - Tradipitant - Additional Information (Detail) Sheet http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail Commitments and Contingencies - Tradipitant - Additional Information (Detail) Details 64 false false R65.htm 2419404 - Disclosure - Commitments and Contingencies - CFTR Activators and Inhibitors - Additional Information (Detail) Sheet http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail Commitments and Contingencies - CFTR Activators and Inhibitors - Additional Information (Detail) Details 65 false false R66.htm 2419405 - Disclosure - Commitments and Contingencies - Purchase Commitments (Detail) Sheet http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetail Commitments and Contingencies - Purchase Commitments (Detail) Details 66 false false R67.htm 2424401 - Disclosure - Public Offering of Common Stock (Details) Sheet http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStockDetails Public Offering of Common Stock (Details) Details http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStock 67 false false R68.htm 2426402 - Disclosure - Accumulated Other Comprehensive Income - Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss) (Detail) Sheet http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail Accumulated Other Comprehensive Income - Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss) (Detail) Details 68 false false R69.htm 2426403 - Disclosure - Accumulated Other Comprehensive Income - Additional Information (Detail) Sheet http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail Accumulated Other Comprehensive Income - Additional Information (Detail) Details 69 false false R70.htm 2431402 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail Stock-Based Compensation - Additional Information (Detail) Details 70 false false R71.htm 2431403 - Disclosure - Stock-Based Compensation - Stock Option - Additional Information (Detail) Sheet http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail Stock-Based Compensation - Stock Option - Additional Information (Detail) Details 71 false false R72.htm 2431404 - Disclosure - Stock-Based Compensation - RSU - Additional Information (Detail) Sheet http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail Stock-Based Compensation - RSU - Additional Information (Detail) Details 72 false false R73.htm 2431405 - Disclosure - Stock-Based Compensation - Summary of Option Activity for 2006 Plan and the 2016 Plan (Detail) Sheet http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail Stock-Based Compensation - Summary of Option Activity for 2006 Plan and the 2016 Plan (Detail) Details 73 false false R74.htm 2431406 - Disclosure - Stock-Based Compensation - Summary of RSU Activity Plan (Detail) Sheet http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail Stock-Based Compensation - Summary of RSU Activity Plan (Detail) Details 74 false false R75.htm 2431407 - Disclosure - Stock-Based Compensation - Total Stock-Based Compensation Expense (Detail) Sheet http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail Stock-Based Compensation - Total Stock-Based Compensation Expense (Detail) Details 75 false false R76.htm 2431408 - Disclosure - Stock-Based Compensation - Black-Scholes-Merton Option Pricing Model for Stock Options Granted (Detail) Sheet http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail Stock-Based Compensation - Black-Scholes-Merton Option Pricing Model for Stock Options Granted (Detail) Details 76 false false R77.htm 2433401 - Disclosure - Employee Benefit Plan (Detail) Sheet http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlanDetail Employee Benefit Plan (Detail) Details http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlan 77 false false R78.htm 2439402 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 78 false false R79.htm 2439403 - Disclosure - Income Taxes - Summary of Domestic and Foreign Components of Income (loss) Before Income Taxes (Details) Sheet http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails Income Taxes - Summary of Domestic and Foreign Components of Income (loss) Before Income Taxes (Details) Details 79 false false R80.htm 2439404 - Disclosure - Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail) Sheet http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail) Details 80 false false R81.htm 2439405 - Disclosure - Income Taxes - Reconciliation Between Statutory Tax Rate and Effective Tax Rate (Detail) Sheet http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateAndEffectiveTaxRateDetail Income Taxes - Reconciliation Between Statutory Tax Rate and Effective Tax Rate (Detail) Details 81 false false R82.htm 2439406 - Disclosure - Income Taxes - Components of Deferred Tax Assets, Net and Related Valuation Allowance (Detail) Sheet http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsNetAndRelatedValuationAllowanceDetail Income Taxes - Components of Deferred Tax Assets, Net and Related Valuation Allowance (Detail) Details 82 false false R83.htm 2439407 - Disclosure - Income Taxes - Valuation Allowance Activity on Deferred Tax Assets (Detail) Sheet http://www.vandapharmaceuticals.com/role/IncomeTaxesValuationAllowanceActivityOnDeferredTaxAssetsDetail Income Taxes - Valuation Allowance Activity on Deferred Tax Assets (Detail) Details 83 false false R84.htm 2439408 - Disclosure - Income Taxes - Summary of Gross Unrecognized Income Tax Benefits (Details) Sheet http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryOfGrossUnrecognizedIncomeTaxBenefitsDetails Income Taxes - Summary of Gross Unrecognized Income Tax Benefits (Details) Details 84 false false R85.htm 2440402 - Disclosure - Earnings per Share (Detail) Sheet http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail Earnings per Share (Detail) Details http://www.vandapharmaceuticals.com/role/EarningsPerShareTables 85 false false R86.htm 2442402 - Disclosure - Quarterly Financial Data (Unaudited) (Detail) Sheet http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail Quarterly Financial Data (Unaudited) (Detail) Details http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedTables 86 false false All Reports Book All Reports vnda1231201910k.htm vnda-20191231.xsd vnda-20191231_cal.xml vnda-20191231_def.xml vnda-20191231_lab.xml vnda-20191231_pre.xml vnda12312019ex231.htm vnda12312019ex311.htm vnda12312019ex312.htm vnda12312019ex321.htm fanapt.gif hetlioz.gif partiiitem5chart.jpg researchanddevelopment.jpg http://xbrl.sec.gov/dei/2019-01-31 http://xbrl.sec.gov/stpr/2018-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/us-gaap/2018-01-31 true true XML 79 R44.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Total Revenues (Detail) - Customer Concentration Risk - Sales Revenue, Net
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Distributor A      
Revenue, Major Customer [Line Items]      
Concentration risk, percentage 38.00% 37.00% 32.00%
Distributor B      
Revenue, Major Customer [Line Items]      
Concentration risk, percentage 23.00% 17.00% 10.00%
Distributor C      
Revenue, Major Customer [Line Items]      
Concentration risk, percentage 12.00% 14.00% 15.00%
Distributor D      
Revenue, Major Customer [Line Items]      
Concentration risk, percentage 12.00% 12.00% 15.00%
Distributor E      
Revenue, Major Customer [Line Items]      
Concentration risk, percentage 11.00% 12.00% 12.00%
Distributor F      
Revenue, Major Customer [Line Items]      
Concentration risk, percentage 0.00% 5.00% 11.00%
XML 80 R40.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Business Organization and Presentation (Detail)
 12 Months Ended
Dec. 31, 2019
product
Segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of operating segments | Segment 1
Number of products in portfolio | product 2
XML 81 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Revenues:      
Net product sales $ 227,188 $ 193,118 $ 165,083
Total revenues 227,188 193,118 165,083
Operating expenses:      
Cost of goods sold excluding amortization 24,488 20,508 17,848
Research and development 48,649 43,594 38,547
Selling, general and administrative 129,736 105,751 123,841
Intangible asset amortization 1,505 1,527 1,750
Total operating expenses 204,378 171,380 181,986
Income (loss) from operations 22,810 21,738 (16,903)
Other income 6,218 3,608 1,472
Income (loss) before income taxes 29,028 25,346 (15,431)
Provision (benefit) for income taxes (86,525) 138 136
Net income (loss) $ 115,553 $ 25,208 $ (15,567)
Net income (loss) per share:      
Basic (in dollars per share) $ 2.17 $ 0.50 $ (0.35)
Diluted (in dollars per share) $ 2.11 $ 0.48 $ (0.35)
Weighted average shares outstanding:      
Basic (in shares) 53,137,562 50,859,947 44,735,146
Diluted (in shares) 54,847,060 53,045,257 44,735,146
XML 82 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Employee Benefit Plan
 12 Months Ended
Dec. 31, 2019
Retirement Benefits [Abstract]  
Employee Benefit Plan Employee Benefit Plan
The Company has a defined contribution plan under IRC Section 401(k). This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Currently, the Company matches fifty percent up to the first six percent of employee contributions. All matching
contributions have been paid by the Company. The Company match vests over a 4-year period and amounted to $0.8 million, $0.9 million and $0.8 million for the years ended December 31, 2019, 2018 and 2017, respectively.
XML 83 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 84 R25.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Quarterly Financial Data (Unaudited)
 12 Months Ended
Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Financial Data (Unaudited) Quarterly Financial Data (Unaudited)
The following is a summary of quarterly financial data for the years ended December 31, 2019 and 2018:
(in thousands, except for per share amounts)
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
Year Ended December 31, 2019
 
 
 
 
 
 
 
Revenues
$
47,713

 
$
59,060

 
$
59,485

 
$
60,930

Gross profit (1)
42,220

 
52,313

 
52,327

 
54,335

Income (loss) from operations
(2,087
)
 
9,895

 
10,759

 
4,243

Net income (loss)
(612
)
 
11,526

 
100,423

 
4,216

Net income (loss) per share, basic
$
(0.01
)
 
$
0.22

 
$
1.88

 
$
0.08

Net income (loss) per share, diluted
$
(0.01
)
 
$
0.21

 
$
1.84

 
$
0.08

Year Ended December 31, 2018
 
 
 
 
 
 
 
Revenues
$
43,592

 
$
47,350

 
$
49,135

 
$
53,041

Gross profit (1)
38,680

 
41,739

 
43,670

 
46,994

Income from operations
2,442

 
3,913

 
6,233

 
9,150

Net income
3,066

 
4,611

 
7,171

 
10,360

Net income per share, basic
$
0.07

 
$
0.09

 
$
0.14

 
$
0.20

Net income per share, diluted
$
0.06

 
$
0.09

 
$
0.13

 
$
0.19

 
(1)
Gross profit includes revenues less cost of goods sold, excluding amortization, and less intangible asset amortization.
XML 85 R29.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Assets Measured at Fair Value on Recurring Basis
The Company held certain assets that are required to be measured at fair value on a recurring basis as of December 31, 2019, as follows:
 
 
 
Fair Value Measurement as of December 31, 2019 Using
(in thousands)
Total Fair Value
 
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
U.S. Treasury and government agencies
$
88,601

 
$
88,601

 
$
—

 
$
—

Corporate debt
137,025

 
—

 
137,025

 
—

Asset-backed securities
48,401

 
—

 
48,401

 
—

Total assets measured at fair value
$
274,027


$
88,601


$
185,426


$
—


The Company held certain assets that are required to be measured at fair value on a recurring basis as of December 31, 2018, as follows:
 
 
 
Fair Value Measurement as of December 31, 2018 Using
(in thousands)
Total Fair Value
 
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
U.S. Treasury and government agencies
$
69,270

 
$
69,270

 
$
—

 
$
—

Corporate debt
105,910

 
—

 
105,910

 
—

Asset-backed securities
21,175

 
—

 
21,175

 
—

Total assets measured at fair value
$
196,355


$
69,270


$
127,085


$
—
XML 86 R62.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments and Contingencies - HETLIOZ - Additional Information (Detail) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended 191 Months Ended
Jan. 31, 2014
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2019
HETLIOZ          
Acquisition of intangible assets   $ 0 $ 25,000 $ 0  
Percentage of future sublicense fees payable to third-party   mid-twenties      
HETLIOZ®          
HETLIOZ          
Acquisition of intangible assets $ 8,000   $ 25,000   $ 37,500
Intangible assets capitalized         $ 33,000
Royalty payable percentage on net sales   10.00%      
Royalty payment period   10 years      
XML 87 R66.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments and Contingencies - Purchase Commitments (Detail)
$ in Millions
 12 Months Ended
Dec. 31, 2019
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Agreements for clinical and marketing services, termination notice period 90 days
Purchase commitments  
2020 $ 9.2
2021 1.0
2022 $ 0.5
XML 88 vnda1231201910k_htm.xml IDEA: XBRL DOCUMENT 0001347178 2019-01-01 2019-12-31 0001347178 2019-06-30 0001347178 2020-02-18 0001347178 2018-12-31 0001347178 2019-12-31 0001347178 2018-01-01 2018-12-31 0001347178 2017-01-01 2017-12-31 0001347178 us-gaap:CommonStockMember 2017-12-31 0001347178 us-gaap:RetainedEarningsMember 2018-12-31 0001347178 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001347178 us-gaap:CommonStockMember 2018-12-31 0001347178 us-gaap:CommonStockMember 2019-12-31 0001347178 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001347178 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001347178 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001347178 us-gaap:CommonStockMember 2016-12-31 0001347178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001347178 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001347178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001347178 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001347178 2016-12-31 0001347178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001347178 us-gaap:RetainedEarningsMember 2017-12-31 0001347178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001347178 us-gaap:RetainedEarningsMember 2016-12-31 0001347178 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001347178 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001347178 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001347178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001347178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001347178 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001347178 us-gaap:RetainedEarningsMember 2019-12-31 0001347178 2017-12-31 0001347178 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001347178 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001347178 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001347178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001347178 vnda:FanaptMember 2018-01-01 2018-12-31 0001347178 vnda:HetliozMember 2018-01-01 2018-12-31 0001347178 vnda:HetliozMember 2019-01-01 2019-12-31 0001347178 vnda:FanaptMember 2019-01-01 2019-12-31 0001347178 vnda:HetliozMember 2017-01-01 2017-12-31 0001347178 vnda:FanaptMember 2017-01-01 2017-12-31 0001347178 vnda:CustomerSixMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001347178 vnda:CustomerSixMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001347178 vnda:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001347178 vnda:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001347178 vnda:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001347178 vnda:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001347178 vnda:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerSixMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:CustomerFourMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:CustomerFiveMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerFourMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerFiveMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0001347178 vnda:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0001347178 vnda:SECSchedule1209AllowanceProductReturnsMember 2019-01-01 2019-12-31 0001347178 vnda:SECSchedule1209AllowanceProductReturnsMember 2018-12-31 0001347178 vnda:SECSchedule1209AllowanceProductReturnsMember 2019-12-31 0001347178 vnda:SECSchedule1209AllowanceProductReturnsMember 2017-12-31 0001347178 vnda:SECSchedule1209AllowanceProductReturnsMember 2016-12-31 0001347178 vnda:SECSchedule1209AllowanceProductReturnsMember 2018-01-01 2018-12-31 0001347178 vnda:SECSchedule1209AllowanceProductReturnsMember 2017-01-01 2017-12-31 0001347178 vnda:NoncurrentInventoryAndOtherMember 2018-12-31 0001347178 vnda:NoncurrentInventoryAndOtherMember 2019-12-31 0001347178 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2019-12-31 0001347178 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2018-12-31 0001347178 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001347178 2018-01-01 2018-02-08 0001347178 2018-02-09 2019-12-31 0001347178 us-gaap:USTreasuryAndGovernmentMember vnda:NoncurrentInvestmentsMember 2019-12-31 0001347178 us-gaap:AssetBackedSecuritiesMember vnda:NoncurrentInvestmentsMember 2019-12-31 0001347178 us-gaap:CorporateDebtSecuritiesMember vnda:NoncurrentInvestmentsMember 2019-12-31 0001347178 vnda:NoncurrentInvestmentsMember 2019-12-31 0001347178 us-gaap:AssetBackedSecuritiesMember vnda:CurrentInvestmentMember 2018-12-31 0001347178 us-gaap:USTreasuryAndGovernmentMember vnda:CurrentInvestmentMember 2018-12-31 0001347178 vnda:CurrentInvestmentMember 2018-12-31 0001347178 us-gaap:CorporateDebtSecuritiesMember vnda:CurrentInvestmentMember 2018-12-31 0001347178 us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001347178 us-gaap:FairValueInputsLevel1Member us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001347178 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0001347178 us-gaap:FairValueInputsLevel3Member 2018-12-31 0001347178 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0001347178 us-gaap:FairValueInputsLevel1Member 2018-12-31 0001347178 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001347178 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001347178 us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0001347178 us-gaap:FairValueInputsLevel3Member us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001347178 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001347178 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001347178 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001347178 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0001347178 us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001347178 us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0001347178 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001347178 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001347178 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001347178 us-gaap:FairValueInputsLevel1Member us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001347178 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001347178 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0001347178 us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001347178 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001347178 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001347178 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001347178 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0001347178 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0001347178 us-gaap:FairValueInputsLevel3Member us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001347178 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001347178 us-gaap:CashEquivalentsMember 2019-12-31 0001347178 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001347178 us-gaap:FurnitureAndFixturesMember 2018-12-31 0001347178 vnda:ComputerHardwareAndOtherEquipmentMember 2019-12-31 0001347178 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001347178 vnda:ComputerHardwareAndOtherEquipmentMember 2019-01-01 2019-12-31 0001347178 vnda:ComputerHardwareAndOtherEquipmentMember 2018-12-31 0001347178 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001347178 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2019-01-01 2019-12-31 0001347178 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2019-01-01 2019-12-31 0001347178 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2019-01-01 2019-12-31 0001347178 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2019-01-01 2019-12-31 0001347178 vnda:LondonLeaseMember 2019-12-31 0001347178 vnda:WashingtonDcLeaseMember 2019-12-31 0001347178 vnda:WashingtonDcLeaseMember vnda:SubleaseMember 2019-12-31 0001347178 vnda:HetliozMember 2018-12-31 0001347178 vnda:HetliozMember 2018-04-01 2018-04-30 0001347178 vnda:FanaptMember 2019-12-31 0001347178 vnda:HetliozMember 2014-01-01 2014-01-31 0001347178 vnda:HetliozMember 2019-12-31 0001347178 vnda:FanaptMember 2018-12-31 0001347178 srt:EuropeMember vnda:RegulatoryApprovalMilestoneMember vnda:TradipitantMember 2019-01-01 2019-12-31 0001347178 vnda:TradipitantMember 2018-07-01 2018-07-31 0001347178 vnda:CftrActivatorsAndInhibitorsMember 2019-01-01 2019-12-31 0001347178 country:US vnda:RegulatoryApprovalMilestoneMember vnda:TradipitantMember 2019-01-01 2019-12-31 0001347178 vnda:CftrActivatorsAndInhibitorsMember srt:MaximumMember vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember 2019-01-01 2019-12-31 0001347178 vnda:CftrActivatorsAndInhibitorsMember vnda:FutureRegulatoryApprovalAndSalesMilestonesMember 2019-01-01 2019-12-31 0001347178 vnda:CftrActivatorsAndInhibitorsMember vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember 2019-01-01 2019-12-31 0001347178 vnda:SalesMilestoneMember vnda:TradipitantMember 2019-01-01 2019-12-31 0001347178 vnda:HetliozMember 2004-02-01 2019-12-31 0001347178 vnda:PreNDAApprovalMilestonesMember vnda:TradipitantMember 2019-12-31 0001347178 vnda:CftrActivatorsAndInhibitorsMember vnda:RegulatoryApprovalMilestoneMember 2019-01-01 2019-12-31 0001347178 vnda:ScenarioFourMember 2016-11-16 2019-12-31 0001347178 vnda:CftrActivatorsAndInhibitorsMember vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember 2019-03-01 2019-03-31 0001347178 vnda:TradipitantMember 2019-01-01 2019-12-31 0001347178 vnda:CftrActivatorsAndInhibitorsMember vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember 2017-01-01 2017-12-31 0001347178 vnda:PublicOfferingMember 2018-03-01 2018-03-31 0001347178 vnda:PublicOfferingMember 2018-03-31 0001347178 us-gaap:OverAllotmentOptionMember 2018-03-01 2018-03-31 0001347178 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001347178 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001347178 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001347178 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-12-31 0001347178 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0001347178 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0001347178 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001347178 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-12-31 0001347178 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0001347178 vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember 2017-01-01 2017-12-31 0001347178 vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember 2019-01-01 2019-12-31 0001347178 vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember 2018-01-01 2018-12-31 0001347178 vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember 2018-12-31 0001347178 vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember 2016-01-01 2016-12-31 0001347178 vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember 2016-12-31 0001347178 vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember 2019-12-31 0001347178 vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember 2017-12-31 0001347178 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001347178 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001347178 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0001347178 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0001347178 us-gaap:RestrictedStockUnitsRSUMember 2016-12-31 0001347178 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0001347178 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001347178 vnda:ServiceOptionAwardsMember 2019-12-31 0001347178 vnda:StockOptionsAndRestrictedStockUnitsRSUsMember vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember 2019-01-01 2019-12-31 0001347178 vnda:ServiceOptionAwardsMember 2019-01-01 2019-12-31 0001347178 vnda:TwoThousandSixteenPlanMember 2019-12-31 0001347178 srt:MaximumMember us-gaap:OtherNoncurrentLiabilitiesMember 2018-12-31 0001347178 stpr:DC 2019-01-01 2019-12-31 0001347178 vnda:IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember 2019-01-01 2019-12-31 0001347178 vnda:EstimatedRealizabilityofDeferredTaxAssetMember 2019-01-01 2019-12-31 0001347178 vnda:OrphanDrugMember 2019-12-31 0001347178 us-gaap:DomesticCountryMember 2019-12-31 0001347178 vnda:IncomeBeforeIncomeTaxesCurrentYearMember 2019-01-01 2019-12-31 0001347178 2019-04-01 2019-06-30 0001347178 2018-10-01 2018-12-31 0001347178 2019-07-01 2019-09-30 0001347178 2018-07-01 2018-09-30 0001347178 2018-04-01 2018-06-30 0001347178 2018-01-01 2018-03-31 0001347178 2019-01-01 2019-03-31 0001347178 2019-10-01 2019-12-31 vnda:product utreg:sqft shares iso4217:USD shares vnda:Segment iso4217:USD pure vnda:installment false --12-31 FY 2019 0001347178 0.001 0.001 150000000 150000000 52477593 53549612 52477593 53549612 27900000 0.001 0.001 20000000 20000000 0 0 0 0 P7Y P11Y P5Y P5Y 0 0 2034-05 2035-02 2035-07 P10Y 10-K true 2019-12-31 false 001-34186 VANDA PHARMACEUTICALS INC. DE 03-0491827 2200 Pennsylvania Avenue NW Suite 300 E Washington DC 20037 202 734-3400 Common Stock, par value $0.001 per share VNDA NASDAQ No No Yes Yes Large Accelerated Filer false false false 731200000 53648617 <div style="line-height:120%;padding-top:8px;text-align:center;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="line-height:120%;padding-top:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Specified portions of the registrant’s proxy statement with respect to the registrant’s </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> Annual Meeting of Stockholders, which is to be filed pursuant to Regulation 14A within 120 days after the end of the registrant’s fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, are incorporated by reference into Part III of this Form 10-K.</span></div> 45072000 61005000 267057000 196355000 26367000 28780000 1140000 994000 14500000 11998000 354136000 299132000 3864000 4417000 11180000 0 23037000 24542000 87680000 0 3851000 4039000 483748000 332130000 27590000 21584000 31915000 31231000 0 200000 59505000 53015000 12455000 0 843000 3693000 72803000 56708000 0 0 54000 52000 631307000 611587000 249000 1000 -220665000 -336218000 410945000 275422000 483748000 332130000 227188000 193118000 165083000 227188000 193118000 165083000 24488000 20508000 17848000 48649000 43594000 38547000 129736000 105751000 123841000 1505000 1527000 1750000 204378000 171380000 181986000 22810000 21738000 -16903000 6218000 3608000 1472000 29028000 25346000 -15431000 -86525000 138000 136000 115553000 25208000 -15567000 2.17 0.50 -0.35 2.11 0.48 -0.35 53137562 50859947 44735146 54847060 53045257 44735146 115553000 25208000 -15567000 6000 -22000 30000 313000 57000 -122000 71000 0 0 248000 35000 -92000 115801000 25243000 -15659000 44000614 44000 477087000 58000 -345859000 131330000 937519 1000 5250000 5251000 10465000 10465000 -15567000 -15567000 -92000 -92000 44938133 45000 492802000 -34000 -361426000 131387000 6325000 6000 100864000 100870000 1214460 1000 6255000 6256000 11666000 11666000 25208000 25208000 35000 35000 52477593 52000 611587000 1000 -336218000 275422000 1072019 2000 6262000 6264000 13458000 13458000 115553000 115553000 248000 248000 53549612 54000 631307000 249000 -220665000 410945000 115553000 25208000 -15567000 1387000 1429000 1234000 13458000 11666000 10465000 3099000 2221000 426000 1505000 1527000 1750000 -87767000 0 0 -1785000 -167000 -587000 -2342000 11207000 -2525000 2764000 4258000 -3652000 722000 -70000 1060000 3508000 -618000 5953000 761000 8223000 -11096000 45947000 29986000 -1983000 0 25000000 0 1019000 368000 1664000 394517000 282395000 148135000 327227000 198103000 139568000 -68309000 -109660000 -10231000 0 100870000 0 6264000 6256000 5251000 6264000 107126000 5251000 -1000 -38000 42000 -16099000 27414000 -6921000 61749000 34335000 41256000 45650000 61749000 34335000 Business Organization and Presentation<div style="line-height:120%;padding-top:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business organization</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vanda Pharmaceuticals Inc. (the Company) </span><span style="font-family:inherit;font-size:10pt;">is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.</span><span style="font-family:inherit;font-size:10pt;"> The Company commenced its operations in 2003 and operates in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> reporting segment. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's commercial portfolio is currently comprised of </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> products, HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> for the treatment of schizophrenia. HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> is the first treatment for Non-24 approved by the U.S. Food and Drug Administration (FDA). In addition, the Company has a number of drugs in development, including:</span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span>HETLIOZ</span><span><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span> (tasimelteon) for the treatment of jet lag disorder, Smith-Magenis Syndrome (SMS), pediatric Non-24 and delayed sleep phase disorder (DSPD);</span></div></td></tr></table><div style="line-height:120%;padding-left:72px;text-indent:-24px;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span>Fanapt</span><span><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span> (iloperidone) for the treatment of bipolar disorder and a long acting injectable (LAI) formulation program for the treatment of schizophrenia;</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><div style="line-height:120%;padding-left:72px;text-indent:-24px;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis and motion sickness;</span></div></td></tr></table><div style="line-height:120%;padding-left:72px;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">VTR-297, a small molecule histone deacetylase (HDAC) inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications;</span></div></td></tr></table><div style="line-height:120%;padding-left:72px;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist, with potential use for the treatment of psychiatric disorders; and</span></div></td></tr></table><div style="line-height:120%;padding-left:72px;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors for the treatment of dry eye and ocular inflammation and for the treatment of secretory diarrhea disorders, including cholera.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:40px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements includes the accounts of Vanda Pharmaceuticals Inc. and its wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.). All intercompany accounts and transactions have been eliminated in consolidation.</span></div> <div style="line-height:120%;padding-top:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business organization</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vanda Pharmaceuticals Inc. (the Company) </span><span style="font-family:inherit;font-size:10pt;">is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.</span><span style="font-family:inherit;font-size:10pt;"> The Company commenced its operations in 2003 and operates in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> reporting segment. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's commercial portfolio is currently comprised of </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> products, HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> for the treatment of schizophrenia. HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> is the first treatment for Non-24 approved by the U.S. Food and Drug Administration (FDA). In addition, the Company has a number of drugs in development, including:</span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span>HETLIOZ</span><span><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span> (tasimelteon) for the treatment of jet lag disorder, Smith-Magenis Syndrome (SMS), pediatric Non-24 and delayed sleep phase disorder (DSPD);</span></div></td></tr></table><div style="line-height:120%;padding-left:72px;text-indent:-24px;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span>Fanapt</span><span><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span> (iloperidone) for the treatment of bipolar disorder and a long acting injectable (LAI) formulation program for the treatment of schizophrenia;</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><div style="line-height:120%;padding-left:72px;text-indent:-24px;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis and motion sickness;</span></div> 1 2 <div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements includes the accounts of Vanda Pharmaceuticals Inc. and its wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.). All intercompany accounts and transactions have been eliminated in consolidation.</span></div> Summary of Significant Accounting Policies<div style="line-height:120%;padding-top:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management’s evaluation could change. Actual results could differ from those estimates.</span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Restricted Cash</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For purposes of the Consolidated Balance Sheets and Consolidated Statements of Cash Flows, cash equivalents represent highly-liquid investments with a maturity date of three months or less at the date of purchase. Cash and cash equivalents include investments in money market funds with commercial banks and financial institutions, and commercial paper of high-quality corporate issuers. Restricted cash relates primarily to amounts held as collateral for letters of credit for leases for office space at the Company’s Washington, D.C. headquarters. </span></div><div style="line-height:120%;padding-top:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets to the total end of period cash, cash equivalents and restricted cash reported within the Consolidated Statement of Cash Flows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,072</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,005</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash included in: </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current inventory and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>578</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>587</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,650</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,749</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketable Securities</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company classifies all of its marketable securities as available-for-sale securities. The Company’s investment policy requires the selection of high-quality issuers. Available-for-sale securities are carried at fair market value, with unrealized gains and losses reported as a component of stockholders’ equity in </span><span style="font-family:inherit;font-size:10pt;">accumulated other comprehensive income (loss)</span><span style="font-family:inherit;font-size:10pt;">. At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. If declines in the value of available for-sale securities are determined to be other-than-temporary, a loss is recorded in earnings in the current period. Interest and dividend income is recorded when earned and included in other income. Premiums and discounts on marketable securities are amortized and accreted, respectively, to earliest call date and maturity, respectively, and included in other income. The Company uses the specific identification method in computing realized gains and losses on the sale of investments, which would be included in the consolidated statements of operations when generated. All available-for-sale marketable securities are available for use in current operations and are classified as current.</span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventory</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory, which is recorded at the lower of cost or net realizable value, includes the cost of third-party manufacturing and other direct and indirect costs and is valued using the first-in, first-out method. The Company capitalizes inventory costs associated with its products upon regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. Inventory not expected to be sold within 12 months following the balance sheet date are classified as non-current.</span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs incurred for products not yet approved by the FDA and for which no alternative future use exists are recorded as expense. Obligations for milestone payments to other pharmaceutical companies that may result in a capitalized intangible asset are recognized when it is deemed probable that the milestone event will occur. In the event a product has been approved by the FDA or an alternative future use exists for a product, patent and license costs are capitalized and amortized on a straight-line basis over the estimated useful economic life of the of the related product patents. For intangible assets related to HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">, the estimated useful life is the estimated economic useful life of the related product patents, the latest of which expires in </span><span style="font-family:inherit;font-size:10pt;">July 2035</span><span style="font-family:inherit;font-size:10pt;">. Intangible assets related Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> have been fully amortized on a straight-line basis to </span><span style="font-family:inherit;font-size:10pt;">November 2016</span><span style="font-family:inherit;font-size:10pt;">. The useful life estimate for Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> was based on the market participant methodology prescribed by ASC 805, and therefore does not reflect the impact of additional Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> patents solely owned by the Company with varying expiration dates, the latest of which is December 2031.</span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation. Depreciation of most property and equipment is provided on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized using a straight-line basis over the lesser of the estimated useful lives of the assets or the terms of the related leases. The costs of additions and improvements are capitalized, and repairs and maintenance costs are charged to operations in the period incurred. Upon retirement or disposition of property and equipment, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in the statement of operations for that period.</span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with Accounting Standards Codification (ASC) 842, Leases, effective January 1, 2019, the Company determines if an arrangement contains a lease at inception. Right-of-use (ROU) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from that lease. For leases with a term greater than 12 months, ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The lease term includes the option to extend the lease when it is reasonably certain the Company will exercise that option. When available, the Company uses the rate implicit in the lease to discount lease payments to present value. In the case the implicit rate is not available, the Company uses its incremental borrowing rate based on information available at the lease commencement date, including publicly available data for instruments with similar characteristics, to determine the present value of lease payments. The Company does not combine lease and non-lease elements for office leases. For existing leases as of January 1, 2019, executory costs are excluded from lease expense, which is consistent with the Company's accounting under ASC 840, Leases. For all leases entered into after January 1, 2019, executory costs are allocated between lease and non-lease elements based upon their relative stand-alone prices.</span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Payable and Accrued Liabilities</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s management is required to estimate accrued liabilities as part of the process of preparing financial statements. The estimation of accrued liabilities involves identifying services that have been performed on the Company’s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date in the financial statements. Accrued liabilities include research and development expenses, such as accrued costs under contracts with clinical monitors, data management organizations and investigators in conjunction with clinical trials, fees to contract manufacturers in conjunction with the production of clinical materials, consulting and professional fees, such as lawyers and fees for marketing and other commercialization activities, accrued compensation and employee benefits, such as accrued bonus, royalties payable under licensing agreements, and other accrued fees. Pursuant to management’s assessment of the services that have been performed on clinical trials and other contracts, the Company recognizes these expenses as the services are provided. Such management assessments include, but are not limited to: (i) an evaluation by the project manager of the work that has been completed during the period, (ii) measurement of progress prepared internally and/or provided by the third-party service provider, (iii) analyses of data that justify the progress, and (iv) management’s judgment. In the event that the Company does not identify certain costs that have begun to be incurred or the Company under- or over-estimates the level of services performed or the costs of such services, the Company’s reported expenses for such period would be too low or too high.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with ASC Subtopic 606 </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;"> (ASC 606), which the Company adopted January 1, 2018, the Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. The Company recognizes revenue when control of the product is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for those product sales, which is typically once the product physically arrives at the customer. Sales taxes, value add taxes, and usage-based taxes are excluded from revenues. Results for reporting period ended December 31, 2017 were not adjusted and continue to be reported in accordance with historic accounting under ASC 605. The impact to the Consolidated Statements of Operations if the Company had applied ASC 606 for the year ended December 31, 2017 is not material. </span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s net product sales consist of sales of HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> and Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">. Net sales by product for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;font-style:italic;">in thousands</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,980</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,835</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,978</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> product sales, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,283</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net product sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>227,188</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>193,118</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165,083</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> is available in the U.S. for distribution through a limited number of specialty pharmacies, and is not available in retail pharmacies. Specialty pharmacy customers include Diplomat Pharmacy, Inc. (a subsidiary of UnitedHealth Group) and Accredo (a subsidiary of Express Scripts). Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> is available in the U.S. for distribution through a limited number of wholesalers and is available in retail pharmacies. Wholesaler customers include Cardinal Health, Inc., AmerisourceBergen </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Drug Corporation, and McKesson Corporation. The Company invoices and records revenue when its customers, specialty pharmacies and wholesalers, receive product from the third-party logistics warehouse which is the point at which control is transferred to the customer. Revenues and accounts receivable are concentrated with these customers. The Company evaluates outstanding receivables to assess collectability. In performing this evaluation, the Company analyzes economic conditions, the aging of receivables and customer specific risks. </span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents each major customer that represented more than 10% of total revenues for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Percent of Net Product Sales</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor B</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor C</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor E</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor F</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents each major customer that represented more than 10% of accounts receivable, net, as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Percent of Accounts Receivable, Net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor B</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor C</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor E</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The transaction price is determined based upon the consideration to which the Company will be entitled in exchange for transferring product to the customer. The Company’s product sales are recorded net of applicable product revenue allowances for which reserves are established and include discounts, rebates, chargebacks, service fees, co-pay assistance and product returns that are applicable for various government and commercial payors. The Company estimates the amount of variable consideration that should be included in the transaction price utilizing the most likely amount method and updates its estimate at each reporting date. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Allowances for rebates, chargebacks and co-pay assistance are based upon the insurance benefits of the end customer, which are estimated using historical activity and, where available, actual and pending prescriptions for which the Company has validated the insurance benefits. Reserves for variable consideration are classified as product revenue allowances on the consolidated balance sheets, with the exception of prompt-pay discounts which are classified as reductions of accounts receivable. The reserve for product returns for which the product may not be returned for a period of greater than one year from the balance sheet date is included as a component of other non-current liabilities in the consolidated balance sheets. Uncertainties related to variable consideration are generally resolved in the quarter subsequent to period end, with the exception of Medicaid rebates, which are dependent upon the timing of when states submit reimbursement claims, and product returns which are resolved during the product expiry period specified in the customer contract. The Company currently records sales allowances for the following:</span></div><div style="line-height:120%;padding-top:8px;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Prompt-pay:</span><span style="font-family:inherit;font-size:10pt;"> Specialty pharmacies and wholesalers are offered discounts for prompt payment. The Company expects that the specialty pharmacies and wholesalers will earn prompt payment discounts and, therefore, deducts the full amount of these discounts from total product sales when revenues are recognized.</span></div><div style="line-height:120%;padding-top:8px;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Rebates:</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program as well as contracted rebate programs with other payors. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contracted discount rates and estimated patient utilization.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Chargebacks:</span><span style="font-family:inherit;font-size:10pt;"> Chargebacks are discounts that occur when contracted indirect customers purchase directly from specialty pharmacies and wholesalers. Contracted indirect customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The specialty pharmacy or wholesaler, in turn, charges back the difference between the price initially paid by the specialty pharmacy or wholesaler and the discounted price paid to the specialty pharmacy or wholesaler by the contracted customer.</span></div><div style="line-height:120%;padding-top:8px;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Medicare Part D Coverage Gap:</span><span style="font-family:inherit;font-size:10pt;"> Medicare Part D prescription drug benefit mandates manufacturers to fund approximately </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients through 2018. Public Law No. 115-123, also known as the Bipartisan Budget Act of 2018 enacted on February 9, 2018 increased the manufacturer discount from </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>70%</span></span><span style="font-family:inherit;font-size:10pt;"> effective in 2019 for applicable drugs. Vanda accounts for the Medicare Part D coverage gap using a point of sale model. Estimates for expected Medicare Part D coverage gap are based in part on historical activity and, where available, actual and pending prescriptions for which the Company has validated the insurance benefits.</span></div><div style="line-height:120%;padding-top:8px;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Service Fees:</span><span style="font-family:inherit;font-size:10pt;"> The Company receives sales order management, data and distribution services from certain customers. These fees are based on contracted terms and are known amounts. The Company accrues service fees at the time of revenue recognition, resulting in a reduction of product sales and the recognition of an accrued liability, unless it is a payment for a distinct good or service from the customer in which case the fair value of those distinct goods or services are recorded as selling, general and administrative expense.</span></div><div style="line-height:120%;padding-top:8px;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Co-payment Assistance:</span><span style="font-family:inherit;font-size:10pt;"> Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Co-pay assistance utilization is based on information provided by the Company’s third-party administrator.</span></div><div style="line-height:120%;padding-top:8px;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Product Returns</span><span style="font-family:inherit;font-size:10pt;">: The Company generally offers direct customers a limited right to return as contractually defined with the customers. The Company considers several factors in the estimation process, including expiration dates of product shipped to customers, inventory levels within the distribution channel, product shelf life, historical return activity, including activity for product sold for which the return period has past, prescription trends and other relevant factors. The Company does not expect returned goods to be resalable. There was no right of return asset as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. The following table summarizes activity for product returns as of and for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, all of which relates to sales of Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Reserve for Product Returns</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,080</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,978</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Credits/payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,939</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December 31, 2017</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,119</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,684</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Credits/payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,616</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,187</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,138</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Credits/payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,205</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,120</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Goods Sold</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of goods sold includes royalties payable, the cost of inventory sold, manufacturing and supply chain costs and product shipping and handling costs related to sales of HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> and Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> to the Company’s distribution partners.</span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses consist primarily of fees for services provided by third parties in connection with the clinical trials, costs of contract manufacturing services, milestone payments, costs of materials used in clinical trials and research and development, costs for regulatory consultants and filings, depreciation of capital resources used to develop products, related facilities costs, and salaries, other employee-related costs and stock-based compensation for research and development personnel. The Company expenses research and development costs as they are incurred for products in the </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">development stage, including manufacturing costs and milestone payments made under license agreements prior to FDA approval. Upon and subsequent to FDA approval, manufacturing and milestone payments related to license agreements are capitalized. Milestone payments are accrued when it is deemed probable that the milestone event will be achieved. Costs related to the acquisition of intellectual property are expensed as incurred if the underlying technology is developed in connection with the Company’s research and development efforts and has no alternative future use.</span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Selling, General and Administrative Expenses</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses consist of salaries, stock-based compensation, facilities and third party expenses. Selling, general and administrative expenses are associated with the activities of the corporate, finance, accounting, information technology, business development, commercial support, trade and distribution, sales, marketing, legal, medical affairs and human resource functions. Additionally, selling, general and administrative expenses included an estimate for the annual Affordable Care Act fee.</span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation costs for all stock-based awards to employees and directors are measured based on the grant date fair value of those awards and recognized over the period during which the employee or director is required to perform service in exchange for the award. The Company recognizes the expense over the award’s vesting period. The fair value of stock options granted and restricted stock units (RSUs) awarded are amortized using the straight-line method. As stock-based compensation expense recognized in the consolidated statements of operations is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Advertising Expense</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company expenses the costs of advertising, including branded promotional expenses, as incurred. Branded advertising expenses, recorded in selling, general and administrative expenses, were </span><span style="font-family:inherit;font-size:10pt;"><span>$3.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The reporting currency of the Company is the U.S. dollar. The functional currency of the Company’s international subsidiaries is the local currency. Assets and liabilities denominated in foreign currencies, including intercompany balances for which settlement is anticipated in the foreseeable future, are translated at exchange rates in effect at the balance sheet date. Foreign currency equity balances are translated at historical rates. Revenues and expenses denominated in foreign currencies are translated at average exchange rates for the respective periods. Foreign currency translation adjustments are recorded in </span><span style="font-family:inherit;font-size:10pt;">accumulated other comprehensive income (loss)</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transactions denominated in currencies other than subsidiaries’ functional currencies are recorded based on exchange rates at the time such transactions arise. Changes in exchange rates with respect to amounts recorded in the consolidated balance sheets related to these items will result in unrealized foreign currency transaction gains and losses based upon period-end exchange rates. The Company also records realized foreign currency transaction gains and losses upon settlement of the transactions. Foreign currency transaction gains and losses are included in other income and were not material for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. Tax rate changes are reflected in income during the period such changes are enacted. Changes in ownership may limit the amount of net operating loss (NOL) carryforwards that can be utilized in the future to offset taxable income. </span><span style="font-family:inherit;font-size:10pt;">Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Certain Risks and Uncertainties</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s products under development require approval from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance the products will receive the necessary clearance. If the Company is denied clearance or clearance is delayed, it may have a material adverse impact on the Company.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s products are concentrated in rapidly-changing, highly-competitive markets, which are characterized by rapid technological advances, changes in customer requirements and evolving regulatory requirements and industry standards. Any failure by the Company to anticipate or to respond adequately to technological developments in its industry, changes in customer requirements or changes in regulatory requirements or industry standards or any significant delays in the development or introduction of products or services could have a material adverse effect on the Company’s business, operating results and future cash flows.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company depends on single source suppliers for critical raw materials for manufacturing, as well as other components required for the administration of its products. The loss of these suppliers could delay the clinical trials or prevent or delay commercialization of the products.</span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash, cash equivalents and marketable securities. The Company places its cash, cash equivalents and marketable securities with highly-rated financial institutions. At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company maintained all of its cash, cash equivalents and marketable securities in two financial institutions. Deposits held with these institutions may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand, and the Company believes there is minimal risk of losses on such balances.</span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment and Geographic Information</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company operates in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> reporting segment and, accordingly, no segment disclosures are presented herein. Foreign sales were not material for each of the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, </span><span style="font-family:inherit;font-size:10pt;">which clarifies and simplifies certain aspects of the accounting for income taxes.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The standard is effective</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company is evaluating this standard to determine if adoption will have a material impact on the Company’s consolidated financial statements.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the U.S. Securities and Exchange Commission (SEC) adopted the final rule under SEC Release No. 33-10532, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure Update and Simplification. </span><span style="font-family:inherit;font-size:10pt;">This final rule amends certain disclosure requirements that are redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expand the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule is effective for the Company for all filings made on or after November 5, 2018. The SEC staff clarified that the first presentation of the changes in shareholders' equity may be included in the first Form 10-Q for the quarter that begins after the effective date of the amendments. The adoption of the final rule did not have a material impact on the Company’s consolidated financial statements.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments – Credit Losses, </span><span style="font-family:inherit;font-size:10pt;">which changes the impairment model for most financial assets and certain other financial instruments. The standard will require the use of a forward-looking “expected loss” model for instruments measured at amortized cost that generally will result in the earlier recognition of allowances for losses. The standard is effective for years beginning after December 15, 2019, and interim periods within annual periods beginning after December 15, 2019. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial results. </span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-2, Leases (Topic 842), which was further clarified by ASU 2018-10, Codification Improvements to Topic 842, Leases, and ASU 2018-11, Leases - Targeted Improvements, issued in July </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018. ASC 842 supersedes existing lease guidance, including ASC 840 Leases. The new leasing standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The new leasing standard requires that lessees will need to recognize an ROU asset and a lease liability for virtually all of their leases, and allows companies to make a policy election as to whether short term leases will be recognized under the requirements of the new standard. The Company elected to exclude short-term leases in the application of the new standard. The lease liability is equal to the present value of lease payments. The ROU asset is based on the liability subject to certain adjustments. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense, similar to accounting for operating leases under ASC 840, while finance leases will result in a front-loaded expense pattern, similar to accounting for capital leases under ASC 840. </span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted the new leasing standard in the first quarter of 2019, using a modified retrospective transition. There was no impact to the opening balance of retained earnings as of the effective date of January 1, 2019 as a result of adoption. Prior period financial statements were not recast. The Company elected the package of transition provisions available for expired or existing contracts, which allowed it to carryforward its historical assessments of (1) whether contracts are or contain leases, (2) lease classification and (3) initial direct costs. The adoption of the new leasing standard on January 1, 2019 resulted in the recognition of </span><span style="font-family:inherit;font-size:10pt;"><span>$15.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> of operating lease liabilities, </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of which were classified as current liabilities, with corresponding ROU assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$12.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of lease prepayments and the balance of deferred lease incentives. The Company does not have any financing leases.</span></div> <div style="line-height:120%;padding-top:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management’s evaluation could change. Actual results could differ from those estimates.</span></div> <div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Restricted Cash</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For purposes of the Consolidated Balance Sheets and Consolidated Statements of Cash Flows, cash equivalents represent highly-liquid investments with a maturity date of three months or less at the date of purchase. Cash and cash equivalents include investments in money market funds with commercial banks and financial institutions, and commercial paper of high-quality corporate issuers. Restricted cash relates primarily to amounts held as collateral for letters of credit for leases for office space at the Company’s Washington, D.C. headquarters. </span></div> <div style="line-height:120%;padding-top:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets to the total end of period cash, cash equivalents and restricted cash reported within the Consolidated Statement of Cash Flows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,072</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,005</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash included in: </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current inventory and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>578</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>587</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,650</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,749</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 45072000 61005000 0 157000 578000 587000 45650000 61749000 <div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketable Securities</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company classifies all of its marketable securities as available-for-sale securities. The Company’s investment policy requires the selection of high-quality issuers. Available-for-sale securities are carried at fair market value, with unrealized gains and losses reported as a component of stockholders’ equity in </span><span style="font-family:inherit;font-size:10pt;">accumulated other comprehensive income (loss)</span><span style="font-family:inherit;font-size:10pt;">. At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. If declines in the value of available for-sale securities are determined to be other-than-temporary, a loss is recorded in earnings in the current period. Interest and dividend income is recorded when earned and included in other income. Premiums and discounts on marketable securities are amortized and accreted, respectively, to earliest call date and maturity, respectively, and included in other income. The Company uses the specific identification method in computing realized gains and losses on the sale of investments, which would be included in the consolidated statements of operations when generated. All available-for-sale marketable securities are available for use in current operations and are classified as current.</span></div> <div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventory</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory, which is recorded at the lower of cost or net realizable value, includes the cost of third-party manufacturing and other direct and indirect costs and is valued using the first-in, first-out method. The Company capitalizes inventory costs associated with its products upon regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. Inventory not expected to be sold within 12 months following the balance sheet date are classified as non-current.</span></div> <div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs incurred for products not yet approved by the FDA and for which no alternative future use exists are recorded as expense. Obligations for milestone payments to other pharmaceutical companies that may result in a capitalized intangible asset are recognized when it is deemed probable that the milestone event will occur. In the event a product has been approved by the FDA or an alternative future use exists for a product, patent and license costs are capitalized and amortized on a straight-line basis over the estimated useful economic life of the of the related product patents. For intangible assets related to HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">, the estimated useful life is the estimated economic useful life of the related product patents, the latest of which expires in </span><span style="font-family:inherit;font-size:10pt;">July 2035</span><span style="font-family:inherit;font-size:10pt;">. Intangible assets related Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> have been fully amortized on a straight-line basis to </span><span style="font-family:inherit;font-size:10pt;">November 2016</span><span style="font-family:inherit;font-size:10pt;">. The useful life estimate for Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> was based on the market participant methodology prescribed by ASC 805, and therefore does not reflect the impact of additional Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> patents solely owned by the Company with varying expiration dates, the latest of which is December 2031.</span></div> <div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation. Depreciation of most property and equipment is provided on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized using a straight-line basis over the lesser of the estimated useful lives of the assets or the terms of the related leases. The costs of additions and improvements are capitalized, and repairs and maintenance costs are charged to operations in the period incurred. Upon retirement or disposition of property and equipment, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in the statement of operations for that period.</span></div> <div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with Accounting Standards Codification (ASC) 842, Leases, effective January 1, 2019, the Company determines if an arrangement contains a lease at inception. Right-of-use (ROU) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from that lease. For leases with a term greater than 12 months, ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The lease term includes the option to extend the lease when it is reasonably certain the Company will exercise that option. When available, the Company uses the rate implicit in the lease to discount lease payments to present value. In the case the implicit rate is not available, the Company uses its incremental borrowing rate based on information available at the lease commencement date, including publicly available data for instruments with similar characteristics, to determine the present value of lease payments. The Company does not combine lease and non-lease elements for office leases. For existing leases as of January 1, 2019, executory costs are excluded from lease expense, which is consistent with the Company's accounting under ASC 840, Leases. For all leases entered into after January 1, 2019, executory costs are allocated between lease and non-lease elements based upon their relative stand-alone prices.</span></div> <div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Payable and Accrued Liabilities</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s management is required to estimate accrued liabilities as part of the process of preparing financial statements. The estimation of accrued liabilities involves identifying services that have been performed on the Company’s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date in the financial statements. Accrued liabilities include research and development expenses, such as accrued costs under contracts with clinical monitors, data management organizations and investigators in conjunction with clinical trials, fees to contract manufacturers in conjunction with the production of clinical materials, consulting and professional fees, such as lawyers and fees for marketing and other commercialization activities, accrued compensation and employee benefits, such as accrued bonus, royalties payable under licensing agreements, and other accrued fees. Pursuant to management’s assessment of the services that have been performed on clinical trials and other contracts, the Company recognizes these expenses as the services are provided. Such management assessments include, but are not limited to: (i) an evaluation by the project manager of the work that has been completed during the period, (ii) measurement of progress prepared internally and/or provided by the third-party service provider, (iii) analyses of data that justify the progress, and (iv) management’s judgment. In the event that the Company does not identify certain costs that have begun to be incurred or the Company under- or over-estimates the level of services performed or the costs of such services, the Company’s reported expenses for such period would be too low or too high.</span></div> <div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><span style="font-family:inherit;font-size:10pt;">In accordance with ASC Subtopic 606 </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span> (ASC 606), which the Company adopted January 1, 2018, the Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. The Company recognizes revenue when control of the product is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for those product sales, which is typically once the product physically arrives at the customer. Sales taxes, value add taxes, and usage-based taxes are excluded from revenues. <div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s net product sales consist of sales of HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> and Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">. Net sales by product for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;font-style:italic;">in thousands</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,980</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,835</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,978</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> product sales, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,283</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net product sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>227,188</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>193,118</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165,083</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 142980000 115835000 89978000 84208000 77283000 75105000 227188000 193118000 165083000 <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> is available in the U.S. for distribution through a limited number of specialty pharmacies, and is not available in retail pharmacies. Specialty pharmacy customers include Diplomat Pharmacy, Inc. (a subsidiary of UnitedHealth Group) and Accredo (a subsidiary of Express Scripts). Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> is available in the U.S. for distribution through a limited number of wholesalers and is available in retail pharmacies. Wholesaler customers include Cardinal Health, Inc., AmerisourceBergen </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Drug Corporation, and McKesson Corporation. The Company invoices and records revenue when its customers, specialty pharmacies and wholesalers, receive product from the third-party logistics warehouse which is the point at which control is transferred to the customer. Revenues and accounts receivable are concentrated with these customers. The Company evaluates outstanding receivables to assess collectability. In performing this evaluation, the Company analyzes economic conditions, the aging of receivables and customer specific risks. </span></div> <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents each major customer that represented more than 10% of total revenues for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Percent of Net Product Sales</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor B</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor C</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor E</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor F</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.38 0.37 0.32 0.23 0.17 0.10 0.12 0.14 0.15 0.12 0.12 0.15 0.11 0.12 0.12 0 0.05 0.11 <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents each major customer that represented more than 10% of accounts receivable, net, as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Percent of Accounts Receivable, Net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor B</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor C</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributor E</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.21 0.30 0.21 0.15 0.18 0.20 0.16 0.13 0.18 0.16 <span style="font-family:inherit;font-size:10pt;"><br/></span><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The transaction price is determined based upon the consideration to which the Company will be entitled in exchange for transferring product to the customer. The Company’s product sales are recorded net of applicable product revenue allowances for which reserves are established and include discounts, rebates, chargebacks, service fees, co-pay assistance and product returns that are applicable for various government and commercial payors. The Company estimates the amount of variable consideration that should be included in the transaction price utilizing the most likely amount method and updates its estimate at each reporting date. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Allowances for rebates, chargebacks and co-pay assistance are based upon the insurance benefits of the end customer, which are estimated using historical activity and, where available, actual and pending prescriptions for which the Company has validated the insurance benefits. Reserves for variable consideration are classified as product revenue allowances on the consolidated balance sheets, with the exception of prompt-pay discounts which are classified as reductions of accounts receivable. The reserve for product returns for which the product may not be returned for a period of greater than one year from the balance sheet date is included as a component of other non-current liabilities in the consolidated balance sheets. Uncertainties related to variable consideration are generally resolved in the quarter subsequent to period end, with the exception of Medicaid rebates, which are dependent upon the timing of when states submit reimbursement claims, and product returns which are resolved during the product expiry period specified in the customer contract. The Company currently records sales allowances for the following:</span></div><div style="line-height:120%;padding-top:8px;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Prompt-pay:</span><span style="font-family:inherit;font-size:10pt;"> Specialty pharmacies and wholesalers are offered discounts for prompt payment. The Company expects that the specialty pharmacies and wholesalers will earn prompt payment discounts and, therefore, deducts the full amount of these discounts from total product sales when revenues are recognized.</span></div><div style="line-height:120%;padding-top:8px;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Rebates:</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program as well as contracted rebate programs with other payors. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contracted discount rates and estimated patient utilization.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Chargebacks:</span><span style="font-family:inherit;font-size:10pt;"> Chargebacks are discounts that occur when contracted indirect customers purchase directly from specialty pharmacies and wholesalers. Contracted indirect customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The specialty pharmacy or wholesaler, in turn, charges back the difference between the price initially paid by the specialty pharmacy or wholesaler and the discounted price paid to the specialty pharmacy or wholesaler by the contracted customer.</span></div><div style="line-height:120%;padding-top:8px;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Medicare Part D Coverage Gap:</span><span style="font-family:inherit;font-size:10pt;"> Medicare Part D prescription drug benefit mandates manufacturers to fund approximately </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients through 2018. Public Law No. 115-123, also known as the Bipartisan Budget Act of 2018 enacted on February 9, 2018 increased the manufacturer discount from </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>70%</span></span><span style="font-family:inherit;font-size:10pt;"> effective in 2019 for applicable drugs. Vanda accounts for the Medicare Part D coverage gap using a point of sale model. Estimates for expected Medicare Part D coverage gap are based in part on historical activity and, where available, actual and pending prescriptions for which the Company has validated the insurance benefits.</span></div><div style="line-height:120%;padding-top:8px;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Service Fees:</span><span style="font-family:inherit;font-size:10pt;"> The Company receives sales order management, data and distribution services from certain customers. These fees are based on contracted terms and are known amounts. The Company accrues service fees at the time of revenue recognition, resulting in a reduction of product sales and the recognition of an accrued liability, unless it is a payment for a distinct good or service from the customer in which case the fair value of those distinct goods or services are recorded as selling, general and administrative expense.</span></div><div style="line-height:120%;padding-top:8px;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Co-payment Assistance:</span><span style="font-family:inherit;font-size:10pt;"> Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Co-pay assistance utilization is based on information provided by the Company’s third-party administrator.</span></div><span style="font-family:inherit;font-size:10pt;font-style:italic;">Product Returns</span><span style="font-family:inherit;font-size:10pt;">: The Company generally offers direct customers a limited right to return as contractually defined with the customers. The Company considers several factors in the estimation process, including expiration dates of product shipped to customers, inventory levels within the distribution channel, product shelf life, historical return activity, including activity for product sold for which the return period has past, prescription trends and other relevant factors. The Company does not expect returned goods to be resalable. There was no right of return asset as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2018</span>. 0.50 0.50 0.70 The following table summarizes activity for product returns as of and for the years ended <span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, all of which relates to sales of Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Reserve for Product Returns</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,080</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,978</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Credits/payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,939</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December 31, 2017</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,119</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,684</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Credits/payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,616</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,187</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,138</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Credits/payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,205</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,120</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3080000 5978000 4939000 4119000 2684000 1616000 5187000 3138000 2205000 6120000 <div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Goods Sold</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of goods sold includes royalties payable, the cost of inventory sold, manufacturing and supply chain costs and product shipping and handling costs related to sales of HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> and Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> to the Company’s distribution partners.</span></div> <div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses consist primarily of fees for services provided by third parties in connection with the clinical trials, costs of contract manufacturing services, milestone payments, costs of materials used in clinical trials and research and development, costs for regulatory consultants and filings, depreciation of capital resources used to develop products, related facilities costs, and salaries, other employee-related costs and stock-based compensation for research and development personnel. The Company expenses research and development costs as they are incurred for products in the </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">development stage, including manufacturing costs and milestone payments made under license agreements prior to FDA approval. Upon and subsequent to FDA approval, manufacturing and milestone payments related to license agreements are capitalized. Milestone payments are accrued when it is deemed probable that the milestone event will be achieved. Costs related to the acquisition of intellectual property are expensed as incurred if the underlying technology is developed in connection with the Company’s research and development efforts and has no alternative future use.</span></div> <div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Selling, General and Administrative Expenses</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses consist of salaries, stock-based compensation, facilities and third party expenses. Selling, general and administrative expenses are associated with the activities of the corporate, finance, accounting, information technology, business development, commercial support, trade and distribution, sales, marketing, legal, medical affairs and human resource functions. Additionally, selling, general and administrative expenses included an estimate for the annual Affordable Care Act fee.</span></div> <div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation costs for all stock-based awards to employees and directors are measured based on the grant date fair value of those awards and recognized over the period during which the employee or director is required to perform service in exchange for the award. The Company recognizes the expense over the award’s vesting period. The fair value of stock options granted and restricted stock units (RSUs) awarded are amortized using the straight-line method. As stock-based compensation expense recognized in the consolidated statements of operations is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</span></div> <div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Advertising Expense</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company expenses the costs of advertising, including branded promotional expenses, as incurred. Branded advertising expenses, recorded in selling, general and administrative expenses, were </span><span style="font-family:inherit;font-size:10pt;"><span>$3.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> 3200000 900000 1300000 <div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The reporting currency of the Company is the U.S. dollar. The functional currency of the Company’s international subsidiaries is the local currency. Assets and liabilities denominated in foreign currencies, including intercompany balances for which settlement is anticipated in the foreseeable future, are translated at exchange rates in effect at the balance sheet date. Foreign currency equity balances are translated at historical rates. Revenues and expenses denominated in foreign currencies are translated at average exchange rates for the respective periods. Foreign currency translation adjustments are recorded in </span><span style="font-family:inherit;font-size:10pt;">accumulated other comprehensive income (loss)</span><span style="font-family:inherit;font-size:10pt;">.</span></div>Transactions denominated in currencies other than subsidiaries’ functional currencies are recorded based on exchange rates at the time such transactions arise. Changes in exchange rates with respect to amounts recorded in the consolidated balance sheets related to these items will result in unrealized foreign currency transaction gains and losses based upon period-end exchange rates. The Company also records realized foreign currency transaction gains and losses upon settlement of the transactions. <div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></div>The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. Tax rate changes are reflected in income during the period such changes are enacted. Changes in ownership may limit the amount of net operating loss (NOL) carryforwards that can be utilized in the future to offset taxable income. 1 <div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, </span><span style="font-family:inherit;font-size:10pt;">which clarifies and simplifies certain aspects of the accounting for income taxes.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The standard is effective</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company is evaluating this standard to determine if adoption will have a material impact on the Company’s consolidated financial statements.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the U.S. Securities and Exchange Commission (SEC) adopted the final rule under SEC Release No. 33-10532, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure Update and Simplification. </span><span style="font-family:inherit;font-size:10pt;">This final rule amends certain disclosure requirements that are redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expand the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule is effective for the Company for all filings made on or after November 5, 2018. The SEC staff clarified that the first presentation of the changes in shareholders' equity may be included in the first Form 10-Q for the quarter that begins after the effective date of the amendments. The adoption of the final rule did not have a material impact on the Company’s consolidated financial statements.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments – Credit Losses, </span><span style="font-family:inherit;font-size:10pt;">which changes the impairment model for most financial assets and certain other financial instruments. The standard will require the use of a forward-looking “expected loss” model for instruments measured at amortized cost that generally will result in the earlier recognition of allowances for losses. The standard is effective for years beginning after December 15, 2019, and interim periods within annual periods beginning after December 15, 2019. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial results. </span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-2, Leases (Topic 842), which was further clarified by ASU 2018-10, Codification Improvements to Topic 842, Leases, and ASU 2018-11, Leases - Targeted Improvements, issued in July </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018. ASC 842 supersedes existing lease guidance, including ASC 840 Leases. The new leasing standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The new leasing standard requires that lessees will need to recognize an ROU asset and a lease liability for virtually all of their leases, and allows companies to make a policy election as to whether short term leases will be recognized under the requirements of the new standard. The Company elected to exclude short-term leases in the application of the new standard. The lease liability is equal to the present value of lease payments. The ROU asset is based on the liability subject to certain adjustments. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense, similar to accounting for operating leases under ASC 840, while finance leases will result in a front-loaded expense pattern, similar to accounting for capital leases under ASC 840. </span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted the new leasing standard in the first quarter of 2019, using a modified retrospective transition. There was no impact to the opening balance of retained earnings as of the effective date of January 1, 2019 as a result of adoption. Prior period financial statements were not recast. The Company elected the package of transition provisions available for expired or existing contracts, which allowed it to carryforward its historical assessments of (1) whether contracts are or contain leases, (2) lease classification and (3) initial direct costs. The adoption of the new leasing standard on January 1, 2019 resulted in the recognition of </span><span style="font-family:inherit;font-size:10pt;"><span>$15.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> of operating lease liabilities, </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of which were classified as current liabilities, with corresponding ROU assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$12.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of lease prepayments and the balance of deferred lease incentives. The Company does not have any financing leases.</span></div> 15800000 2200000 12200000 Marketable Securities<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company’s available-for-sale marketable securities as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, which all have contractual maturities of less than </span><span style="font-family:inherit;font-size:10pt;">two years</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Market</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury and government agencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,535</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,601</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129,860</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130,055</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,355</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,401</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total marketable securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>266,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>313</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>267,057</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company’s available-for-sale marketable securities as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, which all have contract maturities of less than </span><span style="font-family:inherit;font-size:10pt;">one year</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized <br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized<br/>Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair<br/>Market<br/>Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury and government agencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,275</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,270</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,897</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,910</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,189</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,175</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total marketable securities, current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196,361</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(56</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196,355</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company’s available-for-sale marketable securities as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, which all have contractual maturities of less than </span><span style="font-family:inherit;font-size:10pt;">two years</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Market</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury and government agencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,535</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,601</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129,860</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130,055</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,355</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,401</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total marketable securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>266,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>313</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>267,057</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company’s available-for-sale marketable securities as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, which all have contract maturities of less than </span><span style="font-family:inherit;font-size:10pt;">one year</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized <br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized<br/>Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair<br/>Market<br/>Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury and government agencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,275</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,270</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,897</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,910</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,189</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,175</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total marketable securities, current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196,361</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(56</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196,355</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 88535000 68000 2000 88601000 129860000 196000 1000 130055000 48355000 49000 3000 48401000 266750000 313000 6000 267057000 69275000 12000 17000 69270000 105897000 38000 25000 105910000 21189000 0 14000 21175000 196361000 50000 56000 196355000 Fair Value Measurements<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1 — defined as observable inputs such as quoted prices in active markets</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:72px;text-indent:-24px;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2 — defined as inputs other than quoted prices in active markets that are either directly or indirectly observable</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:72px;text-indent:-24px;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3 — defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities classified in Level 1 and Level 2 as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> consist of cash equivalents and available-for-sale marketable securities. The valuation of Level 1 instruments is determined using a market approach, and is based upon unadjusted quoted prices for identical assets in active markets. The valuation of investments classified in Level 2 </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">also is determined using a market approach based upon quoted prices for similar assets in active markets, or other inputs that are observable for substantially the full term of the financial instrument. Level 2 securities include certificates of deposit, commercial paper, corporate notes, and asset-backed securities that use as their basis readily observable market parameters. </span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company held certain assets that are required to be measured at fair value on a recurring basis as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurement as of December 31, 2019 Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets for</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identical Assets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury and government agencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,601</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,601</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>137,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>137,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,401</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,401</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274,027</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,601</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>185,426</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company held certain assets that are required to be measured at fair value on a recurring basis as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurement as of December 31, 2018 Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in<br/>Active Markets for<br/>Identical Assets<br/>(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury and government agencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,270</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,270</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,910</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,910</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,175</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,175</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196,355</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,270</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127,085</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> include </span><span style="font-family:inherit;font-size:10pt;"><span>$7.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of cash equivalents.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also has financial assets and liabilities, not required to be measured at fair value on a recurring basis, which primarily consist of cash, accounts receivable, restricted cash, accounts payable and accrued liabilities, product revenue allowances, and milestone obligations under license agreements, the carrying values of which materially approximate their fair values.</span></div> <div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company held certain assets that are required to be measured at fair value on a recurring basis as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurement as of December 31, 2019 Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets for</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identical Assets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury and government agencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,601</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,601</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>137,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>137,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,401</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,401</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274,027</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,601</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>185,426</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company held certain assets that are required to be measured at fair value on a recurring basis as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurement as of December 31, 2018 Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in<br/>Active Markets for<br/>Identical Assets<br/>(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury and government agencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,270</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,270</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,910</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,910</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,175</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,175</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196,355</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,270</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127,085</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 88601000 88601000 0 0 137025000 0 137025000 0 48401000 0 48401000 0 274027000 88601000 185426000 0 69270000 69270000 0 0 105910000 0 105910000 0 21175000 0 21175000 0 196355000 69270000 127085000 0 7000000.0 Inventory<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluates expiry risk by evaluating current and future product demand relative to product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. Inventory levels are evaluated for the amount of inventory that would be sold within one year. At certain times, the level of inventory can exceed the forecasted level of cost of goods sold for the next twelve months. The Company classifies the estimate of such inventory as non-current. Inventory consisted of the following as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Current assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,140</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>946</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventory, current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,140</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>994</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-Current assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>659</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,109</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,290</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,056</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>516</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventory, non-current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,824</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,892</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> Inventory consisted of the following as of <span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Current assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,140</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>946</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventory, current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,140</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>994</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-Current assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>659</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,109</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,290</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,056</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>516</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventory, non-current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,824</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,892</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 48000 1140000 946000 1140000 994000 659000 86000 1109000 2290000 1056000 516000 2824000 2892000 Property and Equipment<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company’s property and equipment, at cost, as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:59%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Useful Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer and other equipment</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,398</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,642</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5 - 7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,491</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,488</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5 - 11</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,587</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,506</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total property and equipment, gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,476</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,636</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated depreciation and amortization</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,612</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,219</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total property and equipment, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,864</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,417</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> <div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company’s property and equipment, at cost, as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:59%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Useful Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer and other equipment</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,398</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,642</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5 - 7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,491</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,488</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5 - 11</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,587</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,506</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total property and equipment, gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,476</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,636</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated depreciation and amortization</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,612</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,219</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total property and equipment, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,864</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,417</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> P3Y 4398000 3642000 1491000 1488000 4587000 4506000 10476000 9636000 6612000 5219000 3864000 4417000 1400000 1400000 1200000 Leases<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's long-term leases primarily include operating leases and subleases for office space in Washington, D.C. and London, England. The Company recognized ROU assets and lease liabilities related to fixed payments for these long-term operating leases in its Consolidated Balance Sheet as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Company also has short-term leases, including office space in Berlin, Germany.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2011, the Company entered into an operating lease agreement under which it leases </span><span style="font-family:inherit;font-size:10pt;"><span>33,534</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office space for its headquarters at 2200 Pennsylvania Avenue, N.W. in Washington, D.C. Subject to the prior rights of other tenants, the Company has the right to renew the lease for </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;"> following its expiration in July 2028. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the renewal period has not been included in the lease term. The Company has the right to sublease or assign all or a portion of the premises, subject to standard conditions. The lease may be terminated early by the Company or the landlord under certain circumstances.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the Company entered into a sublease agreement under which it subleases an additional </span><span style="font-family:inherit;font-size:10pt;"><span>9,928</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office space for its headquarters at 2200 Pennsylvania Avenue, N.W. in Washington, D.C. The sublease term began in January 2017 and ends in July 2026, but may be terminated earlier by either party under certain circumstances. The Company has the right to sublease or assign all or a portion of the premises, subject to standard conditions.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2016, the Company entered into an operating lease agreement under which it leases </span><span style="font-family:inherit;font-size:10pt;"><span>2,880</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office space in London, England. The Company has the right to renew the lease for </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;"> following its expiration in 2021. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the renewal period has not been included in the lease term. </span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company’s ROU assets and operating lease liabilities as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:35%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Classification on the Balance Sheet</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,180</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,147</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease non-current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease non-current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,602</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:19.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon adoption of the new lease standard, discount rates used for existing leases were established at January 1, 2019.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized operating lease cost of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and short-term operating lease cost of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company also recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of expense related to non-lease elements, such as building maintenance services and utilities, and executory costs associated with the operating leases. For existing leases as of January 1, 2019, executory costs are excluded from operating lease expense, which is consistent with the Company's accounting under ASC 840. For all leases entered into after January 1, 2019, executory costs are allocated between lease and non-lease elements based upon their relative stand-alone prices. For the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$3.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of rent expense, respectively, inclusive of lease expense, non-lease elements, and executory costs for short and long-term operating leases. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of operating lease liabilities is included in operating cash flows and was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below reconciles the Company's future cash obligations to operating lease liabilities recorded on the balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,326</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,332</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,420</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,488</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,182</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,103</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: amount of lease payments representing interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,501</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of future minimum lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,602</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: current obligations under leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,147</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease non-current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At December 31, 2018, future minimum payments under noncancellable operating leases under ASC 840 were as follows:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash Payments Due by Year</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,757</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,483</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,495</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,335</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,420</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,669</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 33534 P5Y 9928 2880 P5Y <div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company’s ROU assets and operating lease liabilities as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:35%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Classification on the Balance Sheet</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,180</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,147</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease non-current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease non-current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,602</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:19.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon adoption of the new lease standard, discount rates used for existing leases were established at January 1, 2019.</span></div> 11180000 2147000 12455000 14602000 P8Y1M6D 0.081 2300000 400000 1400000 3600000 3200000 2500000 <div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below reconciles the Company's future cash obligations to operating lease liabilities recorded on the balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,326</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,332</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,420</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,488</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,182</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,103</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: amount of lease payments representing interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,501</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of future minimum lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,602</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: current obligations under leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,147</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease non-current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2326000 2332000 2355000 2420000 2488000 8182000 20103000 5501000 14602000 2147000 12455000 <div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At December 31, 2018, future minimum payments under noncancellable operating leases under ASC 840 were as follows:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash Payments Due by Year</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,757</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,483</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,495</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,335</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,420</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,669</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 22757000 2483000 2495000 2335000 2355000 2420000 10669000 Intangible Assets<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span><span style="font-family:inherit;font-size:10pt;"> In January 2014, the Company announced that the FDA had approved the New Drug Application (NDA) for HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">. As a result of this approval, the Company met a milestone under its license agreement with Bristol-Myers Squibb (BMS) that required the Company to make a license payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to BMS. The </span><span style="font-family:inherit;font-size:10pt;"><span>$8.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> is being amortized on a straight-line basis over the estimated economic useful life of the related product patents, the latest of which expires in </span><span style="font-family:inherit;font-size:10pt;">July 2035</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2018, the Company met its final milestone under its license agreement when cumulative worldwide sales of HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> reached </span><span style="font-family:inherit;font-size:10pt;"><span>$250.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. As a result of the achievement of this milestone, the Company made a payment to BMS of </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2018. The </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was capitalized as an intangible asset in the first quarter of 2015, was determined to be additional consideration for the acquisition of the HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> intangible asset and is being amortized on a straight-line basis over the estimated economic useful life of the related product patents, the latest of which expires in </span><span style="font-family:inherit;font-size:10pt;">July 2035</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated economic useful life of both the </span><span style="font-family:inherit;font-size:10pt;"><span>$8.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and the </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> intangible assets were changed from </span><span style="font-family:inherit;font-size:10pt;">February 2035</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">July 2035</span><span style="font-family:inherit;font-size:10pt;"> based on the July 2035 expiration date of U.S. patent number 10,376,487 ('487 Patent) issued by the U.S. Patent and Trademark Office in August 2019. The estimated economic useful life of these intangible assets were </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">previously changed from </span><span style="font-family:inherit;font-size:10pt;">May 2034</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">February 2035</span><span style="font-family:inherit;font-size:10pt;"> based on the February 2035 expiration date of U.S. patent number 10,071,977 ('977 Patent) issued by the U.S. Patent and Trademark Office in September 2018.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company’s intangible assets as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:43%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Useful Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 2035</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,963</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,037</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company’s intangible assets as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:43%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Useful Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2035</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,458</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,542</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company also had </span><span style="font-family:inherit;font-size:10pt;"><span>$27.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of fully amortized intangible assets related to Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets are amortized over their estimated useful economic life using the straight-line method. Amortization expense for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,505</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,527</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the future intangible asset amortization schedule as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:24%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Thereafter</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,037</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,647</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 8000000.0 8000000.0 250000000.0 25000000.0 25000000.0 8000000.0 25000000.0 <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company’s intangible assets as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:43%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Useful Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 2035</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,963</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,037</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company’s intangible assets as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:43%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Useful Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2035</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,458</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,542</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 33000000 9963000 23037000 33000000 8458000 24542000 27900000 Amortization expense for the years ended <span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was as follows:</span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,505</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,527</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1505000 1527000 1750000 <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the future intangible asset amortization schedule as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:24%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Thereafter</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,037</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,647</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 23037000 1478000 1478000 1478000 1478000 1478000 15647000 Accounts Payable and Accrued Liabilities<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company’s accounts payable and accrued liabilities as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation and employee benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,597</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,363</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalties payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,904</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,172</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,893</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,593</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consulting and other professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,376</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,924</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,147</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,673</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,532</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,584</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company’s accounts payable and accrued liabilities as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation and employee benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,597</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,363</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalties payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,904</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,172</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,893</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,593</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consulting and other professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,376</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,924</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,147</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,673</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,532</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,584</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 6597000 6363000 5904000 5172000 5893000 5593000 5376000 2924000 2147000 0 1673000 1532000 27590000 21584000 Commitments and Contingencies<div style="line-height:120%;padding-top:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Guarantees and Indemnifications</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has entered into a number of standard intellectual property indemnification agreements in the ordinary course of its business. Pursuant to these agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company’s business partners or customers, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to the Company’s products. The term of these indemnification agreements is generally perpetual from the date of execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. Since inception, the Company has not incurred costs to defend </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lawsuits or settle claims related to these indemnification agreements. The Company also indemnifies its officers and directors for certain events or occurrences, subject to certain conditions.</span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreements</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s rights to develop and commercialize its products are subject to the terms and conditions of licenses granted to the Company by other pharmaceutical companies.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span><span style="font-family:inherit;font-size:10pt;"> In February 2004, the Company entered into a license agreement with BMS under which it received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">. To date, the Company has paid BMS </span><span style="font-family:inherit;font-size:10pt;"><span>$37.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> in upfront fees and milestone obligations, including </span><span style="font-family:inherit;font-size:10pt;"><span>$33.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of regulatory approval and commercial milestones capitalized as intangible assets (see Note 8). The Company has no remaining milestone obligations to BMS. Additionally, the Company is obligated to make royalty payments on HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> net sales to BMS in any territory where the Company commercializes HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> for a period equal to the greater of 10 years following the first commercial sale in the territory or the expiry of the new chemical entity (NCE) patent in that territory. During the period prior to the expiry of the NCE patent in a territory, the Company is obligated to pay a </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> royalty on net sales in that territory. The royalty rate is decreased by half for countries in which no NCE patent existed or for the remainder of the 10 years after the expiry of the NCE patent. The Company is also obligated under the license agreement to pay BMS a percentage of any sublicense fees, upfront payments and milestone and other payments (excluding royalties) that it receives from a third party in connection with any sublicensing arrangement, at a rate which is in the </span><span style="font-family:inherit;font-size:10pt;"><span>mid-twenties</span></span><span style="font-family:inherit;font-size:10pt;">. The Company has agreed with BMS in the license agreement for HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> to use its commercially reasonable efforts to develop and commercialize HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span><span style="font-family:inherit;font-size:10pt;"> Pursuant to the terms of a settlement agreement with Novartis, Novartis transferred all U.S. and Canadian rights in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> franchise to the Company on December 31, 2014. The Company paid directly to Sanofi S.A. (Sanofi) a fixed royalty of </span><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span><span style="font-family:inherit;font-size:10pt;"> of net sales from November 16, 2016 through December 31, 2019 related to manufacturing know-how. The Company is also obligated to pay Sanofi a fixed royalty on Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> net sales equal to </span><span style="font-family:inherit;font-size:10pt;"><span>6%</span></span><span style="font-family:inherit;font-size:10pt;"> on Sanofi know-how not related to manufacturing under certain conditions for a period of up to </span><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span><span style="font-family:inherit;font-size:10pt;"> in markets where the NCE patent has expired or was not issued. The Company is obligated to pay this 6% royalty on net sales in the U.S. through November 2026.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Tradipitant.</span><span style="font-family:inherit;font-size:10pt;"> In April 2012, the Company entered into a license agreement with Eli Lilly and Company (Lilly) pursuant to which the Company acquired an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize an NK-1R antagonist, tradipitant, for all human indications. Lilly is eligible to receive future payments based upon achievement of specified development, regulatory approval and commercialization milestones as well as tiered-royalties on net sales at percentage rates up to the </span><span style="font-family:inherit;font-size:10pt;"><span>low double digits</span></span><span style="font-family:inherit;font-size:10pt;">. To date, the Company has paid Lilly </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in upfront fees and development milestones, including a </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment in July 2018 as a result of enrolling the first subject into a Phase III study for tradipitant. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, remaining milestone obligations include a </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> development milestone due upon the filing of the first marketing authorization for tradipitant either in the U.S. or European Union (E.U.), </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the first approval of a marketing authorization for tradipitant in the U.S. and E.U., respectively, and up to </span><span style="font-family:inherit;font-size:10pt;"><span>$80 million</span></span><span style="font-family:inherit;font-size:10pt;"> for sales milestones. The Company is obligated to use its commercially reasonable efforts to develop and commercialize tradipitant.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">VQW-765.</span><span style="font-family:inherit;font-size:10pt;"> In connection with a settlement agreement with Novartis relating to Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">, the Company received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. Pursuant to the license agreement, the Company is obligated to use its commercially reasonable efforts to develop and commercialize VQW-765 and is responsible for all development costs. The Company has no milestone obligations; however, Novartis is eligible to receive tiered-royalties on net sales at percentage rates up to the mid-teens.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Portfolio of CFTR activators and inhibitors</span><span style="font-family:inherit;font-size:10pt;">. In March 2017, the Company entered into a license agreement with the University of California San Francisco (UCSF), under which the Company acquired an exclusive worldwide license to develop and commercialize a portfolio of CFTR activators and inhibitors. Pursuant to the license agreement, the Company will develop and commercialize the CFTR activators and inhibitors and is responsible for all development costs under the license agreement, including current pre-investigational new drug development work. UCSF is eligible to receive future payments based upon achievement of specified development and commercialization milestones as well as </span><span style="font-family:inherit;font-size:10pt;"><span>single-digit</span></span><span style="font-family:inherit;font-size:10pt;"> royalties on net sales. To date, the Company has paid UCSF </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in upfront fees and development milestones, including an upfront license fee payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2017 and a </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> development milestone payment in the March 2019. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, remaining milestone obligations include </span><span style="font-family:inherit;font-size:10pt;"><span>$12.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> for development milestones and </span><span style="font-family:inherit;font-size:10pt;"><span>$33.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for future </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory approval and sales milestones. Included in the </span><span style="font-family:inherit;font-size:10pt;"><span>$12.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in development milestones is a </span><span style="font-family:inherit;font-size:10pt;"><span>$350,000</span></span><span style="font-family:inherit;font-size:10pt;"> milestone due upon the conclusion of a Phase I study for each licensed product but not to exceed </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in total for the CFTR portfolio.</span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Commitments</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the course of its business, the Company regularly enters into agreements with clinical organizations to provide services relating to clinical development and clinical manufacturing activities under fee service arrangements. The Company’s current agreements for clinical and marketing services may be terminated on generally </span><span style="font-family:inherit;font-size:10pt;"><span>90</span></span><span style="font-family:inherit;font-size:10pt;"> days’ notice without incurring additional charges, other than charges for work completed but not paid for through the effective date of termination and other costs incurred by the Company’s contractors in closing out work in progress as of the effective date of termination. Noncancellable long-term contractual cash obligations include noncancellable purchase commitments longer than one year and primarily relate to commitments for media and data services, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$9.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> are expected to be paid in </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2021</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2022</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> 37500000 33000000.0 0.10 mid-twenties 0.03 0.06 P10Y low double digits 3000000.0 2000000.0 2000000.0 10000000.0 5000000.0 80000000 single-digit 1200000 1000000.0 200000 12200000 33000000.0 12200000 350000 1100000 P90D 9200000 1000000.0 500000 Public Offering of Common Stock<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2018, the Company completed a public offering of </span><span style="font-family:inherit;font-size:10pt;"><span>6,325,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock, including the exercise of the underwriters’ option to purchase an additional </span><span style="font-family:inherit;font-size:10pt;"><span>825,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, at a price to the public of </span><span style="font-family:inherit;font-size:10pt;"><span>$17.00</span></span><span style="font-family:inherit;font-size:10pt;"> per share. Net cash proceeds from the public offering were </span><span style="font-family:inherit;font-size:10pt;"><span>$100.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting the underwriting discounts and commissions and offering expenses.</span></div> 6325000 825000 17.00 100900000 Accumulated Other Comprehensive Income<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accumulated balances related to each component of other comprehensive income (loss), net of taxes, were as follows for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized gain (loss) on marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>236</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>249</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> reclassifications out of </span><span style="font-family:inherit;font-size:10pt;">accumulated other comprehensive income (loss)</span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div> <div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accumulated balances related to each component of other comprehensive income (loss), net of taxes, were as follows for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized gain (loss) on marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>236</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>249</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 13000 7000 236000 -6000 249000 1000 0 Stock-Based Compensation<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span>6,144,430</span></span><span style="font-family:inherit;font-size:10pt;"> shares that were subject to outstanding options and RSUs under the 2006 Equity Incentive Plan (2006 Plan) and the Amended and Restated 2016 Equity Incentive Plan (2016 Plan, and together with the 2006 Plan, Plans). The 2006 Plan expired by its terms on April 12, 2016, and the Company adopted the 2016 Plan. Outstanding options and RSUs under the 2006 Plan remain in effect and the terms of the 2006 Plan continue to apply, but no additional awards can be granted under the 2006 Plan. In June 2016, the Company’s stockholders approved the 2016 Plan. The 2016 Plan has been amended and restated twice to increase the number of shares reserved for issuance, among other administrative changes. Both amendments and restatements of the 2016 Plan were approved by the Company's stockholders. There are a total of </span><span style="font-family:inherit;font-size:10pt;"><span>7,100,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock reserved for issuance under the 2016 Plan, </span><span style="font-family:inherit;font-size:10pt;"><span>3,026,147</span></span><span style="font-family:inherit;font-size:10pt;"> shares of which remained available for future grant as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has granted option awards under the Plans with service conditions (service option awards) that are subject to terms and conditions established by the compensation committee of the board of directors. Service option awards have </span><span style="font-family:inherit;font-size:10pt;"><span>10</span></span><span style="font-family:inherit;font-size:10pt;">-year contractual terms. Service option awards granted to employees and new directors upon their election vest and become exercisable over </span><span style="font-family:inherit;font-size:10pt;"><span>four years</span></span><span style="font-family:inherit;font-size:10pt;">, with the first </span><span style="font-family:inherit;font-size:10pt;"><span>25%</span></span><span style="font-family:inherit;font-size:10pt;"> of the shares subject to service option awards vesting on the first anniversary of the grant date and the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>75%</span></span><span style="font-family:inherit;font-size:10pt;"> of the shares subject to the service option awards in </span><span style="font-family:inherit;font-size:10pt;"><span>36</span></span><span style="font-family:inherit;font-size:10pt;"> equal monthly installments thereafter. Subsequent annual service option awards granted to directors vest and become exercisable in full on the first anniversary of the grant date. Certain service option awards to executives and directors provide for accelerated vesting if there is a change in control of the Company. Certain service option awards to employees and executives provide for accelerated vesting if the respective employee’s or executive’s service is terminated by the Company for any reason other than cause or permanent disability. </span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$9.8</span></span><span style="font-family:inherit;font-size:10pt;"> million of unrecognized compensation costs related to unvested service option awards are expected to be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span><span style="font-family:inherit;font-size:10pt;"> years. No option awards are classified as a liability as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of option activity for the 2006 Plan and the 2016 Plan for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:43%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2006 and 2016 Plans</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;font-style:italic;">(in thousands, except for share and per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price at Grant Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Remaining Term</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,548,336</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,453</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>643,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(290,729</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(605,617</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.87</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(575,206</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding at December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,719,784</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.03</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.63</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,421</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>567,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(232,527</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.99</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(685,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,945</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,369,042</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.28</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,438</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>687,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(53</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(546,344</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,482</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,495,145</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,148</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,371,836</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.53</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,200</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,354,708</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.02</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average grant-date fair value of options granted was </span><span style="font-family:inherit;font-size:10pt;"><span>$10.19</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$10.66</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$7.81</span></span><span style="font-family:inherit;font-size:10pt;"> per share for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. Proceeds from the exercise of stock options amounted to </span><span style="font-family:inherit;font-size:10pt;"><span>$6.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$6.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$5.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Units</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">An RSU is a stock award that entitles the holder to receive shares of the Company’s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company’s stock on the date of grant. The Company has granted RSUs under the Plans with service conditions (service RSUs) that vest in </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> equal annual installments provided that the employee remains employed with the Company. Annual service RSUs granted to directors vest on the first anniversary of the grant date.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$22.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> of unrecognized compensation costs related to unvested service RSUs are expected to be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span><span style="font-family:inherit;font-size:10pt;"> years. No RSUs are classified as a liability as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of RSU activity for the 2006 Plan and the 2016 Plan for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">RSUs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant Date Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,138,428</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>857,336</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(275,613</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(362,313</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unvested at December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,357,838</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.72</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>714,086</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(229,603</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(528,745</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,313,576</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>937,328</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(75,444</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(526,175</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,649,285</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The grant date fair value for the </span><span style="font-family:inherit;font-size:10pt;"><span>526,175</span></span><span style="font-family:inherit;font-size:10pt;"> shares underlying RSUs that vested during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$7.7 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:24px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation Expense</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense recognized for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was allocated as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,207</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,290</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,152</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,376</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,313</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,458</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,666</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,465</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model that uses the assumptions noted in the following table. Expected volatility rates are based on the historical volatility of the Company’s publicly traded common stock and other factors. The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has never paid cash dividends to its stockholders and does not plan to pay dividends in the foreseeable future. Assumptions used in the Black-Scholes-Merton option pricing model for employee and director stock options granted during the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:56%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average expected volatility</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average expected term (years)</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.95</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average risk-free rate</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.26</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.68</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.97</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 6144430 7100000 3026147 P10Y P4Y 0.25 0.75 36 9800000 P1Y4M24D <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of option activity for the 2006 Plan and the 2016 Plan for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:43%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2006 and 2016 Plans</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;font-style:italic;">(in thousands, except for share and per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price at Grant Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Remaining Term</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,548,336</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,453</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>643,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(290,729</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(605,617</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.87</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(575,206</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding at December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,719,784</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.03</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.63</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,421</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>567,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(232,527</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.99</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(685,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,945</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,369,042</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.28</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,438</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>687,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(53</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(546,344</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,482</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,495,145</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,148</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,371,836</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.53</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,200</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,354,708</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.02</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 5548336 11.62 P5Y6M29D 32453000 643000 14.44 290729 10.73 605617 29.87 575206 9.13 3140000 4719784 10.03 P5Y7M17D 24421000 567500 19.22 232527 13.99 685715 9.12 5945000 4369042 11.15 P5Y3M10D 65438000 687500 18.38 53 7.94 15000 14.78 546344 11.47 2482000 4495145 12.21 P5Y6M29D 22148000 3371836 10.31 P4Y6M10D 21200000 4354708 12.02 P5Y5M15D 22039000 10.19 10.66 7.81 6300000 6300000 5300000 4 22800000 P1Y9M18D <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of RSU activity for the 2006 Plan and the 2016 Plan for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">RSUs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant Date Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,138,428</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>857,336</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(275,613</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(362,313</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unvested at December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,357,838</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.72</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>714,086</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(229,603</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(528,745</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,313,576</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>937,328</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(75,444</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(526,175</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,649,285</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1138428 10.07 857336 14.57 275613 11.41 362313 9.78 1357838 12.72 714086 18.93 229603 15.19 528745 12.69 1313576 15.68 937328 19.46 75444 18.93 526175 14.54 1649285 18.04 526175 7700000 <div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense recognized for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was allocated as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,207</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,290</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,152</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,376</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,313</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,458</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,666</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,465</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3207000 1290000 1152000 10251000 10376000 9313000 13458000 11666000 10465000 Assumptions used in the Black-Scholes-Merton option pricing model for employee and director stock options granted during the years ended <span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:56%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average expected volatility</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average expected term (years)</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.95</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average risk-free rate</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.26</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.68</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.97</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 0 0 0.58 0.58 0.57 P5Y11M12D P5Y10M24D P5Y10M20D 0.0226 0.0268 0.0197 Employee Benefit Plan<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has a defined contribution plan under IRC Section 401(k). This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Currently, the Company matches </span><span style="font-family:inherit;font-size:10pt;"><span>fifty percent</span></span><span style="font-family:inherit;font-size:10pt;"> up to the first </span><span style="font-family:inherit;font-size:10pt;"><span>six percent</span></span><span style="font-family:inherit;font-size:10pt;"> of employee contributions. All matching </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">contributions have been paid by the Company. The Company match vests over a </span><span style="font-family:inherit;font-size:10pt;"><span>4</span></span><span style="font-family:inherit;font-size:10pt;">-year period and amounted to </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> 0.50 0.06 P4Y 800000 900000 800000 Income Taxes<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the domestic and foreign components of income (loss) before income taxes for the years ended December 31, 2019, 2018 and 2017:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,794</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,123</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,693</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>234</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>262</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total income (loss) before income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,028</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,346</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,431</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the provision (benefit) for income taxes for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,161</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(66</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(85,624</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,127</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>137</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision (benefit) for income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(86,525</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:24px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company assesses the need for a valuation allowance against its deferred tax asset each quarter through the review of all available positive and negative evidence. Deferred tax assets are reduced by a tax valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. The analysis depends on historical and projected taxable income. Projected taxable income includes significant assumptions related to revenue, commercial expenses and research and development activities. During 2019, after considering all available positive and negative evidence, including but not limited to cumulative income in recent periods, historical, current and future projected results and significant risks and uncertainties related to forecasts, the Company concluded that it was more likely than not that substantially all of its deferred tax assets in the U.S. are realizable in future periods. A valuation allowance has been retained against certain U.S. federal tax attributes with short carryforward periods and District of Columbia state deferred tax assets as of December 31, 2019. A full valuation allowance was recorded against all net U.S. deferred tax assets as of December 31, 2018. </span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The income tax benefit for 2019 was primarily due to the reduction of the Company's valuation allowance against substantially all of its deferred tax assets in the U.S. Tax expense associated with U.S. income before income taxes for the years ended December 31, 2019 and 2018 was offset by a corresponding tax benefit for the reduction of the valuation allowance recorded against tax attributes that were utilized in those periods. Tax benefit associated with U.S. loss before income taxes for the year ended December 31, 2017 was offset by a corresponding tax expense for the increase of the valuation allowance recorded against tax attributes that were generated in that period. The following is reconciliation between the federal statutory tax rate and the Company’s effective tax rate for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal tax at statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Tax Cuts and Job Act (1)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(262.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in valuation allowance - U.S. Tax Cuts and Jobs Act</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>262.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other change in valuation allowance (2)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(357.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development credit (3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Orphan drug credit (3)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Section 162(m) limitation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other tax rate changes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other changes in state deferred taxes (4)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Uncertain tax positions (5)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other items</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(298.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:19.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Includes the effect of the Tax Cuts and Jobs Act, which primarily relates to the remeasurement of existing deferred taxes as a result of the change to the U.S. federal tax rate. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reductions in 2019 valuation allowances include </span><span style="font-family:inherit;font-size:10pt;"><span>$7.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to 2019 U.S. income before income taxes, </span><span style="font-family:inherit;font-size:10pt;"><span>$10.7</span></span><span style="font-family:inherit;font-size:10pt;"> related to adjustments for prior period credit carryforwards and uncertain tax positions and </span><span style="font-family:inherit;font-size:10pt;"><span>$85.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to a change in beginning-of-the-year balances that resulted from a change in circumstances that caused a change in judgment about the realizability of U.S. deferred tax assets in future years. Reductions in 2018 valuation allowances are attributable to 2018 income before income taxes.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 activity includes adjustments to prior year credit carryforwards. As a result of the tax valuation allowance previously recorded against deferred tax assets in the U.S., these adjustments resulted in no change in tax expense.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Includes adjustments to state deferred taxes based on changes to filing jurisdictions. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(5)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 activity includes adjustments to prior year tax positions. As a result of the tax valuation allowance previously recorded against deferred tax assets in the U.S., these adjustments resulted in no change in tax expense. </span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the components of the Company’s deferred tax assets (liabilities) and the related tax valuation allowance as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,034</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,742</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,298</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,202</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued and deferred expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,096</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allowance for returns and uncollectable receivables</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,468</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,247</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development and orphan drug credit carryforwards</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,041</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,066</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,301</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,405</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98,243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113,758</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,994</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,247</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(414</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(576</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,408</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,823</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95,835</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,155</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111,950</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax assets (liabilities)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87,680</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s net deferred tax liability of less than </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of December 31, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> is included as a component of other non-current liabilities. </span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of changes in the Company’s tax valuation allowance for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">of Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Additions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Reductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">End of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111,950</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(103,795</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,155</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116,110</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,036</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,196</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111,950</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146,012</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,403</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42,305</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116,110</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has NOL and other tax credit carryforwards in several jurisdictions. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company has </span><span style="font-family:inherit;font-size:10pt;"><span>$43.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> of deferred tax assets relating to U.S. federal NOL carryforwards, along with deferred tax assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$12.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$24.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to U.S. federal research and development credits and orphan drug credits, respectively. These tax attributes will begin to expire in </span><span style="font-family:inherit;font-size:10pt;"><span>2031</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>2024</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>2030</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. In addition, the Company has </span><span style="font-family:inherit;font-size:10pt;"><span>$8.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> of deferred tax assets relating to U.S. state NOL carryforwards, which primarily relate to the District of Columbia. State NOLs for the District of Columbia will begin to expire in </span><span style="font-family:inherit;font-size:10pt;"><span>2031</span></span><span style="font-family:inherit;font-size:10pt;"> and other state NOLs will begin to expire in </span><span style="font-family:inherit;font-size:10pt;">2021</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits at the beginning of the year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases related to prior year tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,223</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases related to current year tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,518</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits at the end of the year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,741</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The amount of uncertain tax benefits that, if recognized, would impact the effective tax rate is </span><span style="font-family:inherit;font-size:10pt;"><span>$9.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. No material income tax interest or penalties have been recorded, and unrecognized tax benefits are not expected to change materially over the next 12 months. Income tax returns filed by the Company for all periods are open to examination by tax jurisdictions. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company is not under examination by any federal or state tax jurisdiction.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain tax attributes of the Company, including NOLs and credits, would be subject to a limitation should an ownership change as defined under the Internal Revenue Code of 1986, as amended (IRC), Section 382, occur. The limitations resulting from a change in ownership could affect the Company’s ability to utilize its NOLs and credit carryforward (tax attributes). Ownership changes occurred in the years ending December 31, 2014 and December 31, 2008. The Company believes that the ownership changes in 2014 and 2008 will not impact its ability to utilize NOL and credit carryforwards; however, future ownership changes may cause the Company’s existing tax attributes to have additional limitations. </span></div><span style="font-family:inherit;font-size:10pt;">The Tax Cuts and Jobs Act (TCJA) was enacted in December 2017. The TCJA reduces the U.S. federal corporate tax rate from </span><span style="font-family:inherit;font-size:10pt;">35%</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">21%</span>, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously deferred and creates new taxes on certain foreign sourced earnings. During the fourth quarter of 2018, the Company completed its accounting for the tax effects of the TCJA. Effects of the TCJA resulted in no tax expense in 2018 or 2017 as they were fully offset by a change in the Company's tax valuation allowance. <div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the domestic and foreign components of income (loss) before income taxes for the years ended December 31, 2019, 2018 and 2017:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,794</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,123</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,693</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>234</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>262</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total income (loss) before income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,028</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,346</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,431</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 28794000 25123000 -15693000 234000 223000 262000 29028000 25346000 -15431000 <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the provision (benefit) for income taxes for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,161</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(66</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(85,624</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,127</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>137</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision (benefit) for income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(86,525</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 0 0 1161000 53000 65000 81000 99000 -66000 -85624000 0 0 -2127000 0 0 -16000 -14000 137000 -86525000 138000 136000 The following is reconciliation between the federal statutory tax rate and the Company’s effective tax rate for the years ended <span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal tax at statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Tax Cuts and Job Act (1)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(262.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in valuation allowance - U.S. Tax Cuts and Jobs Act</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>262.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other change in valuation allowance (2)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(357.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development credit (3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Orphan drug credit (3)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Section 162(m) limitation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other tax rate changes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other changes in state deferred taxes (4)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Uncertain tax positions (5)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other items</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(298.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:19.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Includes the effect of the Tax Cuts and Jobs Act, which primarily relates to the remeasurement of existing deferred taxes as a result of the change to the U.S. federal tax rate. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reductions in 2019 valuation allowances include </span><span style="font-family:inherit;font-size:10pt;"><span>$7.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to 2019 U.S. income before income taxes, </span><span style="font-family:inherit;font-size:10pt;"><span>$10.7</span></span><span style="font-family:inherit;font-size:10pt;"> related to adjustments for prior period credit carryforwards and uncertain tax positions and </span><span style="font-family:inherit;font-size:10pt;"><span>$85.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to a change in beginning-of-the-year balances that resulted from a change in circumstances that caused a change in judgment about the realizability of U.S. deferred tax assets in future years. Reductions in 2018 valuation allowances are attributable to 2018 income before income taxes.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 activity includes adjustments to prior year credit carryforwards. As a result of the tax valuation allowance previously recorded against deferred tax assets in the U.S., these adjustments resulted in no change in tax expense.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Includes adjustments to state deferred taxes based on changes to filing jurisdictions. </span></div></td></tr></table><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(5)</span></div>2019 activity includes adjustments to prior year tax positions. As a result of the tax valuation allowance previously recorded against deferred tax assets in the U.S., these adjustments resulted in no change in tax expense. 0.210 0.210 0.350 0.018 0.017 0.017 0 0 -2.626 0 0 2.626 -3.576 -0.164 -0.478 0.109 0.091 -0.090 0.171 -0.027 0.063 0.027 0.031 0.081 -0.005 -0.007 -0.026 0 0.059 0.051 0.263 0 0 -0.010 -0.039 -0.130 0.030 0.016 -0.027 -2.981 0.005 -0.009 -7500000 -10700000 -85600000 <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the components of the Company’s deferred tax assets (liabilities) and the related tax valuation allowance as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,034</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,742</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,298</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,202</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued and deferred expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,096</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allowance for returns and uncollectable receivables</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,468</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,247</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development and orphan drug credit carryforwards</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,041</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,066</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,301</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,405</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98,243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113,758</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,994</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,247</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(414</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(576</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,408</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,823</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95,835</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,155</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111,950</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax assets (liabilities)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87,680</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 52034000 55742000 5298000 5202000 2101000 2096000 1468000 1247000 36041000 48066000 1301000 1405000 98243000 113758000 1994000 1247000 414000 576000 2408000 1823000 95835000 111935000 8155000 111950000 87680000 15000 100000 <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of changes in the Company’s tax valuation allowance for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">of Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Additions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Reductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">End of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111,950</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(103,795</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,155</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116,110</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,036</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,196</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111,950</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146,012</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,403</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42,305</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116,110</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 111950000 0 103795000 8155000 116110000 4036000 8196000 111950000 146012000 12403000 42305000 116110000 43300000 12000000.0 24000000.0 2031 2024 2030 8700000 2031 <div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits at the beginning of the year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases related to prior year tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,223</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases related to current year tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,518</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits at the end of the year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,741</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 0 0 8223000 0 0 1518000 0 0 9741000 0 0 9700000 Earnings per Share<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic earnings per share (EPS) is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding. Diluted EPS is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding, plus potential outstanding common stock for the period. Potential outstanding common stock includes stock options and shares underlying RSUs, but only to the extent that their inclusion is dilutive.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the calculation of basic and diluted net income (loss) per share of common stock for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands, except for share and per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,553</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,567</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,137,562</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,859,947</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,735,146</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,709,498</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,185,310</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,847,060</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,045,257</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,735,146</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic and diluted:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.17</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.50</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.48</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Antidilutive securities excluded from calculations of diluted net income (loss) per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,932,024</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>903,265</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,136,515</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company incurred a net loss for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;"> causing inclusion of any potentially dilutive securities to have an anti-dilutive effect, resulting in dilutive loss per share and basic loss per share attributable to common stockholders being equivalent.</span></div> Earnings per Share<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic earnings per share (EPS) is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding. Diluted EPS is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding, plus potential outstanding common stock for the period. Potential outstanding common stock includes stock options and shares underlying RSUs, but only to the extent that their inclusion is dilutive.</span></div> <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the calculation of basic and diluted net income (loss) per share of common stock for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands, except for share and per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,553</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,567</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,137,562</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,859,947</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,735,146</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,709,498</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,185,310</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,847,060</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,045,257</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,735,146</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic and diluted:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.17</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.50</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.48</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Antidilutive securities excluded from calculations of diluted net income (loss) per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,932,024</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>903,265</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,136,515</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 115553000 25208000 -15567000 53137562 50859947 44735146 1709498 2185310 0 54847060 53045257 44735146 2.17 0.50 -0.35 2.11 0.48 -0.35 1932024 903265 3136515 Legal Matters<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fanapt</span><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">. The Company has been involved in litigation with Roxane Laboratories, Inc. (Roxane) and its affiliates, West-Ward Pharmaceuticals International Limited and West-Ward Pharmaceuticals Corp (West-Ward), since the Company filed a lawsuit against Roxane in the U.S. District Court for the District of Delaware (Delaware District Court) for patent infringement in June 2014. The lawsuit was filed in response to Roxane’s submission to the U.S. Food and Drug Administration (FDA) of an Abbreviated New Drug Application (ANDA) for a generic version of Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> prior to the expiration of certain of the Company’s patents covering Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">, including U.S. Patent No. 8,586,610 (‘610 Patent). In August 2016, the Delaware District Court ruled in the Company’s favor, permanently enjoining Roxane from manufacturing, using, </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">selling, offering to sell, distributing or importing any generic iloperidone product described in Roxane’s ANDA until the expiration of the ‘610 Patent in November 2027, or May 2028 if the Company obtains pediatric exclusivity. In April 2018, following an appeal by Roxane of the Delaware District Court’s decision to the Federal Circuit Court of Appeals (Federal Circuit), the Federal Circuit affirmed the Delaware District Court’s ruling. In June 2018, West-Ward, having replaced Roxane as defendants following the acquisition of Roxane by West-Ward’s parent company, Hikma Pharmaceuticals PLC, petitioned the Federal Circuit for a rehearing en banc. In August 2018, the Federal Circuit denied West-Ward's petition. In January 2019, West-Ward filed a petition in the U.S. Supreme Court for a writ of certiorari seeking reversal of the Federal Circuit’s decision. In March 2019, the U.S. Supreme Court invited the Solicitor General of the U.S. to file a brief in the matter expressing the views of the U.S. In January 2020, the U.S. Supreme Court denied West-Ward's petition for writ of certiorari.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2015, the Company filed six separate patent infringement lawsuits in the Delaware District Court against Roxane, Inventia Healthcare Pvt. Ltd. (Inventia), Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin), Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd. (Taro), and Apotex Inc. and Apotex Corp. (Apotex, and collectively with Roxane, Inventia, Lupin and Taro, the Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants). These lawsuits were filed in response to the submission to the FDA by each of the Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">Defendants of ANDAs for generic versions of Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> prior to the expiration of the ‘610 Patent in November 2027 or the U.S. Patent No. 9,138,432 in September 2025. The Company entered into separate confidential stipulations with each of Inventia and Lupin regarding any potential launch of their generic versions of Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">. The parties are scheduled to provide the court with a status report in March 2020 with respect to the remaining lawsuits against the other Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">Defendants.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">. In April and May 2018, the Company filed three separate patent infringement lawsuits in the Delaware District Court against Teva Pharmaceuticals USA, Inc. (Teva), MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (MSN) and Apotex (collectively with Teva and MSN, the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants) after having received Paragraph IV certification notice letters (Paragraph IV Letters) from each of the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants alleging that certain of the Company's patents covering HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> (collectively, the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> Patents) were invalid, unenforceable and/or would not be infringed by the manufacture, use or sale of their generic versions of HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">, as described in the ANDAs submitted to the FDA by each of the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants, prior to the expiration of the latest to expire of the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> Patents in 2034. Each of the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> Patents are listed in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Approved Drug Products with Therapeutic Equivalence Evaluations</span><span style="font-family:inherit;font-size:10pt;"> (Orange Book). In December 2018, the Company filed amended complaints against each of the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants following the receipt of additional Paragraph IV Letters from Teva and Apotex concerning its Orange Book listed '977 Patent, which expires in 2035. These lawsuits are scheduled for trial in October 2020.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2019, April 2019, and May 2019, the Company filed three additional patent infringement lawsuits in the Delaware District Court against the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants following the receipt of additional Paragraph IV Letters from each concerning its Orange Book listed U.S. Patent No. 10,149,829, which expires in 2033. These lawsuits have been consolidated with the other lawsuits against the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants and are also scheduled for trial in October 2020.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November and December 2019, the Company filed additional patent infringement lawsuits in the Delaware District Court against Apotex and Teva, respectively, for infringement of its Orange Book listed U.S. Patent No. 10,376,487 ('487 Patent) following the receipt of additional Paragraph IV Letters from Apotex and Teva regarding the '487 Patent, which expires in July 2035. Teva asserted a counterclaim for a declaratory judgment that the ‘487 Patent is invalid. The Company answered Teva’s counterclaim by denying their allegation that the ‘487 Patent is invalid. In January 2020, the Company filed two additional patent infringement lawsuits in the Delaware District Court against Teva and Apotex for infringement of its Orange Book-listed U.S. Patent No. 10,449,176 (‘176 Patent) following the receipt of additional Paragraph IV Letters from Teva and Apotex regarding the ‘176 Patent, which expires in January 2033. A trial date has not yet been scheduled for these lawsuits.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, the Company received an additional Paragraph IV Letter from MSN concerning the '487 patent, in which MSN alleges that the ‘487 Patent is invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale offer for sale, or importation of MSN's generic version of HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> as described in MSN's ANDA. The Company intends to vigorously pursue a patent infringement lawsuit permanently enjoining MSN from infringing the claims of the ‘487 Patent.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Matters</span><span style="font-family:inherit;font-size:10pt;">. In April 2018, the Company submitted a protocol amendment to the FDA, proposing a 52-week open-label extension (OLE) period for patients who had completed the tradipitant Phase II clinical study (2301) in gastroparesis. In May 2018, based on feedback from the FDA, the Company amended the protocol limiting the duration of treatment in the 2301 study to a total of three months, while continuing to seek further dialogue with the FDA on extending the study duration to 52-weeks. As a part of this negotiation process, in September 2018, the Company submitted a new follow-on 52-week OLE protocol to the FDA (2302) for patients who had completed the 2301 study. While waiting for further feedback, the Company did not enroll any patients in any study beyond 12 weeks. In December 2018, the FDA imposed a partial clinical hold (PCH) on </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the two proposed studies, stating that the Company is required first to conduct additional chronic toxicity studies in canines, monkeys or minipigs before allowing patients access in any clinical protocol beyond 12 weeks. At that time, the FDA informed the Company that the original PCH was not based on any safety or efficacy data related to tradipitant, but, rather. that these additional toxicity studies were required by a guidance document. Subsequently, the FDA has taken the position that an additional study was required in order for the FDA to have adequate toxicology data to undertake a risk analysis of tradipitant.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 5, 2019, the Company filed a lawsuit against the FDA in the U.S. District Court for the District of Columbia (DC District Court), challenging the FDA’s legal authority to issue the PCH, and seeking an order to set it aside. In February 2019, the FDA filed a Motion for Voluntary Remand to the Agency and for a Stay of the Case. In March 2019, the DC District Court granted the FDA’s request for voluntary remand and returned the matter to the FDA for further consideration. In April 2019, the FDA provided its remand response, in which it indicated that, upon review of scientific literature and tradipitant data, it believes that a PCH continues to be appropriate until the Company has adequate safety data from a nine-month non-rodent toxicity study. In May 2019, the Company filed an amended complaint, and in July 2019, the Company filed a Motion for Summary Judgment based on its continuing belief after review of the FDA’s remand response that additional chronic toxicity studies are unjustified, and that it has provided the FDA with sufficient information regarding the safety of tradipitant to justify the continued study of tradipitant in patients beyond 12 weeks, in accordance with applicable law and FDA regulations. The FDA filed a reply and cross-motion for summary judgment in October 2019 and an oral hearing was held on December 13, 2019. On January 31, 2020, the Court granted the FDA's cross-motion for summary judgment and granted judgment in favor of the FDA on the Company's claims. The Company is evaluating its options, including a potential appeal, and the Company intends to continue vigorously pursuing its interests in the matter.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2019, a qui tam action filed against the Company was unsealed by order of the DC District Court. The qui tam action, which was filed under seal in March 2017, was brought by a former Company employee on behalf of the U.S., 28 states and the District of Columbia (collectively, the Plaintiff States) and the policyholders of certain insurance companies under the Federal False Claims Act and state law equivalents to the Federal False Claims Act and related state laws. The complaint alleged that the Company violated these laws through the promotion and marketing of its products Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> and HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> and sought, among other things, treble damages, civil penalties for each alleged false claim, and attorneys’ fees and costs. By virtue of the DC District Court having unsealed the original complaint, the Company learned that in January 2019, the U.S. Department of Justice (the DOJ), as well as the Plaintiff States, elected not to intervene in the qui tam action at that time. In May 2019, the plaintiff filed an amended complaint under seal repeating the same allegations and seeking the same relief. According to a filing unsealed in June 2019, the DOJ reaffirmed its decision not to intervene and incorporated its prior filing, indicating that neither the DOJ nor the Plaintiff States were intervening regarding the original complaint. Although the DOJ and the Plaintiff States have elected not to intervene, the plaintiff may litigate this action and the DOJ and the Plaintiff States may later seek to intervene in the action. In August 2019, the Company filed a motion to dismiss, and in October 2019 the plaintiff filed a reply. The Company intends to vigorously defend itself in the case. The Court will hear the Company's motion to dismiss on March 20, 2020.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2019, a securities class action, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gordon v. Vanda Pharmaceuticals Inc.</span><span style="font-family:inherit;font-size:10pt;">, was filed in the U.S. District Court for the Eastern District of New York naming the Company and certain of its officers as defendants. An amended complaint was filed in July 2019. The amended complaint, filed on behalf of a purported stockholder, asserts claims on behalf of a putative class of all persons who purchased the Company’s publicly traded securities between November 4, 2015 and February 11, 2019, for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The amended complaint alleges that the defendants made false and misleading statements and/or omissions regarding Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">, HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">and the Company’s interactions with the FDA regarding tradipitant between November 3, 2015 and February 11, 2019. The Company believes that it has meritorious defenses and intends to vigorously defend this lawsuit. The Company does not anticipate that this litigation will have a material adverse effect on its business, results of operations or financial condition. However, this lawsuit is subject to inherent uncertainties, the actual cost may be significant, and the Company may not prevail. The Company believes it is entitled to coverage under its relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2019, a shareholder derivative complaint, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Samuel Williams vs. Mihael Polymeropoulos, et al.</span><span style="font-family:inherit;font-size:10pt;">, was filed in the U.S. District Court for the Eastern District of New York naming certain current and former Company directors and officers as defendants. In September 2019, a shareholder derivative complaint, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Michael Bavaro v. Mihael Polymeropoulos, et al.</span><span style="font-family:inherit;font-size:10pt;">, was filed in the Delaware District Court naming certain current and former Company directors and officers as defendants. In October 2019, the Company filed a motion to transfer the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bavaro </span><span style="font-family:inherit;font-size:10pt;">case to the Eastern District of New York, where the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gordon </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Williams</span><span style="font-family:inherit;font-size:10pt;"> cases are pending. In February 2020, the Delaware District Court issued an order staying the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bavaro</span><span style="font-family:inherit;font-size:10pt;"> case pending the resolution of the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Williams</span><span style="font-family:inherit;font-size:10pt;"> case. These complaints, filed on behalf of purported stockholders, derivatively on behalf of the Company, assert claims for alleged breach of fiduciary duties by certain of the Company’s current and former directors and officers. The Company believes that it has meritorious defenses and intends to vigorously defend these lawsuits. The Company </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">does not anticipate that this litigation will have a material adverse effect on its business, results of operations or financial condition. However, these lawsuits are subject to inherent uncertainties, the actual cost may be significant, and the Company may not prevail. The Company believes it is entitled to coverage under its relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> In July 2017, the CHMP issued a negative opinion recommending against approval of Fanaptum</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the E.U. The CHMP was of the opinion that the benefits of Fanaptum</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> did not outweigh its risks and recommended against marketing authorization. In March 2018, the Company filed an application seeking annulment of the EMA’s negative opinion and the subsequent European Commission decision refusing marketing authorization of Fanaptum in the European General Court. In December 2019, the General Court issued its judgment dismissing the action, leaving the EMA opinion and Commission decision intact. The Company is considering its options to appeal the decision.</span></div> Quarterly Financial Data (Unaudited)<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of quarterly financial data for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands, except for per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">First</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Second</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Third</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fourth</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,713</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,060</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,485</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,930</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit (1)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,313</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,327</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,335</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) from operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,087</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,895</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,759</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(612</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,526</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100,423</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,216</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) per share, diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.84</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,592</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,350</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,041</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit (1)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,680</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,739</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,670</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,994</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,442</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,233</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,066</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,611</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,171</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,360</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income per share, basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income per share, diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.06</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:19.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit includes revenues less cost of goods sold, excluding amortization, and less intangible asset amortization.</span></div> <div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of quarterly financial data for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands, except for per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">First</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Second</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Third</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fourth</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,713</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,060</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,485</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,930</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit (1)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,313</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,327</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,335</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) from operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,087</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,895</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,759</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(612</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,526</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100,423</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,216</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) per share, diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.84</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,592</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,350</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,041</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit (1)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,680</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,739</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,670</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,994</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,442</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,233</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,066</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,611</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,171</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,360</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income per share, basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income per share, diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.06</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:19.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit includes revenues less cost of goods sold, excluding amortization, and less intangible asset amortization.</span></div> 47713000 59060000 59485000 60930000 42220000 52313000 52327000 54335000 -2087000 9895000 10759000 4243000 -612000 11526000 100423000 4216000 -0.01 0.22 1.88 0.08 -0.01 0.21 1.84 0.08 43592000 47350000 49135000 53041000 38680000 41739000 43670000 46994000 2442000 3913000 6233000 9150000 3066000 4611000 7171000 10360000 0.07 0.09 0.14 0.20 0.06 0.09 0.13 0.19 XML 89 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover Page - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Feb. 18, 2020
Jun. 30, 2019
Cover page.      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2019    
Document Transition Report false    
Entity File Number 001-34186    
Entity Registrant Name VANDA PHARMACEUTICALS INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 03-0491827    
Entity Address, Address Line One 2200 Pennsylvania Avenue NW    
Entity Address, Address Line Two Suite 300 E    
Entity Address, City or Town Washington    
Entity Address, State or Province DC    
Entity Address, Postal Zip Code 20037    
City Area Code 202    
Local Phone Number 734-3400    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Trading Symbol VNDA    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Documents Incorporated by Reference
DOCUMENTS INCORPORATED BY REFERENCE
Specified portions of the registrant’s proxy statement with respect to the registrant’s 2020 Annual Meeting of Stockholders, which is to be filed pursuant to Regulation 14A within 120 days after the end of the registrant’s fiscal year ended December 31, 2019, are incorporated by reference into Part III of this Form 10-K.
    
Amendment Flag false    
Document Fiscal Year Focus 2019    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001347178    
Current Fiscal Year End Date --12-31    
Entity Common Stock, Shares Outstanding   53,648,617  
Entity Public Float     $ 731.2
XML 90 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Accounts Receivable, Net (Detail) - Credit Concentration Risk - Accounts Receivable
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Distributor A    
Concentration Risk [Line Items]    
Concentration risk, percentage 21.00% 30.00%
Distributor B    
Concentration Risk [Line Items]    
Concentration risk, percentage 21.00% 15.00%
Distributor C    
Concentration Risk [Line Items]    
Concentration risk, percentage 18.00% 20.00%
Distributor D    
Concentration Risk [Line Items]    
Concentration risk, percentage 16.00% 13.00%
Distributor E    
Concentration Risk [Line Items]    
Concentration risk, percentage 18.00% 16.00%
XML 91 R41.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Summary of Significant Accounting Policies - Additional Information (Detail)
$ in Thousands
 1 Months Ended 12 Months Ended 23 Months Ended
Feb. 08, 2018
Dec. 31, 2019
USD ($)
Segment
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2019
USD ($)
Jan. 01, 2019
USD ($)
Summary Of Significant Accounting Policies [Line Items]            
Percentage of insurance coverage gap allocated for prescription drugs under Medicare Part D 50.00%       70.00%  
Advertising expenses   $ 3,200 $ 900 $ 1,300    
Number of reportable segments | Segment   1        
Total lease liabilities   $ 14,602     $ 14,602  
Operating lease current liabilities   2,147 0   2,147  
Operating lease right-of-use assets   $ 11,180 $ 0   $ 11,180  
Accounting Standards Update 2016-02            
Summary Of Significant Accounting Policies [Line Items]            
Total lease liabilities           $ 15,800
Operating lease current liabilities           2,200
Operating lease right-of-use assets           $ 12,200
XML 92 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Statement of Comprehensive Income [Abstract]      
Net income (loss) $ 115,553 $ 25,208 $ (15,567)
Other comprehensive income (loss):      
Net foreign currency translation gain (loss) 6 (22) 30
Change in net unrealized gain (loss) on marketable securities 313 57 (122)
Tax provision on other comprehensive income (71) 0 0
Other comprehensive income (loss), net of tax 248 35 (92)
Comprehensive income (loss) $ 115,801 $ 25,243 $ (15,659)
XML 93 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Inventory (Detail) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Current assets    
Work-in-process $ 0 $ 48
Finished goods 1,140 946
Total inventory, current 1,140 994
Non-Current assets    
Raw materials 659 86
Work-in-process 1,109 2,290
Finished goods 1,056 516
Total inventory, non-current $ 2,824 $ 2,892
XML 94 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management’s evaluation could change. Actual results could differ from those estimates.
Cash, Cash Equivalents and Restricted Cash
For purposes of the Consolidated Balance Sheets and Consolidated Statements of Cash Flows, cash equivalents represent highly-liquid investments with a maturity date of three months or less at the date of purchase. Cash and cash equivalents include investments in money market funds with commercial banks and financial institutions, and commercial paper of high-quality corporate issuers. Restricted cash relates primarily to amounts held as collateral for letters of credit for leases for office space at the Company’s Washington, D.C. headquarters. 
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets to the total end of period cash, cash equivalents and restricted cash reported within the Consolidated Statement of Cash Flows:
 
December 31,
(in thousands)
2019
 
2018
Cash and cash equivalents
$
45,072

 
$
61,005

Restricted cash included in:
 
 
 
Prepaid expenses and other current assets
—

 
157

Non-current inventory and other
578

 
587

Total cash, cash equivalents and restricted cash
$
45,650

 
$
61,749


Marketable Securities
The Company classifies all of its marketable securities as available-for-sale securities. The Company’s investment policy requires the selection of high-quality issuers. Available-for-sale securities are carried at fair market value, with unrealized gains and losses reported as a component of stockholders’ equity in accumulated other comprehensive income (loss). At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. If declines in the value of available for-sale securities are determined to be other-than-temporary, a loss is recorded in earnings in the current period. Interest and dividend income is recorded when earned and included in other income. Premiums and discounts on marketable securities are amortized and accreted, respectively, to earliest call date and maturity, respectively, and included in other income. The Company uses the specific identification method in computing realized gains and losses on the sale of investments, which would be included in the consolidated statements of operations when generated. All available-for-sale marketable securities are available for use in current operations and are classified as current.
Inventory
Inventory, which is recorded at the lower of cost or net realizable value, includes the cost of third-party manufacturing and other direct and indirect costs and is valued using the first-in, first-out method. The Company capitalizes inventory costs associated with its products upon regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. Inventory not expected to be sold within 12 months following the balance sheet date are classified as non-current.
Intangible Assets
Costs incurred for products not yet approved by the FDA and for which no alternative future use exists are recorded as expense. Obligations for milestone payments to other pharmaceutical companies that may result in a capitalized intangible asset are recognized when it is deemed probable that the milestone event will occur. In the event a product has been approved by the FDA or an alternative future use exists for a product, patent and license costs are capitalized and amortized on a straight-line basis over the estimated useful economic life of the of the related product patents. For intangible assets related to HETLIOZ®, the estimated useful life is the estimated economic useful life of the related product patents, the latest of which expires in July 2035. Intangible assets related Fanapt® have been fully amortized on a straight-line basis to November 2016. The useful life estimate for Fanapt® was based on the market participant methodology prescribed by ASC 805, and therefore does not reflect the impact of additional Fanapt® patents solely owned by the Company with varying expiration dates, the latest of which is December 2031.
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation. Depreciation of most property and equipment is provided on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized using a straight-line basis over the lesser of the estimated useful lives of the assets or the terms of the related leases. The costs of additions and improvements are capitalized, and repairs and maintenance costs are charged to operations in the period incurred. Upon retirement or disposition of property and equipment, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in the statement of operations for that period.
Leases
In accordance with Accounting Standards Codification (ASC) 842, Leases, effective January 1, 2019, the Company determines if an arrangement contains a lease at inception. Right-of-use (ROU) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from that lease. For leases with a term greater than 12 months, ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The lease term includes the option to extend the lease when it is reasonably certain the Company will exercise that option. When available, the Company uses the rate implicit in the lease to discount lease payments to present value. In the case the implicit rate is not available, the Company uses its incremental borrowing rate based on information available at the lease commencement date, including publicly available data for instruments with similar characteristics, to determine the present value of lease payments. The Company does not combine lease and non-lease elements for office leases. For existing leases as of January 1, 2019, executory costs are excluded from lease expense, which is consistent with the Company's accounting under ASC 840, Leases. For all leases entered into after January 1, 2019, executory costs are allocated between lease and non-lease elements based upon their relative stand-alone prices.
Accounts Payable and Accrued Liabilities
The Company’s management is required to estimate accrued liabilities as part of the process of preparing financial statements. The estimation of accrued liabilities involves identifying services that have been performed on the Company’s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date in the financial statements. Accrued liabilities include research and development expenses, such as accrued costs under contracts with clinical monitors, data management organizations and investigators in conjunction with clinical trials, fees to contract manufacturers in conjunction with the production of clinical materials, consulting and professional fees, such as lawyers and fees for marketing and other commercialization activities, accrued compensation and employee benefits, such as accrued bonus, royalties payable under licensing agreements, and other accrued fees. Pursuant to management’s assessment of the services that have been performed on clinical trials and other contracts, the Company recognizes these expenses as the services are provided. Such management assessments include, but are not limited to: (i) an evaluation by the project manager of the work that has been completed during the period, (ii) measurement of progress prepared internally and/or provided by the third-party service provider, (iii) analyses of data that justify the progress, and (iv) management’s judgment. In the event that the Company does not identify certain costs that have begun to be incurred or the Company under- or over-estimates the level of services performed or the costs of such services, the Company’s reported expenses for such period would be too low or too high.

Revenue Recognition
In accordance with ASC Subtopic 606 Revenue from Contracts with Customers (ASC 606), which the Company adopted January 1, 2018, the Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. The Company recognizes revenue when control of the product is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for those product sales, which is typically once the product physically arrives at the customer. Sales taxes, value add taxes, and usage-based taxes are excluded from revenues. Results for reporting period ended December 31, 2017 were not adjusted and continue to be reported in accordance with historic accounting under ASC 605. The impact to the Consolidated Statements of Operations if the Company had applied ASC 606 for the year ended December 31, 2017 is not material. 
The Company’s net product sales consist of sales of HETLIOZ® and Fanapt®. Net sales by product for the years ended December 31, 2019, 2018 and 2017 were as follows:
 
Year Ended December 31,
(in thousands)
2019
 
2018
 
2017
HETLIOZ® product sales, net
$
142,980

 
$
115,835

 
$
89,978

Fanapt® product sales, net
84,208

 
77,283

 
75,105

Total net product sales
$
227,188


$
193,118


$
165,083


HETLIOZ® is available in the U.S. for distribution through a limited number of specialty pharmacies, and is not available in retail pharmacies. Specialty pharmacy customers include Diplomat Pharmacy, Inc. (a subsidiary of UnitedHealth Group) and Accredo (a subsidiary of Express Scripts). Fanapt® is available in the U.S. for distribution through a limited number of wholesalers and is available in retail pharmacies. Wholesaler customers include Cardinal Health, Inc., AmerisourceBergen
Drug Corporation, and McKesson Corporation. The Company invoices and records revenue when its customers, specialty pharmacies and wholesalers, receive product from the third-party logistics warehouse which is the point at which control is transferred to the customer. Revenues and accounts receivable are concentrated with these customers. The Company evaluates outstanding receivables to assess collectability. In performing this evaluation, the Company analyzes economic conditions, the aging of receivables and customer specific risks. 
The following table presents each major customer that represented more than 10% of total revenues for the years ended December 31, 2019, 2018 and 2017:
 
Year Ended December 31,
Percent of Net Product Sales
2019
 
2018
 
2017
Distributor A
38
%
 
37
%
 
32
%
Distributor B
23
%
 
17
%
 
10
%
Distributor C
12
%
 
14
%
 
15
%
Distributor D
12
%
 
12
%
 
15
%
Distributor E
11
%
 
12
%
 
12
%
Distributor F
—
%
 
5
%
 
11
%

The following table presents each major customer that represented more than 10% of accounts receivable, net, as of December 31, 2019 and 2018:
 
December 31,
Percent of Accounts Receivable, Net
2019
 
2018
Distributor A
21
%
 
30
%
Distributor B
21
%
 
15
%
Distributor C
18
%
 
20
%
Distributor D
16
%
 
13
%
Distributor E
18
%
 
16
%

The transaction price is determined based upon the consideration to which the Company will be entitled in exchange for transferring product to the customer. The Company’s product sales are recorded net of applicable product revenue allowances for which reserves are established and include discounts, rebates, chargebacks, service fees, co-pay assistance and product returns that are applicable for various government and commercial payors. The Company estimates the amount of variable consideration that should be included in the transaction price utilizing the most likely amount method and updates its estimate at each reporting date. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Allowances for rebates, chargebacks and co-pay assistance are based upon the insurance benefits of the end customer, which are estimated using historical activity and, where available, actual and pending prescriptions for which the Company has validated the insurance benefits. Reserves for variable consideration are classified as product revenue allowances on the consolidated balance sheets, with the exception of prompt-pay discounts which are classified as reductions of accounts receivable. The reserve for product returns for which the product may not be returned for a period of greater than one year from the balance sheet date is included as a component of other non-current liabilities in the consolidated balance sheets. Uncertainties related to variable consideration are generally resolved in the quarter subsequent to period end, with the exception of Medicaid rebates, which are dependent upon the timing of when states submit reimbursement claims, and product returns which are resolved during the product expiry period specified in the customer contract. The Company currently records sales allowances for the following:
Prompt-pay: Specialty pharmacies and wholesalers are offered discounts for prompt payment. The Company expects that the specialty pharmacies and wholesalers will earn prompt payment discounts and, therefore, deducts the full amount of these discounts from total product sales when revenues are recognized.
Rebates: Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program as well as contracted rebate programs with other payors. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contracted discount rates and estimated patient utilization.
Chargebacks: Chargebacks are discounts that occur when contracted indirect customers purchase directly from specialty pharmacies and wholesalers. Contracted indirect customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The specialty pharmacy or wholesaler, in turn, charges back the difference between the price initially paid by the specialty pharmacy or wholesaler and the discounted price paid to the specialty pharmacy or wholesaler by the contracted customer.
Medicare Part D Coverage Gap: Medicare Part D prescription drug benefit mandates manufacturers to fund approximately 50% of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients through 2018. Public Law No. 115-123, also known as the Bipartisan Budget Act of 2018 enacted on February 9, 2018 increased the manufacturer discount from 50% to 70% effective in 2019 for applicable drugs. Vanda accounts for the Medicare Part D coverage gap using a point of sale model. Estimates for expected Medicare Part D coverage gap are based in part on historical activity and, where available, actual and pending prescriptions for which the Company has validated the insurance benefits.
Service Fees: The Company receives sales order management, data and distribution services from certain customers. These fees are based on contracted terms and are known amounts. The Company accrues service fees at the time of revenue recognition, resulting in a reduction of product sales and the recognition of an accrued liability, unless it is a payment for a distinct good or service from the customer in which case the fair value of those distinct goods or services are recorded as selling, general and administrative expense.
Co-payment Assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Co-pay assistance utilization is based on information provided by the Company’s third-party administrator.
Product Returns: The Company generally offers direct customers a limited right to return as contractually defined with the customers. The Company considers several factors in the estimation process, including expiration dates of product shipped to customers, inventory levels within the distribution channel, product shelf life, historical return activity, including activity for product sold for which the return period has past, prescription trends and other relevant factors. The Company does not expect returned goods to be resalable. There was no right of return asset as of December 31, 2019 or 2018. The following table summarizes activity for product returns as of and for the years ended December 31, 2019, 2018 and 2017, all of which relates to sales of Fanapt®:
 
(in thousands)
Reserve for Product Returns
Balances at December 31, 2016
$
3,080

Additions
5,978

Credits/payments
(4,939
)
Balances at December 31, 2017
4,119

Additions
2,684

Credits/payments
(1,616
)
Balances at December 31, 2018
5,187

Additions
3,138

Credits/payments
(2,205
)
Balances at December 31, 2019
$
6,120


Cost of Goods Sold
Cost of goods sold includes royalties payable, the cost of inventory sold, manufacturing and supply chain costs and product shipping and handling costs related to sales of HETLIOZ® and Fanapt® to the Company’s distribution partners.
Research and Development Expenses
Research and development expenses consist primarily of fees for services provided by third parties in connection with the clinical trials, costs of contract manufacturing services, milestone payments, costs of materials used in clinical trials and research and development, costs for regulatory consultants and filings, depreciation of capital resources used to develop products, related facilities costs, and salaries, other employee-related costs and stock-based compensation for research and development personnel. The Company expenses research and development costs as they are incurred for products in the
development stage, including manufacturing costs and milestone payments made under license agreements prior to FDA approval. Upon and subsequent to FDA approval, manufacturing and milestone payments related to license agreements are capitalized. Milestone payments are accrued when it is deemed probable that the milestone event will be achieved. Costs related to the acquisition of intellectual property are expensed as incurred if the underlying technology is developed in connection with the Company’s research and development efforts and has no alternative future use.
Selling, General and Administrative Expenses
Selling, general and administrative expenses consist of salaries, stock-based compensation, facilities and third party expenses. Selling, general and administrative expenses are associated with the activities of the corporate, finance, accounting, information technology, business development, commercial support, trade and distribution, sales, marketing, legal, medical affairs and human resource functions. Additionally, selling, general and administrative expenses included an estimate for the annual Affordable Care Act fee.
Stock-Based Compensation
Compensation costs for all stock-based awards to employees and directors are measured based on the grant date fair value of those awards and recognized over the period during which the employee or director is required to perform service in exchange for the award. The Company recognizes the expense over the award’s vesting period. The fair value of stock options granted and restricted stock units (RSUs) awarded are amortized using the straight-line method. As stock-based compensation expense recognized in the consolidated statements of operations is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
Advertising Expense
The Company expenses the costs of advertising, including branded promotional expenses, as incurred. Branded advertising expenses, recorded in selling, general and administrative expenses, were $3.2 million, $0.9 million and $1.3 million for the years ended December 31, 2019, 2018 and 2017, respectively.
Foreign Currency
The reporting currency of the Company is the U.S. dollar. The functional currency of the Company’s international subsidiaries is the local currency. Assets and liabilities denominated in foreign currencies, including intercompany balances for which settlement is anticipated in the foreseeable future, are translated at exchange rates in effect at the balance sheet date. Foreign currency equity balances are translated at historical rates. Revenues and expenses denominated in foreign currencies are translated at average exchange rates for the respective periods. Foreign currency translation adjustments are recorded in accumulated other comprehensive income (loss).
Transactions denominated in currencies other than subsidiaries’ functional currencies are recorded based on exchange rates at the time such transactions arise. Changes in exchange rates with respect to amounts recorded in the consolidated balance sheets related to these items will result in unrealized foreign currency transaction gains and losses based upon period-end exchange rates. The Company also records realized foreign currency transaction gains and losses upon settlement of the transactions. Foreign currency transaction gains and losses are included in other income and were not material for the years ended December 31, 2019, 2018 and 2017, respectively.
Income Taxes
The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. Tax rate changes are reflected in income during the period such changes are enacted. Changes in ownership may limit the amount of net operating loss (NOL) carryforwards that can be utilized in the future to offset taxable income. Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement.
Certain Risks and Uncertainties
The Company’s products under development require approval from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance the products will receive the necessary clearance. If the Company is denied clearance or clearance is delayed, it may have a material adverse impact on the Company.
The Company’s products are concentrated in rapidly-changing, highly-competitive markets, which are characterized by rapid technological advances, changes in customer requirements and evolving regulatory requirements and industry standards. Any failure by the Company to anticipate or to respond adequately to technological developments in its industry, changes in customer requirements or changes in regulatory requirements or industry standards or any significant delays in the development or introduction of products or services could have a material adverse effect on the Company’s business, operating results and future cash flows.
The Company depends on single source suppliers for critical raw materials for manufacturing, as well as other components required for the administration of its products. The loss of these suppliers could delay the clinical trials or prevent or delay commercialization of the products.
Concentrations of Credit Risk
Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash, cash equivalents and marketable securities. The Company places its cash, cash equivalents and marketable securities with highly-rated financial institutions. At December 31, 2019, the Company maintained all of its cash, cash equivalents and marketable securities in two financial institutions. Deposits held with these institutions may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand, and the Company believes there is minimal risk of losses on such balances.
Segment and Geographic Information
The Company operates in one reporting segment and, accordingly, no segment disclosures are presented herein. Foreign sales were not material for each of the years ended December 31, 2019, 2018 and 2017.
Recent Accounting Pronouncements
In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company is evaluating this standard to determine if adoption will have a material impact on the Company’s consolidated financial statements.
In August 2018, the U.S. Securities and Exchange Commission (SEC) adopted the final rule under SEC Release No. 33-10532, Disclosure Update and Simplification. This final rule amends certain disclosure requirements that are redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expand the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule is effective for the Company for all filings made on or after November 5, 2018. The SEC staff clarified that the first presentation of the changes in shareholders' equity may be included in the first Form 10-Q for the quarter that begins after the effective date of the amendments. The adoption of the final rule did not have a material impact on the Company’s consolidated financial statements.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses, which changes the impairment model for most financial assets and certain other financial instruments. The standard will require the use of a forward-looking “expected loss” model for instruments measured at amortized cost that generally will result in the earlier recognition of allowances for losses. The standard is effective for years beginning after December 15, 2019, and interim periods within annual periods beginning after December 15, 2019. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial results.
In February 2016, the FASB issued ASU 2016-2, Leases (Topic 842), which was further clarified by ASU 2018-10, Codification Improvements to Topic 842, Leases, and ASU 2018-11, Leases - Targeted Improvements, issued in July
2018. ASC 842 supersedes existing lease guidance, including ASC 840 Leases. The new leasing standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The new leasing standard requires that lessees will need to recognize an ROU asset and a lease liability for virtually all of their leases, and allows companies to make a policy election as to whether short term leases will be recognized under the requirements of the new standard. The Company elected to exclude short-term leases in the application of the new standard. The lease liability is equal to the present value of lease payments. The ROU asset is based on the liability subject to certain adjustments. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense, similar to accounting for operating leases under ASC 840, while finance leases will result in a front-loaded expense pattern, similar to accounting for capital leases under ASC 840.
The Company adopted the new leasing standard in the first quarter of 2019, using a modified retrospective transition. There was no impact to the opening balance of retained earnings as of the effective date of January 1, 2019 as a result of adoption. Prior period financial statements were not recast. The Company elected the package of transition provisions available for expired or existing contracts, which allowed it to carryforward its historical assessments of (1) whether contracts are or contain leases, (2) lease classification and (3) initial direct costs. The adoption of the new leasing standard on January 1, 2019 resulted in the recognition of $15.8 million of operating lease liabilities, $2.2 million of which were classified as current liabilities, with corresponding ROU assets of $12.2 million, net of lease prepayments and the balance of deferred lease incentives. The Company does not have any financing leases.
XML 95 R28.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Marketable Securities (Tables)
 12 Months Ended
Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]  
Summary of Available-for-Sale Marketable Securities
The following is a summary of the Company’s available-for-sale marketable securities as of December 31, 2019, which all have contractual maturities of less than two years:
(in thousands)
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair
Market
Value
U.S. Treasury and government agencies
$
88,535

 
$
68

 
$
(2
)
 
$
88,601

Corporate debt
129,860

 
196

 
(1
)
 
130,055

Asset-backed securities
48,355

 
49

 
(3
)
 
48,401

Total marketable securities
$
266,750


$
313


$
(6
)

$
267,057

The following is a summary of the Company’s available-for-sale marketable securities as of December 31, 2018, which all have contract maturities of less than one year:
(in thousands)
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair
Market
Value
U.S. Treasury and government agencies
$
69,275

 
$
12

 
$
(17
)
 
$
69,270

Corporate debt
105,897

 
38

 
(25
)
 
105,910

Asset-backed securities
21,189

 
—

 
(14
)
 
21,175

Total marketable securities, current
$
196,361


$
50


$
(56
)

$
196,355
XML 96 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock-Based Compensation
 12 Months Ended
Dec. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation Stock-Based Compensation
As of December 31, 2019, there were 6,144,430 shares that were subject to outstanding options and RSUs under the 2006 Equity Incentive Plan (2006 Plan) and the Amended and Restated 2016 Equity Incentive Plan (2016 Plan, and together with the 2006 Plan, Plans). The 2006 Plan expired by its terms on April 12, 2016, and the Company adopted the 2016 Plan. Outstanding options and RSUs under the 2006 Plan remain in effect and the terms of the 2006 Plan continue to apply, but no additional awards can be granted under the 2006 Plan. In June 2016, the Company’s stockholders approved the 2016 Plan. The 2016 Plan has been amended and restated twice to increase the number of shares reserved for issuance, among other administrative changes. Both amendments and restatements of the 2016 Plan were approved by the Company's stockholders. There are a total of 7,100,000 shares of common stock reserved for issuance under the 2016 Plan, 3,026,147 shares of which remained available for future grant as of December 31, 2019.
Stock Options
The Company has granted option awards under the Plans with service conditions (service option awards) that are subject to terms and conditions established by the compensation committee of the board of directors. Service option awards have 10-year contractual terms. Service option awards granted to employees and new directors upon their election vest and become exercisable over four years, with the first 25% of the shares subject to service option awards vesting on the first anniversary of the grant date and the remaining 75% of the shares subject to the service option awards in 36 equal monthly installments thereafter. Subsequent annual service option awards granted to directors vest and become exercisable in full on the first anniversary of the grant date. Certain service option awards to executives and directors provide for accelerated vesting if there is a change in control of the Company. Certain service option awards to employees and executives provide for accelerated vesting if the respective employee’s or executive’s service is terminated by the Company for any reason other than cause or permanent disability.
As of December 31, 2019, $9.8 million of unrecognized compensation costs related to unvested service option awards are expected to be recognized over a weighted average period of 1.4 years. No option awards are classified as a liability as of December 31, 2019.
The following is a summary of option activity for the 2006 Plan and the 2016 Plan for the years ended December 31, 2019, 2018, and 2017:
2006 and 2016 Plans
(in thousands, except for share and per share amounts)
Number of
Shares
 
Weighted Average
Exercise Price at Grant Date
 
Weighted Average
Remaining Term
(Years)
 
Aggregate
Intrinsic
Value
Outstanding at December 31, 2016
5,548,336

 
$
11.62

 
5.58
 
$
32,453

Granted
643,000

 
14.44

 
 
 
 
Forfeited
(290,729
)
 
10.73

 
 
 
 
Expired
(605,617
)
 
29.87

 
 
 
 
Exercised
(575,206
)
 
9.13

 
 
 
3,140

Outstanding at December 31, 2017
4,719,784

 
10.03

 
5.63
 
24,421

Granted
567,500

 
19.22

 
 
 
 
Forfeited
(232,527
)
 
13.99

 
 
 
 
Exercised
(685,715
)
 
9.12

 
 
 
5,945

Outstanding at December 31, 2018
4,369,042

 
11.15

 
5.28
 
65,438

Granted
687,500

 
18.38

 
 
 
 
Forfeited
(53
)
 
7.94

 
 
 
 
Expired
(15,000
)
 
14.78

 
 
 
 
Exercised
(546,344
)
 
11.47

 
 
 
2,482

Outstanding at December 31, 2019
4,495,145

 
12.21

 
5.58
 
22,148

Exercisable at December 31, 2019
3,371,836

 
10.31

 
4.53
 
21,200

Vested and expected to vest at December 31, 2019
4,354,708

 
12.02

 
5.46
 
22,039


The weighted average grant-date fair value of options granted was $10.19, $10.66 and $7.81 per share for the years ended December 31, 2019, 2018 and 2017, respectively. Proceeds from the exercise of stock options amounted to $6.3 million, $6.3 million and $5.3 million for the years ended December 31, 2019, 2018 and 2017, respectively.
Restricted Stock Units
An RSU is a stock award that entitles the holder to receive shares of the Company’s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company’s stock on the date of grant. The Company has granted RSUs under the Plans with service conditions (service RSUs) that vest in four equal annual installments provided that the employee remains employed with the Company. Annual service RSUs granted to directors vest on the first anniversary of the grant date.
As of December 31, 2019, $22.8 million of unrecognized compensation costs related to unvested service RSUs are expected to be recognized over a weighted average period of 1.8 years. No RSUs are classified as a liability as of December 31, 2019.
The following is a summary of RSU activity for the 2006 Plan and the 2016 Plan for the years ended December 31, 2019, 2018, and 2017:
RSUs
Number of
Shares
 
Weighted
Average
Grant Date Fair Value
Unvested at December 31, 2016
1,138,428

 
$
10.07

Granted
857,336

 
14.57

Forfeited
(275,613
)
 
11.41

Vested
(362,313
)
 
9.78

Unvested at December 31, 2017
1,357,838

 
12.72

Granted
714,086

 
18.93

Forfeited
(229,603
)
 
15.19

Vested
(528,745
)
 
12.69

Unvested at December 31, 2018
1,313,576

 
15.68

Granted
937,328

 
19.46

Forfeited
(75,444
)
 
18.93

Vested
(526,175
)
 
14.54

Unvested at December 31, 2019
1,649,285

 
18.04


The grant date fair value for the 526,175 shares underlying RSUs that vested during the year ended December 31, 2019 was $7.7 million.
Stock-Based Compensation Expense
Stock-based compensation expense recognized for the years ended December 31, 2019, 2018 and 2017 was allocated as follows:
 
Year Ended December 31,
(in thousands)
2019
 
2018
 
2017
Research and development
$
3,207

 
$
1,290

 
$
1,152

Selling, general and administrative
10,251

 
10,376

 
9,313

Total stock-based compensation expense
$
13,458

 
$
11,666

 
$
10,465


The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model that uses the assumptions noted in the following table. Expected volatility rates are based on the historical volatility of the Company’s publicly traded common stock and other factors. The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has never paid cash dividends to its stockholders and does not plan to pay dividends in the foreseeable future. Assumptions used in the Black-Scholes-Merton option pricing model for employee and director stock options granted during the years ended December 31, 2019, 2018 and 2017 were as follows:
 
Year Ended December 31,
 
2019
 
2018
 
2017
Expected dividend yield
—
%
 
—
%
 
—
%
Weighted average expected volatility
58
%
 
58
%
 
57
%
Weighted average expected term (years)
5.95

 
5.90

 
5.89

Weighted average risk-free rate
2.26
%
 
2.68
%
 
1.97
%
EXCEL 97 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 98 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Legal Matters
 12 Months Ended
Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Legal Matters Legal Matters
Fanapt®. The Company has been involved in litigation with Roxane Laboratories, Inc. (Roxane) and its affiliates, West-Ward Pharmaceuticals International Limited and West-Ward Pharmaceuticals Corp (West-Ward), since the Company filed a lawsuit against Roxane in the U.S. District Court for the District of Delaware (Delaware District Court) for patent infringement in June 2014. The lawsuit was filed in response to Roxane’s submission to the U.S. Food and Drug Administration (FDA) of an Abbreviated New Drug Application (ANDA) for a generic version of Fanapt® prior to the expiration of certain of the Company’s patents covering Fanapt®, including U.S. Patent No. 8,586,610 (‘610 Patent). In August 2016, the Delaware District Court ruled in the Company’s favor, permanently enjoining Roxane from manufacturing, using,
selling, offering to sell, distributing or importing any generic iloperidone product described in Roxane’s ANDA until the expiration of the ‘610 Patent in November 2027, or May 2028 if the Company obtains pediatric exclusivity. In April 2018, following an appeal by Roxane of the Delaware District Court’s decision to the Federal Circuit Court of Appeals (Federal Circuit), the Federal Circuit affirmed the Delaware District Court’s ruling. In June 2018, West-Ward, having replaced Roxane as defendants following the acquisition of Roxane by West-Ward’s parent company, Hikma Pharmaceuticals PLC, petitioned the Federal Circuit for a rehearing en banc. In August 2018, the Federal Circuit denied West-Ward's petition. In January 2019, West-Ward filed a petition in the U.S. Supreme Court for a writ of certiorari seeking reversal of the Federal Circuit’s decision. In March 2019, the U.S. Supreme Court invited the Solicitor General of the U.S. to file a brief in the matter expressing the views of the U.S. In January 2020, the U.S. Supreme Court denied West-Ward's petition for writ of certiorari.
In 2015, the Company filed six separate patent infringement lawsuits in the Delaware District Court against Roxane, Inventia Healthcare Pvt. Ltd. (Inventia), Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin), Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd. (Taro), and Apotex Inc. and Apotex Corp. (Apotex, and collectively with Roxane, Inventia, Lupin and Taro, the Fanapt® Defendants). These lawsuits were filed in response to the submission to the FDA by each of the Fanapt® Defendants of ANDAs for generic versions of Fanapt® prior to the expiration of the ‘610 Patent in November 2027 or the U.S. Patent No. 9,138,432 in September 2025. The Company entered into separate confidential stipulations with each of Inventia and Lupin regarding any potential launch of their generic versions of Fanapt®. The parties are scheduled to provide the court with a status report in March 2020 with respect to the remaining lawsuits against the other Fanapt® Defendants.
HETLIOZ®. In April and May 2018, the Company filed three separate patent infringement lawsuits in the Delaware District Court against Teva Pharmaceuticals USA, Inc. (Teva), MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (MSN) and Apotex (collectively with Teva and MSN, the HETLIOZ® Defendants) after having received Paragraph IV certification notice letters (Paragraph IV Letters) from each of the HETLIOZ® Defendants alleging that certain of the Company's patents covering HETLIOZ® (collectively, the HETLIOZ® Patents) were invalid, unenforceable and/or would not be infringed by the manufacture, use or sale of their generic versions of HETLIOZ®, as described in the ANDAs submitted to the FDA by each of the HETLIOZ® Defendants, prior to the expiration of the latest to expire of the HETLIOZ® Patents in 2034. Each of the HETLIOZ® Patents are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). In December 2018, the Company filed amended complaints against each of the HETLIOZ® Defendants following the receipt of additional Paragraph IV Letters from Teva and Apotex concerning its Orange Book listed '977 Patent, which expires in 2035. These lawsuits are scheduled for trial in October 2020.
In March 2019, April 2019, and May 2019, the Company filed three additional patent infringement lawsuits in the Delaware District Court against the HETLIOZ® Defendants following the receipt of additional Paragraph IV Letters from each concerning its Orange Book listed U.S. Patent No. 10,149,829, which expires in 2033. These lawsuits have been consolidated with the other lawsuits against the HETLIOZ® Defendants and are also scheduled for trial in October 2020.
In November and December 2019, the Company filed additional patent infringement lawsuits in the Delaware District Court against Apotex and Teva, respectively, for infringement of its Orange Book listed U.S. Patent No. 10,376,487 ('487 Patent) following the receipt of additional Paragraph IV Letters from Apotex and Teva regarding the '487 Patent, which expires in July 2035. Teva asserted a counterclaim for a declaratory judgment that the ‘487 Patent is invalid. The Company answered Teva’s counterclaim by denying their allegation that the ‘487 Patent is invalid. In January 2020, the Company filed two additional patent infringement lawsuits in the Delaware District Court against Teva and Apotex for infringement of its Orange Book-listed U.S. Patent No. 10,449,176 (‘176 Patent) following the receipt of additional Paragraph IV Letters from Teva and Apotex regarding the ‘176 Patent, which expires in January 2033. A trial date has not yet been scheduled for these lawsuits.
In January 2020, the Company received an additional Paragraph IV Letter from MSN concerning the '487 patent, in which MSN alleges that the ‘487 Patent is invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale offer for sale, or importation of MSN's generic version of HETLIOZ® as described in MSN's ANDA. The Company intends to vigorously pursue a patent infringement lawsuit permanently enjoining MSN from infringing the claims of the ‘487 Patent.
Other Matters. In April 2018, the Company submitted a protocol amendment to the FDA, proposing a 52-week open-label extension (OLE) period for patients who had completed the tradipitant Phase II clinical study (2301) in gastroparesis. In May 2018, based on feedback from the FDA, the Company amended the protocol limiting the duration of treatment in the 2301 study to a total of three months, while continuing to seek further dialogue with the FDA on extending the study duration to 52-weeks. As a part of this negotiation process, in September 2018, the Company submitted a new follow-on 52-week OLE protocol to the FDA (2302) for patients who had completed the 2301 study. While waiting for further feedback, the Company did not enroll any patients in any study beyond 12 weeks. In December 2018, the FDA imposed a partial clinical hold (PCH) on
the two proposed studies, stating that the Company is required first to conduct additional chronic toxicity studies in canines, monkeys or minipigs before allowing patients access in any clinical protocol beyond 12 weeks. At that time, the FDA informed the Company that the original PCH was not based on any safety or efficacy data related to tradipitant, but, rather. that these additional toxicity studies were required by a guidance document. Subsequently, the FDA has taken the position that an additional study was required in order for the FDA to have adequate toxicology data to undertake a risk analysis of tradipitant.
On February 5, 2019, the Company filed a lawsuit against the FDA in the U.S. District Court for the District of Columbia (DC District Court), challenging the FDA’s legal authority to issue the PCH, and seeking an order to set it aside. In February 2019, the FDA filed a Motion for Voluntary Remand to the Agency and for a Stay of the Case. In March 2019, the DC District Court granted the FDA’s request for voluntary remand and returned the matter to the FDA for further consideration. In April 2019, the FDA provided its remand response, in which it indicated that, upon review of scientific literature and tradipitant data, it believes that a PCH continues to be appropriate until the Company has adequate safety data from a nine-month non-rodent toxicity study. In May 2019, the Company filed an amended complaint, and in July 2019, the Company filed a Motion for Summary Judgment based on its continuing belief after review of the FDA’s remand response that additional chronic toxicity studies are unjustified, and that it has provided the FDA with sufficient information regarding the safety of tradipitant to justify the continued study of tradipitant in patients beyond 12 weeks, in accordance with applicable law and FDA regulations. The FDA filed a reply and cross-motion for summary judgment in October 2019 and an oral hearing was held on December 13, 2019. On January 31, 2020, the Court granted the FDA's cross-motion for summary judgment and granted judgment in favor of the FDA on the Company's claims. The Company is evaluating its options, including a potential appeal, and the Company intends to continue vigorously pursuing its interests in the matter.
In February 2019, a qui tam action filed against the Company was unsealed by order of the DC District Court. The qui tam action, which was filed under seal in March 2017, was brought by a former Company employee on behalf of the U.S., 28 states and the District of Columbia (collectively, the Plaintiff States) and the policyholders of certain insurance companies under the Federal False Claims Act and state law equivalents to the Federal False Claims Act and related state laws. The complaint alleged that the Company violated these laws through the promotion and marketing of its products Fanapt® and HETLIOZ® and sought, among other things, treble damages, civil penalties for each alleged false claim, and attorneys’ fees and costs. By virtue of the DC District Court having unsealed the original complaint, the Company learned that in January 2019, the U.S. Department of Justice (the DOJ), as well as the Plaintiff States, elected not to intervene in the qui tam action at that time. In May 2019, the plaintiff filed an amended complaint under seal repeating the same allegations and seeking the same relief. According to a filing unsealed in June 2019, the DOJ reaffirmed its decision not to intervene and incorporated its prior filing, indicating that neither the DOJ nor the Plaintiff States were intervening regarding the original complaint. Although the DOJ and the Plaintiff States have elected not to intervene, the plaintiff may litigate this action and the DOJ and the Plaintiff States may later seek to intervene in the action. In August 2019, the Company filed a motion to dismiss, and in October 2019 the plaintiff filed a reply. The Company intends to vigorously defend itself in the case. The Court will hear the Company's motion to dismiss on March 20, 2020.
In February 2019, a securities class action, Gordon v. Vanda Pharmaceuticals Inc., was filed in the U.S. District Court for the Eastern District of New York naming the Company and certain of its officers as defendants. An amended complaint was filed in July 2019. The amended complaint, filed on behalf of a purported stockholder, asserts claims on behalf of a putative class of all persons who purchased the Company’s publicly traded securities between November 4, 2015 and February 11, 2019, for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The amended complaint alleges that the defendants made false and misleading statements and/or omissions regarding Fanapt®, HETLIOZ® and the Company’s interactions with the FDA regarding tradipitant between November 3, 2015 and February 11, 2019. The Company believes that it has meritorious defenses and intends to vigorously defend this lawsuit. The Company does not anticipate that this litigation will have a material adverse effect on its business, results of operations or financial condition. However, this lawsuit is subject to inherent uncertainties, the actual cost may be significant, and the Company may not prevail. The Company believes it is entitled to coverage under its relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient.
In July 2019, a shareholder derivative complaint, Samuel Williams vs. Mihael Polymeropoulos, et al., was filed in the U.S. District Court for the Eastern District of New York naming certain current and former Company directors and officers as defendants. In September 2019, a shareholder derivative complaint, Michael Bavaro v. Mihael Polymeropoulos, et al., was filed in the Delaware District Court naming certain current and former Company directors and officers as defendants. In October 2019, the Company filed a motion to transfer the Bavaro case to the Eastern District of New York, where the Gordon and Williams cases are pending. In February 2020, the Delaware District Court issued an order staying the Bavaro case pending the resolution of the Williams case. These complaints, filed on behalf of purported stockholders, derivatively on behalf of the Company, assert claims for alleged breach of fiduciary duties by certain of the Company’s current and former directors and officers. The Company believes that it has meritorious defenses and intends to vigorously defend these lawsuits. The Company
does not anticipate that this litigation will have a material adverse effect on its business, results of operations or financial condition. However, these lawsuits are subject to inherent uncertainties, the actual cost may be significant, and the Company may not prevail. The Company believes it is entitled to coverage under its relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient.
In July 2017, the CHMP issued a negative opinion recommending against approval of Fanaptum® (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the E.U. The CHMP was of the opinion that the benefits of Fanaptum® did not outweigh its risks and recommended against marketing authorization. In March 2018, the Company filed an application seeking annulment of the EMA’s negative opinion and the subsequent European Commission decision refusing marketing authorization of Fanaptum in the European General Court. In December 2019, the General Court issued its judgment dismissing the action, leaving the EMA opinion and Commission decision intact. The Company is considering its options to appeal the decision.
XML 99 R35.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accumulated Other Comprehensive Income (Tables)
 12 Months Ended
Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss)
The accumulated balances related to each component of other comprehensive income (loss), net of taxes, were as follows for the years ended December 31, 2019 and 2018:
(in thousands)
December 31,
2019
 
December 31,
2018
Foreign currency translation
$
13

 
$
7

Unrealized gain (loss) on marketable securities
236

 
(6
)
Accumulated other comprehensive income
$
249

 
$
1
XML 100 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2019
Property, Plant and Equipment [Abstract]  
Summary of Property and Equipment-at Cost
The following is a summary of the Company’s property and equipment, at cost, as of December 31, 2019 and 2018:
(in thousands)
Estimated
Useful Life
(Years)
 
December 31, 2019
 
December 31, 2018
Computer and other equipment
3
 
$
4,398

 
$
3,642

Furniture and fixtures
5 - 7
 
1,491

 
1,488

Leasehold improvements
5 - 11
 
4,587

 
4,506

Total property and equipment, gross
 
 
10,476

 
9,636

Accumulated depreciation and amortization
 
(6,612
)
 
(5,219
)
Total property and equipment, net
 
 
$
3,864

 
$
4,417
XML 101 R39.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Quarterly Financial Data (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Financial Data
The following is a summary of quarterly financial data for the years ended December 31, 2019 and 2018:
(in thousands, except for per share amounts)
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
Year Ended December 31, 2019
 
 
 
 
 
 
 
Revenues
$
47,713

 
$
59,060

 
$
59,485

 
$
60,930

Gross profit (1)
42,220

 
52,313

 
52,327

 
54,335

Income (loss) from operations
(2,087
)
 
9,895

 
10,759

 
4,243

Net income (loss)
(612
)
 
11,526

 
100,423

 
4,216

Net income (loss) per share, basic
$
(0.01
)
 
$
0.22

 
$
1.88

 
$
0.08

Net income (loss) per share, diluted
$
(0.01
)
 
$
0.21

 
$
1.84

 
$
0.08

Year Ended December 31, 2018
 
 
 
 
 
 
 
Revenues
$
43,592

 
$
47,350

 
$
49,135

 
$
53,041

Gross profit (1)
38,680

 
41,739

 
43,670

 
46,994

Income from operations
2,442

 
3,913

 
6,233

 
9,150

Net income
3,066

 
4,611

 
7,171

 
10,360

Net income per share, basic
$
0.07

 
$
0.09

 
$
0.14

 
$
0.20

Net income per share, diluted
$
0.06

 
$
0.09

 
$
0.13

 
$
0.19

 
(1)
Gross profit includes revenues less cost of goods sold, excluding amortization, and less intangible asset amortization.
XML 102 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Inventory
 12 Months Ended
Dec. 31, 2019
Inventory Disclosure [Abstract]  
Inventory Inventory
The Company evaluates expiry risk by evaluating current and future product demand relative to product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. Inventory levels are evaluated for the amount of inventory that would be sold within one year. At certain times, the level of inventory can exceed the forecasted level of cost of goods sold for the next twelve months. The Company classifies the estimate of such inventory as non-current. Inventory consisted of the following as of December 31, 2019 and 2018:
(in thousands)
December 31,
2019
 
December 31,
2018
Current assets
 
 
 
Work-in-process
$
—

 
$
48

Finished goods
1,140

 
946

Total inventory, current
$
1,140

 
$
994

Non-Current assets
 
 
 
Raw materials
$
659

 
$
86

Work-in-process
1,109

 
2,290

Finished goods
1,056

 
516

Total inventory, non-current
$
2,824

 
$
2,892
XML 103 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accounts Payable and Accrued Liabilities
 12 Months Ended
Dec. 31, 2019
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities
The following is a summary of the Company’s accounts payable and accrued liabilities as of December 31, 2019 and 2018:
(in thousands)
December 31,
2019
 
December 31,
2018
Compensation and employee benefits
$
6,597

 
$
6,363

Royalties payable
5,904

 
5,172

Research and development expenses
5,893

 
5,593

Consulting and other professional fees
5,376

 
2,924

Operating lease liabilities
2,147

 
—

Other
1,673

 
1,532

Total accounts payable and accrued liabilities
$
27,590

 
$
21,584
XML 104 R77.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Employee Benefit Plan (Detail) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Retirement Benefits [Abstract]      
Defined contribution plan employer matching percent 50.00%    
Defined contribution plan maximum employee contribution percent 6.00%    
Defined contribution plan vesting period 4 years    
Defined contribution plan matching amount $ 0.8 $ 0.9 $ 0.8
XML 105 R73.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock-Based Compensation - Summary of Option Activity for 2006 Plan and the 2016 Plan (Detail) - 2006 Plan and 2016 Plan - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Number of Shares        
Beginning balance (in shares) 4,369,042 4,719,784 5,548,336  
Granted (in shares) 687,500 567,500 643,000  
Forfeited (in shares) (53) (232,527) (290,729)  
Expired (in shares) (15,000)   (605,617)  
Exercised (in shares) (546,344) (685,715) (575,206)  
Ending balance (in shares) 4,495,145 4,369,042 4,719,784 5,548,336
Exercisable (in shares) 3,371,836      
Vested and expected to vest at end of period (in shares) 4,354,708      
Weighted Average Exercise Price at Grant Date        
Beginning balance (in dollars per share) $ 11.15 $ 10.03 $ 11.62  
Granted (in dollars per share) 18.38 19.22 14.44  
Forfeited (in dollars per share) 7.94 13.99 10.73  
Expired (in dollars per share) 14.78   29.87  
Exercised (in dollars per share) 11.47 9.12 9.13  
Ending balance (in dollars per share) 12.21 $ 11.15 $ 10.03 $ 11.62
Exercisable (in dollars per share) 10.31      
Vested and expected to vest at end of period (in dollars per share) $ 12.02      
Weighted Average Remaining Term (Years)        
Weighted Average Remaining Term 5 years 6 months 29 days 5 years 3 months 10 days 5 years 7 months 17 days 5 years 6 months 29 days
Exercisable 4 years 6 months 10 days      
Vested and expected to vest at end of period 5 years 5 months 15 days      
Aggregate Intrinsic Value        
Beginning balance $ 65,438 $ 24,421 $ 32,453  
Exercised 2,482 5,945 3,140  
Ending balance 22,148 $ 65,438 $ 24,421 $ 32,453
Exercisable 21,200      
Vested and expected to vest at end of period $ 22,039      
XML 106 R83.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Valuation Allowance Activity on Deferred Tax Assets (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Tax Disclosure [Abstract]      
Balance at Beginning of Year $ 111,950 $ 116,110 $ 146,012
Additions 0 4,036 12,403
Reductions (103,795) (8,196) (42,305)
Balance at End of Year $ 8,155 $ 111,950 $ 116,110
XML 107 R58.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets - Summary of Intangible Assets (Detail) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Jan. 31, 2014
Dec. 31, 2019
Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]      
Net Carrying Amount   $ 23,037 $ 24,542
HETLIOZ®      
Finite-Lived Intangible Assets [Line Items]      
Intangible assets, estimated future useful life 2034-05 2035-07 2035-02
Gross Carrying Amount   $ 33,000 $ 33,000
Accumulated Amortization   9,963 8,458
Net Carrying Amount   23,037 24,542
Fanapt®      
Finite-Lived Intangible Assets [Line Items]      
Gross Carrying Amount   $ 27,900 $ 27,900
XML 108 R50.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Property and Equipment - Property and Equipment-at Cost (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 10,476 $ 9,636
Accumulated depreciation and amortization (6,612) (5,219)
Property and equipment, net $ 3,864 4,417
Computer and other equipment    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life (Years) 3 years  
Property and equipment, gross $ 4,398 3,642
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 1,491 1,488
Furniture and fixtures | Minimum    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life (Years) 5 years  
Furniture and fixtures | Maximum    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life (Years) 7 years  
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 4,587 $ 4,506
Leasehold improvements | Minimum    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life (Years) 5 years  
Leasehold improvements | Maximum    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life (Years) 11 years  
XML 109 R54.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Maturities (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Leases [Abstract]    
2020 $ 2,326  
2021 2,332  
2022 2,355  
2023 2,420  
2024 2,488  
Thereafter 8,182  
Total minimum lease payments 20,103  
Less: amount of lease payments representing interest (5,501)  
Present value of future minimum lease payments 14,602  
Less: current obligations under leases (2,147) $ 0
Operating lease non-current liabilities $ 12,455 $ 0

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